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 I 
Abstract 
Maternal diet in pregnancy and early infant diet have been implicated in the aetiology 
of obesity and allergy. This thesis aims to investigate the effect of maternal nutrition 
during pregnancy and infant feeding practices in early life on the development of 
obesity and allergic outcomes in children.  
 
This research was conducted as two separate complementary studies. The first 
synthesised the best available evidence from randomised clinical trials, by conducting 
two systematic reviews, of the effectiveness of maternal nutritional/dietary 
interventions during pregnancy to prevent obesity and allergic outcomes in offspring. 
The second collected data prospectively from the Portsmouth Birth Cohort registry on 
maternal diet during pregnancy as well as feeding practices of babies at 2 and 6 
months of age, and assessed how these nutritional behaviours affected the 
development of weight and allergic outcomes in babies by 6 months of age.  
 
The systematic reviews provided evidence that prenatal supplementation of 
probiotics, fatty acids and vitamins could protect against childhood eczema, 
sensitisation and wheeze respectively. However, nutritional/dietary interventions did 
not prevent obesity in children. The second study showed three main findings: 1) 
higher maternal consumption of sugar during pregnancy was associated with lower 
weight Z-score both at birth and at 6 months of age; 2) partially breast-fed babies 
compared to dominantly breast-fed and formula-fed babies at 2 months had lower 
weight Z-score at 2 and 6 months of age; 3) the introduction of wheat at 3-6 months 
compared to later introduction was associated with fewer allergic symptoms at 6 
months of age. 
 
The novel findings of this research have implications for practice. Notably, Vitamin D 
intake in pregnancy was found to prevent wheeze in children; however, longer-term 
follow-ups of these studies is necessary to determine whether Vitamin D could also 
protect against childhood asthma. Findings of the cohort highlight the importance of 
healthy diet in pregnant women and early feeding practices in babies for the 
development of obesity and allergies in babies. Longer-term follow-up of these babies 
in a larger sample is needed to validate these results. 
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Chapter 1: General introduction 
1.1. Background 
The first 1,000 days of life, the period between a woman’s pregnancy and her baby’s 
second birthday is key to good health for a life-time. The new developmental model 
states the origin of many chronic diseases including metabolic disorders/obesity and 
allergies stem from this period (Barker, 2012), thus the very early days in an infant’s 
life provides a unique opportunity to build and improve the health of future 
generations. In this context, the role of environmental factors such as diet and 
lifestyle-related behaviours are key for primary/early prevention of chronic diseases 
(Mayor et al., 2015; Thornburg & Marshall, 2015). In fact, the foetus starts 
responding to the external stimuli when in utero and hence, factors such as maternal 
diet could directly programme an infant’s immune system without necessarily 
affecting birth size (Campbell et al., 1996; Jansson & Powell, 2007; Ravelli et al., 
1998; Roseboom et al., 2001; Shiell et al., 2001). Women in the Western world 
predominantly follow an inadequate and unbalanced diet while many women in 
developing countries suffer from malnutrition; both circumstances could have long-
term impact on the health of their babies (Barker, 2012). On this basis, interventions 
aiming to improve nutritional adequacy in pregnant women could considerably 
contribute towards reducing the incidence of chronic diseases.  
 
The influence of nutrition on the development of a baby is also prominent after birth 
when the infant comes into contact with the postnatal environment via breast or 
bottle-feeding and later through weaning and introduction of other foods. It is well 
documented that maternal diet and the composition of breast milk have 
immunomodulatory effects on the infant’s immune system and consequently could 
initiate the development of chronic diseases later in life (Munblit et al., 2017; Victora 
et al., 2016). 
 
An overwhelming body of evidence from experimental and epidemiological studies 
suggests that poor early life environment, stimulated by both quantity and quality of 
nutrients during the critical phases of development i.e. in utero and early postnatal life 
can make evident changes in the developing foetus (Bertram & Hanson, 2001; 
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Armitage et al., 2004; Barker 1990; Langley-Evans, Phillips & Jackson, 1994; 
Whincup et al., 2008). In other words, either under or over-nutrition during both 
gestation and postnatal life could induce an adaptive response to environmental 
signals in the developing foetus/child, which allows its developmental growth to be 
modified towards nutritional thrifts for future environmental insults (Gluckman & 
Hanson 2004; Wells 2009). These effects, termed as programming (Lucas 1991), 
establish permanent physiological and metabolic states in the foetus, and could 
potentially increase the risk of a range of long-term health conditions in adulthood, 
including non-communicable diseases (NCD) (Lillycrop 2011; Langley-Evans 2015). 
Large population studies on babies exposed to large historical famines have shed 
more light on the links between nutritional balance during early stages of life and later 
risk of diseases. It has been shown that babies born during or immediately after these 
incidents had an elevated risk of type-2 diabetes mellitus, hypertension and metabolic 
syndrome (Li et al., 2011; Schulz, 2010; Thurner et al., 2013). 
  
The mechanisms through which the nutritional challenges in early life could introduce 
lasting changes in the foetus, which could link to its future health, are not fully 
understood. Current knowledge proposes that intrauterine nutrient availability can 
alter the epigenome, the chemical compound that can instruct DNA, but the sequence 
in DNA (Doherty, Mann, Tremblay, Bartolomei, Schultz 2000; Khosla, Dean, Reik, 
Feil 2001). These epigenetic marks in the regulation of imprinted genes cause 
heritable alterations to the phenotype of the offspring (Swali, McMullen, Hayes, 
Gambling, McArdle & Langley-Evans 2011; Swali, McMullen, Hayes, Gambling, 
McArdle & Langley-Evans 2012). Two main factors of epigenetic influences are 
DNA methylation and histone modifications where DNA methylation delivers 
mechanism for gene silencing and the histon modification either allow gene 
transcription or silence expression (Jaenisch & Bird, 2003; Burdge, Hanson, Slater-
Jefferies, & Lillycrop 2007). Nutritional imbalances, excess or deficit of nutrients, in 
early life stage are most likely to affect DNA methylation as evidence from the Dutch 
famine study showed methylation differences at the Insulin-like Growth Factor 2 
(IGF2) locus between individuals exposed to famine and their unexposed siblings 
(Heijmans et al., 2008). Despite recent advances in this area, there is still a need for 
greater understanding of mechanisms which could explain the role of early nutritional 
status and development of epigenetic markers and thus phenotype and later disease 
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risk (Lillycrop & Burdge 2015). It is also necessary to add that the existing 
knowledge is largely reliant on experimental studies which should be replicated in 
human studies because of the structural and physiological differences. 
 
Given the importance of nutrition and its influential role on developing chronic 
diseases in today’s world, the United Nations has declared 2016-2025 as the decade 
of nutrition (World Health Organization, 2017). This calls for a change in how we 
define the quality of nutrition since globally malnutrition in all its forms (under-
nutrition, micronutrient deficiency, overweight/obesity) affects a large proportion of 
people, while a balanced rich diet from the earliest days in life could be the solution to 
good health in the next generation(s). This thesis will examine the effect of maternal 
nutrition in pregnancy, in two systematic reviews of interventional studies and also in 
an original prospective birth cohort, and feeding practices early in life and their 
potential as risk factors for childhood allergies and obesity. 
1.2. Aims and research questions 
The aim of this research programme was to assess whether maternal diet during 
pregnancy and early infant feeding could affect the development of obesity and 
allergic outcomes in their offspring. Two separate complementary studies were 
conducted to address this aim.  
 
Study 1 (systematic reviews and meta-analyses):  
The following research questions were examined in this first study: 
-Are nutritional/dietary interventions during pregnancy effective in preventing 
allergic disorders in offspring? 
-Are nutritional/dietary interventions during pregnancy effective in preventing obesity 
in offspring? 
Study 2 (prospective observational study in the city of Portsmouth of pregnant women 
and their children at 2 and 6 months age follow-ups): 
The following research questions were examined in this second study: 
-Does quality of maternal diet during pregnancy affect weight/birth Z-score at 6 
months of age? 
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-Does quality of maternal diet during pregnancy affect incidence of allergies at 6 
months of age?  
-Do infant feeding practices at 2 months of age affect weight/Z-scores at 2 and 6 
months? 
-Do infant dietary behaviours at 6 months of age affect the development of allergies at 
6 months? 
Of note, the city of Portsmouth, as one of the deprived cities in the UK, has a health 
status below the national average and there are significant health inequalities (Hirsch 
& Valadez, 2014). In this context, children and young people are particularly 
disadvantaged and more targeted interventions are required. The results of the 
observational study, as the first cohort in the city with the potential for longitudinal 
follow-ups, can provide valuable data that are locally relevant and informative at a 
national level. 
1.3. Rationale of the study design  
Evidence-based practice (EBP) is nowadays the cornerstone of clinical practice and 
its importance in day-to-day practice has long been recognised. The term EBP was 
first described in 1996 by Professor David Sackett as “the conscientious, explicit and 
judicious use of current best evidence in making decisions about the care of the 
individual patients. The practice of EBP means integrating individual clinical 
expertise with the best available external clinical evidence from systematic research” 
(Sackett, Rosenberg, Muir Gray, Haynes, Richardson 1996). From a clinical point of 
view, EBP values the clinical expertise of clinicians while also taking into account 
patients’ values in combination with the best research evidence. Effective EBP 
demands time and involves five essential steps (Sackett, et al., 1997; McKibbon 
1998). Following formulating an answerable research question (1
st
), the available 
evidence needs to be retrieved from valid resources (2
nd
) which subsequently leads to 
the appraisal of the evidence in order to make a sound decision (3
rd
). Further steps 
comprise applying the decision and then evaluation/analysing the outcome obtained 
from using the evidence respectively. In the above EBP cycle, formulating a good 
clear research question is a key step that helps to efficiently search for the previous 
work done and also, to identify the appropriate type of study design.  
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In the hierarchy of evidence, meta-analyses and systematic reviews provide the 
strongest evidence since they answer a precisely formulated research question 
applying rigorous systematic methods to identify, appraise, collect and analyse data 
from the available and selected literature. A particular benefit of doing a systematic 
review is that it brings together a number of separately conducted studies, with 
different quality and sometimes contrasting findings, and synthesises their results to 
produce summaries of the evidence (Cook, Mulrow, Haynes 1997). Meta-analyses 
can be conducted if there is a possibility to unite data from individual studies and re-
analyse using established statistical methods.  
 
 
Figure 1.1. Hierarchy of evidence in the study design (adapted from Melnyk 
2011) 
Systematic reviews, if well conducted, could provide reliable objective answers to a 
specific clinical question and also, identify the gap(s) in the current evidence.  
Likewise, it can be decided how their findings are generalisable to populations, 
settings and treatment variations and therefore, could help health practitioners to 
make informed decision-makings.  
 
Randomised controlled trials (RCTs), at the 2
nd
 level of hierarchy of evidence, use an 
experimental design in order to test the effectiveness of a new treatment, diagnosis or 
screening method. A basic trial design follows a PICO format: population of interest 
(P), the intervention(s) (I), comparison/control defined as placebo/standard treatment 
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(C) and outcome-assessing the efficacy of the intervention (O). A well-designed RCT 
involves random assignment and blinding of participants to either a treatment or 
control group thus reducing the risk of potential biases. Cohort studies (which fall 
below the RCTs in the hierarchy of evidence) are the strongest observational study. 
Cohort studies follow a group of people with similar characteristics/exposure(s) over 
time and compare their outcomes with a similar group that are not affected by the 
same exposure (Evans 2003).  
 
Given the importance of systematic reviews in clinical decision-making, the first 
study in this PhD project aimed to synthesis the best available evidence from RCTs, a 
highly ranked evidence-based study, on the effectiveness of nutritional interventions 
in pregnant women for the prevention of allergies and obesity outcomes, as the two 
most common NCDs in children. In the second study, a cohort approach was used, as 
the highest ranked evidence-based observational study design, to investigate how is 
the dietary intake of pregnant women in Portsmouth and how this intake was related 
to allergies and growth outcomes in their babies. Feeding practices of babies were 
also collected at 2 and 6 months in a prospective approach. The cohort study was best 
choice for the second study since women could neither have been randomised to 
follow a specific diet nor to breast or bottle feed their babies.   
1.4. Thesis layout 
The opening chapter of this thesis, chapter two reviews the relevant literature on early 
origins of allergies and obesity, including the literature specific to individual chapters 
of this thesis. Following an introduction to the Developmental Origins of Health and 
Disease (DOHaD) theory (Barker, 2012), the literature review continues with a 
detailed background on definition, prevalence and diagnosis of allergies and obesity; 
it then outlines the primary risk factors, in utero and postnatal milieu for these 
conditions. The chapter ends with a discussion around reasoning on prenatal 
nutritional interventions for the primary prevention of childhood allergies and obesity. 
Of note, the literature review is outlined separately for allergic and obesity outcomes.  
 
Chapter three presents the synthesis of evidence from RCTs on the effectiveness of 
maternal dietary interventions (pro/prebiotics, fatty acids, food avoidance 
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interventions, vitamins/supplements) during pregnancy for the prevention of allergic 
diseases in offspring. The chapter outlines the methodology for the conduct of 
systematic reviews and subsequently, the results and risk of bias (ROB) assessments 
are separately presented for each intervention group. 
 
Chapter four describes the synthesis of evidence from RCTs on the effectiveness of 
maternal dietary interventions (fatty acids, pro/prebiotics, low glycemic index, 
lifestyle change, vitamins/supplements) during pregnancy for the prevention of 
obesity in offspring. It follows a similar outline to that of chapter three.  
 
Chapter five describes the first cohort study on the quality of maternal diet and infant 
feeding practices on weight/age Z-scores. Participants for this study were pregnant 
women from the Portsmouth birth cohort registry and their children who were 
followed up at 2 and 6 months of age. The associations between the defined risk 
factors and outcomes are investigated in linear regression models.  
 
Chapter six reports the effects of the quality of maternal diet and infant dietary 
behaviours at 6 months of age on developing allergies in the same cohort. Statistical 
analyses were conducted for individual risk factors and the influential effect of all 
factors were examined in a logistic regression model.  
 
Chapter seven describes the overall findings from the conducted systematic reviews 
and meta-analyses and discusses the results in the context of current literature. The 
findings from the cohort studies are also collated and discussed in view of existing 
literature. The implications from the conducted studies are outlined and future 
research needs along with the strengths and limitations of the research addressed. 
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Chapter 2: Literature review 
2.1. Overview of the chapter  
This literature review intends to give an overview of the early origins of allergies and 
obesity. It first explores the concept of the Developmental Origins of Health and 
Disease (DOHaD) theory and then reviews the current evidence in the area of 
childhood allergy and obesity. It describes the definition, prevalence and diagnosis of 
allergic disorders and obesity and the risk factors for these conditions both in utero 
and in the postnatal environment as well as early prevention strategies focusing on 
prenatal nutrition interventions. 
 
2.2. Developmental Origins of Health and Disease theory   
The DOHaD theory focuses on the key sensitive stages of human development 
defined as plasticity course and provides a novel model for early prevention of 
common chronic diseases (Barker, 1997; Gillman, 2005). This theory challenges the 
traditional attitude to the origins of disease as it proposes that the development period 
is not dictated by a hard-wired genetic programme; instead the organism responds to 
the surrounding environment and so the risk of many diseases is set during this time 
(Bernal Autumn, 2010). Subsequent to the substantial increase in the incidence of 
many Non-communicable Diseases (NCDs) during the last 20-40 years, it has been 
proposed that there is an important role for environmental factors in the onset of these 
complex conditions and that the role of fixed genetic variation is far less than 
previously believed (Barouki, Gluckman, Grandjean, Hanson, & Heindel, 2012). In 
other words, while genes may predispose individuals to develop these diseases, these 
conditions develop only if relevant environmental and lifestyle factors occur. NCDs, 
also known as chronic diseases, are diseases that are not passed from one person to 
another, typically characterised with a long duration and slow progression. Main types 
of NCDs are Cardiovascular Diseases (CVDs), which claim 17.3 million deaths a 
year, followed by cancers, chronic respiratory diseases and asthma, diabetes (Lim et 
al., 2012) as well as allergic diseases. NCDs are characterised by chronic, low-grade 
inflammation, highlighting the involvement of the immune system, a common feature 
to allergic diseases. NCDs and allergy also share common life-style related and 
environmental risk factors including modern dietary patterns and environmental 
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pollutants (Prescott, 2014). Therefore allergies are considered in the context of NCDs 
as the most common and early-onset NCD. NCDs pose an enormous global burden 
and account for 36 million deaths per year (World Health Organisation, 2010), where 
childhood obesity is linked with a raised level of premature death in adulthood (The 
World Health Organisation, 2014). The most recent systematic analysis for the Global 
Burden of Disease reported a continued rise of NCD burden between 1990 and 2010 
and indicated the increased contribution of the nutrition-related risk factors to this 
burden (Lim et al., 2012). NCDs are closely linked to lifestyle factors including poor 
dietary patterns, low physical activity, tobacco use and harmful use of alcohol 
(Kvaavik, Batty, Ursin, Huxley, & Gale, 2010; World Health Organisation, 2010). 
Therefore, NCDs can be defined as lifestyle-related diseases, which are a 
consequence of population adaptation to an unnatural environment (Sagner et al., 
2014).  
 
The rapid rise in the prevalence of obesity and diet-related NCDs has become a public 
health concern necessitating attention in both developing and developed countries 
(Lobstein & Brinsden, 2014). Being overweight or obese is well defined as an NCD- 
associated chronic health condition that potentially increases the risk of developing 
coronary heart disease, type 2 diabetes and some cancers. Therefore, new approaches 
towards disease prevention with emphasis on early interventions need to be widely 
investigated. A rational approach through nutritional interventions alongside reducing 
environmental chemical exposures in pre-pregnancy, during pregnancy and also the 
first few years of life could be the key towards clearer answers on the origins of 
NCDs (Barouki et al., 2012). The potential that NCDs can be prevented is of 
significant importance and warrants further investigation. This approach could, in 
principle, have a very large impact on reducing disease incidence and also the cost of 
healthcare. 
 
The epidemiology, risk factors and prenatal nutritional preventative approaches to 
allergies as NCD and obesity as a potential risk factor for NCDs are discussed further 
in the following sections. The epidemiological data are drawn from childhood studies 
as this is the area of interest in this programme of research.  
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2.3. Definition of allergy, symptoms and diagnosis  
Clemens von Pirquet, the Viennese paediatrician first coined the term allergy in 1906 
originating from the two Greek words “allos” (other or different) and “ergia” (energy 
or action) (Igea, 2013).  
 
In the current nomenclature for allergy, developed by the appointed Task Force in the 
European Academy of Allergology and Clinical Immunology (EAACI) (Johansson et 
al., 2004), hypersensitivity is used as an umbrella term for describing objectively 
reproducible adverse reaction(s) to a defined stimulus at a dose that is tolerated by 
normal people. Hypersensitivity is subdivided into allergic and non-allergic 
hypersensitivity. The main differentiating factor between the two is that allergic 
hypersensitivity involves adaptive immune system. Based on the mechanism 
involved, allergic hypersensitivity is further subdivided into those mediated by 
immunoglobulin E (IgE-mediated) and those not mediated by immunoglobulin E (non 
IgE-mediated). Inflammation in the latter could be caused by either allergen-specific 
lymphocytes or IgG immunoglobulin isotype. This is shown in Figure 2.1.  
 
The molecular pathways involved in IgE-mediated allergies are complex and not very 
well understood.  In brief, T cells are key on initiating allergic reactions in the body 
where there is an imbalance from T regulatory (Treg) cells, also called Th1 cells, 
towards allergen specific type 2 helper T (Th2) phenotype (Palomares, Akdis, Martin-
Fontecha, Akdi, 2017). In other words, while the dominance of Treg cells in healthy 
individuals inhibits allergic responses to different allergens, a reduced immune 
suppression could lead to a shift towards Th2 subsets and thus, developing allergies 
(Akdi, et al., 2004; Palomares, et al., 2014). 
Another common term in the field of allergy is “atopy” which describes a genetic 
predisposition to producing immunoglobulin E in response to allergens, due to 
personal or familial tendency (Johansson et al., 2001). Likewise, the “atopic march” 
denotes the natural course of allergic disease in which early onset of atopic dermatitis 
and food allergy in infancy precedes the developing of wheeze/asthma and allergic 
rhinitis in childhood (Bantz, Zhou, Zheng, 2014).  
 
 11 
 
 
Figure 2.1. Nomenclature of allergy, adapted from Johansson et al., 2004 
 
Known allergic diseases include asthma, rhinitis, conjunctivitis, atopic dermatitis 
(eczema), urticaria, food hypersensitivity, drug hypersensitivity, insect sting or bite 
hypersensitivity and anaphylaxis (Johansson 2004). It should be noted that these are 
umbrella terms since these diseases could also be initiated by non-IgE-mediated 
process. Therefore the term allergic disease should be applied when an 
immunologically mediated sequence is triggered. Asthma is one example of a 
heterogeneous disease caused by many environmental factors. A genetic 
predisposition has, however, been established as the main risk factor for developing 
IgE-mediated asthma to common aeroallergens (Holgate et al., 2013) and this needs 
to be differentiated as “allergic asthma”. Dermatitis is also an umbrella term for a 
local inflammation of the skin and when an IgE-immunoglobulin-associated reaction 
is involved the appropriate term is “atopic eczema” or an “allergic dermatitis”. 
Similarly, the term “food allergy” should also be applied if immunologic mechanisms 
are found to be involved.  
 
Allergic diseases can affect individuals at any age, although allergies frequently begin 
early on in infancy. During the first months of life, infants are prone to developing 
atopic dermatitis, food allergies and recurrent wheezing, whereas asthma and allergic 
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rhinitis usually occur later in childhood (Bieber, Leung, Gamal, & Ivancevich, 2013). 
Allergies can also be triggered by a wide range of indoor and outdoor factors such as 
foods, pets, mould, insect sting, drug, and pests. Generally speaking, allergens are 
members of a rather limited number of protein families, which are capable of binding 
to specific antibodies (van Ree, 2014). Manifestation of allergies to cow’s milk 
protein (CMP) is the most common in the first few months when the infant is exposed 
to cow’s milk via breast milk, infant formula or solid foods. Moreover, allergic 
reactions to foods, particularly in children, are primarily caused by eight foods, 
namely cow’s milk, egg, wheat, soy, peanut, tree nuts, fish and shellfish (Allen & 
Koplin, 2012).  
 
A summarised checklist of related physical symptoms of allergic diseases, either 
single, systemic or in combination, is presented in Table 2.1.  
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Table 2.1. Common allergic diseases and their related physical symptoms
*
 
Asthma 
 Recurrent episodes of wheezing 
 Breathlessness 
 Chest tightness and cough, particularly at 
night or the early morning 
Atopic dermatitis 
 Pruritus 
 Facial and patch eczema lesions 
 Generalised body eczema 
 Crusty erosions due to scratching 
 Restless and agitated 
 Lichenification in chronic cases 
Food allergy 
 Cutaneous reactions (urticaria, 
angioedema, contact rash) 
 Gastrointestinal reactions (oral allergy 
syndrome, nausea/vomiting, abdominal 
pain, diarrhea, constipation, enteritis & 
colitis) 
 Respiratory reactions (asthma, 
rhinoconjunctivitis, laryngeal edema) 
 Other reactions (anaphylaxis) 
Allergic rhinitis 
 Stuffed-up nose 
 Runny nose  
 Postnasal drip 
 Red itching eyes 
 Watering eyes 
 Repeated sneezing 
 Headache 
 Nasal itching 
 Facial pain 
 Ear pain 
Anaphylaxis 
 Cutaneous symptoms (itching, flushing, 
hives, angioedema) 
 Respiratory symptoms (shortness of 
breath, wheeze, cough, rhinitis) 
 Cardiovascular symptoms (dizziness, 
syncope, hypotension) 
 Abdominal symptoms (nausea, vomiting, 
diarrhoea, cramping pain) 
 Other symptoms (headache, sub-sternal 
pain, seizure) 
Allergic conjunctivitis (ocular allergy) 
 Itching 
 Tearing 
 Redness 
 Chemosis 
 Lid oedema 
 Photophobia 
Drug hypersensitivity 
 Skin (urticaria, angioedema) 
 Respiratory (asthma, acute lung 
infiltrates, hypersensitivity pneumonitis) 
 Hematologic (eosinophilia, cytopenias) 
 Hepatic (cholestasis, hepatocellular 
damage) 
 Renal (glumerolonephritis, nephrotic 
syndrome) 
 Anaphylaxis 
 Serum sickness 
 Drug fever 
 Vasculitis 
Urticaria (chronic spontaneous type) 
 Wheals 
 Angioedema 
 Both of the above 
 
Insect sting/bite hypersensitivity 
 Allergic systemic reactions (cutaneous, 
respiratory, cardiovascular, 
gastrointestinal) 
 Systemic toxic reactions 
 
*Adapted from WAO White book and EAACI Atlas 
 
Management of allergic diseases principally relies on applying appropriate diagnostic 
methods and identifying the causative allergens. The first step in diagnosis is taking a 
thorough allergy-focused history, accompanied by physical examination, which 
should include questions regarding (Sánchez-Borges, Ivancevich, Pérez, & Ansotegui, 
2013):  
 Present illness and symptoms 
 Sources of exposure to allergens or irritants at work or other environment 
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 Personal or passive tobacco exposure, including a review of previous 
evaluations and treatments 
 The impact of illness 
 Review of systems 
 Presence of other organ-related diseases and medications 
 Psychosocial setting and past medical history 
 Prior drug or food allergies as well as the family history  
 
When an adequate medical history suggests sensitisation to causative allergic factors, 
the next step is for relevant allergen-specific tests to be performed by qualified 
healthcare professionals trained in allergy. A number of in vivo and in vitro tests are 
introduced for the diagnosis of allergic diseases. These include immediate-type skin 
tests, in vitro allergen-specific IgE, basophil-based tests, organ challenge tests, patch 
tests, total serum IgE, serum tryptase, eosinophil cationic protein, eosinophils in blood 
and other biologic fluids, additional procedures (including spyrometry, bronchoscopy, 
nitric oxide in exhaled air) and environmental determinations. The Double-Blind 
Placebo-Controlled Food Challenge (DBPCFC) is the gold standard for the diagnosis 
of any food allergy (Sampson et al., 2012). 
 
Skin tests are the main in vivo diagnostic tools for IgE-mediated allergies and are easy 
to perform, reproducible and cheap (Sánchez-Borges, et al., 2013). The tests are either 
percutaneous or intracutaneous on the skin of the inner forearm or the upper back. If 
wheal and flare reactions form 15-20 minutes after the introduction of a suspected 
allergen, an allergic response is developed. The level of response largely depends on 
the degree of sensitivity, the number of mast cells and the potency of the allergic 
extract. To minimise the negative and false positive results, positive control 
(histamine dihydrochloride or phosphate) and a negative control (glycerosaline 
diluent) is used. A positive test result does not prove clinical allergy on its own and 
needs to be supported with findings from the medical history and physical 
examination. In contrast, a negative test result does not necessarily indicate that the 
disorder is not caused by the suspected allergen. Patients are advised to avoid taking 
antihistamines and certain medications including topical corticosteroids and tricyclic 
antidepressants before taking the test to prevent false negative results.  
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Skin Prick Tests (SPTs), also termed percutaneous or puncture tests, are the most 
common technique for detecting allergies. A positive result is considered when a 
wheal response of at least 3mm diameter larger than negative control alone occurs 
(Sánchez-Borges, et al., 2013). SPTs are identified as the best method for detecting 
sensitisation to inhalant and food allergens (Genser & Schmid-Grendelmeier, 2014).  
 
Intradermal or intracutaneous tests are 10,000 times more sensitive than SPTs but 
have higher rates of false positive results. They are typically performed when prick 
tests are negative in the presence of a clear history of exposure coupled with 
symptoms and are best known for diagnosis of venom and drug allergies (Genser & 
Schmid-Grendelmeier, 2014). 
 
In vitro tests are the benchmark methods in the diagnosis of allergies (Sánchez-
Borges, et al., 2013). The most common of these is a serological test measuring levels 
of allergen-specific IgE immunoglobulin (sIgE). Raised level of sIgE in the serum 
indicates that an allergy may exist and such a result needs to be correlated with 
symptoms and a positive medical history of exposure to allergen.  
 
2.4. Allergic disorders in children  
As explained, allergy is an immunologically mediated and allergen-specific 
hypersensitivity manifesting mainly in the skin and mucous membranes. This 
involves different pathomechanisms and hence different approaches to diagnosis, 
therapy and prevention can be taken (Ring, 2014).  
 
Allergic diseases have seen a rise worldwide with children suffering the highest 
burden of the diseases in the last two decades (Kaliner & Giacco, 2013). A time trend 
analysis for allergic diseases in the UK, not including asthma, showed that they are 
still amongst the most common disorders (Gupta, Sheikh, Strachan, & Anderson, 
2007), accounting for 6% of all GP consultations (the Royal College of Physicians 
Working Party, 2003). It is estimated that the direct cost of allergic diseases to the 
NHS is in the order of £1 billion per annum (Gupta, 2004) not including the financial 
impact of school or workdays lost, lower productivity or diminished quality of life 
(Department of Health Allergy Services Review Team, 2006). 
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The most common allergic disorders in children are food allergies, asthma and 
eczema (Pawankar, Canonica, Holgate, Lockey, & Blaiss, 2013).  
 
Food allergies 
A systematic review on diagnosing and managing common food allergies concluded 
that there are difficulties making precise estimates of food allergies due to differing 
definitions, methods of diagnosis, dietary exposures and geographical variations 
(Chafen et al., 2010). Nationally representative population-based studies from the US 
and Canada showed the self-reported prevalence of food allergy in children to be 
6.53% in 2007-2010 (McGowan & Keet, 2013) and 6.7% in 2008-2009 (Soller et al., 
2012), respectively. Data from an unselected birth cohort of pregnant women on the 
Isle of Wight, UK also showed that cumulative incidence of food hypersensitivity, 
defined by food challenges and/or a good clinical history, was estimated 6.8% in 
children at 10 years old (Venter et al., 2016). A systematic review and meta-analysis 
of 56 European studies conducted between 2000-2012 found point and overall 
lifetime prevalence of self-reported food allergies at 5.6% and 17.3%, respectively 
with higher rate of point prevalence reported in children (Nwaru et al., 2014). The 
studies included in this review had moderate level of bias due to the heterogeneity in 
their methodology and diagnostic methods. In general, the major drawback with self-
report estimates of food allergy is that they are limited in part by the subjective nature 
of the data. The changing patterns of food allergy burden in children is investigated in 
a global collaborative project between the World Allergy Organisation (WAO) and 
Worldwide Universities Network (WUN) in 2012, targeting the 93 national and 
regional member societies of WAO (Prescott et al., 2013). Data on food allergy were 
sourced from the existing data in 89 countries; 12 in Western Europe (including the 
UK), 5 in Scandinavia and 17 in Central/Eastern Europe, 18 in Asia and Oceania, 15 
in the Americas, 10 in the Middle East and 12 in Africa; comprised of 83 WAO 
member and 6 non-member countries. It should be noted that there was no data on 
food allergy prevalence in over half of the countries included in the survey, and 
precise Open Food Challenge (OFC) data was available in only 10% of the countries. 
Data from this study suggests that some regions in Asia show comparable data for the 
prevalence of food allergies to European regions and more importantly, there has been 
an increasing trend of food allergies in both developing and developed countries over 
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the past 10-15years. Furthermore, the most common food allergens in children <5 
years were reported to be cow’s milk, egg, peanuts and shellfish, with similar patterns 
in all regions.  
 
Asthma 
Asthma is the most prevalent chronic disease in children, with the highest asthma 
rates reported in the UK and Ireland in both Europe and the world (Gibson, 
Loddenkemper, Sibille, Lundbäck, & Fletcher, 2013). The International Study of 
Asthma and Allergies in Childhood (ISAAC) assessed the prevalence and severity of 
asthma symptoms in its phase three survey in 233 centres from 97 countries using a 
standardised written questionnaire (Lai et al., 2009). The comprehensive worldwide 
estimate from this survey in children 6-7 years of age showed the occurrence of 
severe asthma symptoms ranged from 3.2% in Asia-Pacific and Northern and Eastern 
Europe to 9.5% in Oceania. A relatively high prevalence (≥7.5%) was also observed 
in Latin America and English-speaking countries. The most recent study on the global 
burden of asthma in children (Asher & Pearce, 2014) highlighted prominent 
differences in asthma symptoms, characterised by wheeze in the past 12 months in 
children. Some high-prevalence centres in high-income countries showed higher 
asthma rates from 1990 to the 2000s, and at the same time, higher rates of asthma 
were also observed in many low and middle-income countries. These numbers 
indicate an increasing overall burden of asthma worldwide suggesting that there is a 
universal declining trend for disparities in childhood asthma prevalence.  
 
Eczema 
The phase three ISAAC study has also provided updated global data for the 
prevalence of eczema symptoms in children aged 6-7 years from 143 centres across 
60 countries of the 97 countries included (Odhiambo, Williams, Clayton, Robertson, 
& Asher, 2009). The results indicated that the prevalence of current eczema 
symptoms ranged from 0.9% in India to 22.5% in Ecuador and that lifetime reported 
eczema differed between 1.2% in Lithuania and Mexico to 38.6% in Sweden. Higher 
prevalence of current eczema (≥15%) was reported in five of the world regions 
including the UK in Western Europe. Data from this survey indicates that eczema 
(atopic dermatitis) is a major public health concern at a global level.  
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2.5. Risk factors for developing allergies  
Looking at the early origins of allergy, there is evidence that a number of familial, in 
utero, maternal nutritional and environmental factors as well as early postnatal 
feeding practices are linked to the development of these conditions. In examining this 
area, the specific number of studies mentioned related to risk factors are based on the 
search results from Pubmed and also, references of conducted systematic reviews and 
overview of systematic reviews.  
 
2.5.1. Family history and in utero environment for childhood allergy 
During pregnancy, genetic and a number of environmental factors impact on the risk 
of developing allergic diseases in the offspring.  
 
Familial history of allergic disease 
Familial history of allergic diseases is an influential risk factor in developing allergies 
in a child (Johansson et al., 2004). It is well documented that allergy can be inherited 
from first-degree relatives with allergies (Böhme, Wickman, Lennart Nordvall, 
Svartengren, & Wahlgren, 2003; Kjellman & Johansson, 1976) with additional risk in 
a child with an atopic mother (Ruiz, Kemeny, & Price, 1992). Data from studies on 
monozygotic twins suggest that the genetic heredity for asthma varies between 0.36-
0.75 with higher risk of heredity for peanut allergy at 0.82 (Koppelman, Los, & 
Postma, 1999; Sicherer et al., 2000). During pregnancy, the genetic heredity of allergy 
affects the normal function of the immune system with evident markers at birth. 
Maternal atopy influences the gene expression of regulatory T-cells (Treg) and Th2 
cytokine levels in cord blood (Liu et al., 2011), leading to an impaired balance of Treg 
to Th2 cells and consequently raised level of IgE and increased reaction to allergens 
early in life (Fu et al., 2013).  
 
Maternal obesity 
Several observational studies have assessed the association between Body Mass Index 
(BMI) and Gestational Weight Gain (GWG) during pregnancy and the development 
of childhood wheeze and asthma. A systematic review and meta-analysis investigated 
the evidence from 14 observational studies, published between 1996 to 2013 (Forno, 
Young, Kumar, Simhan, & Celedón, 2014). The included studies defined and 
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measured BMI and GWG differently and the outcomes were also varied, reported at 
various age points. The pooled results showed that maternal overweight or obesity in 
pregnancy and those with high GWG were even more at risk of having children with 
asthma or wheeze-ever, independently from offspring’s BMI (OR=1.31; 95% 
CI=1.16-1.49, 11 studies and OR=1.16; 95% CI=1.00-1.34, five studies, respectively). 
High statistical heterogeneity were found in meta-analyses and additionally, studies 
did not control for the role of potential confounders such as maternal asthma. Further 
data from large birth cohort studies have shown that maternal pre-pregnancy obesity 
and high maternal BMI in early pregnancy were associated with an increased risk of 
developing asthma/wheezing (Harskamp-Van Ginkel, London, Magnus, Gademan, & 
Vrijkotte, 2015) and asthma only in the offspring (Ekström et al., 2015); however the 
offspring’s BMI has a mediating role in this association. In general, the evidence from 
observational studies is limited due to a number of confounders that could affect the 
associations between maternal obesity and GWG in pregnancy and development of 
asthma/wheezing in offspring. In fact, the effect of maternal obesity on childhood 
asthma/wheezing could be explained by a number of direct and indirect mechanisms 
defined as either causal (e.g. atopic family history) or confounder (e.g. child’s BMI) 
factors and need to be considered in prevention strategies. 
 
Prenatal maternal smoking 
Epigenetic studies have documented that in utero tobacco exposure alters the 
expression of genes that are involved in the onset of childhood asthma (Patil et al., 
2013; Scholtens et al., 2014). The effect of exposure to tobacco smoke during 
pregnancy and developing childhood wheeze and asthma has been studied in a 
number of observational studies. Data from two cohorts on the influence of 
grandmaternal smoking during pregnancy with the mother and the risk of developing 
wheeze/asthma in their grandchildren have shown contradictory findings, with one 
study showing no effect (Miller, Henderson, Northstone, Pembrey, & Golding, 2014), 
and another study indicting a positive association (Magnus et al., 2015).  
There are currently 79 prospective studies (cohorts and cross-sectional) that 
investigated the exposure to passive smoke during pregnancy as a risk factor for 
developing childhood respiratory diseases such as wheeze and asthma. The 
publication dates of studies ranges from as early as 1985 to 2011 and reported the 
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defined outcome(s) either as current or lifetime for various age ranges. The studies 
were conducted both on at risk populations (parents with a history of asthma and/or 
allergies, low birth infants) and unselected populations. The majority of studies have 
relied on self-reported data to measure the exposure to passive tobacco smoke, and a 
few studies provided objective measures i.e. plasma cotinine (Murray et al., 2004). 
The source of exposure stated as either maternal, paternal/household or both at 
different times of prenatal, postnatal or both across studies. When estimating the 
effect of association between smoking and the development of respiratory outcomes, 
some studies controlled for the role of potential confounders such as dose-response, 
birth-weight and gestational week in children by conducting adjusted analysis 
whereas many have relied on unadjusted associations. The largest study is the Danish 
National Birth Cohort, involving 34,793 mother-child pairs, which reported that 
smoking during pregnancy, for “less than everyday” and “everyday” independently, 
predicted the risk of “wheeze ever” in children by 18 months in adjusted analysis 
(OR=1.22, 95% CI=1.01-1.49) and (OR=1.46, 95% CI=1.36-1.56) respectively 
(Linneberg, Simonsen, Petersen, Stensballe, & Benn, 2006).  
Given the large number of conducted studies and variability in their design and 
reported outcomes, it is difficult to reach a conclusive result for the association 
between smoke exposure and development of childhood wheeze and asthma based on 
individual primary studies. A number of systematic reviews have been conducted on 
the topic. The most recent review (Silvestri, Franchi, Pistorio, Petecchia, & Rusconi 
2015) included a total of 43 papers from 29 birth cohorts that were only carried out on 
unselected populations and presented the results in two age groups: infants and pre-
school children, schoolchildren and adolescents. The reviewers rated methodological 
quality of some of the included studies as poor, mainly because they did not use 
adjusted outcome measures. The meta-analysis of 13 studies showed that prenatal 
exposure to maternal smoking increased the risk of wheezing/asthma in children 
under 6 years old (OR=1.36; 95% CI=1.19-1.55). When only high-quality studies 
were included in the meta-analysis, the results remained significant. The pooled 
estimates were similar for the age of older children over 6 years for wheezing/asthma 
(OR=1.22, 95% CI=1.03-1.44). The findings from this systematic review are in 
agreement with the previous review on the topic by Burke, et al., (2012) that included 
studies on both at risk and unselected populations. Altogether, the studies included in 
this review were of a different quality and with inconsistent findings for the reported 
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outcomes; nevertheless, the results of this review provide evidence-based results of 
the current literature that prenatal smoking exposure has an influential effect on the 
risk of developing childhood respiratory diseases.  
Prenatal maternal stress (PNMS) 
Prenatal psychological stress might lead to an increased risk of childhood wheeze and 
asthma via genome-wide alterations in DNA-methylation (Trump et al., 2016). The 
role of PNMS on developing allergic conditions in children has been the interest of 
researchers worldwide. Sixteen studies have addressed the issue so far, published 
between 2004 and 2014. With the exception of two cross-sectional studies, the 
remainder were prospective cohort studies. PNMS was measured differently across 
studies including negative life events, anxiety/depression, bereavement, distress and 
job strain. Furthermore, PNMS was mostly measured subjectively using self-reported 
data in the studies and also, at different time-points in pregnancy from first to third 
trimester. All studies controlled for confounders by conducting adjusted analyses; 
however, there was a wide heterogeneity between studies for the type of covariates 
included. The largest population-based cohort from Sweden included 3.2 million 
births between 1973 and 2004, and assessed the relationship between maternal 
exposure to death of a spouse or child, either close to pregnancy time or during 
pregnancy, and risk of hospitalisation for asthma in offspring that were followed-up 
by December 2006 (Khashan et al., 2012). Its findings indicated that prenatal 
exposure to bereavement in any exposure period was related to a higher risk of 
asthma in offspring (RR=1.20; 95% CI=1.03-1.39) and there was a higher risk where 
bereavement happened during pregnancy or was related to death of a spouse.  
In order to provide a more precise understanding for the association between PNMS 
and atopic diseases in children, a systematic review has been conducted (Andersson et 
al., 2016). This review included 16 observational human studies and did not perform 
meta-analysis due to high-heterogeneity observed between studies in terms of the 
study design, exposures and outcomes. Overall, the authors reported that a positive 
association between PNMS and different atopic conditions was reported in 21 of the 
25 statistical analyses conducted in the included studies. The results of this systematic 
review suggests a role for adverse life events and stress during pregnancy in the 
development of allergic conditions in children, which could be explained by the 
immunomodulatory effects of PNMS on the foetal immune system. Future studies 
might also consider objective methods for measuring PNMS such as interview-based 
 22 
approaches, since stress is a complex concept and interviews could provide more 
reliable information on the nature of stress including the period and severity that it has 
been experienced.  
Maternal exposure to medicines 
Shaheen and colleagues investigated the potential interactions between prenatal intake 
of acetaminophen, also known as paracetamol, and maternal antioxidant genotypes on 
childhood asthma (Shaheen, Newson, Smith, & Henderson, 2010). They reported that 
the effect could be modified by maternal genotype at antioxidant-encoding genes 
proposing a causal relationship. Several pathophysiological mechanisms are also 
described for the association between paracetamol use and childhood asthma such as 
the glutathione pathway, imbalance of Th1 to Th2 ratio and anti-genetic effect 
mediated by IgE (Lourido-Cebreiro, Salgado, Valdes, & Gonzalez-Barcala, 2017). 
The use of medicines during pregnancy and their effect on childhood allergies has 
been scrutinised in a number of population-based studies. To date, there are 10 
observational studies that reported prenatal maternal use of paracetamol, as a common 
pain-reliever and anti-fever drug and its long-lasting effect on the development of 
asthma in children. The studies were conducted worldwide, published between 2002 
to 2013 involving mother-child pairs. There was a wide variation between studies 
with regard to design (cross-sectional vs. cohort), measuring the time of exposure to 
paracetamol in pregnancy (early, mid and late stages), frequency of use, controlling 
for different confounders and different follow-up time-points. The largest study from 
the Danish National Birth cohort initially involved 90,549 mothers and 12,733 
completed the final follow-up questionnaire when their child was 7 years old 
(Rebordosa, Kogevinas, Sørensen, & Olsen, 2008). Physician-diagnosed asthma at 18 
months and seven years was associated with paracetamol use at any time during 
pregnancy (RR=1.18; 95% CI=1.13-1.23) and (RR=1.15; 95% CI=1.02-1.29) 
respectively. Taking paracetamol only during the first trimester of pregnancy also 
elevated the risk of persistent wheezing at 18 months and seven years.  
A systematic review and meta-analysis was undertaken to summarise the available 
evidence on this topic, including only cohort studies that reported asthma outcomes 
after age 5 years (Cheelo et al., 2015). The review did not include data from cross-
sectional studies since these data are at higher risk of recall bias and could dominate 
the overall findings. Overall, the 11 included studies were rated as adequate for 
assessment of exposure while the assessment of outcome was not satisfactory in most 
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studies due to unadjusted analysis conducted. The meta-analysis of five studies 
showed that any use of paracetamol during the first trimester of pregnancy elevated 
the risk of childhood asthma (OR=1.39; 95% CI=1.01-1.91); however heterogeneity 
of 64.2% was observed between studies. A stronger relationship was found for 
paracetamol use during the second and third trimesters and studies were homogenous 
(OR=1.49; 95% CI=1.37-1.63, three studies). Overall the heterogeneity observed 
between studies was because those that conducted adjusted analysis included diverse 
confounders that might have attenuated the associations. To conclude, the current 
evidence for the association between maternal use of paracetamol during pregnancy 
and developing asthma is not definitive since several primary and secondary 
confounders could affect this association such as recall bias, smoke exposure and 
respiratory tract infections.  
 
Studies have also looked at the impact of acid-suppressive drugs during pregnancy, 
Proton Pump Inhibitors (PPIs) and Histamine 2-Receptor Antagonists (H2RAs), on 
development of childhood asthma and other allergic diseases in the offspring. Whilst 
data from some birth cohorts reported an increased risk in unadjusted analysis for 
asthma and other allergic diseases in the offspring (Andersen et al., 2012; Källén, 
Finnström, Nygren, & Otterblad Olausson, 2013; Mulder et al., 2014) a very recent 
study from the Health Improvement Network in the UK on pregnancies between 
January 1996 to December 2010 showed no significant association for PPIs but only 
for H2RAs, after adjusting for the underlying covariates (Cea Soriano, Hernández-
Díaz, Johansson, Nagy, & García-Rodríguez, 2016).  
Furthermore, a birth cohort from Italy evaluated the role of prenatal exposure to 
antibiotics and development of wheezing in the offspring and reported only third 
trimester exposure was associated with an increased risk of “ever and recurrent 
wheezing” and the effect was attenuated in adjusted analysis (Popovic et al., 2016). 
Altogether, these findings emphasis the fact that when interpreting the results of in 
utero exposure to medicines on later childhood allergic diseases, the intrinsic 
limitations such as differences between study design/power as well as the role of 
diverse confounders including maternal comorbidities, genetic and environmental 
factors due to nature of observational studies need to be considered. The current 
evidence is therefore not definitive and cannot warrant changing the guidelines. 
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2.5.2. Maternal diet during pregnancy and development of childhood 
allergies  
Data on the effect of prenatal diet and development of allergic diseases in offspring 
primarily originated from observational studies and thus could largely be biased by a 
range of confounding factors. Nevertheless, these findings highlight the role of 
epigenetic mechanisms through which maternal diet during pregnancy may influence 
foetal gene expression and the development of immune system and metabolic 
function in children.  
 
Restricted maternal diet during pregnancy could predict the development of allergic 
diseases later in life. Data from a cohort of pregnant women exposed to famine in the 
Netherlands during World War II showed that under-nutrition in early and mid 
gestation increased the risk of obstructive airway disease but not IgE concentrations 
or lung function in children (Lopuhaä et al., 2000). This finding is further supported 
by animal studies showing that protein restriction in rats had an adverse effect on 
respiratory development in their pups (Pike et al., 2014).  
    
Numerous observational studies have assessed the possible association between 
prenatal nutrition during pregnancy and childhood allergic conditions. There are 
currently 65 papers published from 1990 to 2014, involving a range of sample sizes 
and various designs: cross-sectional, case-control and cohort studies. There are wide 
variations between studies in terms of the type and definition of diet since many have 
only measured intake of individual food items/micronutrients or consumption of 
specific food group(s), and others assessed dietary patterns. In addition, only a few 
studies have conducted adjusted analyses, considering the role of confounders. 
Moreover, many studies did not systemically record diet during pregnancy, using 
daily register or Food Frequency Questionnaire(s) (FFQ), and some only collected 
and/or reported data on individual nutrient intakes. In addition, only a handful of 
studies have comprehensively assessed maternal dietary intake accompanied by 
analysing relevant biological markers, either in mother or infant. Likewise, the 
definition/description of outcomes are largely varied across studies and they report 
various follow-up durations. Finally, the associations between consumption of 
different foods or food groups have been inconsistent and contradictory across 
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studies, possibly because of inconsistencies between the defined foods or food groups. 
The largest prospective birth cohort is from Denmark, including 60,466 mother-child 
pairs and collected data on Vitamins A, E and K, using validated FFQ in mid 
pregnancy. This study showed that “ever admitted asthma” and “current asthma” were 
related with maternal total Vitamin K intake (highest quintile (Q) vs. lowest: 1.23; 
95% CI=1.01-1.50) and (Q5 vs. Q1: 1.30; 95% CI=0.99-1.70) respectively (Maslova, 
Hansen, Strom, Halldorsson, & Olsen, 2014). Consumption of Vitamin A and E 
during pregnancy in this study showed a weak inverse association with childhood 
allergic rhinitis. Studies on maternal dietary patterns during pregnancy have also 
defined different terminology and reported diverse findings. The largest study was the 
Avon longitudinal study, in the UK that investigated the association between overall 
dietary patterns in pregnancy using FFQ completed at 32-weeks of pregnancy and 
allergic outcomes in offspring (Shaheen, et al., 2009). The study involved 14,062 
mother-child pairs and results did not show any associations between dietary patterns 
and allergic outcomes, adjusted for relevant confounders. To reach a conclusive 
result, meta-analyses have been conducted to systematically evaluate the current body 
of evidence for probable associations between maternal diet during pregnancy and 
development of allergies in offspring. The most recent systematic review included 
only cohort studies (a total of 32 birth cohorts: 29 prospective and 3 retrospective) 
that objectively assessed maternal nutrition during pregnancy using systematic 
recording and reporting development of childhood asthma, wheezing, eczema and 
other atopic conditions (Beckhaus et al., 2015). The overall quality of included studies 
was judged as good and satisfactory; however most studies were rated as inadequate 
for the outcome assessment and follow-up. The review evaluated the associations 
between consumption of a range of micronutrients (vitamins, magnesium, zinc, 
selenium, etc.), fruits, vegetables, fish, meat, dairy, fats, Mediterranean diet and other 
dietary patterns as well as sweetened beverages during pregnancy across cohorts and 
development of childhood allergies. Pooled estimates of meta-analyses indicated that 
prenatal intake of Vitamin D (OR=0.58, 95% CI=0.38-0.88, four studies); Vitamin E 
(OR=0.6; 95% CI=0.46-0.78, five studies) and Zinc (OR=0.62; 95% CI=0.40=0.97, 
three studies) during pregnancy were protective against development of childhood 
wheeze. The results of this review did not find any associations between consumption 
of these or other foods/nutrients/dietary patterns and development of other childhood 
allergies. Another systematic review that included 42 studies with different designs 
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(12 cohorts, four case-control and 26 cross-sectional studies) only investigated the 
evidence for intake of fruit and vegetables during pregnancy and risk of wheezing and 
asthma in children (Seyedrezazadeh et al., 2014). The sub-group meta-analyses for 
the study design and fruit/vegetable categories indicated that highest intake of fruits 
and vegetables during pregnancy, in either study designs, were protective against 
childhood wheeze but not asthma. Collectively, the current evidence for the role of 
maternal diet during pregnancy and the development of allergic disorders in offspring 
is limited due to high heterogeneity between studies and few studies that could 
contribute in meta-analyses. This stresses the need for further robust adequately 
powered epidemiological studies and ideally, standard definition of food groups as 
well as nutritional patterns. In addition, diet needs to be assessed using validated 
dietary methods and preferably be linked to the dietary assessments with biological 
analysis. More importantly, there is a paucity of evidence from RCTs that could 
potentially address the role of maternal nutritional factors during pregnancy for 
prevention of childhood allergies. 
2.5.3. Breast-feeding practices and development of childhood allergies  
The role of breast-feeding and the prevention of allergic diseases has been assessed in 
several observational studies and to date the evidence is not conclusive. This reflects 
the discrepancies between the studies with regard to their methodological quality and 
design as well as the role of confounding factors such as duration of breast-feeding, 
weaning practices, cultural practices in different populations and definition of allergic 
outcomes. Another key issue in studies of this type is the need to rely on 
observational data alone, as the exposure to breast-feeding cannot be randomised.  
 
To date, there are 89 observational studies that have assessed whether breast-feeding 
could influence developing asthma and allergic outcomes in children. The studies are 
of different designs, mainly cohorts as well as cross-sectional and case-control, 
published between 1981 to 2016. The samples in studies were of small to large scale 
and of either at risk or unselected population. There are wide variations between 
studies with regard to measurement of exposure to breast-feeding and its duration, 
definition of outcomes and also, duration of follow-up. In addition, substantial 
heterogeneity exists between studies for controlling the key confounders such as 
socio-economic status and family history of allergic diseases. The largest study is 
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conducted on two national British birth cohorts and retrospectively investigated the 
occurrence of wheezing and asthma illness at age 16 in 20,528 children (Lewis et al., 
1996). This study did not show a significant association between breast-feeding 
duration and asthma and/or wheezy bronchitis, in adjusted analyses for risk factors 
including birth weight and social class. A systematic review and meta-analysis has 
been conducted to systematically analyse the possible effects of breast-feeding on 
prevention of childhood allergies, providing an update to the current knowledge in the 
field (Lodge et al., 2015). This review included 89 observational studies, which 
comprised of 53 cohort, 33 cross-sectional and 3 case-control studies. The reviewers 
judged that the evidence from cohort studies were of better quality compared to other 
study designs and generally, the cohorts and case-control studies were rated as 
satisfactory to very good quality. Meta-analysis of 29 cohort, cross-sectional and 
case-control studies showed that duration of breast-feeding, defined as more versus 
less, was protective against development of childhood asthma in 5-18 years of age 
(OR=0.90; 95% CI=0.84-0.97); however heterogeneity of 63% was observed between 
the included studies. Further subgroup analyses of studies by country income revealed 
some evidence of a reduced risk for asthma at ages 5-18 years with higher duration of 
breast-feeding in high-income countries although the effect was more prominent in 
low and middle-income countries (OR=0.86; 95% CI=0.79-0.94). In addition, pooled 
estimate from five studies stratified by familial history of allergies did not find an 
association between duration of breast-feeding and developing asthma at 5-18 years. 
Pooled estimates for other allergic outcomes showed that breast-feeding also 
decreased the risk of developing allergic rhinitis by ≤5 years of age and eczema by ≤2 
years of age; however, high statistical heterogeneity (≥70) was found between studies.  
 
More recent data from the Prediction of Allergies in Taiwanese Children (PATCH) 
birth cohort reported the effect of breast-feeding on developing childhood allergies 
(Chiu et al., 2016). The study enrolled 189 children and the follow-up results by 4 
years of age showed that exclusive or partial breast-feeding for ≥6 months was 
associated with lower rate of sensitisation to milk and also eczema in children, only at 
ages 1 and 1.5 years. The findings from this study also highlights how the sample, 
exposure and outcome of interest can be defined differently in the conducted studies 
and therefore, formulating conclusive results is difficult. To summarise, the evidence 
for the influence of breast-feeding on allergic diseases in offspring is weak and this is 
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mainly due to high heterogeneity observed between the conducted studies including 
study design and confounding factors. Measurement of breast-feeding could be at risk 
of recall bias in cross-sectional studies, and more particularly for allergic outcomes 
measured later in life such as asthma. Generally speaking, the effect of breast-feeding 
on allergy is complicated by many factors, including timing of the introduction and 
type of solid foods (Grimshaw et al., 2013). Population-based studies need to address 
these confounding factors in order to provide a better understanding for the role of 
breast-feeding on developing allergic diseases in children. 
2.5.4. Introduction of solid foods and development of childhood allergies  
Complementary feeding by introduction of solid foods into an infant’s diet, known as 
weaning in the UK, is a significant landmark in the growth process of children. 
Throughout this thesis, the terms complementary feeding and weaning will be used 
interchangeably to describe this process. An overview of the recommendations for 
infant feeding advice and practices have changed considerably during the last decades 
as described below: 
 1900: late introduction of solids by 1 year 
 1960s: early introduction of solids <4 months 
 1970s: delayed solids >4 months 
 1990: delayed solids >6 months 
It has also been a common practice that the introduction of specific allergenic foods 
needs to be delayed by up to 3 years. Currently, the Global Strategy for Infant and 
Young Child Feeding, provided by the World Health Organisation (WHO), 
recommends that infants need to be exclusively breast fed during the first 6 months of 
life and commencing nutritive complementary foods afterwards (World Health 
Orgnisation, 2003) and continued breast-feeding up to 2 years and beyond if possible 
(World Health Organisation, 2011). This strategy has been adopted by the UK 
government, which encourages parents with a more pragmatic approach of around 6 
months of exclusive breast-feeding, but the introduction of solids should not be 
started earlier than 17 weeks of age (Department of Health, 2003). 
 
Whilst current guidelines advise starting solid foods between 4-6 months, with a 
variety including iron rich foods, there are concerns regarding the delayed timing of 
high allergenic foods beyond 4 or 6 months. The existing infant feeding information 
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leaflet for parents in the UK advises that if complementary foods are introduced 
earlier than 6 months of age, some potentially allergenic foods should be avoided 
(Department of Health, 2008). During the last decades, cumulative evidence from 
observational and interventional studies combined with a rising trend of food allergies 
has raised concerns about the beneficial effect of delayed introduction of highly 
allergenic foods. As a result, and despite there being no clear guidance for the optimal 
age of timing of introduction, current guidelines for primary prevention of food 
allergy do not advise late introduction of allergenic foods (Chan et al., 2014; 
Fleischer, Spergel, Assa, & Pongracic, 2013; Muraro et al., 2014). 
 
The influence of timing of allergenic food introduction to the infant’s diet on 
developing allergies in children has been examined in numerous observational and 
RCTs. There have been around 69 observational studies with different designs of 55 
cohort, 2 nested case control studies, 12 case-control or cross-sectional studies, 
published between 1979 to 2015. Studies were conducted at high risk (atopic) or 
unselected (non-atopic) population. Exposure was assessed to introduction of a single 
or multiple high allergenic foods such as cow’s milk, egg, fish and reported various 
outcome measures for varied age ranges. There were high heterogeneities between 
studies for defining and assessment of outcome as well as adjustment for potential 
confounders. The largest cohort study from Israel investigated early exposure to 
cow’s milk protein in 13,019 infants by telephone interviews and assessed occurrence 
of allergic outcomes using SPTs or oral challenge (Katz et al., 2010). The study 
findings showed that regular consumption of cow’s milk in the first 14 days of life 
was related to a lower risk of developing cow’s milk allergy. Given the large number 
of studies and inconsistencies between the reported outcomes, a systematic review 
and meta-analysis appraised the evidence from observational studies on how the 
timing of introduction of allergenic foods during infancy may influence the risk of 
childhood allergic diseases (Ierodiakonou et al., 2016). The reviewers judged the 
methodological quality of many of the included studies as low for outcome 
assessment and adjustment for potential confounders. In total, timing of fish 
introduction between 6-9 months and developing food allergy was reported in three 
studies. Because of statistical heterogeneity, it was not possible to conduct a meta-
analysis; nevertheless, findings of all the three studies reported that early fish 
introduction was associated with lower risk of allergic sensitisation to any allergen or 
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food allergens. Pooled estimate of four cohort studies in meta-analyses for fish 
introduction before 6-12 months showed a lower risk for allergic rhinitis either at ≤4 
years (OR=0.59; 95% CI=0.40-0.87) or 5-14 years (OR=0.68; 95% CI=0.47-0.98). In 
addition, meta-analysis of three cohort studies showed an association between fish 
introduction between 8-12 months and reduced risk of recurrent wheeze at ≤4 years 
(OR=0.72; 95% CI=0.59-0.87). Despite the fact that the meta-analyses indicate there 
is an association between fish introduction early in life and development of allergies 
in children, even pooled, these studies are small and therefore the evidence is not 
robust. Timing of introduction of other allergenic foods was not associated with 
developing childhood food allergy, allergic sensitisation or rhinitis and wheeze. The 
reviewers also reported that timing of allergenic food introduction and risk of eczema 
was not consistent across the observational studies and did not conduct meta-analyses. 
To summarise, the current evidence from observational studies for timing of 
allergenic food introduction and development of food allergies is not certain mainly 
because of high heterogeneity between studies and the small number of studies 
contributing to meta-analyses. 
 
There are 24 RCTs that evaluated the efficacy of early introduction of highly 
allergenic foods in infants and prevention of allergic diseases. The studies were 
published between 1966 to 2016 and conducted on at high-risk or unselected 
population. These RCTs either introduced multiple or single allergenic foods and the 
duration of intervention varied from early short-term to early sustained introduction to 
trials of delayed allergenic food. Some interventions were also multifaceted where 
dietary components were administered together with environmental control measures 
such as house dust mite avoidance and tobacco smoke. Most studies compared cow’s 
milk versus soya milk formula and additionally, many intervention studies for egg 
introduction and developing egg allergy only published abstracts and did not share 
full trial findings. Furthermore, the outcome measures were defined and measured 
differently across studies and reported at various age points. The largest open-label 
controlled trial was conducted in the US and allocated at birth 1,750 Caucasian 
children, with a positive or negative family history of allergic diseases, to breast-feed 
versus either cow’s milk or soya milk groups for six months (Halpern et al., 1973). 
Half of the babies, regardless of their family history of allergies, were also allocated 
to take egg yolk before 3 weeks with the other half after 6 months. A physician 
 31 
assessed the outcome when the children were 7 years old and the incidence of allergy 
was similar between breast-fed infants with the two other substitute formula groups. 
The development of allergies was also comparable in the egg yolk groups. Also, 
Learning Early About Peanut Allergy (LEAP) was the first open-label RCT to assess 
the efficacy of early introduction of dietary peanut in 640 high-risk infants between 4-
11 months as a primary prevention strategy (Du Toit et al., 2015). This study showed 
the risk of developing peanut allergy (assessed by food challenges) at 5 years was 
lower in the peanut consumption group compared to the avoidance group (13.7% vs. 
1.9%), corresponding to 11.8% absolute difference in risk (95% CI=3.4-20.3). The 
inconsistencies between the conducted RCTs have prompted researchers to conduct a 
systematic evaluation of the current literature and Ierodiakonou and colleagues (2016) 
also included RCTs in their review. The reviewers rated the methodological quality of 
included interventional studies as low in almost 42% of studies because of selection 
(biased selection of individuals, thus affecting proper randomisation) and attrition 
(unequal loss of participants) bias as well as assessment of outcome(s). Of note, the 
study by Halpern et al. (1973) was not included in the meta-analyses since the paper 
did not report denominators for outcome data. The meta-analysis of evidence on five 
interventions, with a moderate heterogeneity, indicated that early introduction to egg 
between 4-6 months compared to later introduction decreased the risk of egg allergy 
(RR=0.56; 95% CI=0.36-0.87). The sensitivity analysis conducted by excluding 
studies with only abstract publication yielded comparable results. The pooled estimate 
from four trials did not show an association between timing of egg introduction and 
egg sensitisation. Because there were sufficient egg introduction studies, the 
reviewers conducted a further heterogeneity-adjusted trial sequential analysis and 
reported that further large trials are needed to conclude that early egg introduction 
lowers the risk of childhood egg allergy by at least 30% (relative risk). Moreover, 
meta-analysis of two RCTS indicated there was a protective effect from introducing 
peanut between 4 to 11 months compared to later introduction and developing peanut 
allergy (RR=0.29; 95% CI=0.11=0.74); however high heterogeneity of 66% was 
found. In general, no associations were found for timing of introduction of cow’s milk 
or other allergenic foods and, individual allergenic food with developing childhood 
food allergy or allergic sensitisation. In addition, timing of allergenic food 
introduction was not associated with the risk of allergic rhinitis, wheeze and eczema 
in the offspring. Collectively, data from this systematic review showed statistically 
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significant associations only for egg and peanut allergies in offspring. The results of 
heterogeneity-adjusted trial sequential analysis for egg introduction trials warrant 
further trials to quantify the scale of treatment effect. Although there were a small 
number of studies included in meta-analyses and the studied populations and 
interventions were varied across trials the results of this review provides an evidence-
base that suggests current guidelines may need to revise their advice for delayed 
introduction of some allergenic foods.   
 
Emerging evidence from conducted research is, to some extent, translated into clinical 
practice. The National Institute of Allergy and Infectious Disease (NIAID) have 
included an addendum to their guideline recommending high-risk children need to be 
introduced to peanut-containing foods as early as 4-6 months of age; however, it 
concluded that the current evidence regarding early introduction of egg in not 
sufficient (Togias et al., 2017). The recent Scientific Advisory Committee on 
Nutrition (SACN) report in the UK suggested that exclusive breast-feeding to around 
6 months old in children should remain as before, and the introduction of peanut 
and/or egg needs to start along with other solids (Scientific Advisory Committee on 
Nutrition, 2017). It appears the weaning debate about early introduction of allergenic 
foods continues; however the consistent messages are: being developmentally ready is 
the crucial step to start weaning; introduction of allergenic food need not be delayed; 
and once introduced, allergenic food should be continued to reduce the risk of food 
allergies.  
 
2.5.5. Postnatal environmental factors and development of childhood 
allergies 
A number of indoor and outdoor environmental factors in early life are also deemed 
to be risk factors for developing allergic disorders later in life.  
Postnatal smoking 
Postnatal exposure to either maternal or parental smoking and risk of developing 
asthma and wheezing in offspring was investigated in 29 observational studies (cohort 
and cross-sectional), published between 1989 to 2001. Studies are of small to large 
scale, conducted on at risk and unselected populations, defined and measured 
exposure to smoking as well as the outcomes differently. The effect estimates for the 
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associations between smoking and developing asthma/wheeze were reported either 
unadjusted or adjusted for varied confounders and reported for various age groups. A 
systematic review and meta-analysis conducted by Silvestri and colleagues (Silvestri, 
et al., 2015) assessed the evidence only from 19 cohort studies that reported exposure 
to postnatal smoking and development of asthma/wheeze in offspring. Pooled 
estimates of meta-analyses for postnatal exposure to maternal and parental smoking 
separately showed an increased risk for wheezing in the past 12 months (OR=1.21; 
95% CI=1.13.1.31, eight studies) and (OR=1.30; 95% CI=1.13-1.51, seven studies) 
respectively. Also, eight studies investigated the association between postnatal smoke 
exposure and asthma or wheezing in schoolchildren and adolescence. There were 
large inconsistencies between these studies with regards to exposure and outcome and 
therefore, it was not possible to conduct a meta-analysis. Collectively, these data 
originate from observational studies that relied on self-reported data and therefore, are 
exposed to recall bias and misclassification of smoking behaviour that could have 
underestimated the effects of postnatal smoke exposure. Large statistical 
heterogeneity was also found between the included studies in meta-analyses. This 
systematic review only included cohort studies as the strongest observational study 
design that are less exposed to different types of bias than cross-sectional studies; 
nevertheless heterogeneity in the included studies such as measures of exposure and 
outcome did not allow estimating the pooled effect for longer term effects of postnatal 
smoke exposure and childhood asthma and /or wheeze. This highlights the need for 
larger cohort studies that could assess the longer-term effects of postnatal exposure 
and childhood asthma/wheeze. 
 
Living environment (the farm-effect) 
Documented evidence suggests maternal farm exposure during pregnancy regulates 
immunomodulatory responses in the offspring, which is linked to an elevation in the 
number and function of Treg cells in cord blood resulting in suppression of pro-allergic 
immune responses i.e. TH2 cytokines (Schaub et al., 2009). The role of underlying 
immunologic mechanisms of postnatal farm exposure on the risk of developing 
childhood allergies is also assessed in the Protection against Allergy: Study in Rural 
Environments (PASTURE) birth cohort in a sub-sample of farm-exposed versus non-
farm-exposed children at 4.5 years from 5 European countries (Lluis et al., 2014). The 
study findings verified that farming environment and particularly intake of farm milk 
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increases the Treg cell numbers and activated T-cell-numbers that is inversely 
associated with childhood atopic sensitisation and asthma. Over 50 epidemiological 
studies have examined the associations between growing-up on a farm and childhood 
and/or adulthood wheeze/asthma and allergic sensitisation. Studies are of small to 
large scale, published as early as 1999 and are mainly cross-sectional. Across studies, 
exposure to farm living were measured differently (farm residence, parental 
occupation or combination) and the definition and measurement of outcome varied. 
The disease prevalence data reported for different age groups and the effect estimates 
were controlled for confounders such as age, gender, and familial history in few of the 
studies, and different associations reported. The largest study was conducted in rural 
regions of Germany, Austria and Switzerland and is part of the multidisciplinary 
study to identify the genetic and environmental causes of asthma in these European 
countries (Loss et al., 2011). The study investigated the effect of farm milk 
consumption and other farm-related exposures among 8,334 school-aged children and 
serum samples were provided by 7,606 to assess sIgE levels. Consumption of raw 
milk showed protective associations, independent from other farm-exposures with 
developing childhood asthma, atopy and hay fever (adjusted OR=0.59, 0.74 and 0.51 
respectively). Intake of boiled farm milk as well as viable bacterial count and total fat 
content of milk did not show significant associations whereas increased levels of the 
whey proteins Bovine Serum Albumin (BSA), alpha-lactalbumin and beta-
lactoglobulin reduced the risk of developing asthma but not atopy.  
 
A systematic review and meta-analysis was conducted to assess the evidence for the 
farm-effect from a range of epidemiological studies (Genuneit, 2012). The review 
included 39 studies published by September 2011. Methodological flaws were 
reported in the included studies such as sample size and reporting of crude estimates. 
Meta-analyses of 11 studies showed a protective effect of farm-residence on doctor-
diagnosed asthma (OR=0.77; 95% CI=0.60-0.99); however high statistical 
heterogeneity of 68% was observed between the included studies. Pooled estimates of 
all studies which defined farm-exposure differently also yielded similar results with 
higher heterogeneity of 76%. Including only studies with a good methodological 
quality, conducted in and around the Alps in Europe, decreased the between study 
heterogeneity for doctor-diagnosed asthma (52%) and current wheeze (0%). 
Altogether, current evidence confirms the farm-effect as a protective factor for 
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childhood allergies despite various sources of heterogeneity between the conducted 
studies. It can be hypothesised that early contact with livestock and consuming 
unprocessed cow’s milk leads to a much more diverse microbiom in children living 
on a farm which is a strong protector for asthma and other allergies. Further research 
could address the sources of heterogeneity across studies more rigorously, assessing 
the farm-effect on sub-phenotypes of asthma and allergies. 
 
Other living environmental exposures 
Several epidemiological studies, published as early as 1995, have investigated 
whether pet ownership could be related to developing childhood asthma and/or 
allergic sensitisation. Many studies are cross-sectional, conducted among various 
populations from small to larger scale and defined various classifications of exposure. 
Diverse findings have been reported from these studies, and few considered the role 
of confounders; therefore, it is difficult to make a definite conclusion on the 
association. Here, data are reported from birth cohorts that are exposed to lower bias 
and could report more reliable data. A US birth cohort study, the Childhood Origins 
of Asthma (COAST) study, assessed the role of dog ownership in 289 children with a 
familial history of allergies, by 3 years age (Bufford et al., 2008). The results showed 
that dog exposure in infancy and particularly around birth reduced the risk of 
developing AD and wheeze and it was also associated with changes in immune 
development such as Interleukin-5 (IL-5) and IL-13 responses. The findings from this 
study are limited because it involved a small sample of children at risk of developing 
allergies and the findings cannot be generalised to other populations.  
 
To advance the current understanding on this topic, a systematic review and meta-
analysis of a large database from 11 European birth cohorts examined the relationship 
between exposure to pets in early childhood and development of childhood allergies 
by 6-10 years age (Lødrup Carlsen et al., 2012). The heterogeneities between studies 
for the definition of exposure and outcome reported for various age groups was 
minimised in this review since the reviewers were able to collect and combine 
individual participant data from 11 birth cohorts rather than using published risk 
estimates. The pooled estimates of the 11 studies did not find an association between 
any pet ownership (cats, dogs, birds and rodents) during the first 2 years of life and 
development of asthma, allergic asthma or allergic rhinitis at school age, comparable 
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results were shown for children with and without allergies. There was some evidence 
that keeping furry pets could prevent sensitisation to aeroallergens. Collectively, data 
from this review could have been biased by the method of data collection because 
some cohorts relied on parent-reported questionnaires for allergic diseases and 
additionally, number of pets at home was not asked for in most cohorts. Another point 
is the cultural differences as well as different life-styles could affect keeping some 
specific types of pets and this could limit findings from different populations. Further 
analyses combining large birth cohorts from different regions might provide stronger 
evidence for the association between early pet exposure and developing childhood 
allergies.  
 
Indoor exposure to mould and dampness in early life as a risk factor in developing 
childhood allergies has also been studied in over 70 epidemiological studies. Most 
studies have reported the exposure response relationships, whilst some reported 
exposure to mold endotoxins. The studies are of various designs (cohorts, case-
control, cross-sectional), from small to large scale and conducted on at risk or 
unselected populations. The definition of outcome and its measurement varied across 
studies and were reported at different age points. The Pollution and the Young 
(PATY) study is the largest survey that assessed exposure to visible indoor mold and 
childhood respiratory health from 12 cross-sectional studies conducted in Russia, 
North America and 10 Eastern and Western European countries (Antova et al., 2008). 
Exposure to mold showed a direct association with developing respiratory diseases in 
children, including nocturnal and morning cough in adjusted analyses and the 
associations were consistent across studies. Considering the diversity of the reported 
outcomes in conducted studies, there is no clear direction for the associations between 
mold exposure and childhood allergies. A systematic review and meta-analysis of 
studies published “between January 1980 to July 2010” assessed the association 
between domestic mold and mold components with childhood asthma and allergies 
(Tischer, Chen, & Heinrich, 2011). The review included 61 studies of different 
designs that only reported exposure response relationships. Pooled estimate of 
different study designs showed that domestic visible mold exposure was associated 
with an increased risk of childhood asthma (OR=1.49; 95% CI=1.28-1.72, 21 studies), 
wheeze (OR=1.68; 95% CI=1.48-1.90, 19 studies) and allergic rhinitis (OR=1.39; 
95% CI=1.28-1.51, 10 studies). The result for exposure to mould-derived components 
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and allergic diseases in children remains inconclusive because there were a small 
number of studies and it was not possible to conduct a meta-analysis. To summarise, 
the findings from this review might be limited by including various study designs and 
allergic outcomes measured for different age groups; nevertheless the findings 
indicate a positive association between exposure to mold and development of 
childhood allergies. Further research might address measuring specific microbial 
biomarkers at home using longitudinal studies with longer follow-ups to allow for 
better measurement of longer-term health effects in children.  
2.6. Prenatal nutritional approaches for prevention of 
childhood allergies 
The focus of first studies in this PhD research (the systematic reviews) has been on 
nutritional interventions during pregnancy and the prevention of allergic disorders. 
The inclusion criteria for interventions were that they solely started during pregnancy 
and could either terminated at delivery or continued after birth in mothers, infant or 
both. Therefore postnatal nutritional interventions either in infants or mothers e.g. 
consuming hydrolised formula, maternal exclusion diets during lactation are beyond 
the scope of this PhD and not discussed in the following sections. 
2.6.1. Dietary restrictions for pregnant women 
For decades the primary prevention of allergic disorders in infants was reliant on the 
concept of reducing or completely avoiding highly allergenic foods such as dairy 
products and peanuts during pregnancy particularly in women with a family history of 
atopy. It was believed that prenatal exposure to allergenic foods could have 
modulating effects on the programming of the immune system in the growing foetus 
leading to sensitisation (Zeiger, 2003) and therefore an elimination diet during 
pregnancy could curtail developing allergies early in life. Although there is good 
evidence that food allergens from maternal diet could cross the placenta, the 
mechanisms of foetal immune responses to food allergens is not well understood 
(Edelbauer et al., 2004). Moreover, the current evidence from a systematic review on 
reduction or avoidance interventions during pregnancy for prevention of allergies has 
questioned the significance of these strategies (Kramer & Kakuma, 2012). Growing 
evidence suggests that early exposure to allergens could protect against the 
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development of allergies in infants (Bunyavanich et al., 2014; Frazier, Camargo, 
Malspeis, Willett, & Young, 2014; Young, 2015). 
  
For the purpose of this PhD, a systematic review of prenatal interventions on the 
modification of diet during pregnancy was conducted using a different inclusion 
criteria to the existing systematic review (Kramer & Kakuma, 2012). 
2.6.2. Nutritional interventions during pregnancy  
A number of prenatal nutritional approaches have been introduced for prevention of 
allergies in infants. To avoided bias caused by selecting specific dietary interventions, 
all interventions were included in the review i.e. probiotics, fatty acids and vitamins. 
 
Foetal origins of allergy indicate that infants with allergy have an altered balance of 
gut microorganisms early in life (Nauta, Ben Amor, Knol, Garssen, & van der Beek, 
2013), and it is thought that this may lead to them developing other allergic outcomes 
such as asthma (Abrahamsson et al., 2014) and atopy later in life (Fujimura et al., 
2016). Since early exposure to the maternal microbiom in infants starts during 
pregnancy and continues through delivery until after birth, the microbial diversity in 
mothers plays an important role in the healthy balance of microorganisms and 
development of immune system in infants (Rautava, Luoto, Salminen, & Isolauri, 
2012). This has prompted an interest in whether early interventions involving 
probiotics in pregnant women might promote developing a healthy immune system in 
the foetus, with an impact on subsequent risk of allergic diseases in infants (Nylund et 
al., 2013; Renz, Brandtzaeg, & Hornef, 2012). 
 
The Long-Chain Poly-Unsaturated Fatty acids (PUFAs) family, mostly known by 
omega-3 (n-3) and omega-6 (n-6) products, are involved in immune-regulation and 
inflammatory pathways (Tilley, Coffman, & Koller, 2001). The n-3 fatty acids 
include Eicosapentaenoic Acid (EPA), Dococapentaenoic Acid (DPA) and 
Docosahexanoic Acid (DHA), and are recognised as having anti-inflammatory 
properties. The n-6 fatty acids, principally Arachidonic Acid (AA), are identified as 
having pro-inflammatory effects (Calder, 2011, 2014). Western diet is mainly shifted 
towards higher intake of n-6 PUFAs by increased consumption of vegetable oils and a 
corresponding decrease in intake of foods rich in n-3 PUFAs e.g. seafood and oily 
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fish. Higher concentrations of AA (n-6 PUFAs) promote the production of 
inflammatory mediators such as prostaglandins and leukotriene, which compete with 
the synthesis of EPA in cellular phospholipids membranes. Subsequently, a diet rich 
in sources of EPA and DHA could lead to a reduction in inflammatory mediators and 
also alter the balance of TH1 to TH2 (Meydani et al., 1991; Thies et al., 2001; Trebble, 
Wootton, Miles, & Mullee, 2003), a recognised hallmark of allergic diseases. 
Furthermore, observational studies summarised in a narrative systematic review 
(Kremmyda et al., 2011) has shown an association between lower levels of oily fish 
intake during pregnancy and the development of allergies in children. Collectively, 
these data suggest that n-3 fatty acid supplementation during pregnancy may hold 
promise as a strategy to reduce childhood allergies.  
Vitamin D plays an important role in the immune system and also the development 
and function of lung, and a recent review including both animal models and human 
studies discussed the many roles that Vitamin D could promise for the prevention of 
allergic diseases (Litonjua, 2009). Animal models have also shown that intake of 
antioxidants such as vitamin C might protect the growth and development of lung in 
infants exposed to maternal nicotine (Maritz & Rayise, 2011). Moreover, data from a 
systematic review on observational studies indicated that consumption of vitamins is 
associated with a lower risk of allergic diseases (Nwaru et al., 2014). More recent 
observational studies have also proposed the potential that Vitamin D could prevent 
allergic respiratory diseases and other allergies (Baız Nour, Dargent-Molina, Wark, 
Souberbielle, Annesi-Maesano, & Parkville, 2014; Chawes et al., 2014; Jones, 
Palmer, Zhang, & Prescott, 2012; Morales et al., 2012). Together, these data form the 
foundation of the hypothesis that intake of vitamins in pregnant women could protect 
against developing asthma and other allergic diseases in the offspring. 
2.6.3. Summary of the literature review for allergic diseases 
Allergic diseases are complex conditions and are a product of hereditary tendency 
along with numerous dietary and environmental exposures including contact with 
allergens. This multifactorial mechanism for developing allergies suggests that gene 
expression involved in developing allergies could largely be regulated in response to 
environmental stimuli, termed epigenetics. Although there is a gap in our current 
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understanding of the whole range of factors, exposures and interactional effects in 
allergy risk, appreciating the multifaceted nature of allergies points out the 
importance of very early preventive interventions as well as early development of 
therapeutic approaches in at risk infants (Lockett, Huoman, & Holloway, 2015).  
2.7. Obesity in children 
The word “obesity” first appeared in the English language in the 17th century as a 
descriptive word for excessive fatness (Eknoyan, 2006). Excessive accumulation of 
fat in the body that could impair an individual’s health is defined as obesity (The 
World Health Organisation, 2014). The identification of obesity as a condition that 
could cause pathophysiological complications dates back a century to when its health 
consequences were first recognised (Beller, 1977; Bray, 1973). In theory, obesity as 
an actual disease was first recognised by the WHO in 1948, including it in the 
International Classification of Diseases (ICD) (James, 2008).  
 
The exponential rise in the incidence of obesity over the past few decades has led 
WHO to declare it as a global public health crisis demanding immediate actions (The 
World Health Organisation, 2005). Obesity rates have almost doubled since 1980 with 
an estimated 13% of the world’s adult population being obese in 2014 (The World 
Health Organisation, 2014). A systematic review of published papers from 1990 to 
June 2009 estimated that the global direct costs of obesity is between 0.7-2.8% of a 
country’s total healthcare costs (Withrow & Alter, 2011). In the UK, the overall 
number of obese people has tripled throughout the last 20 years (Natioanl Audit 
Office, 2001), based on the recent data, the financial burden on the NHS of being 
overweight or obese is estimated about £5.1 billion (Scarborough et al., 2011). 
Meanwhile, the indirect costs of obesity to businesses are also important due to poor 
productivity and absence from work (Butland et al., 2007).  
 
High prevalence of childhood obesity is a serious public health issue and is reported 
as a potential risk factor for a range of morbidities and medical conditions that occur 
later in life (European Association for the Study of Obesity, 2015; Kipping, Jago, & 
Lawlor, 2008). The latest figures of the National Child Measurement Programme 
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(NCMP) in the UK showed that 19.1% and 14.2% of children aged 10-11 years were 
obese and overweight respectively (Lifestyle statistical team, 2015). This programme 
also reports that 9.1% and 12.8% of children at 4-5 years are obese and overweight 
respectively. 
2.8. Obesity complications, diagnosis and the subgroups  
Nowadays obesity is well recognised as a chronic disease that can cause a number of 
health problems but principally diabetes, cardiovascular diseases and several types of 
cancer (Bray, 2004; Haslam & Philip, 2005). A systematic review and meta-analysis 
of 207 published cohort studies revealed that obesity and being overweight, with a J-
shaped dose-response, are a risk factor for all cause mortality (Aune et al., 2016). In 
addition, this systematic review showed the lowest dose-response curve was observed 
among “never smokers” and “healthy never smokers” with BMI ranging between 23-
24 and 22-23 respectively. Furthermore it has been shown that regional fat stored in 
the visceral depots i.e. central obesity, compared to subcutaneous fat, increases the 
risk of medical disorders (Kissebah & Krakower, 1994; Mauriège et al., 1993). 
Children with obesity also face developing a number of health and psychological 
morbidities and are prone to developing several medical conditions in adulthood 
including type-2 diabetes (Diabetes, 2010; The, Richardson, & Gordon-Larsen, 2013), 
asthma (Egan & Ettinger, 2013), obstructive sleep apnoea (Narang & Mathew, 2012) 
and musculoskeletal disorders (Paulis, Silva, Koes, & Van Middelkoop, 2014). It is 
well documented that about 40% of overweight children could develop 
overweight/obesity in adolescence and 75-80% of obese adolescents will continue to 
become obese adults (Lifshitz, 2008). 
BMI is the most common anthropometric index for measuring obesity indirectly and 
is practical at the population level (The World Health Organisation, 2014). The 
agreed internationally thresholds identify a BMI ≥25 as “overweight” and BMI≥30 as 
“obese” in adults and is calculated by a person’s body weight (kg) divided by height 
(metres) squared. The term BMI was first coined by Alphonse Quetelet, a Belgian 
astronomer and statistician who defined the average man by measuring weights and 
heights of the French and Scottish armies (Eknoyan, 2006). The appropriateness of 
BMI for differentiating between different types of obese individuals has been argued. 
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A recent survey has conducted a cluster analysis on the Yorkshire Health Study, from 
2010 to 2012, including the demographic and behavioural information of individuals 
with BMI≥30 (Green et al., 2016). The analysis in this study found six types of obese 
people as heavy drinking males, younger healthy females, affluent healthy elderly, the 
physically sick but contented elderly, unhappy anxious middle-aged and individuals 
with the poorest health. This observed heterogeneity in individuals with obesity has 
important policy implications that could allow for more targeted approaches to 
obesity at a general level.  
 
In children, the classification of BMI needs to be adjusted for age and sex based on 
the WHO child growth standards (The World Health Organisation, 2014). In the UK, 
the Scientific Advisory Committee on Nutrition (SACN) recommended that the WHO 
2006 child growth standards for infants and children should be used between 2 weeks 
and 24 months. Then, the 1990 UK reference charts can be applied from age 2 
onwards (Scientific Advisory Committee on Nutrition, 2007). A number of methods 
are used for measurement of childhood obesity. Direct measurements, for example by 
dual energy X-ray absorptiometry, have a higher accuracy compared to indirect 
approaches, but are not appropriate for wide spread use at the population level (Goran 
& Goran, 1998). In this situation, indirect measures such as BMI, skinfolds and waist 
circumference (Goran & Goran, 1998) including bio-impedance methods such as 
BodPod and PeaPod are more practical and provide more reliable measures on body 
composition that are better suited for research surveys (Ma et al., 2004).  
2.9. Risk factors for developing obesity  
Both genetic and environmental factors during pre-conception and pregnancy as well 
as early life factors may impact on the risk of developing obesity in a child. In 
examining this area, the specific number of studies mentioned related to risk factors 
are based on the search results from Pubmed and also, references of conducted 
systematic reviews and overview of systematic reviews.  
2.9.1. Genetic and in utero environment as a risk factor for childhood 
obesity 
Evidence for a genetic component in obesity has come in part from studies on twins. 
A systematic review of studies on monozygotic and dizygotic pairs, using structural 
equation modeling, showed the heritability of BMI ranged from 61-80% over all age 
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categories in both sexes whereas the distinct environmental influences elevated from 
14-40% with increasing age (Nan et al., 2012). Furthermore, observational studies 
have indicated that parental obesity independently predicts the risk of their children 
being overweight (Agras, Hammer, McNicholas, & Kraemer, 2004; Fuemmeler, 
Lovelady, Zucker, & Østbye, 2013). Rankinen et al. (2006) have reviewed candidate 
genes for human obesity that have been identified through a variety of approaches 
including Mendelian syndromes, linkage studies and genetic association studies. 
However the evidence for most of these candidate genes is obtained from studies with 
a small sample size and a low number of genetic variants tested per gene and hence, 
consistent associations are reliable for only a handful of the listed genes. The advent 
of Genome-Wide Association Studies (GWAS) has provided a strong indication for 
the role of certain genetic variants in the development of obesity and its major 
complication metabolic syndrome (Aguilera, Olza, & Gil, 2013). Interestingly, data 
from 10 years of Finnish twin research into obesity showed that despite the high 
genetic predisposition for weight gain, the risk can largely be modified by 
environmental factors and maintaining an active lifestyle (Naukkarinen, Rissanen, 
Kaprio, & Pietiläinen, 2012). A survey from the US also assessed how genetic risk 
score for high BMI could have differed in response to the obesity epidemic in two 
birth cohorts born between 1900-1958 and 1992-2014 (Walter et al., 2016). Their 
findings indicated that the role of the genetic risk score was stronger in the cohort 
born later, suggesting a greater role for genetic components in an obesogenic 
environment.  
 
Maternal obesity 
Well-documented research indicates maternal obesity in pregnancy influences 
maturation of the neonate’s immune system by reducing the number and function of 
key innate immune cells in cord blood which in turn correlate with an elevated risk of 
chronic inflammatory diseases in offspring (Wilson et al., 2015). Epigenetic studies 
also indicate there are differences in DNA methylation in the offspring of obese 
versus healthy BMI mothers during pregnancy (Sharp et al., 2015) and this 
observation is more evident in particular candidate-genes for obesity i.e. Aryl-
Hydrocarbon Receptor Repressor (AHRR) (Burris et al., 2015). Growing evidence 
from epidemiological studies suggests that maternal pre-pregnancy obesity and 
excessive GWG are closely linked to a higher risk of obesity in children. A review of 
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the systematic reviews for the early predictors of obesity in children listed high 
maternal BMI and being overweight prior to pregnancy as potential risk factors for 
childhood obesity (Cameron et al., 2015). The evidence is based, however, on 
observational studies that do not imply a causal association and, furthermore, 
originates from studies with different sample sizes and study design with few being 
controlled for potential confounders. Furthermore, a systematic review and meta-
analysis of 30 cohort and cross-sectional studies showed that maternal obesity is 
associated with the risk of foetal macrosomia, ≥4000gr weight at birth (Gaudet, 
Ferraro, Wen, & Walker, 2014). It is worth mentioning that birth weight alone does 
not reflect either foetal growth trajectory or body composition. A number of studies 
investigated the associations between GWG and developing childhood obesity. The 
studies are mainly cohorts that collected data either prospectively or retrospectively, 
from various socio-economic and ethnic backgrounds and have reported mixed 
results. The definition and measurement of exposure and outcome are different across 
studies. A systematic review has endeavoured to provide an evidence from studies 
that reported GWG as an exposure for childhood obesity (Mamun, Mannan, & Doi, 
2014). The review included 15 studies and the pooled estimate of 12 studies showed 
that excessive GWG is a strong predictor of childhood obesity, from early life to 18 
years and above (RR=1.40; 95% CI=1.23-1.59). Furthermore, the risk is higher when 
the excess weight is gained during early to mid-pregnancy, as reported in another 
review (Lau, Liu, Archer, McDonald, & Liu, 2014). To conclude, data from 
epigenetic and epidemiological studies strongly suggest maternal obesity as a risk 
factor for childhood obesity that initiates epigenetic changes as an underlying 
mechanism for obesity in the offspring. 
 
Gestation diabetes mellitus  
Gestational Diabetes Mellitus (GDM) is also identified as a risk factor for childhood 
obesity. It has been shown that maternal glycaemia has a role in epigenetic mediation 
of leptin, an adipokine responsible for regulating energy balance, in the foetus (Allard 
et al., 2015). A synthesis of evidence from observational surveys investigated how 
maternal diabetes including gestational diabetes could influence the risk of obesity in 
children (Logan, Gale, Hyde, Santhakumaran, & Modi, 2017). Meta-analysis of three 
studies showed infants of mothers with GDM had a higher fat mass but lower fat free 
mass in early days of life. Collectively, data from epigenetic and observational studies 
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suggest a strong role for GDM as a risk factor for childhood obesity, although the 
longer-term health risks need to be established.  
 
Maternal smoking 
Some childhood obesity may also be explained by maternal smoking during 
pregnancy. There is robust evidence that prenatal exposure to maternal smoking is 
linked to altered DNA methylation of AHRR in the offspring (Burris et al., 2015; 
Joubert et al., 2012). The effect of exposure to prenatal smoking on childhood obesity 
is assessed in numerous observational studies. Studies are of different design, include 
small to large samples and have been conducted in different world regions. Studies 
were heterogeneous for measurement of exposure and outcome and had varied 
duration of follow-up. Only a few studies controlled their analyses for confounders 
and a range of covariates were considered. The Nurses’ Health Study II is the largest 
birth cohort in US that assessed the effect of prenatal exposure to parental smoking 
and obesity in 35,370 children by 18 years of age (Harris, Willett, & Michels, 2013). 
Adjusted analysis for socio-economic and behavioural variables showed that maternal 
smoking during pregnancy for doses of 1-14, 15-24 and >25 cigarettes per day 
increased the risk of obesity by 18 years age (OR=1.26; 95% CI=1.16-1.37), 
(OR=1.46; 95% CI=1.30-1.63) and (OR=1.43; 95% CI=1.10-1.86) respectively. The 
influence of prenatal smoking on childhood obesity is systematically investigated in a 
recent meta-analysis of 39 observational studies (Rayfield & Plugge, 2017). The 
quality of included studies was rated as good for most studies. The pooled estimate of 
nine studies showed an association between maternal smoking during pregnancy and 
development of childhood obesity (adjusted OR=1.55; 95% CI=1.40-1.73). To 
summarise, the current evidence implies that prenatal maternal smoking is a strong 
contributor for childhood obesity and suggests that smoking cessation during 
pregnancy could be encouraged as an effective preventive approach.  
2.9.2. Maternal diet during pregnancy and development of childhood 
obesity 
Extensive research has explored the influence of maternal intake of various nutrients 
and dietary patterns during pregnancy specifically on infant’s birth weight and these 
are discussed in Chapter 5. The focus of this section is on studies that assessed how 
maternal diet during pregnancy could contribute to childhood obesity in whole life. 
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This has been the subject of a number of observational studies with an interest in the 
intake of particular foods. Maternal fat consumption in pregnancy as a risk factor for 
developing obesity in children is largely examined in birth cohorts. Measurement of 
exposure and its intake in pregnancy (first, mid or late trimesters) as well as outcome 
measures and the duration of follow-up varied across studies. A large discrepancy 
exists between the reported results for obesity outcome in children where some 
studies have reported beneficial effects and others reported no associations. This 
could be because of a number of factors such as study power and role of confounders. 
Therefore, there is a lack of clear evidence for prenatal consumption of fatty acids and 
childhood obesity. A systematic review and meta-analysis from 15 European and the 
US birth cohorts was conducted to assess the effect of fish intake during pregnancy, a 
major dietary source of LC-PUFA, and its influence on childhood BMI trajectories, 
with 2-year follow-up intervals until the age of 6 years (Stratakis et al., 2016). Of the 
19 eligible European birth cohorts, 14 studies included in this review and individual 
data by 6 years age, with 2-year follow-up intervals was harmonised and combined by 
reviewers. It was shown that children born to mothers with higher intake of fish 
prenatally, more than 3 times/week, versus lower fish intake, had higher BMI values 
from infancy through mid childhood. Also, pooled adjusted results showed fish intake 
>3 times/week was associated with rapid growth in infants (OR=1.22; 95% CI=1.05-
1.42) and elevated risk of overweight/obesity at 4 and 6 years (OR=1.14; 95% 
CI=0.99-1.32) and (OR=1.22; 95% CI=1.01-1.47) respectively. This finding can be 
explained by the programming influence of PUFAs during the intrauterine period that 
could lead to higher growth of adipocytes in the foetus. Despite differences in 
consumption levels of fish across Europe and the US, the findings of this review 
provide evidence for the role of high intake of n-3 PUFAs on childhood obesity. 
 
The prospective Finnish birth cohort, not included in the review discussed above, has 
also examined the effect of dietary fatty acids consumption in late pregnancy on 
childhood obesity between 2-7 years (Hakola et al., 2016). In girls, a U-shaped 
association was observed and the lowest and highest quartiles of the n-6/n-3 ratio in 
maternal diet, compared to the two middle quartiles which were associated with 
greater adjusted probability of obesity. In boys, the AR/DHA+EPA ratio showed a 
relation with obesity in the adjusted analysis. Additionally, neither saturated nor 
mono-unsaturated fatty acids were related to obesity in either sex. This cohort is the 
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first study that has reported associations between childhood obesity measures and 
individual fatty acids by means of multiple testing. These results could also reflect the 
cultural differences in dietary behaviours. For example, the intake of seafood and 
plant n-3 PUFAs in Finland are among the highest in world whereas intake of n-6 is at 
the lowest.  
The Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort also 
investigated the relationship between consumption of artificially sweetened beverages 
during pregnancy and the infant’s BMI at 1-year of age (Azad et al., 2016). An 
adjusted analysis in this study showed that regular intake versus no-consumption of 
artificially sweetened beverages in pregnant women increased the risk of being 
overweight by 2-fold in the offspring (OR=2.19; 95% CI=1.23-3.88). Furthermore, 
other cohort studies in Netherland and Ireland found no relationship between intake of 
carbohydrate, fat or protein during pregnancy and child obesity (Heppe et al., 2013; 
Murrin, Shrivastava, Kelleher, & Group, 2013). Interestingly, the Growing Up in 
Singapore Towards Healthy Outcomes study found that high intake of both 
carbohydrate and sugar during pregnancy was associated with higher BMI at 2-4 
years of age (Chen et al., 2017). Collectively, data from these cohorts provide 
evidence for the role of sugar and other foods consumed during pregnancy with 
childhood obesity; nonetheless their results could be subject to residual and 
unmeasured confounding factors.  
2.9.3. Breast-feeding and development of childhood obesity 
The role of breast-feeding on childhood obesity has been of much interest. To date, 
there is only one RCT that evaluated the promotion of breast-feeding and in their 
findings they reported no association between the exclusiveness and duration of 
breast-feeding on childhood obesity at 6.5 years (Kramer et al., 2007). This is likely 
to be because the study was underpowered to detect the hypothesised effects 
(Ruckinger & von Kries, 2009).  
 
There are currently more than 105 observational studies that evaluated whether 
breast-feeding could influence development of obesity in children, published between 
1970 to 2014 in developing and developed countries. The study designs differed from 
cohort (prospective or retrospective) to cross-sectional and are of small to larger size. 
Exposure to breast-feeding were defined differently in the studies such as ever versus 
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never, exclusive breast-feeding for time points of  <3, ≥4 and ≥6, 4-6 and 6-7 months 
versus never or less breast-fed. The outcome of interest was also reported for different 
age groups and adjusted for underlying variables mainly in cohort studies. Studies 
also used different criteria for measurement of overweight/obesity including Centers 
for Disease Control and Prevention (CDC) percentiles, International Obesity Task 
Force (IOTF) cutoffs, national reference data from Germany (BMI ≥97th percentile) 
as well as alternate BMI percentiles. The main weakness of studies that collected the 
data retrospectively was the length of recall of breast-feeding. The largest cohort 
conducted is the Scottish cohort that recruited 32,200 children between 1995-1996 
and reported the obesity outcomes by 3-3.5 years (Armstrong & Reilly, 2002). It was 
reported that breast-fed infants had a lower rate of obesity (BMI≥98th percentile) 
(OR=0.70; 95% CI=0.61-0.80), adjusted for socioeconomic status, birth weight and 
sex. Given the large number of studies and inconsistency between the reported results 
on this topic, six systematic reviews with different inclusion criteria have been 
conducted published from 2004 to 2015. A recent overview of systematic reviews by 
Patro-Gołąb et al. (2016) has assessed the available evidence from the existing 
systematic reviews as well as two overviews of systematic reviews for exposure to 
breast-feeding on childhood BMI and obesity. The reviewers appraised the quality of 
systematic reviews included in their overview as high for one review, as low in one 
review with the remainder of medium quality. Overall, this evaluation of the current 
evidence, based on high-quality studies, indicates that ever breast-feeding leads to a 
modest reduction (13%) in childhood overweight and obesity, and a shorter duration 
is associated with a lesser protection. It should be noted however that the effect of 
residual confounders cannot be excluded. Interestingly, when only considering 
exclusive breast-feeding, no association was observed for later risk of childhood 
obesity. Collectively, the evidence-base highlights the impact of breast-feeding 
behaviours on developing obesity in children and could be introduced as an early 
preventive strategy. 
The content of breast milk and its association with childhood obesity has also been 
assessed in studies. The Copenhagen prospective birth cohort study demonstrated that 
DHA levels in breast-milk, but not n-6/n-3 ratio, were directly associated with 
childhood BMI and fat mass from 2-7 years (Pedersen, Lauritzen, Brasholt, Buhl, & 
Bisgaard, 2012). Furthermore, it has been shown that breast milk of obese women 
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contains a higher level of n-6 to n-3 fatty acids suggesting that obesity is connected to 
an elevated pro-inflammatory fatty acid profile (Panagos et al., 2016). 
Differences between breast-fed and formula-fed infants, in terms of developing 
obesity later in life, have been of much interest. Data from the Western Australian 
Pregnancy Cohort (Raine) Study in Perth indicated that a longer duration of breast-
feeding reduced weight z-scores between birth and 1-year age (Oddy et al., 2014). 
Also, the age of introduction of formula was a significant risk factor for BMI 
trajectory from birth to 14 years with introducing formula at less than 6 months being 
associated with overweight or obese at 20 years. Studies have also found that breast 
milk in comparison to artificial formula milk contains lower protein and also 
stimulates less plasma insulin levels, and therefore leads to a reduced growth velocity 
in breast-fed infants (Oddy, 2012; Ziegler, 2006). Altogether, these data suggest the 
protective effect of a longer duration of breast-feeding against developing obesity 
later in life, so mothers might be advised to introduce formula at an older age.    
2.9.4. Introduction of solid foods and development of childhood obesity 
The effect of timing of introduction of complementary foods and types of food 
introduced is assessed in 30 observational studies, published “between 1978 to 2011”. 
Introduction of solids as the exposure in studies was defined differently for various 
age cut-offs including 2, 3, 4, 5 or 6 months, 4-5 or 4-6 months. Measures of weight 
and height/length were reported in all studies, whereas few measured BMI and z-
scores as well as other growth and body composition measures such as skin-fold, 
circumference and ponderal index. Studies were also different for the duration of 
follow-up from less than 1 year to adulthood. The effect of confounders was 
considered in the majority of the studies; however there were wide variations between 
studies in the confounders measured such as maternal BMI and socio-economic 
status. Measurement of obesity outcome varied across studies. The Millennium 
Cohort Study in the UK is the largest study that investigated the effect of the timing 
of the introduction of solids as one of the risk factors for childhood obesity (Hawkins, 
Cole, Law, & Group, 2009). The study included a pool of 13,188 singleton children, 
born between 2000 and 2002 and defined childhood obesity by IOTF cut-offs for 
BMI. The findings of this study reported that introduction of solids at less than 4 
months was associated with higher BMI at 3 years age (adjusted OR=1.12; 95% 
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CI=1.02-1.23). The association between timing and type of solid food introduction on 
obesity measures in children is investigated in six systematic reviews, published 
between 2001 to 2015. A recent overview of reviews assessed the available evidence 
from these systematic reviews and did not conduct meta-analysis (Patro-Goł ąb et al., 
2016). In this overview, the quality of the conducted systematic reviews was rated as 
low for one and as medium for the remainder. This evaluation of the current evidence 
concluded that the effect of either overall timing of complementary feeding or the 
introduction before 15 weeks or four months on childhood obesity is not consistent. 
Furthermore, the available evidence does not suggest an association between types or 
patterns of complementary feeding as well as overall energy intake or sugar-
sweetened beverage and early and late childhood obesity. In brief, the introduction of 
solids and its effect on obesity in children could be confounded by many underlying 
factors and needs to be considered in further studies.  
2.10. Postnatal environmental factors and development of 
childhood obesity  
The intestinal microbiota in infants has been suggested to play a significant role in 
childhood obesity. Two nested case-control studies in the prospective Finnish 
probiotic RCT, examining the compositional development of gut bacteria in infants, 
reported that a microbiota profile higher in bifidobacteria is protective against obesity 
in children whereas a microbiota in favour of Staphylococcus aureus is a risk factor 
for obesity later in life (Kalliomaki, Collado, Salminen, & Isolauri, 2008; Luoto et al., 
2011). This finding suggests a role for gut microbiological environments on metabolic 
programming early in life.  
 
Accelerated growth in infancy is also a risk factor for obesity in children and has been 
investigated in a number of observational studies. These studies are very 
heterogeneous in their design, sample and also definition and measurement of 
outcome using different criteria such as CDC percentiles, WHO charts and BMI 
percentiles. The Collaborative Perinatal Project, including 12 sites across the US, is 
the largest cohort that prospectively assessed the rapid rate of weight gain during the 
first 4 months of life with childhood overweight at 7 years age (Stettler, Zemel, 
Kumanyika, & Stallings, 2002). Adjusted analysis for several confounders showed an 
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association between higher rapid weight gain in early life and being overweight at 7 
years old (OR=1.38; 95% CI=1.32-1.44). A systematic review including only cohort 
studies was conducted to investigate the evidence on this topic. A total of 10 cohorts 
were included, conducted across Europe, the US and the Seychelles (Druet et al., 
2012). Using an external reference, weight SD scores at birth and 1-year age were 
estimated for each included child. Adjusted individual-level meta-analysis for sex, 
age and birth weight indicated that for each unit rise in weight SD scores from birth to 
1-year of age, the risk of childhood obesity was doubled (OR-1.97; 95% CI=1.83-
2.12) and also a higher risk was found for adult obesity (OR=1.23; 95% CI=1.16-
1.30). Furthermore, a recent synthesis of 45 observational studies indicated that 
higher weight-for-length in the first two years of life was reported as a significant risk 
factor for childhood obesity in all studies (Woo Baidal et al., 2016). To summarise, 
the current evidence suggests that infant growth patterns in early life could be 
considered as an early preventive strategy for childhood obesity. The underlying 
mechanisms and potential confounders need to be addressed in further research. 
 
The duration of sleep in infancy as a risk factor for childhood obesity is investigated 
in 38 observational studies. Studies were of different designs, mainly cross-sectional 
and published between 1990 to 2009 involving small to larger populations. Short 
duration of sleep, as the exposure was defined and measured differently in the 
conducted studies and obesity as the outcome measure, was also assessed using 
various criteria. Moreover, a range of different variables have been considered as 
confounders in studies. The largest birth cohort study was the Avon longitudinal study 
of parents and children in the UK that followed up 8,234 children by 7 years of age 
(Reilly et al., 2005). Short sleep duration (<10.5 hours) at age 3 years was reported as 
a risk factor for higher BMI, defined as ≥95th percentile relative to reference data for 
the UK population in 1990 (OR=1.45; 95% CI=1.10-1.89). Given the large 
heterogeneity between studies, a systematic review has assessed the evidence from 
current literature. This review only included longitudinal studies since the 
associations between sleep duration and developing obesity have been controlled for 
potential confounders more rigorously in prospective cohorts compared to cross-
sectional studies. The evidence from 7 included studies was consistent and reported 
an inverse relation between the duration of sleep and later obesity in children (Magee 
& Hale, 2012). More recent data from the KOALA birth cohort study, including 2,322 
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children born between 2001 to 2003 in the Netherlands, reported that a longer night-
time sleep was associated with lower BMI or overweight by age 9 years, but not the 
daytime sleep (Bolijn, Gubbels, Sleddens, Kremers, & Thijs, 2016). Altogether, the 
current evidence suggests a role for short sleep duration and developing childhood 
obesity; however there are wide inconsistencies between studies for definition and 
measurement of exposure and outcomes as well as controlling for confounding 
factors. Experimental research may provide elucidating answers for the underlying 
mechanisms.  
2.11. Prenatal nutritional approaches for prevention of 
childhood obesity 
2.11.1. Nutritional interventions during pregnancy  
A number of prenatal nutritional approaches have been introduced for prevention of 
obesity in infants. To avoided bias caused by selecting specific dietary interventions, 
all interventions were included in the review i.e. probiotics, fatty acids, diet-related 
and lifestyle approaches. 
 
Evidence from experimental studies suggest that throughout pregnancy, both the fatty 
acid composition in maternal diet, specifically a ratio of n-6/n-3 fatty acid (Massiera 
et al., 2003), and also the amount of fat consumed (Armitage, Taylor, & Poston, 
2005), are key elements for adipose tissue growth in the offspring. This finding could 
have an impact on the adipocyte number and fat cell size in infants since human 
adipose tissue starts to develop in the second trimester of pregnancy (Ailhaud & 
Hauner, 2004). It seems that fat cells acquired at an early stage in life determine the 
level of fully differentiated adipocytes later in life, with only approximately 10% of 
fat cells being replaced across all ages and at all levels of BMI (Spalding, Arner, & 
Westermark, 2008). Animal studies also indicated that AA, the major n-6 PUFA, may 
have a stimulatory effect on fat cell development, whereas DHA and EPA, the n-3 
LCPUFA, counteract this process (Muhlhausler & Ailhaud, 2013). The anti-obesity 
effects of the latter are well recognised at decreased levels of adipose cells in tissue as 
well as lipid synthesis (Flachs, Rossmeisl, Bryhn, & Kopecky, 2009). Over recent 
decades, the dominance of n-6 fatty acids in diets, particularly in industrialised 
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countries, provides an indirect evidence that the n-6/n-3 fatty acid ratio may have a 
potential causal association with adipose tissue development during critical early 
phases of life (Ailhaud, Massiera, & Weill, 2006; Muhlhausler & Ailhaud, 2013). 
Findings from observational studies, however, do not support an association between 
n-6 and n-3 LCPUFA levels in maternal or cord blood and adiposity-related outcomes 
in offspring (de Vries et al., 2014; Donahue et al., 2011; Moon et al., 2013), as their 
results could be influenced by many underlying factors. Collectively these data 
suggest that maternal intake of n-3 fatty acids during pregnancy could be a good 
approach for early prevention of obesity later in life.  
 
Experimental models have revealed that obesity is associated with altered gut 
microbial composition (Ley et al., 2005) and observational studies have shown that 
the gut microbiota of obese individuals is altered or less diverse compared to non-
obese subjects (Ley, Turnbaugh, Klein, & Gordon, 2006; Turnbaugh et al., 2009). 
Also, key results from animal models reveal that the composition of gut microbiota 
modulates immune programming and can reduce the risk of obesity and metabolic 
diseases (Renz, et al., 2012; Turnbaugh et al., 2006). The development of gut 
colonisation occurs early in life since the foetus is initially exposed to maternal 
microbiota during pregnancy and delivery. Therefore, modification of gut microbiota 
in pregnant women with probiotics is proposed as a promising approach in reducing 
the risk of childhood obesity. Probiotics, as living microorganisms, can exert health 
benefits beyond inherent general nutrition and provide a safe microbial stimulus as 
part of the natural gut flora (Borriello et al., 2003; Guarner & Schaafsma, 1998). 
These characteristics make them a novel dietary choice in pregnancy. 
2.11.2. Diet-related and lifestyle interventions during pregnancy 
As discussed in section 2.9.1, an unfavourable intrauterine environment in pre-
pregnancy caused by maternal obesity, excess GWG and GDM are proposed as 
potential risk factors in the development of obesity in offspring and thus identifying 
preventive approaches are of utmost importance. In its revised guidelines, the Institute 
of Medicine (IOM) has defined lower GWG targets during pregnancy for obese 
women at pre-pregnancy (Institute of Medicine and National Research Council, 2009) 
with the aim that defined GWG ranges could prevent short and long-term health 
outcomes in mother and child. Evidence also reveals that excess maternal weight gain 
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during pregnancy, beyond the recommended level, occurs in 53% of pregnant women 
already defined as exceeding normal weight gain (Simas et al., 2011). Since the 
excess nutrients required during pregnancy are shared between the mother and her 
foetus, early prevention strategies propose a window of opportunity for both 
monitoring weight in pregnant women and early prevention of obesity in infants. In 
this context, antenatal dietary interventions focused on the quality of the diet, and 
lifestyle advice involving physical activities, or a combination of both approaches are 
promising strategies for early prevention of childhood obesity. 
2.12. Summary of the literature review for obesity 
Obesity as a disease cannot be explained through genetics alone. It is clear that 
environmental factors play a significant role in the development of obesity early in 
life and thus are largely modifiable. Effective treatments for obesity are limited, and 
therefore environmental and nutritional approaches at early stages of life i.e. during 
pre-pregnancy and pregnancy could introduce an excellent opportunity to minimise 
susceptibility to lifelong obesity.  
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Chapter 3: The effectiveness of maternal nutritional/dietary 
interventions during pregnancy and the risk of developing 
allergic disorders in the offspring: systematic reviews and 
meta-analyses 
3.1. Overview of the chapter  
This chapter presents systematic reviews of literature describing the most recent 
available evidence from RCTs on the effectiveness of maternal dietary interventions 
during pregnancy for the prevention of allergic diseases in offspring. Dietary 
interventions explored include Pro/Prebiotics, Fatty Acids, Food Interventions and 
Vitamins/Supplements. The methodology section outlines: how the comprehensive 
literature search was conducted, the eligibility criteria used to assess studies against 
the defined inclusion criteria, and the techniques used for assessing the quality of 
included studies. The results section is divided by intervention type and by the Risk of 
Bias (ROB) assessment. The data is then presented in a descriptive manner. Where 
possible, the effect of outcomes have been presented using meta-analyses and where 
not possible, through narrative description. The discussion section summarises the 
findings from this systematic review, structured for each intervention type, and makes 
comparisons with the current literature and defines areas for further research.  
3.2. Objectives 
To conduct systematic reviews assessing the effectiveness of maternal dietary 
interventions during pregnancy for prevention of allergic disorders in the offspring 
3.3. Methods and protocol for the systematic reviews  
A protocol was developed adopting the approach of a Cochrane Systematic Review 
and finalised on 5
th
 January 2015 (appendix 3.1) for the conduct of this systematic 
review, published in PROSPERO and accessible via the web-link below: 
(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015024397) 
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3.3.1. Criteria for considering studies for review 
3.3.1.1. Types of studies 
Only RCTs including cluster randomised controlled trials and quasi-randomised 
controlled trials were included. The review considered studies, which documented 
clinical outcome data and had a follow-up period of at-least one month postnatally.  
Systematic reviews, editorials, discussion papers, reports, case studies, case series, 
non-controlled before and after studies and animal studies were excluded. 
3.3.1.2. Types of participants 
Pregnant women from across the world selected from the general population and their 
offspring were considered as the target group in this systematic review. Studies 
conducted in high risk populations were not excluded. 
3.3.1.3. Types of interventions 
Studies reporting one or more of the following interventions during pregnancy were 
included:  
a. Pro/Prebiotic supplementation 
b. Fatty acid supplementation 
c. Food-based dietary advice (promoting a healthy diet) or food-based nutrient 
interventions 
d. Vitamin/Multivitamin, supplementation and minerals (will be mentioned as 
Vitamins hereafter) 
Trials were also included if the intervention(s) had been extended after pregnancy 
either in breast-feeding mothers, the infants or both. Studies within each of the above 
mentioned interventions were grouped under one umbrella intervention i.e. any 
pro/prebiotics, fatty acids, food intervention and vitamins, regardless of their specific 
applied intervention. 
3.3.1.4. Outcomes of interest 
Trials were included if they had reported clinical outcomes of allergy, either as a 
primary or secondary endpoint, in the offspring from infancy to adulthood. The 
primary and secondary outcome measures were defined as allergic diseases including 
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infantile wheeze. Where possible, outcomes that had utilised validated questionnaires 
were considered. 
3.3.2. Search strategy for identification of studies 
A comprehensive search strategy, including all the relevant synonyms for the main 
concepts, was developed covering the main bibliographic databases (see appendix 
3.2). 
3.3.2.1. Electronic searches 
Trials were identified through systematic searches within three main electronic 
databases, as advised by the Cochrane collaboration (Lefebvre, Manheimer, & 
Glanville, 2011): 
a. Cochrane Library (current issue) including: 
 Cochrane Database of Systematic Reviews (CDSR)  
 CENTRAL (trials) 
 Database of Abstracts of Reviews of Effect (DARE) 
b. MEDLINE (EBSCOhost)  
c. SCOPUS 
When searching MEDLINE, the subject-specific terms were combined with the 
Cochrane Highly Sensitive Search Strategy for identifying randomised trials in 
MEDLINE: sensitivity-maximising version (Lefebvre, et al., 2011). We adapted the 
preliminary search strategy for MEDLINE (EBSCOhost) for use in the other 
databases when relevant. All databases were searched from their inception date to the 
end December 2014 (appendix 3.2).  
In addition a number of supplementary searches were carried out as listed below: 
a. ISI Web of Science (Thomson Web of Knowledge) (conference proceeding) 
b. Clinicaltrials.gov 
c. WHO International Clinical Trials Registry Platform (ICTRP) 
d. E-theses Online Services (ETHoS ) 
The clinical trials registry and WHO platform were searched for ongoing and recently 
completed trials. Conference proceedings were identified through the ISI Web of 
Science and, to retrieve theses the British Library ETHoS was searched (Green & 
Higgins, 2011). No language or publication status restrictions were imposed. 
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3.3.2.2. Searching other sources of evidence 
References of all identified studies and key systematic reviews in this area were 
checked for potentially relevant studies not identified by the above search strategy. 
There have been a number of systematic reviews that have evaluated the use of 
prenatal and/or postnatal probiotics as well as fatty acids for prevention of allergic 
diseases in offspring, with only one systematic review assessing the effectiveness of 
food interventions in this area. It is worth noting that there are no systematic reviews 
investigating the effectiveness of vitamin supplementations in pregnant women for 
prevention of allergies in offspring. 
 
Systematic reviews of probiotics interventions have mostly investigated individual 
outcomes, mainly respiratory diseases or skin-related disorders (Azad et al., 2013; 
Betsi, Papadavid, & Falagas, 2008; Dang et al., 2013; Doege et al., 2012; Elazab et 
al., 2013; Lee, Seto, & Bielory, 2008; Pelucchi et al., 2012; Tang, Lahtinen, & Boyle, 
2010) with one review assessing food allergy and sensitisation (Zhang et al., 2016). 
Of these, the review conducted by Doege et al., (2012) evaluated the impact of 
supplementation with probiotics on atopic eczema only for interventions introduced 
during pregnancy, whereas all the other reviews assessed the effectiveness of 
probiotics supplementation that commenced either prenatally, prenatal and continued 
postnatal or only postnatal. There are also two systematic reviews for fatty acids 
interventions in pregnant women. The review by Kremmyda et al., (2011) has 
narratively described the studies that supplemented women with n-3 Long Chain Poly 
Unsaturated Fatty Acids (n-3 LCPUFA) either prenatally only or prenatally continued 
postnatal for prevention of allergies in children; no meta-analyses were conducted. 
The other review has measured specific outcomes of asthma and atopic dermatitis in 
studies supplementing fatty acids prenatally, and conducted meta-analyses (Klemens, 
Berman, & Mozurkewich, 2011). Furthermore, the only review of food-based 
interventions during pregnancy has reported maternal and infant outcomes at birth 
(gestational weight gain, preterm birth, cord blood IgE) as well as childhood allergic 
outcomes measured at different time points (Kramer & Kakuma, 2012). 
  
The main purpose of the current systematic review was to establish the most up to 
date evidence from RCTs, which have introduced the dietary intervention only 
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throughout pregnancy with a minimum follow-up of one month after birth. We have 
also aimed to investigate a comprehensive range of allergic outcomes presented in the 
trials. After the start date of the current systematic review, four reviews on the 
effectiveness of probiotics (Cuello-Garcia et al., 2015; Zuccotti et al., 2015) and fatty 
acids (Best, Gold, Kennedy, Martin, & Makrides, 2016; Gunaratne, Makrides, & 
Collins, 2015) for prevention of multiple allergic outcomes in children have been 
published. Nevertheless, all these reviews either had different inclusion criteria and 
involved limited searching or considered different allergic outcomes.   
 
The uniqueness of present systematic review in comparison to the previously 
conducted reviews is that we have looked specifically at the dietary interventions that 
started during pregnancy. This allowed us to investigate the evidence of whether the 
early commencement of dietary supplementations in pregnant women prevents 
childhood allergic outcomes. We have also included the most up-to-date follow-up 
data from the included trials in the meta-analyses.  
3.3.3. Data collection and analysis 
3.3.3.1. Selection of studies 
The main reviewer (Mariam Vahdaninia, MV) initially screened all the search results 
against the eligibility criteria and all those clearly irrelevant, were excluded from 
further consideration. Thereafter, a tailored eligibility form was devised and used by 
MV to appraise the retrieved studies, abstract and full text, for relevance against the 
full inclusion criteria (appendix 3.3). Where there was uncertainty about inclusion of 
a particular study, other members of the review team were consulted and a consensus 
was reached about the study eligibility. All the included studies were discussed and 
approved by the review team and a Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) flowchart was developed. EndNote Reference 
Manager software was used to manage and record references.  
 
Studies that did not meet the eligibility criteria are detailed in the table of 
characteristics of excluded studies (appendix 3.4).  
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3.3.3.2. Data extraction and management  
EPPI Reviewer 4 (ER4) software was employed to manage the systematic review 
process. A detailed tailored data extraction tool was developed by MV and piloted on 
two of the included studies. Changes were made as appropriate and the final draft of 
the data extraction tool was discussed and agreed within the supervisory team 
(appendix 3.5). The main reviewer (MV) extracted the following baseline and detailed 
study characteristics from the included studies: 
a. Study details: country, recruitment period, setting, ethics, informed consent 
and funding body  
b. Trial type: details of trial design, number & name of study groups/arms, 
intention to treat analysis (ITT) 
c. Study sample: comparability of groups, women’s age, risk of atopy in the 
studied sample, number at randomisation, number at follow-up, number of 
missing participants, reasons for missing, time points measured, length of 
follow-up 
d. Intervention/comparison: detailed information about type of pro and 
prebiotics/fatty acids/vitamins/food avoidance, timing in pregnancy, mode of 
intervention delivery during pregnancy and/or infancy, total duration of 
intervention, side effects and detailed information about comparison used e.g. 
type, mode of delivery 
e. Reported outcomes: all the reported clinical allergic end points, either as 
primary or secondary outcome, with the relevant definition e.g. point and or 
cumulative prevalence, crude or adjusted, combination of some outcomes 
f. Diagnosis method: all methods defined for measuring the reported outcomes, 
e.g. questionnaires, clinical examinations and/or laboratory test(s) 
 
All relevant data was extracted by MV. For studies with more than one control group, 
only the data for the placebo arm were extracted as a comparator. 
 
Throughout the data extraction process, any disagreements about the interventions 
and outcomes were discussed and resolved within the review team. There was no 
blinding of the authors’ names, institutions, journals or the outcomes of the trials 
during the process. Ten percent of all the extracted data was randomly selected and 
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double checked by a second reviewer (Heather Mackenzie, HM) for accuracy against 
the trial reports. Data was presented descriptively in tables and where possible, data 
were combined and meta-analyses performed by utilising ER4, following the methods 
described in the Cochrane Handbook of Systematic Reviews of Interventions (Deeks, 
Higgins, & Altman, 2011), further details of which are provided below.  
3.3.4. Assessment of risk of bias in included studies 
The quality of each included trial was assessed by MV, using the risk of bias tool 
described in the Cochrane Handbook for Systematic Reviews for Interventions 
(Higgins, Altman, & Sterne, 2011). Risk of bias was considered according to the 
following domains: 
a. Random sequence generation: was the allocation sequence adequately 
generated? 
b. Allocation concealment: was allocation adequately concealed? 
c. Blinding of participants and personnel: was knowledge of the allocated 
intervention adequately prevented throughout the study i.e. blinded? 
d. Blinding of outcome assessments: was knowledge of the outcome assessment 
adequately prevented i.e. blinded? 
e. Incomplete outcome data: were incomplete outcome data adequately 
addressed for every outcome? 
f. Selective outcome reporting: were reports of the study free of selective 
outcome reporting? 
g. Other biases: was the study free from any other problems that could put it at 
risk of bias e.g. comparability of control group at entry, industry funding? 
Based on these criteria, each study was scored using a three-point scale: low risk of 
bias, high risk of bias, unclear. Disagreements resolved with the review team which 
consisted of MV & HM and if required, by consensus with a third reviewer (Tara 
Dean, TD). The risk of bias results were presented in risk of bias tables and were 
taken into account when considering treatment effect.  
3.3.4.1. Measurement of treatment effect 
Dichotomous data was analysed as risk ratios or relative risk (RR) with 95% 
confidence intervals and continuous data as mean difference or standardised mean 
difference, with 95% confidence intervals (CI).  
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3.3.4.2. Unit of analysis issues 
In trials with more than one intervention arm, multiple pairwise comparisons of 
intervention groups versus comparator were avoided. Therefore, data from different 
intervention arms were pooled for an overall comparison with the control or placebo 
arm. The weight assigned to the control group was considered as the total number of 
participants in the comparator group versus the total number of participants in the 
combined intervention arms (Deeks, et al., 2011). Similarly, in studies with more than 
one comparator arm, defined as placebo and no treatment, only data from the placebo 
arm was compared with the intervention arm.  
3.3.4.3. Handling missing data 
All of the relevant reported information for the number of missing participants was 
extracted and, if undocumented, this was incorporated into the assessment of risk of 
bias.  
 
In most of the studies, the missing data was reported to be as a result of loss to follow-
up and was commonly stated as being normally distributed across the study arms. As 
only a small number of studies had reported the results based on ITT, the per-protocol 
analysis was used for the systematic review. Studies that performed ITT analysis are 
identified in the table of characteristics of included studies (Table 3.2).  
3.3.4.4. Assessment of heterogeneity 
To measure statistical heterogeneity between effect sizes of included studies, within 
each umbrella intervention group and for each allergy outcome separately, we used 
visual inspection of forest plots and also, the χ2 test for heterogeneity with a P Value 
<0.05 (Deeks, Altman, & Bradburn, 2001). The I
2 
statistics were used to quantify the 
amount of possible variability in effect estimates that is due to heterogeneity rather 
than chance (I
2 30 moderate heterogeneity, I2 ≥75 considerable heterogeneity). 
Moreover, studies with a similar comparator, within each umbrella intervention 
group, were grouped to run meta-analyses. 
 
With regards to clinical heterogeneity, two key issues were considered. Firstly, data 
for all reported allergic outcomes from the included trials were extracted, crude or 
adjusted. The following outcomes were considered for this systematic review (Table 
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3.1). Only crude reported outcomes and also, the longest available follow-up 
measures were selected for this systematic review and entered in meta-analyses.  
 
Table 3.1. List of the outcomes of interest for this systematic review 
Main Allergic outcomes  Comments
*
  
Any allergic disease(s) Latest available follow-up data 
Wheeze Latest available follow-up data 
Eczema Latest available follow-up data, includes atopic dermatitis 
Asthma Latest available follow-up data 
Rhinitis Latest available follow-up data, excludes rhino-conjunctivitis  
Food Allergy 
Latest available follow-up data (may include various methods of 
measurement)  
Anaphylaxis Presented narratively as reported in one study only  
Angioedema Presented narratively as reported in one study only  
SPT
**
 and IgE tests
***
   
SPT (any positive) Either latest available follow-up data or earlier reports 
Specific IgE Either latest available follow-up data or earlier reports 
*Either point or cumulative prevalence  **Skin Prick Test   ***Immunoglobulin E 
 
Secondly, as there were a number of published systematic reviews on the 
effectiveness of probiotics, fatty acids and food interventions during pregnancy for 
prevention of allergic disorders in offspring, a broad definition of allergic outcomes 
was employed in meta-analyses, which allowed for clinical heterogeneity in all the 
included studies. As mentioned in section 3.3.2.2, the current body of evidence from 
systematic reviews has investigated the effectiveness of prenatal and/or postnatal 
probiotics for prevention of selected allergic outcomes in children. These reviews also 
scrutinised the effectiveness of probiotics in sub-group analyses for the type of 
participants (mother only, both mother & infant, infant only), timing of intervention, 
probiotic dose and organism, risk of developing allergy in infant, diagnosis method of 
allergic diseases, duration of follow-up, geographical area and risk of bias (Azad et 
al., 2013; Dang et al., 2013; Doege et al., 2012; Elazab et al., 2013; Pelucchi et al., 
2012; Zhang et al., 2016). The most recent review by Cuello-Garcia et al., 2015 
looked at all allergic outcomes as the probiotic intervention was applied time points: 
during pregnancy (trans-placental), in breast-feeding mothers (indirect evidence), in 
infants by oral preparation or milk formula (direct evidence) or a combined approach 
for timing i.e. during pregnancy and continued after birth. For fatty acid interventions, 
the Gunaratne et al. (2015) review included all allergic outcomes and measured the 
evidence only from trials supplementing n-3 LCPUFA as the intervention, either in 
pregnancy or lactation, and reported detailed outcomes of IgE and non IgE-mediated 
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allergic disorders including sensitivity analyses. The systematic review by Best et al. 
(2016) investigated the evidence from observational and RCTs separately that only 
used n-3 LCPUFA supplements during pregnancy and reported IgE-mediated allergic 
outcomes in the offspring. The only systematic review for food-based intervention 
trials by Kramer and Kakuma (2012) also conducted sub-group analyses for different 
follow-up time points and specific food allergens. 
 
Based on the above-mentioned, broad definitions of allergic outcomes were 
introduced into the conducted meta-analyses in current systematic review and sub-
group analyses were avoided for the criteria as defined below:  
a. Duration of intervention; prenatal only or continued postnatal 
b. Specific strain/type of pro/prebiotics, fatty acids, food-based interventions 
c. Method of diagnosis 
d. Length of follow-up 
e. Selected/unselected sample 
f. Dosage/frequency/delivery mode of intervention 
g. Study location & setting 
j. Where reported, cumulative prevalence/incidence are included in meta-analyses and 
if not reported, point prevalence(s) are considered  
k. Outcomes solely based on parental report, which applies to the broadest definition 
of the outcome, have been reported descriptively.  
It was believed that this approach could add to the current evidence base and offer a 
view for the overall benefit of prenatal dietary interventions for prevention of 
childhood allergies.  
3.3.4.5. Assessment of reporting biases 
Every effort was made to identify unpublished studies through searching abstracts and 
ongoing trials databases as described in section 3.3.2. Publication bias was assessed 
using funnel plots, when there were ≥10 studies included in the meta-analysis because 
the power of the test would be high enough to distinguish chance from real 
asymmetry (Egger, Davey Smith, Schneider, & Minder, 1997; Sterne, Egger, & 
Smith, 2001). The asymmetry was assessed visually in the plots produced using ER4, 
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and no formal statistical tests were conducted. The funnel plots were helpful to 
explore possible small study biases for some of the primary outcomes.  
3.3.4.6. Data synthesis  
All meta-analyses were conducted using a random-effects model in view of the 
clinical and methodological differences between included studies. Dichotomous data 
were entered as events and the number of participants. Data were pooled using 
random-effects model only where heterogeneity was reported as ≤75% and also 
relative risk (RR) was reported as a statistical choice in conducting the meta-analyses, 
as it is easy to interpret (Deeks et al., 2011). 
 
3.4. Changes to the protocol  
There were four changes made to the protocol whilst conducting the review. Firstly, 
in the protocol for this review, it was initially stated that in trials with multiple 
intervention groups, data for the control group would be used for each intervention 
group comparison and the weight assigned to the control group would be reduced by 
dividing the number of participants in the control group by the number of intervention 
groups. However for more clarity, and as recommended by Cochrane Collaboration 
(Deeks et al., 2011), it was decided to pool the data for each intervention arm in these 
trials and make the comparison for the pooled intervention arm versus the control 
group. So, the weight assigned to the intervention group was considered as the total 
number of participants in intervention arms divided by the number of participants in 
the control group.  
 
Secondly, it was intended to use the per-protocol analysis for conducting all the meta-
analyses; however this was not possible for some papers as ITT was the only 
available data, and these reported data were used in performing meta-analyses. 
 
Thirdly, it was planned to narratively describe study results when outcome data was 
solely based on parental reporting. However for one of the papers which utilised food 
intervention, the outcomes “atopic eczema, with parental opinion” as well as ‘food 
allergy, parental report’ are entered in meta-analysis, as these were the only specific 
reported outcome in the study. 
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Lastly, as a broad definition of allergic disorders has been considered in this review, 
in terms of statistical and clinical heterogeneity, we did not plan to conduct any 
detailed sub-group and/or sensitivity analyses for pre/probiotic, fatty acid and food 
intervention studies. However where required, some sub-group analyses have been 
performed and the explanation for this has been provided in the accompanying text. It 
is worth mentioning, since this is the first systematic review for vitamin 
supplementations on prevention of allergic diseases in the offspring, we have 
conducted sub-group analyses for this dietary group. However it was not possible to 
conduct sensitivity analyses since there were a limited number of studies that could 
contribute in the meta-analyses in the dietary group as vitamins.  
3.5. Results 
3.5.1. Studies identified through searches and total included studies 
Searches of electronic databases were initially carried out between November and 
December 2014 and updated on 31
st
 January 2016. The searches yielded a total of 
3,271 references and as specified in the protocol, removal of duplicates and non-
relevant studies (1,384) from the 1,489 included studies for screening the title and 
abstract left 105 papers for further consideration. Of the remaining 105 references, 46 
were excluded after closer inspection showed that they had either reported an 
inappropriate study outcome or had inappropriate study design/participants and in the 
case of one paper, that it was fabricated data. Of the studies excluded due to 
inappropriate design at this stage, one was in Spanish and a native Spanish speaker 
was consulted to find out whether the paper met the inclusion criteria for this 
systematic review. As the study was a non-randomised trial, with food avoidance as 
the intervention, it was excluded (listed in Appendix 3.4).  
 
Full-text screening of the remaining 59 papers showed that they were either a study 
protocol (n=2) or earlier published reports of the included studies (n=29). These 
earlier reports, hereafter referred to ‘linked records/companion papers’, were used to 
extract any relevant data of the initial trial, if required. Also, supplementary searches 
from other databases resulted in two papers. As a result, a total number of 32 studies 
were included in the systematic reviews. The PRISMA flow diagram is shown in 
Figure 3.1.  
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Figure 3.1. PRISMA flowchart for the literature search strategy-Allergy 
outcomes 
 
The list of the included studies that met the inclusion criteria for this systematic 
review, by intervention type, is shown in Table 3.2. All trials were in English and had 
been carried out in various countries across the world. The descriptive findings, risk 
of bias assessment and effects of interventions are structured by intervention in the 
following sections.  
 
	
	
	
 
 
	
	 	
	
	
	 	
		 	
	
	
	
		
	 	
	
	
	
	
	
	
*
To supplement the electronic searching, the reference lists of papers selected for full text screening as well as 
key systematic reviews on the topic were scrutinised to identify any further studies. 
**
Earlier reports/papers of the trials included in the systematic reviews and were used for data extraction if 
required	
*
Additional papers 
identified (n=2) 
Full texts considered for data extraction 
(n=32) 
Papers selected for further 
screening on abstract 
(n=105) 
Papers excluded (n=46): 
Inappropriate Study 
outcome (n=21) 
Fabricated data (n=1) 
Inappropriate Study 
design (n=18) 
Inappropriate 
Participants (n=6) 
Papers selected for full-text 
screening (n=59) 
 
Papers excluded 
following further 
screening (n=31): 
Study protocol (n=2) 
Linked record (n=29)
**	
 
 
Records identified 
through database 
searching 
(total=3,271):   
MEDLINE (n= 427) 
COCHRANE  
(n=1,465) 
SCOPUS (n=1,364),  
OTHER 
DATABASES, as 
specified in the 
protocol (n=15) 
 
Records excluded (total=1,782): 
Reviews/Meta-analysis/Protocols 
(n=1,778) 
Guidelines (n=2) 
Magazines (n=2) 
Original studies included for screening 
the title and abstracts, as specified in 
the protocol (n=1,489) 
Papers excluded 
(n=1,384): 
Non-relevant, 
non-randomised 
& inappropriate 
populations  
(n=1,284)  
Duplicates 
(n=100) 
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Table 3.2. List of the included trials 
Probiotic Interventions AOD ITT Fatty Acid Interventions AOD ITT 
Kalliomäki 2003 ✓ NI Dunstan 2003 ✓ NI 
Kalliomäki 2007 ✓ NI Olsen 2008 ✓ - 
Huurre 2008 ✓ NI Linnamaa 2010 ✓ - 
Kopp 2008 ✓ - Furuhjelm 2011 ✓ - 
Niers 2009 ✓ - Noakes 2012 ✓ NI 
Kuitunen 2009 ✓ - Palmer 2013 - ✓ 
Kim 2010 ✓ - Escamilla-Nunez 2014 ✓ - 
Dotterud 2010  ✓ ✓ Food Interventions 
Boyl 2011 ✓ ✓ Lilja 1989 ✓ - 
Rautava 2012 ✓ ✓ Zeiger 1992 ✓ - 
Ou 2012 ✓ ✓ Fälth-Magnusson 1992 ✓ - 
Abrahamsson 2013 ✓ NI Lovegrove 1994 ✓ - 
Wickens 2013 ✓ ✓ Vitamin Interventions 
Allen 2014 ✓ ✓ Greenough 2010 ✓ Yes 
Gorissen 2014 ✓ ✓ Goldring 2013 ✓ No 
Simpson 2015 ✓ ✓ McEvoy 2014 ✓ Yes 
   Chawes 2016 - Yes  
   Litonjua 2016 - Yes  
*For studies with data available on both observed and ITT analysis, the observed data are included in meta-analysis.  
Ante. AOD=Analysis on the Observed Data; ITT=Intention to Treat Analysis, some trials have conducted the ITT only for 
certain outcomes; NI=No Information 
 
3.5.2. Presentation of the results 
The Meta-analyses for assessing the effect of intervention are structured by the 
intervention type. Within each intervention category, studies are grouped and assessed 
for the clinical outcome(s) of interest for this systematic review. Detailed descriptions 
of the outcomes included in the meta-analyses are also presented. As described in 
section 3.3.4.4, meta-analyses were conducted using a random effect model and with 
the exception for vitamin studies, no detailed sub group analyses were conducted for 
the pro/prebiotics, fatty acids and food intervention dietary groups.  
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3.5.3. Description of included studies of maternal pro/prebiotic 
consumption during pregnancy and prevention of allergic diseases in the 
offspring 
Of the 32 included trials, 16 examined the impact of probiotic interventions on the 
development of allergic diseases in offspring, including 3,567 children (this number 
also comprises the three earlier reports of the included trials). One study only 
examined the impact of a combination of probiotics and prebiotics on the 
development of allergic diseases in offspring (Kuitunen, Kukkonen, & Savilahti, 
2009) while all other studies have used different strains of probiotics only. In the case 
of three trials, both the reports of an earlier as well as the latest follow-up data were 
included, since some of the outcomes of interest for this systematic review were 
reported only in the earlier published papers of these trials. These studies were as 
below:  
i. Kalliomäki, Salminen, Poussa, & Isolauri, 2007 reported the longer follow-up of 
Kalliomaki, Salminen, Poussa, Arvilommi, & Isolauri, 2003 
ii. Gorissen et al., 2014 reported the longer follow-up of Niers et al., 2009   
iii. Simpson, Dotterud, Storrø, Johnsen, & Øien, 2015 reported the longer follow-up 
of Dotterud, Storrø, Johnsen, & Oien, 2010  
 
The detailed characteristics of the included trials, their companion papers and study 
population are shown in Table 3.3. In total, four studies were conducted in Finland 
and the rest in Sweden, United Kingdom, Australia, Norway, Korea, Germany, 
Netherlands, New Zealand and Taiwan. All studies used placebo as their 
comparator/control.  
 
The longest follow-up period was 7 years, in the study conducted by (Abrahamsson, 
Jakobsson, Bjorksten, Oldaeus, & Jenmalm, 2013), followed by 6 years in studies by 
(Gorissen et al., 2014; Kalliomäki, et al., 2007; Simpson, et al., 2015; Wickens et al., 
2013). The largest study sample was reported in (Kuitunen, et al., 2009) with 1,223 
mothers enrolled followed by Wickens et al. (2013) and (Allen et al., 2014) with 511 
and 454 pregnant mothers at enrolment respectively. The smallest sample size was 
observed in studies conducted by (Kopp, Hennemuth, Heinzmann, & Urbanek, 2008) 
and (Kim et al., 2010) with 105 and 112 mothers randomised at recruitment 
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respectively. 
 
With the exception of two studies (Allen et al., 2014; Simpson, et al., 2015), the study 
sample was selected from the families with a reported history of atopic diseases.  
 
The most frequently reported outcomes listed were: wheeze, eczema, asthma and 
positive SPT.  
 
Compliance with the intervention was assessed by a variety of methods, including 
maternal interview or daily diaries, counting of unused supplements and faecal 
examination. Method of adherence to intervention was not reported in the studies 
conducted by (Huurre, Laitinen, Rautava, Korkeamäki, & Isolauri, 2008; Kalliomaki, 
et al., 2003; Kopp, Hennemuth, Heinzmann, & Urbanek, 2008; Ou et al., 2012; 
Rautava, Luoto, Salminen, & Isolauri, 2012). 
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Table 3.3. Characteristics of included trials and study population on pro/prebiotics and prevention of allergy in offspring 
Primary 
article  
Companion 
articles 
Country, 
enrolment 
period 
Trial 
type
*
 
Study intervention 
& comparator 
No. of 
participants
**
 
No. at last  
F-U
***
 
Time points 
measured 
Age at last  
F-U 
Sample: high 
risk of Atopy 
Outcomes 
reported 
 
(Kalliomaki 
et al., 2003) 
 
(Kalliomaki et 
al., 2001) 
(Rautava, 
Kalliomäki, & 
Isolauri, 2002) 
 
Finland 
1997-98 
PC-
RCT 
LGG Probiotics & 
Placebo 
159 mothers 107 (53 vs. 
54) 
1, 1.5, 2  & 
4yrs. 
4yrs. Yes -Eczema 
-Asthma 
-SPT (any positive) 
-SPT (peanut) 
-SPT (CAT) 
-SPT (Cod) 
-SPT (grass) 
-SPT (Dog) 
-Food Allergy 
-Rhinitis 
-SPT (Birch) 
-SPT (Alder) 
(Kalliomaki 
et al., 2007)  
(Kalliomaki et 
al., 2001) 
(Rautava, et al., 
2002) 
Finland 
1997-98 
PC-
RCT 
LGG Probiotics & 
Placebo 
159 mothers 116 (53 vs. 
62) 
1, 1.5, 2, 4 & 
6yrs. 
6yrs. Yes -Eczema 
-Asthma 
-SPT (any positive) 
-Rhinitis 
(Huurre,  et 
al., 2008) 
 
(Piirainen, 
Isolauri, 
Lagstrom, & 
Laitinen, 2006)  
Finland  
2002-unclear 
PC-
RCT 
Mixed probiotics & 
placebo 
140 mothers 140 (72 vs. 
68) 
1,6 & 12 
months 
1yr. Yes -Eczema 
-SPT (any positive) 
 
(Kopp, et al., 
2008)  
 
(Kopp et al., 
2008) 
 
Germany  
2002-04 
PC-
RCT 
LGG & Placebo 105 mothers 94 (50 vs. 
44) 
6,12 & 24 
months 
2yrs. Yes 
 
-Wheeze 
-Eczema 
-Upper Respiratory 
Tract Infection  
-Any IgE 
(Niers et al., 
2009) 
 
(Gorissen et al., 
2014) 
Netherlands 
2004-05 
PC-
RCT 
Mixed Probiotic 
bacteria & placebo 
156 mothers 98 (50 vs. 
48) 
3, 6, 12 & 
24months 
 
2yrs. Yes -Eczema 
-SPT (any positive) 
-SPT (food) 
-Specific IgE 
-Sensitisation 
(Either positive SPT 
or/& sIgE >0.35 
IU/ml) 
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Primary 
article  
Companion 
articles 
Country, 
enrolment 
period 
Trial 
type
*
 
Study intervention 
& comparator 
No. of 
participants
**
 
No. at last  
F-U
***
 
Time points 
measured 
Age at last  
F-U 
Sample: high 
risk of Atopy 
Outcomes 
reported 
 
-SPT (Inhalation 
allergens) 
-Any IgE 
(Kuitunen, et 
al., 2009) 
 
(Kukkonen, 
Nieminen, 
Poussa, Savilahti, 
& Kuitunen, 
2006)  
(Kukkonen et al., 
2007) 
(Kukkonen et al., 
2008)  
Finland 
2000-03 
PC-
RCT 
Mixed Probiotic & 
placebo 
1,223 mothers 891 (445 
vs. 446) 
3, 6, 12, 
24months & 
5yrs. 
5yrs. Yes -Allergic disease(s) 
-Eczema 
-Asthma 
-SPT (any positive) 
-Specific IgE 
-Sensitisation (Any 
positive SPT &/or 
sIgE >0.7 IU/ml) 
-Rhinitis 
(Kim et al., 
2010)  
 
None  Korea 
2005-06 
PC-
RCT 
Mixed Probiotics & 
placebo 
112 mothers 68 (33 vs. 
35) 
3, 6 & 12 
months 
1yr. Yes -Eczema 
-IgE-associated 
eczema 
-Specific IgE (any 
food) 
-Any IgE 
-Probable Food 
Allergy (egg) -
Probable food 
allergy (cow’s milk) 
(Dotterud, et 
al., 2010)  
(Simpson, et al., 
2015)  
Norway 
2003-05 
PC-
RCT 
Pro milk & placebo 
milk 
415 mothers 278 (138 
vs. 140) 
2yrs 2yrs. No -Eczema 
-Asthma 
-SPT (any positive) 
-Specific IgE 
-Allergic 
Rhinoconjunctivitis 
-Atopic sensitised 
(Boyle et al., 
2011)  
 
(Boyle et al., 
2008) 
(Lahtinen, 
Boyle, 
Kivivuori, 
Oppedisano, 
Australia 
2006-08 
PC-
RCT 
LGG & placebo 250 mothers 212 (109 
vs. 103) 
3, 6 & 12 
months 
1yr. Yes -Eczema 
-SPT (any positive) 
-SPT (egg) 
-SPT (peanut) 
-SPT (cows milk) 
-SPT (food) 
-SCORAD (0, 1-25, 
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Primary 
article  
Companion 
articles 
Country, 
enrolment 
period 
Trial 
type
*
 
Study intervention 
& comparator 
No. of 
participants
**
 
No. at last  
F-U
***
 
Time points 
measured 
Age at last  
F-U 
Sample: high 
risk of Atopy 
Outcomes 
reported 
 
Smith, 2009)  25-50, >50) 
-SPT (aeroallergen) 
(Rautava, et 
al., 2012)  
 
None Finland 
2005-09 
PC-
RCT 
2 diff. mixed 
probiotic arms & 
placebo 
241 mothers 205 (73 vs. 
70 vs. 62) 
6, 12 & 24 
months 
2yrs. Yes -Eczema 
-SPT (any positive) 
(Ou et al., 
2012) 
 
Kuo 2012 
(conference 
presentation) 
Taiwan  
2002-06 
PC-
RCT  
LGG Probiotics & 
placebo 
191 mothers 128 (65 vs. 
63) 
6, 18 & 36 
months 
3yrs. Yes 
 
 
-Any Allergic 
disease(s) 
-Wheeze 
-Eczema 
-Specific IgE 
-Sneezing and/or 
snuffling 
-Any IgE 
(Abrahamsson
, et al., 2013)  
 
(T R 
Abrahamsson et 
al., 2007) 
(Bottcher, 
Abrahamsson, 
Fredriksson, 
Jakobsson, & 
Bjorksten, 2008) 
(Forsberg, 
Abrahamsson, 
Bjorksten, & 
Jenmalm, 2014)  
Sweden  
2001-03 
PC-
RCT 
Lactobacillus 
reuteri & placebo 
 
232 mothers 
 
184 (94 vs. 
90) 
2 & 7yrs. 7yrs. Yes -Any Allergic 
disease(s) 
-Wheeze 
-Eczema 
-Asthma 
-SPT (any positive) 
-Allergic 
Rhinoconjunctivitis 
-Respiratory allergy 
-Urticaria 
-SCORAD 
(Wickens et 
al., 2013) 
 
(Wickens et al., 
2008) 
(Wickens et al., 
2012) 
(Dekker et al., 
2009) (S.L. 
Prescott et al., 
2008) 
New 
Zealand 
2004-05  
PC-
RCT 
2 diff mixed 
probiotic arms & 
placebo 
511 mothers 422(134 
vs. 144 vs. 
144) 
2, 4 & 6yrs. 6yrs. Yes -Wheeze 
-Eczema 
-Asthma 
-Allergic 
Rhinoconjunctivitis 
-SPT (any positive) 
-Specific IgE 
-SCORAD 
-Any IgE 
(Allen et al., (Allen et al., the UK PC- Mixed probiotic & 454  378 (187 6months & 2yrs. No -Wheeze 
-Eczema (atopic) 
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Primary 
article  
Companion 
articles 
Country, 
enrolment 
period 
Trial 
type
*
 
Study intervention 
& comparator 
No. of 
participants
**
 
No. at last  
F-U
***
 
Time points 
measured 
Age at last  
F-U 
Sample: high 
risk of Atopy 
Outcomes 
reported 
 
2014) 2010)  
 
2005-unclear RCT placebo mother-infant 
dyads 
vs. 191) 2yrs. -Asthma 
-SPT (any positive) 
-SPT (egg) 
-SPT (HDM) 
-SPT (cows milk) 
-SPT (CAT) 
-SPT (grass) 
-Food Allergy 
-Rhinitis 
-Cough 
-Chronic cough 
-Sneezing and/or 
snuffling 
(Gorissen et 
al., 2014) 
 
(Niers et al., 
2009) 
 
Netherlands 
2004-05 
PC-
RCT 
Mixed Probiotic & 
placebo 
156 mothers 83 (39 vs. 
44) 
3, 12 & 
24months, 
6yrs. 
6yrs. Yes -Eczema 
-Asthma 
-Food Allergy 
-Rhinitis 
(Simpson, et 
al., 2015) 
(Dotterud, et al., 
2010) 
Norway 
2003-05 
PC-
RCT 
Probiotic milk & 
placebo milk 
415 mothers 163 (81 vs. 
82) 
2 & 6yrs. 6yrs. No -Eczema 
-Asthma 
-Allergic 
sensitisation (any 
SPT or Specific 
IgE) 
-Allergic 
Rhinoconjunctivitis 
-Wheeze 
-Lower respiratory 
tract infection 
+Published data and conference presentations, No unique data were extracted from conference abstracts          
*Placebo Controlled-Randomised Controlled Trial 
**Indicates the number at randomisation, where recruitment has occurred prenatally           
***Follow-up 
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Table 3.4 shows the details of the pro/prebiotic interventions and placebo used in 
included trials. In all studies the intervention and placebo groups had comparable 
baseline characteristics at recruitment. It is worth noting that the Abrahamsson et al. 
(2013) study reported higher antibiotic prescription during the first year of life in the 
intervention vs. placebo group (p=0.03).  
 
Only one study administered probiotics solely during pregnancy (Boyle et al., 2011). 
In the remainder, the probiotic interventions were continued after pregnancy either in 
mothers only or with both mothers and their infants for a period of time (Table 3.4). 
The longest duration of intervention was 25 months (Wickens et al., 2013) and the 
shortest was 2-4 weeks (Boyle et al., 2011). In five studies, a single strain of 
probiotics was used (Abrahamsson et al., 2013; Boyl et al., 2011; Kalliomäki et al., 
2003 & 2007; Kopp et al., 2008; Ou et al., 2012); whereas a mixed strain of probiotics 
was employed in the other included trials. For the purpose of this systematic review, 
all the probiotic intervention studies, whether they used mixed or single strains of 
probiotics, have been grouped together under one umbrella as “any probiotics”.  
 
Two studies included two active intervention arms employing different mixed strains 
of probiotics in each intervention group and comparing these with a placebo (Rautava, 
et al., 2012; Wickens et al., 2013). For reporting purposes and as recommended by the 
Cochrane Handbook (Deeks et al., 2011), data from the two different active 
intervention arms were pooled when entered into meta-analysis.  
 
Probiotic preparations included oil drops, capsules, milk and sachets. The study 
conducted by Huurre,  et al., 2008 provided women with nutritional advice during 
pregnancy and breastfeeding as well as randomising them to receive mixed probiotics. 
The dietary counselling focused on the amount and type of fat and also the amount of 
fibre in their diet.  
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Table 3.4. Characteristics of pro/prebiotics interventions in included trials 
Primary 
article  
Comparable 
baseline 
characteristic  
Participants 
receiving 
intervention 
Timing of  
Intervention in 
pregnancy 
Intake of 
Intervention 
from/until
*
 
Duration of 
intervention 
(months)
**
 
Probiotic 
organism
***
 
Placebo 
 
Mode of 
delivery 
Total daily dose 
(Colony 
Forming Units) 
(Kalliomaki et 
al., 2003;  
Kalliomaki et 
al., 2007) 
Yes Prenatally and 
postnatally in 
mothers and 
infants 
2–4wks before 
expected 
delivery 
6 months in  
B-F mothers 
6.5-7 LGG Microcrystalline 
cellulose 
Capsule 1 × 10
10 
CFU/day, daily 
 
(Huurre,  et 
al., 2008) 
Yes Prenatally and 
postnatally in 
mothers  
From 1st 
trimester of 
pregnancy 
9wks to 
4months 
(exclusive BF) 
10.5-11 LGG + BL 
Bb12 
Microcrystalline 
cellulose & 
dextrose 
anhydrates 
Capsule  1 × 10
10 
CFU/day for 
each probiotic 
strain, daily 
(Kopp, et al., 
2008) 
Yes Prenatally and 
postnatally in 
mothers and 
infants 
4–6wks before 
expected 
delivery 
3 months  7-7.5  LGG Microcrystalline 
cellulose 
Capsule 5 × 10
9 
CFU/day 
Twice a day 
(Niers et al., 
2009; 
Gorissen et 
al., 2014) 
Yes Prenatally and 
postnatally in 
mothers and 
infants 
During the last 
6wks of 
pregnancy 
34wks to 
12mon 
postnatal 
13.5  BB W23 + 
BL W52 + 
LL W58 
Carrier of the 
probiotic 
product i.e. rice 
starch & 
maltodextran 
Sachets 1 × 10
10 
CFU/day 
for each 
probiotic strain, 
3g daily 
(Kuitunen, et 
al., 2009) 
Yes Prenatally and 
postnatally in 
infants 
From 36wks of 
gestation 
6 months 
postnatal 
6.5-7 LC705 +  
LC705 
+bb99 + Pf 
Microcrystalline 
cellulose 
Capsule 5 × 10
9
,
 
5 × 10
9
, 
2× 10
8
, 2 × 10
9
 
CFU/day, twice 
a day 
(Kim et al., 
2010) 
Yes Prenatally and 
postnatally in 
mothers and 
infants 
From 8wks 
before the 
expected 
delivery 
3 months after 
delivery 
8 BB BGN4 + 
BL AD011 + 
LA AD031  
malt dextrin and 
alpha-corn 
without 
probiotic 
bacteria 
Sachets  1.6 × 10
9 
CFU/day 
for each 
probiotic strain, 
daily 
(Dotterud, et 
al., 2010; 
Simpson, et 
al., 2015) 
Yes Prenatally and 
postnatally in 
mothers  
From 36 wks. 36wks to 
3mon 
Postnatal 
3.5-4  LGG + BA 
(subsp. lactis 
Bb-12) + La-
5 
Sterile milk  
(with no 
probiotic 
bacteria) 
Milk 5 × 10
10 
+ 5 × 
10
9 
CFU/day, 
250mL daily 
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Primary 
article  
Comparable 
baseline 
characteristic  
Participants 
receiving 
intervention 
Timing of  
Intervention in 
pregnancy 
Intake of 
Intervention 
from/until
*
 
Duration of 
intervention 
(months)
**
 
Probiotic 
organism
***
 
Placebo 
 
Mode of 
delivery 
Total daily dose 
(Colony 
Forming Units) 
(Boyle et al., 
2011) 
Yes Prenatally  From 36 wks. 36wks to 
delivery 
2-4 wks. LGG malt dextrin Capsule 1 × 10
10 
CFU/day, daily 
(Rautava, et 
al., 2012) 
Yes Prenatally and 
postnatally in 
mothers  
2mon before 
expected 
delivery day 
28wks to 
2mon 
postnatal 
4 LPR+BL999 
or 
ST11+BL99
9  
Same dietary 
supplement 
without 
probiotics 
Sachets 
1 × 10
9 
CFU/day, daily 
for each 
probiotic strain  
(Ou et al., 
2012) 
Yes Prenatally and 
postnatally in 
mothers and 
infants 
Beginning from 
24wks 
24wks to 
6mon 
postnatal 
9.5-10 LGG  Micro-
crystalline 
cellulose 
Capsule 
1 × 10
10  
CFU/day, daily
 
 
(Abrahamsson
, et al., 2013) 
Yes, higher 
Antibiotic 
prescription 
during the first 
year of life in 
Int. vs. 
placebo in 1
st
y 
of life 
Prenatally and 
postnatally in 
infants 
From 36+0 wks. 36wks to 
12mon 
postnatal 
12.5-13  L. reuteri Same oil 
without any 
bacteria 
Oil drops 1 × 10
8
 
CFU/day, 
5 drops daily 
(Wickens et 
al., 2013) 
Yes Prenatally and 
postnatally in 
mothers and 
infants 
From 35wks 
gestation 
35wks to 2yrs. 
postnatal 
25-25.5 BA HN019 
or L 
rhamnosus 
HN001 
Dextran, salt, 
and a yeast 
extract 
Capsule 
9 × 10
9
,
 
6 × 10
9 
CFU/day, daily 
(Allen et al., 
2014) 
Yes Prenatally and 
postnatally in 
infants 
From 36 wks. 36wks to 
6mon 
postnatal 
7 LS + LP + 
BB + BA 
malt dextrin 
powder 
 
Vegetarian 
capsule 
1 × 10
10 
CFU/day, daily 
*Abbreviations: WKS= weeks, MON= months, BF=Breast-Feeding 
**Indicates total duration in pregnancy plus after birth either in mothers only or both mother and infant, if applicable  
***LS=Lactobacillus Salivarius , LP=Lactobacillus  Paracasei, LGG=Lactobacillus rhamnosus GG, La-5=Lactobacillus.acidophilus 5,  LL=Lactococcus. Lactis, LA=Lactobacillus.acidophilus, BA=Bifidobacterium 
Animalis, BB=Bifidobacterium Bifidum, BL= Bifidobacterium Lactis, Bb=Bifidobacterium breve, Pf=Propionibacterium freudenreichii
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3.5.4. Risk of bias in studies of maternal pro/prebiotic consumption during 
pregnancy and prevention of allergic diseases in the offspring 
The summary of risk of bias in trials on pro/prebiotic studies is presented in Figure 
3.2. The reviewer’s judgment for the risk of bias assessment of pro/prebiotic studies is 
shown in appendix 3.6.  
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Study author Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Kalliomäki 
(2003) 
+ + + + + + ? 
Kalliomaki (2007) + + ? + - + ? 
Huurre (2008) ? ? ? + - + - 
Kopp (2008) + ? ? + + + + 
Niers (2009) ? ? ? + + + + 
Kuitunen (2009) + + + ? ? + + 
Kim (2010) + + + + - + + 
Dotterud (2010) + + + + ? + + 
Boyle (2011) + + + + + + + 
Ou (2012) ? + + + ? + ? 
Rautava (2012) + + + + + + + 
Abrahamsson 
(2013) 
? + - - - + - 
Wickens (2013) + + - + - + + 
Allen (2014) + + + + + + + 
Gorissen (2014) ? ? - - + + ? 
Simpson (2015) + + - - - + + 
 
Random Sequence 
Generation   69% 31%   
 
Allocation 
Concealment   
 
75% 25%   
 
Double Blinding   
 
50% 25% 25% 
 
Blinding of 
Outcome 
Assessment   
75% 6% 19% 
 
Incomplete 
Outcome Data   
 
44% 18% 38% 
 
 80 
Selective Outcome 
Reporting   
 
100%    
 
Other Sources of 
Bias   
 
69% 19% 12% 
 
 
Low risk of bias  High risk of bias   Unclear risk of bias  
 
 
Figure 3.2. Summary of risk of bias assessment in the included trials of pro/prebiotics and prevention of allergy in the offspring 
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3.5.4.1. Random sequence generation (selection bias) 
Of the 16 included trials, eleven studies were assessed as having a low likelihood of 
selection bias (Allen et al., 2014; Boyl et al., 2011; Dotterud et al., 2010; Kalliomaki 
et al., 2003; Kalliomäki et al. 2007; Kim et al., 2010; Kopp et al., 2008; Kuitunen et 
al., 2009; Rautava et al., 2012; Simpson et al., 2015; Wickens et al., 2013). The 
treatment allocation in these studies was carried out using a computer generated 
randomisation system. The risk of selection bias in the remaining studies was unclear 
as they either had not reported their method of randomisation or just stated that they 
had used block randomisation with no further information. 
3.5.4.2. Allocation concealment  
The method of allocation concealment was not clear in four studies (Gorissen et al., 
2014; Huurre, et al., 2008; Kopp et al., 2008; Niers et al., 2009). The remaining 
studies kept the allocation concealed from the staff involved with the study.   
3.5.4.3. Double blinding (performance bias) 
There was no blinding of either staff and/or participants at the time of extended 
follow-up in four studies (Abrahamsson, et al., 2013; Gorissen et al., 2014; Simpson 
et al., 2015; Wickens et al., 2013). Four studies gave no indication of blinding, of 
either staff or participants, and were recorded as having an unclear risk (Huurre et al., 
2008; Kalliomaki et al., 2007; Kopp et al., 2008; Niers et al., 2009). The rest of the 
studies stated that their trial was double-blinded by keeping the codes blinded to 
research staff throughout the study and also, by ensuring an equal appearance and 
smell for the intervention and placebo supplementations. 
3.5.4.4. Blinding of outcome assessment (detection bias) 
Only three of the 16 included studies were rated as having high risk of bias for 
blinding of outcome assessment (Abrahamsson, et al., 2013; Gorissen et al., 2014; 
Simpson et al., 2015), as their extended follow-up study was only single-blinded to 
either the parents and/or investigator(s). One study was rated as unclear for the 
blinding of outcome assessment (Kuitunen, et al., 2009) and the remainder were 
classified as low risk.  
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3.5.4.5. Incomplete outcome data (attrition bias) 
Completeness of data was ranked as high risk in six studies (Abrahamsson et al., 
2013; Huurre et al., 2008; Kalliomaki et al., 2007; Kim et al., 2010; Simpson et al., 
2015; Wickens et al., 2013). Two studies had a high loss to follow-up and did not 
specify the reasons for missing participants (Abrahamsson et al., 2013; Kalliomäki et 
al., 2007) and one reported the outcomes for different sub-samples within study arms 
(Huurre et al., 2008). Wickens et al. (2013) used imputed analysis for a number of the 
reported outcomes and the two remaining studies (Kim et al., 2010 and Simpson et 
al., 2015) were affected by a high rate of attrition due to participants’ refusal and non-
compliance. Three studies (Dotterud et al., 2010; Kuitunen, et al., 2009; Ou et al., 
2012) were rated as unclear as they did not specify the reasons for loss to follow-up. 
The rest of the studies were rated as low risk of bias as missing data were balanced 
across groups.  
3.5.4.6. Selective outcome reporting (reporting bias) 
All the pre-specified outcomes, either published in the protocol for the study or listed 
in the manuscript, were reported including the cumulative prevalence of allergic 
disorders and consequently all the included trials were deemed to have a low risk of 
bias.  
3.5.4.7. Other potential sources of bias 
Each included study was assessed for other factors that might contribute to additional 
risk of bias. Two studies were rated as being at high risk of further bias (Abrahamsson 
et al., 2013; Huurre,  et al., 2008). In one, participants reported that they continued to 
consume the study intervention product after delivery despite this not being part of the 
study protocol (Abrahamsson et al., 2013). In the other, Huurre et al. (2008) reported 
no information as to whether women have been aware of their allocation or whether 
they have consumed the probiotic strain(s) after their intervention was completed. 
Four studies were rated as unclear for further risk of bias (Gorissen et al., 2014; 
Kalliomaki et al., 2003; Kalliomäki et al., 2007, Ou et al., 2012) since there was no 
information provided regarding whether the participants have consumed the 
pro/prebiotics supplement afterwards. The remaining studies were classified as low 
risk of any further bias. 
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3.5.5. Meta-analyses of effectiveness of maternal pro/prebiotics 
consumption during pregnancy and prevention of allergic diseases in the 
offspring 
Pooled results from meta-analyses in the studies that examined the effectiveness of 
maternal pro/prebiotic supplementations during pregnancy for the prevention of 
allergic outcomes in offspring are presented in the following section. Funnel plots are 
presented for outcomes that have been reported by a sufficient number of studies 
(≥10). 
3.5.5.1. Any ‘Allergic Diseases’ as an outcome for pro/prebiotic intervention 
The use of pro/prebiotic products during pregnancy for prevention of allergic diseases 
was assessed in three studies. Figure 3.3 shows the Forest plot for pro/prebiotics 
versus placebo in pregnant women for the prevention of allergic diseases in offspring. 
Any ‘allergic disease’ was defined differently in the included studies. These are 
described as below: 
Abrahamsson et al. (2013): Allergic disease was defined as “asthma, allergic 
rhinoconjunctivitis (ARC), allergic urticaria and eczema” with the child having had 
symptoms of and/or having been treated for the actual allergic disease during the last 
12 months. Children with allergic disease before school age who did not have any 
symptoms during the last 12 months were defined as healthy. This outcome was 
measured at 2 and 7 year follow-ups and reported as positive at any of the time points.  
Kuitunnen et al. (2009): The outcome considered was ‘allergic diseases with or 
without positive SPT response and/or IgE >0.7kU/L’. Allergic diseases were defined 
as food allergy, eczema, asthma or allergic rhinitis. The outcome was measured as a 
cumulative prevalence at 5 years. 
Ou et al. (2012): Any allergic disease was defined by any phenotypes of allergy as 
physician-diagnosed asthma, allergic rhinitis, and atopic dermatitis (AD), plus 
sensitisation. The outcome was reported as point prevalence at 3 years. 
Statistically, these studies were largely homogeneous, with 0% variation between 
studies attributable to heterogeneity as opposed to sampling error (χ2=0.49, p=0.78, 
I
2
=0%). The result of meta-analysis did not show an association between maternal 
intake of pro/prebiotics during pregnancy and prevention of allergic diseases in the 
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offspring (Risk Ratio (RR)= 0.979, 95% Confidence Interval (CI)= 0.88-1.086; 1,157 
children) (Figure 3.3).  
 
Figure 3.3. Forest plot of pro/prebiotics vs. placebo for any allergic diseases  
Measure: Binary: risk ratio 
Heterogeneity: Q = 0.497; df = 2; p = 0.78; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.979 (0.881, 1.09) 
 
 
 
 
 
 
3.5.5.2. Asthma as an outcome measure for pro/prebiotic intervention 
Seven included studies measured the effect of pro/prebiotic products consumption 
during pregnancy on prevention of asthma in offspring (Figure 3.4). In studies 
included in the meta-analysis asthma was defined as follows:  
Abrahamsson et al. (2013): Two criteria were used for the diagnosis of Asthma: 1) 
doctor diagnosis and asthma symptoms and/or use of asthma medication during the 
last 12 months; 2) wheeze or nocturnal cough and a positive reversibility test and/or 
pathological fractional exhaled nitric oxide (FENO) value. This outcome was measured 
at 2 and 7 years follow-ups and reported as positive at any of the time points. 
Allen et al. (2014): All reported asthma was used whether diagnosed by a health 
professional or not, and assessed by follow-up questionnaires. This outcome was 
reported as the cumulative prevalence at 2 years. 
Gorrisen et al. (2014): Asthma was defined based on at least one of the following 
four criteria: i) doctors diagnosed asthma active in the past 12 months; ii) parental 
reported wheezing in the past 12 months; iii) use of asthma medication in the past 12 
months; iv) an at least 9% reversibility in the forced expiratory volume in half a 
second Forced Expiratory Volume (FEV0.5) or in one second (FEV1). The outcome 
Outcome: Any allergic diseases Probiotics n/N Placebo n/N 
Abrahamsson 56/94 51/90 
Kuitunne 234/445 245/446 
Ou 11/41 12/41 
Subtotal 580 577 
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was reported as point prevalence at 6 years 
Kalliomaki et al. (2007): Asthma was defined by whether the child had been 
qualified by the Social Insurance Institution of Finland for a special reimbursement 
for asthma medication. This outcome was reported as the point prevalence at 7 years.  
Kuitunnen et al. (2009): The outcome considered was ‘Asthma all, with or without 
sensitisation’. It was diagnosed if the child had 2 doctor-diagnosed wheezing episodes 
plus continuous cough, exercise-induced symptoms or verified reversible bronchial 
obstruction in oscillometry. The outcome was reported as the cumulative prevalence 
at 5 years. 
Simpson et al. (2015): The outcome considered was ‘Current Asthma’ measured at 6 
years. This was defined by a positive answer to both questions “Has your child ever 
been diagnosed with asthma by a doctor?” and “In the past 12 months, has your child 
been treated with tablets, inhalers or other medications for wheezing, chest tightness 
or asthma?”.  
Wickenze et al. (2013): Current Asthma was diagnosed using ISAAC questionnaire 
for a history of asthma plus wheeze or inhaler use in the last 12 months in children. 
This outcome was reported as the point prevalence at 6 years. 
 
The results of the pooled analysis for asthma risk reduction in offspring following 
pro/prebiotic intervention during pregnancy are shown in Figure 3.4. There was no 
evidence of statistical heterogeneity between studies (χ2=5.77, P=0.44, I2=0%). The 
result of meta-analysis did not show an association between maternal intake of 
pro/prebiotics during pregnancy and prevention of asthma in the offspring (RR=1.04, 
95% CI= 0.85-1.27, 2,317 children).  
 
Figure 3.4. Forest plot of pro/prebiotics vs. placebo for asthma 
Measure: Binary: risk ratio 
Heterogeneity: Q = 5.77; df = 6; p = 0.449; I-squared = 0%; tau-squared = 0. 
Random effects model: 1.04 (0.851, 1.27) 
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Outcome: Asthma Probiotics n/N Placebo n/N 
Abrahamsson 17/94 15/90 
Allen 23/171 20/179 
Gorissen 5/39 8/44 
Kalliomaki 9/53 3/62 
Kuitunnen 58/436 63/446 
Simpson 3/136 1/145 
Wickens 68/278 35/144 
Subtotal 1207 1110 
 
3.5.5.3. Eczema as an outcome measure for pro/prebiotic intervention 
The meta-analysis on the maternal consumption of pro/prebiotics during pregnancy 
and its effectiveness on prevention of eczema in the offspring is shown in Figure 3.5. 
In total, 13 studies were included in the meta-analysis. Included trials used different 
definitions of eczema but for this systematic review, all the definitions were 
considered. The definition of eczema used by trials included in the meta-analysis were 
as below: 
Abrahamsson et al. (2013): The outcome considered was ‘Eczema, IgE-associated or 
not’. Eczema was defined as a pruritic, chronic or chronically relapsing non-infectious 
dermatitis with typical features and distribution, as suggested by Hanifin (Hanifin & 
Rajka 1980). This outcome was measured at 2 and 7 years follow-ups and reported as 
positive at any of the time points. 
Allen et al. (2014): All reported eczema of any duration and whether diagnosed by a 
health professional or not were used in this study. Eczema was defined as an itchy 
rash affecting the face, scalp or extensor surfaces of the limbs in infants and flexures 
in older children and of duration ≥4 weeks and with ≥1 exacerbation by age 24 
months based on the information from follow-up questionnaires. This outcome was 
measured as the cumulative prevalence at 2 years. 
Boyle et al. (2011): Eczema ever was defined according to the UK Eczema Working 
 87 
Party criteria (Williams, Burney, Pembroke, & Hay 1994). The definition included a 
history of itchy skin, scratching or rubbing plus at least three of the following: family 
history of atopic disease; history of generally dry skin; history of skin rash affecting 
the flexures, cheeks or outer surfaces of the limbs; onset of rash under the age of 2 
years; visible dermatitis at any study visit affecting the flexures, cheeks or outer 
surfaces of the limbs. The outcome for this study was reported as the point prevalence 
at 1 year. 
Huurre et al. (2008): Atopic eczema was diagnosed using the Hanifin criteria. The 
outcome was reported as the point prevalence at 1 year. 
Kalliomaki et al. (2007): The diagnosis of eczema was made on the basis of both a 
questionnaire and a clinical examination. In particular, diagnosis of eczema was 
confirmed if there had been pruritic eczematous lesions with typical location and with 
relapsing or chronic course during the last 12 months. This study reported the 
outcome as the cumulative risk for developing eczema during the first 7 years of life.  
Kim et al. (2010): Eczema was confirmed when the skin lesions met the criteria of 
Hanifin. This study reported the outcome as the cumulative incidence at 1 year. 
Kopp et al. (2008): The outcome considered was ‘atopic dermatitis’ and was 
confirmed by pruritus, facial or extensor involvement, or both, and chronic relapsing 
course by using Williams UK Working Party’s criteria (Williams, et al., 1994). 
Physicians who were blinded to the allocated treatment conducted the physical 
examinations. The outcome was reported as the cumulative incidence during the first 
2 years.  
Kuitunen et al. (2009): The outcome considered was ‘all eczema, IgE and non-IgE 
mediated’. Eczema was diagnosed according to the Williams UK Working Party’s 
criteria (Williams, et al., 1994) which meant an itchy skin plus 3 or more of the 
following: family history of atopic disease, dry skin during the previous 12 months, 
history of eczema, or visible eczema at typical sites. The outcome was reported as the 
cumulative prevalence at 0-5 years. 
Gorissen et al. (2014): Eczema was defined according to the Williams UK Working 
Party’s criteria (Williams, et al., 1994). This outcome was reported as the point 
prevalence at 6 years. 
Ou et al. (2012): The outcome considered was ‘Eczema ever’ and assessed using the 
modified ISAAC questionnaire including the physician-diagnosis of atopic dermatitis. 
This outcome was reported as the point prevalence at 3 years. 
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Rautava et al. (2012): Eczema was diagnosed according to the criteria introduced by 
Hanifin (Hanifin & Rajka, 1980), based on the following features: pruritus, typical 
morphology and distribution, and a chronic relapsing course. The last criterion was 
fulfilled if the infant had 2 episodes of eczema with duration of at least 1 month each 
during the first 2 years of life. If the skin condition persisted without periods of 
remission, the eczema was considered chronically persistent. This outcome was 
reported as the cumulative incidence at 2 years. 
Simpson et al. (2015): The outcome considered was ‘atopic dermatitis’ and was 
assessed during the clinical examination(s) using the Williams UK Working Party’s 
criteria (Williams, et al., 1994) and were asked about having atopic dermatitis at any 
point up to 6 years. This study reported the outcome as the cumulative incidence 
estimate at 6 years. 
Wickens et al. (2013): Eczema was assessed by study nurses at follow-up and 
determined as present if there was a history of an itchy rash since turning 4 years, plus 
2 or more of the following: (i) a generally dry skin since 4 years, (ii) a history of 
asthma or hay fever ever, (iii) flexural involvement since 4 years around the eyes, 
sides or fronts of the neck, elbow or knee flexures, or fronts of ankles, (iv) visible 
atopic eczema present at any of these sites. This outcome was measured at 2, 4 and 6 
years follow-ups and reported as positive at any of the time points.  
 
For Gorrisen et al. (2014), the cumulative prevalence of atopic eczema was reported 
in the earlier report of this study (Niers et al., 2009) and their results showed no 
difference in the cumulative incidence of atopic eczema during the 2 years follow-up 
period (χ2 test, p=0.876). However, the cumulative incidence of parental reported 
eczema at 1 year [23/50 (probiotics) vs. 30/48 (placebo)] and 2 years [27/50 
(probiotics) vs. 33/48 (placebo)] showed a significant difference between the groups 
(p<0.05). 
A high level of statistical heterogeneity was observed between studies (χ2=35.5, 
P=0.00039, I
2
=66.2%). The results of meta-analysis showed an association between 
maternal intake of pro/prebiotics during pregnancy and prevention of eczema in the 
offspring (RR=0.79, 95% CI=0.67-0.93, 3,271 children).  
Figure 3.5. Forest plot of pro/prebiotics vs. placebo for any eczema 
Measure: Binary: risk ratio 
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Heterogeneity: Q = 35.3; df = 12; p = 0.000422; I-squared = 66%; tau-squared = 
0.0468. 
 
Random effects model: 0.791 (0.674, 0.928) 
 
 
Outcome: Eczema Probiotics n/N Placebo n/N 
Abrahamsson 39/94 36/90 
Allen 119/214 132/226 
Boyle 42/122 47/120 
Gorissen 13/39 14/44 
Huurre 7/72 12/68 
Kalliomaki 22/75 40/102 
Kim 12/33 22/35 
Kopp 19/50 14/44 
Kuitunnen 175/445 193/446 
Ou 16/65 16/64 
Rautava 41/143 44/62 
Simpson 22/71 36/82 
Wickens 123/309 82/156 
Subtotal 1,732 1,539 
 
Visual inspection of the funnel plot for trials on pro/prebiotics for prevention of any 
eczema in children suggests no likelihood of publication bias. Although some 
evidence of variances between studies in terms of sample size and methodological 
quality is evident.  
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Figure 3.6. Funnel plot for pro/prebiotic trials for prevention of any eczema 
 
3.5.5.4. Wheeze as an outcome measure for pro/prebiotic intervention 
In total seven studies were included in a meta-analysis measuring the effect of 
pro/prebiotic intake during pregnancy for prevention of wheeze in the offspring 
(Figure 3.7). The definitions of wheeze, as described in the included trials, were as 
follows: 
Abrahamsson et al. (2013): Wheeze was defined as an episode with obstructive 
airway symptoms. This outcome was measured at 2 and 7 years follow-ups and 
reported as positive at any of the time points. 
Allen et al. (2014): Wheezing without symptoms of a virus infection (assessed by 
follow-up questionnaires). It is not clear whether the outcome reported as cumulative 
or point prevalence at 2 years. 
Boyle et al. (2011): History of wheeze (undefined) was recorded as the outcome. This 
outcome was reported as the point prevalence at 1 year. 
Kopp et al., 2008: Wheeze was defined as ≥5 episodes of wheezing bronchitis during 
the first 2 years of life 
Ou et al. (2012): Wheeze-ever was defined using the modified ISAAC questionnaire 
asking about symptoms of wheezing. This outcome was reported as the point 
prevalence at 3 years. 
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Simpson et al. (2015): Wheeze was defined by a positive answer to both questions 
“Has your child ever had whistling in the chest?” and “Has your child ever had 
episodes of wheezing or tightness in the chest?”. This outcome was reported as 
cumulative incidence at 6 years. 
Wickens et al. (2013): Wheeze was defined by asking standard questions relating to 
wheezing from the ISAAC questionnaire. This outcome was reported for cases 
completing at least one follow-up time point at 2, 4 and 6 years. 
 
A moderate level of heterogeneity was observed between studies (χ2=11.3, P=0.07, 
I
2
=46.8%). The result of meta-analysis did not show an association between maternal 
intake of pro/prebiotics during pregnancy and prevention of wheeze in the offspring 
(RR=0.91, 95% CI= 0.73-1.36, 1,773 children).  
 
Figure 3.7. Forest plot of pro/prebiotics vs. placebo for wheeze 
Measure: Binary: risk ratio 
Heterogeneity: Q = 11.3; df = 6; p = 0.0799; I-squared = 46.8%; tau-squared = 
0.0352. 
Random effects model: 0.913 (0.733, 1.14) 
 
 
 
Outcome: Wheeze Probiotics n/N Placebo n/N 
Abrahamsson 18/94 14/90 
Allen 50/214 55/171 
Boyle 27/122 29/120 
Kopp 13/50 4/44 
Ou 14/65 11/64 
Simpson 46/132 55/142 
Wickens 189/309 102/156 
Subtotal 986 787 
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3.5.5.5. Rhinitis as an outcome measure for pro/prebiotic intervention 
Four studies were included in a meta-analysis measuring the effect of pro/prebiotic 
intake during pregnancy for prevention of rhinitis in the offspring (Figure 3.8). For 
the purpose of this systematic review, only studies that have reported “Rhinitis” as an 
outcome measure are considered and studies that reported “Allergic 
Rhinoconjunctivitis” as an allergic outcome were excluded (reported by: 
Abrahamsson et al., 2013; Wickens et al., 2013; Simpson et al., 2015). The definitions 
of rhinitis in the included trials were as follows: 
Allen et al. (2014): Allergic rhinitis (reported or diagnosed by a health professional). 
This outcome was reported as the cumulative prevalence at 2 years. 
Gorissen et al. (2014): Allergic rhinitis was defined according to the Allergic Rhinitis 
and its Impact on Asthma (ARIA) guidelines. This outcome was reported as the point 
prevalence at 6 years. 
Kalliomaki et al. (2007): Allergic rhinitis was defined as nasal discharge, blockage, 
sneezing, and itching related to allergen exposure and sensitisation. This outcome was 
reported as the point prevalence at 7 years.  
Kuitunen et al. (2009): The outcome considered was ‘rhinitis, positive inhalant SPT 
response, sIgE level >0.7 kU/L, or both’. Rhinitis was defined according to ARIA 
guidelines as 2 or more symptoms of nasal discharge, blockage, and sneeze/itch 
recurrently during antigen contact. This outcome was reported as cumulative 
prevalence at 0-5 years. 
There was a moderate level of statistical heterogeneity between studies (χ2=4.37, 
P=0.19, I
2
=36.6%). The results of meta-analysis did not show an association between 
maternal intake of pro/prebiotics during pregnancy and prevention of rhinitis in the 
offspring (RR=1.36, 95% CI=0.84-2.19, 1,479 children) (Figure 3.8).  
 
Figure 3.8. Forest plot of pro/prebiotics vs. placebo for rhinitis 
Measure: Binary: risk ratio 
Heterogeneity: Q = 4.73; df = 3; p = 0.192; I-squared = 36.6%; tau-squared = 0.0909. 
Random effects model: 1.36 (0.842, 2.19) 
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Outcome: Rhinitis Probiotics n/N Placebo n/N 
Allen 10/190 10/201 
Gorissen 5/39 1/44 
Kalliomaki 12/53 6/62 
Kuitunnen 92/444 85/446 
Subtotal 726 753 
 
3.5.5.6. Food allergy as an outcome measure for pro/prebiotic intervention 
In total three studies were included in a meta-analysis measuring the effect of 
pro/prebiotic intake during pregnancy for prevention of food allergy in the offspring 
(Figure 3.9). Food allergy was defined as below: 
Allen et al. (2014): Any reported food allergy (undefined). This outcome was 
reported as the point prevalence at 2 years. 
Gorissen et al. (2014): Food allergy was defined as doctor diagnosed food allergy, 
combined with sensitisation to food allergens as well as assessment using a slightly 
modified ISAAC questionnaire. This outcome was reported as the point prevalence at 
6 years. 
Kalliomaki et al. (2003): Allergies to cow’s milk was diagnosed by DBPCC and was 
reported as the point prevalence at 4 years. 
Studies were largely homogeneous with no variation observed between the included 
trials (χ2=2.04, P=0.56, I2=0%). The result of meta-analysis did not show an 
association between maternal intake of pro/prebiotics during pregnancy and 
prevention of food allergy in the offspring (RR=0.85, 95% CI=0.54-1.32, 594 
children) (Figure 3.9).  
 
Figure 3.9. Forest plot of pro/prebiotics vs. placebo for food allergy 
Measure: Binary: risk ratio 
Heterogeneity: Q = 2.04; df = 3; p = 0.564; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.812 (0.506, 1.3) 
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Outcome: Food allergy Probiotics n/N Placebo n/N 
Allen 22/200 31/204 
Gorissen 4/39 2/44 
Kalliomaki 2/53 2/54 
Subtotal 292 302 
 
3.5.5.7. Raised specific Immunoglobulin E (sIgE) as an outcome measure for 
pro/prebiotic intervention 
Six studies were included in a meta-analysis examining the effect of pro/prebiotic 
intake during pregnancy and its possible effect on a positive sIgE result in offspring 
(Figure 3.10). The definition of a positive sIgE result described by different studies is 
reported below:  
Dotterud et al. (2010): A positive level of sIgE was defined as sIgE ≥0.35 kU/L-1. 
sIgE
 
was measured for mite (Dermatophagoides pteronyssinus), mould 
(Cladosporium herbarum), cat and dog dander, birch, timothy (grass) and mugwort 
pollen, hen’s egg white, codfish, hazelnut and peanut allergens. This outcome was 
reported as the point prevalence at 2 years. 
Kim et al. (2010): sIgE to food was measured against common food allergens (egg 
white, cow’s milk, wheat, peanut, soybean, and buckwheat). Antigen-specific IgE 
levels ≥0.35 kU/L were considered positive. This outcome was reported as the point 
prevalence at 1 year. 
Kuitunne et al. (2009): Positive level of any sIgE was defined as sIgE >0.7 kU/L. 
sIgE antibodies were measured against milk, egg white, birch, timothy, cat and dog, 
peanut, and D pteronyssinus by using the ImmunoCAP system. This outcome was 
reported as the cumulative prevalence at 0-5 years. 
Niers et al. (2009): Positive result was defined as a concentration of sIgE ≥0.35 
IU/ml. sIgE was conducted for food panel of egg white, cow’s milk, peanut, house 
dust mite, and cat dander epithelium on the IMMULITE 2000. This outcome was 
reported as the point prevalence at 2 years. 
Ou et al. (2012): The outcome considered was ‘sensitisation by the detection of one 
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or more common allergen-specific IgE antibodies in blood’. Positive level of sIgE 
was defined as sIgE >0.7 kU/L. Allergen-sIgE sensitisation was assessed to six 
common allergens, two common inhaled allergens [Dermatophagoides pteronyssinus 
(Der p) and cockroach], and four common food allergens (egg white, milk protein, 
shrimp, and peanut), which have prevalence of sensitisation greater than 5% in the 
study country, Taiwan. This outcome was reported as the point prevalence at 3 years.  
Wickens et al. (2013): Positive sIgE was defined as sIgE ≥0.35 kU/L. sIgE was 
measured to six allergens (egg white, peanut, cow’s milk, cat pelt, Dermatophagoides 
pteronyssinus, and mixed grass pollen) using Stallergenes 1 mm lancets. This 
outcome was reported as the point prevalence at 6 years. 
 
It is important to note that the cut-off to determine a positive sIgE result differed 
across the studies and, with the exception of the study by Dotterud et al (2010); all 
studies were conducted in high-risk population with a family history of atopy. A 
moderate level of heterogeneity was observed between the studies (χ2=6.26, P=0.28, 
I
2
=20.1%). The results of meta-analysis (Figure 3.10) did not show an association 
between maternal intake of pro/prebiotics during pregnancy and positive sIgE in 
children (RR=1.02, 95% CI=0.86-1.20, 1,543 children). 
 
Also the meta-analysis including only studies with a cut-off of ≥0.35 kU/L to measure 
a positive sIgE did not modify the results (RR=1.08, 95% CI=0.774, 1.49) (Forest plot 
not shown). 
 
Figure 3.10. Forest plot of pro/prebiotics vs. placebo for positive sIgE in 
offspring 
Measure: Binary: risk ratio 
Heterogeneity: Q = 6.26; df = 5; p = 0.282; I-squared = 20.1%; tau-squared = 0.00861  
Random effects model: 1.02 (0.864, 1.2) 
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Outcome: sIgE Probiotics n/N  Placebo n/N 
Dotterud 19/138 13/140 
Kim 12/31 15/29 
Kuitunnen 152/375 137/362 
Niers 9/44 4/46 
Ou 17/41 22/41 
Wickens 103/198 51/98 
Subtotal 827 716 
 
3.5.5.8. Positive Skin Prick Test (SPT) to any allergen as an outcome measure for 
pro/prebiotic intervention 
Ten studies were included in a meta-analysis measuring the effect of pro/prebiotic 
intake during pregnancy and sensitisation, as measured by SPT in the offspring 
(Figure 3.11). Sensitisation was measured by SPT and a positive reaction was 
described in the included trials as below: 
Abrahamsson et al. (2013): The outcome considered was ‘any positive SPT’. SPTs 
were carried out with egg white, fresh skimmed cow’s milk (lipid concentration 
0.5%) and standardised cat, dog, birch, peanut, mite (Der p) and timothy extracts. 
Histamine hydrochloride (10 mg/ml) was used as positive and albumin diluent as 
negative control. The test was regarded as positive if the mean diameter of the wheal 
was ≥3 mm. This outcome was measured at 2 and 7 years follow-ups and reported as 
positive at any of the time points. 
Allen et al. (2014): The outcome considered was ‘any positive SPT’. The tests were 
performed using common food allergens (cow’s milk, hen’s egg), aeroallergens 
(house dust mite, cat dander, grass pollen) and positive (histamine) and negative 
controls. The response to an allergen was considered positive if there was a wheal 
diameter ≥3 mm. This outcome was reported as the point prevalence at either 6 
months or 2 years. 
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Boyle et al. (2011): The outcome considered was ‘any positive SPT’. The tests were 
performed to house dust mite, cat, ryegrass pollen, cow’s milk, egg and peanut 
positive (10% histamine chloride) and negative (glycerin-saline) controls. Atopy was 
defined as a SPT wheal diameter ≥3 mm greater than the negative control to any 
single allergen tested. This outcome was reported as the point prevalence at 1 year. 
Dotterude et al. (2010): The outcome considered was ‘any positive SPT’. The tests 
were measured to mite (Dermatophagoides pteronyssinus=Der p), mould 
(Cladosporium herbarum), cat and dog dander, birch, timothy (grass) and mugwort 
pollen, hen’s egg white, codfish, hazelnut and peanut allergens. For cow’s milk, fresh 
skimmed milk was used. It is not clear what wheal diameter was considered as a 
positive result; the paper only reports that the reading of the tests followed 
standardised procedures. This outcome was reported as the point prevalence at 2 
years. 
Huurre et al. (2008): The outcome considered was ‘Positive SPT’. The antigens 
tested for SPT included cow’s milk, egg white, wheat and rice flour both diluted 1/10 
(w/v) with 0.9% (w/v) sodium chloride, gliadin diluted 1 mg/mL with an 
ethanol/glyceroleum/ALK-diluent mixture, cod, soya bean, birch, six grasses, cat, 
dog, Der p allergen, latex and potato, carrot and banana by prick–prick technique. 
There is no information what wheal diameter was considered as a positive result. This 
outcome was reported as the point prevalence at 2 years. 
Kalliomaki et al. (2003): The outcome considered was ‘any positive SPT’. The tests 
were conducted to cow’s milk, egg white, wheat flour diluted 1/10 (wt/vol) with 0.9% 
(wt/ vol) sodium chloride, gliadin diluted 1/1000 (wt/vol) with 0.9% (wt/vol) sodium 
chloride, cod, soya bean, hazelnut, peanut, birch, mugwort, alder, 6 local grasses, cat, 
dog, and Der p allergen, and latex. A test was considered positive if a wheal of ≥3 
mm was observed in response to any of the allergens in the presence of an appropriate 
response to the positive control (10 mg/mL histamine dihydrochloride) and no 
response to the negative control (allergen diluent; ALK-Abello). This outcome was 
reported as the point prevalence at 4 years. 
Kuitunen et al. (2009): The outcome considered was ‘Any positive SPT’. The tests 
were performed to cat, dog, birch, timothy, mugwort, Der p, cow’s milk, egg, wheat, 
and peanut allergens at 2 and 5 years with commercial solutions or fresh food 
dilutions with 0.9% sodium chloride. Positive and negative controls were as histamine 
chloride and glycerin respectively. A wheal diameter of ≥3 mm in the presence of 
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negative control was considered positive according to the European Academy of 
Allergology and Clinical Immunology (EAACI) recommendations. This outcome was 
reported as the cumulative prevalence at 0-5 years. 
Niers et al. (2009): The outcome considered was ‘Positive SPT’. The tests were 
performed with allergen extracts for egg white, cow’s milk, peanut, hazelnut, cat, dog, 
house dust mite (Der p), birch, and grass. A wheal diameter of ≥3 mm at 15 min was 
considered positive. This outcome was reported as the point prevalence at 2 years. 
Rautava et al. (2012): The outcome considered was ‘SPT positive’. The tests were 
performed for cow’s milk, egg white, and wheat and rice flour both diluted 1/10 (w/v) 
with 0.9% (w/v) sodium chloride, gliadin diluted 1 mg/mL with an 
ethanol/glyceroleum/ ALK-diluent mixture, cod, soy bean, birch, 6 grasses, cat, dog, 
Der p allergen, latex, potato, carrot, and banana by prick-prick technique. Reactions 
were read at 10 to 15 minutes and a mean diameter of the wheal of at least 3 mm was 
considered in the presence of a negative control. This outcome was reported as the 
point prevalence at 2 years.  
Wickens et al. (2013): The outcome considered was ‘SPT sensitisation’. Australian 
Society of Clinical Immunology and Allergy (ASCIA) guidelines were used to 
measure SPT reactions to egg white, peanut, cow’s milk, cat pelt, Der p, and mixed 
grass pollen. SPT sensitisation was defined as a mean wheal diameter ≥3 mm to one 
or more allergens after subtraction of the negative control. This outcome was reported 
as the cumulative prevalence at 6 years.  
 
Statistically, these studies were largely homogeneous with no variation between 
studies (χ2=6.56, P=0.68, I2=0%). The result of meta-analysis did not show an 
association between maternal intake of pro/prebiotics during pregnancy and 
prevention of sensitisation in the offspring (RR=0.91, 95% CI=0.82-1.02, 2,877 
children).  
 
Figure 3.11. Forest plot of pro/prebiotics vs. placebo for sensitisation to any 
allergen, measured by SPT 
Measure: Binary: risk ratio 
Heterogeneity: Q = 6.56; df = 9; p = 0.683; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.917 (0.822, 1.02) 
 
 99 
 
 
 
Outcome: Positive SPT Probiotics n/N Placebo n/N 
Abrahamsson 29/82 37/82 
Allen 18/177 32/173 
Boyle 35/107 33/101 
Dotterud 6/138 5/140 
Huurre 21/72 21/68 
Kalliomaki 10/50 9/50 
Kuitunnen 165/443 164/445 
Niers 4/46 4/47 
Rautava 36/149 17/65 
Wickens 120/293 72/149 
Subtotal  1,557 1,320 
 
Visual inspection of the funnel plot for trials on pro/prebiotics for prevention of 
childhood sensitisation suggests the possibility of publication bias e.g. statistical 
power of studies, varied methodological quality. 
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Figure 3.12. Funnel plot for pro/prebiotic trials for sensitisation 
 
3.5.6. Discussion of the evidence synthesis of pro/prebiotics consumption 
during pregnancy and prevention of allergic diseases in the offspring 
3.5.6.1. Summary of main results 
This systematic review summarised data from 16 placebo-controlled randomised 
controlled trials (PC-RCTs) of maternal intake of pro/prebiotics for prevention of 
childhood allergies, including a total of 3,567 children with follow-up duration 
ranging from 1-7 years (mean 3.56 years). Trials were at risk of bias with 25% rated 
either unclear or high risk for their performance bias. Studies also had varied duration 
of follow-up and generally had small sample sizes. Wide variety was observed for the 
choice of probiotic strain and there were little similarity between studies for dosage, 
timing and duration of intervention. The findings from this systematic review and 
meta-analysis do not provide evidence of a protective association between intake of 
pro/prebiotics during pregnancy and subsequent development for a number of allergic 
conditions including asthma, wheeze, rhinitis, food allergy and sensitisation to 
allergens as measured by sIgE and SPTs. However, there appeared to be an effect for 
eczema. The meta-analysis of thirteen studies showed a significantly reduced risk of 
developing any eczema in offspring (RR=0.79, 95% CI=0.67-0.93, 3,271 children). 
The current knowledge of mechanism that through which probiotics could reduce the 
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risk of eczema is not well understood. Furthermore, while no effect was observed for 
sensitisation in offspring (measured by SPT to any allergen) following pre/probiotic 
intake during pregnancy, the upper bound was very close to 1 and could be considered 
borderline (RR=0.91, 95% CI=0.82-1.02, 10 trials, 2,877 children). Overall, these 
analyses need to be viewed with caution given the risk of bias in included trials and 
statistical heterogeneity observed for some outcomes including eczema.  
3.5.6.2. Overall completeness and applicability of evidence 
There was a low quality of evidence that probiotic supplementation during pregnancy 
is effective for prevention of a number of allergic manifestations in the offspring. The 
meta-analysis for the outcome of “any eczema” also showed high statistical 
heterogeneity between the included trials (I
2
=66.2%). The heterogeneity between the 
trials limited the findings and random effect models were used to pool the results. 
Heterogeneity in the included trials resulted from varied dosage, mode of 
administration and type of probiotics as well as the timing and duration of 
interventions. There were also great differences between studies with regards to their 
sample size, duration of follow-up and diverse locations/settings.  
 
Some evidence of publication bias was also observed from the visual inspection of 
funnel plot created for the outcome of “sensitisation, measured by SPT”. 
3.5.6.3. Quality of evidence 
Overall, the trials were at moderate to high risk of bias, for the summary of risk of 
bias assessment (Figure 3.2). A large proportion of studies were rated as unclear on 
many risk of bias domains and some had high risk of bias for individual quality 
domains (Figure 3.2). High loss to follow-up was rated as unclear and high risk of 
bias in 18 and 38% of studies respectively. Also the small size of the studies might 
have led to lack of precision which result in downgrading the quality of body of 
evidence.  
3.5.6.4. Strength and weakness of this systematic review for pro/prebiotic 
consumption during pregnancy 
The main distinction of this systematic review is that it includes only trials that have 
started intake of probiotics during pregnancy, thus, crucially, allows the effect of 
prenatal intake of probiotics for prevention of childhood allergies to be isolated. An 
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additional strength is that the systematic review followed an a priori published 
protocol, using a comprehensive search strategy that allowed for a complete coverage 
of all the relevant literature through citation databases, trial registries and conference 
proceedings. In addition, a range of allergic outcomes were considered for the present 
review and the most up-to-date results from the trials, reported as the longest 
available follow-up data, were included in the meta-analyses.  
 
A limitation of the current review is that following the initial draft of the protocol 
some subsequent changes were made. Sub-group analyses were not conducted as 
planned since the effectiveness of prenatal and/or postnatal probiotics is investigated 
in the existing systematic reviews by various sub-group analyses. It is worth noting 
that sub-group analyses, conducted in these reviews, are mainly susceptible to type II 
errors due to relatively small sample sizes in trials and present a large statistical 
heterogeneity across the trials. However, with this exception, the established 
methodological guidelines from the protocol were followed, and there was a clear 
rational for deviations from the protocol. Consequently, data were pooled from trials 
conducted in diverse populations (infants with a family history of atopy and 
unselected samples) and using different probiotic formulations and doses and with a 
variety of quality.  
3.5.6.5 Agreement and disagreement with other reviews 
While the current systematic review was underway, two systematic reviews on the 
effectiveness of probiotics for prevention of allergies in offspring were published 
(Cuello-Garcia et al., 2015; Zuccotti et al., 2015). These reviews had a similar scope 
to that of the current systematic review investigating a range of allergic outcomes in 
children. However there are a number of key differences between this systematic 
review and that of Cuello-Garcia et al. (2015) and Zuccotti et al. (2015). Firstly, both 
of these reviews had different inclusion criteria where they have included studies that 
administered probiotics either prenatally (continued or not after birth) or only 
postnatally.  Whereas, the present review only included studies that administered 
probiotics during pregnancy (and where continued, but not commenced postnatally). 
Secondly, both reviews had a limited searching where Cuello-Garcia and colleagues 
(2015) have excluded the extended follow-up reports for some of the unique RCTs 
included in their systematic review i.e. Abrahamsson et al (2013); Wickens et al. 
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(2013) and furthermore two other trials by Allen et al. (2014) and Gorissen et al. 
(2014) are not identified by the reviewers. The extended follow-up data from 
Dotterud et al. (2010) trial, reported by Simpson et al. (2015), was published after the 
release of Cuello-Garcia et al. (2015) review and has therefore not been included in 
their review. The review by Zuccotti et al. (2015) included 10 of the 13 original trials 
included in the present systematic review, two trials not identified (Kuitunnen et al., 
2009 and Allen et al., 2014) and one excluded since it used a milk-based probiotic 
(Dotterud et al., 2010). Thirdly, the reviews by Cuello-Garcia et al. (2015) and 
Zuccotti et al., (2015) included both the earlier reports and/or reports on a sub-sample 
of an original RCT accompanied by the report of its longer-term follow-up in a 
number of conducted meta-analyses. Examples for the review by Cuello-Garcia and 
colleagues (2015) are Kukkonen et al. (2007) as the earlier report of Kuitunen et al. 
(2009) and Marschan et al. (2008), which is a report on a sub-sample of its original 
trial by Kukkunen et al. (2007). For the Zuccotti et al., (2015) review are Wickens et 
al., at 2008, 2012 and 2013 and Abrahamsson et al., at 2007 and 2013 in the same 
meta-analysis conducted. The current systematic review however, included only the 
latest available data, and where possible cumulative prevalence rather point 
prevalence, that reported the extended follow-up from their original RCTs on prenatal 
intake of probiotics. Furthermore, the Cuello-Garcia et al., (2015) and Zuccotti et al., 
(2015) reviews conducted sub-group analyses for the probiotic strain, follow-up 
duration and sample separately for pregnant women only, breast-feeding mothers 
only, infants only and pregnant with/without breast-feeding mothers with/without 
infants. However, sub-group met-analyses were not conducted in the existing 
systematic review. Moreover, both reviews by Cuello-Garcia et al. (2015) and 
Zuccotti et al., (2015) review have combined the wheeze/asthma together in meta-
analyses whereas separate meta-analyses for wheeze and asthma outcomes were 
conducted in this review. In addition, studies with more than one intervention arm are 
included separately in meta-analyses in the previously conducted reviews i.e. Rautava 
et al., (2012) and Wickens et al., (2013) and more importantly, they did not split the 
number of participants in the control group for each intervention arm. But in the 
current review, the study arms were combined and compared versus the placebo 
group. Finally, in this review meta-analyses for sensitisation, measured by sIgE and 
SPT, were conducted and these analyses were not addressed in the reviews by Cuello-
Garcia et al. (2015) and Zuccotti et al., (2015).  
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There are also key differences in the scope and approach of the existing systematic 
review with the other related systematic reviews, listed in section 3.3.2.2. With the 
exception of one review by Doege et al. 2012 that included only studies with prenatal 
intake of probiotics, all other reviews included both studies that administered 
probiotics either prenatally or only postnatally. Furthermore, all these reviews have 
focused on selected allergic outcomes. It is also important to note that these reviews 
have not included the follow-up data of many original RCTs and only the earlier 
reports of RCTs are included in the meta-analyses such as Kuitunen et al. (2009) and 
Kalliomäki et al. (2007) trials. Furthermore, a number of previous systematic reviews 
have included both an original trial as well as a report on its sub-sample in the same 
meta-analysis (examples as above). The current systematic review only included the 
longest available follow-up data from included original RCTs in meta-analyses and 
additionally, a clear distinction was made between an original trial and its further 
reports, either on its sub-samples or earlier follow-ups and these are reported as the 
companion papers. The exception to this is where we included the earlier reports of 
three RCTs, as described in section 3.5.3 since the outcome of interest was only 
reported in these earlier reports (and not in the follow-up reports). 
 
The above-mentioned discussion highlights some key limitations in the previously 
conducted systematic reviews on this topic jeopardising the confidence that one can 
put in their results. Initially, they have failed to address the latest follow-up data for 
some of the included trials and thus to assess the longer-term effect of probiotic 
intervention. In addition, some of the unique RCTs were excluded from these reviews 
not enabling an evaluation of a comprehensive list of all the available studies 
conducted in the field. Another important issue is that the meta-analysis results of 
these reviews might have been biased by the fact that they have double or even triple 
counted one set of study participants in one analysis i.e. including the earlier and later 
reports from the same original trial, and consequently there is a risk that effects of 
intervention might have been overestimated in the analyses of these reviews (Sterne, 
Egger, & Moher, 2011). 
 
The results from the present systematic review provides an update to the earlier 
systematic reviews of pro/prebiotics for prevention of childhood allergic diseases; 
nevertheless our results are not directly comparable to other reviews. Our results on 
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prenatal intake of probiotics, including the most up-to-date follow-up data from 
included trials in the meta-analysis, are in agreement with the results of existing 
systematic reviews indicating that consumption of probiotics might reduce the risk of 
childhood eczema. In our review, a broad definition of eczema was considered, atopic 
and non-atopic, and therefore a bigger RR and wider 95% CI was observed in 
comparison with that of the reviews by Cuello-Garcia et al. (2015) and Zuccotti et al., 
(2015) (RR=0.79, 95% CI=0.67-0.92 vs. RR=0.71, 95% CI=0.59-0.84 and RR=0.78, 
95% CI=0.69-0.89), respectively. Our findings did not support that intake of 
pro/prebiotics during pregnancy effected the development of other allergic outcomes 
similar to the findings reported in other reviews. Our results also did not provide 
evidence that prenatal intake of pro/prebiotics affected the development of 
sensitisation (measured by positive SPT to any allergen) in children; however the 
upper boundary of 95% CI is very close to 1 (RR=0.91, 95 % CI=0.82-1.02). Pooled 
analysis of a review conducted by Zhang et al., (2016); including prenatal and 
postnatal probiotic interventions, reported a reduced risk of sensitisation in children as 
measured by either SPT or sIgE and the effect is more significant when including 
studies that supplemented probiotics prenatally. It is worth adding that the reviewers 
did not make a distinction between sensitisation diagnosed by SPT or sIgE, and where 
there has been a report for both tests in the included trials, they have considered the 
results for SPT only in their analysis. This might limit the interpretation of these 
findings in practice as to which test might have better precision for assessing 
sensitisation.  
3.5.6.6. Author’s conclusion 
Implications for practice 
This systematic review found that there are no positive effects of prenatal probiotic 
consumption for reducing the risk of development of most of the allergic outcomes. 
However, there is some evidence that suggests probiotic consumption during 
pregnancy could reduce the risk of developing all types of eczema in children and 
might also protect against childhood sensitisation. Nevertheless, the evidence from 
the current body of literature is not conclusive due to the risk of bias, different 
methods for reporting the outcome measures across studies, timing of intervention, 
variability of the probiotics and dosage used, and the diverse locations/settings.  
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Implications for research  
Taking the quality of the available evidence into account, the effect of probiotic 
intake during pregnancy for prevention of childhood allergies needs to be further 
investigated in well-designed and executed RCTs.  
 
Optimal timing of probiotic intervention is a fundamental factor that needs to be 
addressed in further trials. Most of the conducted trials have administered the 
intervention later in pregnancy. The immunomodulatory effects of probiotics are well 
recognised where they promote a healthy immune system development, and metabolic 
regulation in foetus (Nylund et al., 2013). This highlights the prominence of early 
interventions and the notion of using probiotics in pre-pregnancy and as early as 
pregnancy to optimise maternal and foetal microbiom. In addition, the transmission of 
probiotic strains might vary where a study showed that only a specific strain of 
probiotic was detectable in infant stool samples (Dotterud et al., 2015). The 
uncertainties regarding the choice of probiotics, dose, timing, mode of administration 
as well as the ideal duration of intervention requires further investigation. It is worth 
mentioning that with the exception of one study by Kuitunen et al., (2009) that used a 
combination of pre and probiotics, all other included trials in the current review 
administered probiotics only as the intervention. The efficacy of prebiotics and 
probiotics for prevention of childhood allergies, additionally, need to be differentiated 
in future trials. 
 
Well-planned, multi-centre, coordinated RCTs with large samples designed to 
measure and report the outcomes in a consistent way, and focusing on different 
aspects including type of study sample i.e. atopic vs. non-atopic could provide 
stronger evidence regarding the impact of these dietary interventions during 
pregnancy on allergic outcomes in the offspring. Also, the majority of the studies 
were conducted in developed countries, and it remains a priority to understand the 
effectiveness of probiotics for prevention of allergic outcomes in offspring among the 
underreported populations. 
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3.5.7. Description of included studies of maternal fatty acid consumption 
during pregnancy and prevention of allergic diseases in the offspring  
In total, seven studies (which included 2,492 children) examined the impact of fatty 
acid supplementation during pregnancy on the development of allergic diseases in 
offspring. The characteristics of the included trials, their companion papers and study 
population are presented in Table 3.5. Two studies were conducted in Australia and 
the rest were conducted in Mexico, Sweden, Finland, United Kingdom and Denmark.  
 
The study conducted by Escamilla-Nuñez et al., (2014) had the largest sample size, 
randomising 1,094 pregnant women. This was followed by the Olsen et al., (2008) 
and  Palmer et al., (2013) studies with 533 and 706 participants randomised 
respectively. The lowest sample sizes of 98 and 123 were respectively reported for the 
studies carried out by Dunstan et al., (2003a) and Noakes et al., (2012) respectively 
(Table 3.5).  
 
The studies also varied in the length of their follow-up. The longest follow-up period 
was 16 years, reported in Olsen et al. (2008), followed by the Palmer et al. (2013) 
which reported a 3 year follow-up period. Studies conducted by Furuhjelm et al., 
(2011); Linnamaa et al., (2010) had a follow-up time of 2 years and the shortest 
follow-up period (one year) reported in the study by Dunstan et al. (2003a).  
 
Of the total seven fatty acids studies, four were conducted amongst a population with 
a high risk of atopy (Dunstan, Mori, Barden, et al., 2003a; Furuhjelm et al., 2011; 
Noakes et al., 2012; Palmer et al., 2013) and the other three were conducted with an 
unselected sample (Escamilla-Nuñez et al., 2014; Linnamaa et al., 2010; Olsen et al., 
2008). Eczema and asthma were the most frequently reported allergic outcomes in 
these studies. Also, while there was a later publication from a study published in 2010 
(Linnamaa et al., 2010), data was extracted from the 2010 report since the follow-up 
paper (Linnamaa et al., 2013) only reported pre-clinical outcomes (Breast milk 
cytokine concentration in pg/ml). 
 
Compliance with the intervention was measured by different methods, including total 
number of capsules actually consumed, women’s self-report of oily fish intake using 
food frequency questionnaires during pregnancy, telephone calls reminder(s) as well 
as assessing plasma concentration of LCPUFA either at birth or a few weeks after 
delivery.     
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Table 3.5. Characteristics of included trials and study population on fatty acids and prevention of allergy in offspring 
Primary article  Companion 
articles 
Country, 
enrolment 
period 
Trial 
type
*
 
Name and 
number of 
study arms 
No. of 
participants
**
 
No. at 
last  
F-U
***
 
Time 
points 
measured 
Age at 
last F-U 
Sample: 
high risk of 
Atopy 
Outcomes 
reported 
 
(Dunstan, et al., 
2003a) 
 
(Barden et al., 
2004)  
(Barden, Dunstan, 
Beilin, Prescott, & 
Mori, 2006) 
(Denburg et al., 
2005)  
(Dunstan et al., 
2003b) 
(Prescott, Barden, 
Mori, & Dunstan, 
2007) 
(Meldrum, D’Vaz, 
Dunstan, Mori, & 
Prescott, 2011) 
Australia  
1999-2001 
PC-RCT Fish-oil 
supplement 
and control 
98 mothers 83 (40 
vs. 43) 
12 months 1yr. Yes -Wheeze 
-Eczema 
-Asthma 
-SPT (any 
positive) 
-SPT (egg) 
-SPT (peanut) 
-SPT (HDM) 
-SPT (cows milk) 
-SPT (CAT) 
-Food Allergy 
-Anaphylaxis 
-Angioedema 
-Chronic cough 
-SCORAD >= 25 
(Olsen et al., 
2008) 
(Olsen et al., 
1992) 
Denmark 
1989-90 
PC-RCT Fish oil vs. 
No oil vs. 
Olive oil 
533 mothers 528 (263 
vs. 129 
vs. 136) 
16yrs. 16yrs. No -Any Allergic 
disease(s) 
-Asthma 
(Linnamaa et 
al., 2010)  
 
(Linnamaa et al., 
2013) 
Finland 
2004-08 
PC-RCT Blackcurrant 
seed oil & 
olive oil 
322 mothers 177 
(85 vs. 
92) 
3, 12 & 24 
months 
2yrs. No -Eczema 
-SPT (egg) 
-SCORAD 
-Any IgE 
(Furuhjelm et 
al., 2011)  
 
(Furuhjelm et al., 
2009)   
 
Sweden 
2003-05 
PC-RCT Omega-3 
group or 
placebo 
145 mothers 116 
(53 vs. 
63) 
3, 6, 12 & 
24 months 
2yrs. Yes -Eczema 
-Asthma 
-SPT (any 
positive) 
-SPT (egg) 
-SPT (milk) 
-SPT (food) 
-SPT (wheat) 
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Primary article  Companion 
articles 
Country, 
enrolment 
period 
Trial 
type
*
 
Name and 
number of 
study arms 
No. of 
participants
**
 
No. at 
last  
F-U
***
 
Time 
points 
measured 
Age at 
last F-U 
Sample: 
high risk of 
Atopy 
Outcomes 
reported 
 
-Specific IgE 
-Food Allergy 
-Allergic 
Rhinoconjunctivit
is 
-SCORAD 
(Noakes et al., 
2012)  
 
(Helmersson-
Karlqvist et al., 
2012;  
Miles et al., 2011; 
Urwin et al., 
2014)  
 
UK. 
No 
reported 
RCT
#
 Salmon & 
Control 
123 mothers 86 (48 
vs. 38) 
Birth & 6 
months 
6 
months 
Yes -Wheeze 
-Eczema 
-SPT (any 
positive) 
-SPT (egg) 
-SPT (cows milk) 
-SPT (CAT) 
-SPT(Cod) 
-SPT (grass) 
-SPT (Dog) 
-Sensitisation 
(non-identified) 
-Chest infection 
-Pneumonia/ 
bronchiolitis 
-SCORAD 
-SPT (Derp 1) 
-Any IgE 
-Itchy skin 
-Dry skin 
(Palmer et al., 
2013) 
(Palmer et al., 
2012)  
(Makrides et al., 
2010)  
(Makrides et al., 
2009) 
Australia  
2006-08 
PC-RCT N-3 
LCPUFA & 
control 
700 mothers 638 (333 
vs. 305) 
12 & 36 
months 
3yrs. Yes -Any Allergic 
disease(s) 
-Eczema 
-Asthma 
-SPT (egg) 
-SPT (peanut) 
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Primary article  Companion 
articles 
Country, 
enrolment 
period 
Trial 
type
*
 
Name and 
number of 
study arms 
No. of 
participants
**
 
No. at 
last  
F-U
***
 
Time 
points 
measured 
Age at 
last F-U 
Sample: 
high risk of 
Atopy 
Outcomes 
reported 
 
-SPT (CAT)  
-SPT (Cod) 
-SPT (grass) 
-SPT (wheat) 
-Cashew nut 
sensitisation 
-Sesame seed 
sensitisation 
-Food Allergy 
-Olive tree 
sensitisation 
-
Dermatophagoide
s (pteronyssinus 
sensitisation) 
-Dermatophagoides 
(srinae 
sensitisation) 
Sensitisation 
-Rhinitis 
-Alternaria tenuis 
sensitisation 
(Escamilla-
Nuñez et al., 
2014)  
 
(Ramakrishnan et 
al., 2010)  
(Imhoff-Kunsch 
et al., 2011) 
(Lee et al., 2014)  
Mexico 
2005-07 
PC-RCT Docosahexa
enoic acid or 
Placebo 
1,094 
mothers 
869 (429 
vs. 440) 
1, 3, 6, 9, 
12 & 18 
months 
18 
months 
No -Wheezing 
-Cough 
-Breathing 
Difficulty 
-Phlegm & Nasal  
-Discharge 
-Fever 
+Published data and conference presentation, no unique data were extracted from conference abstracts      *Placebo Controlled-Randomised Controlled Trial 
**Indicates the number at randomisation, where recruitment has occurred prenatally         ***Follow-Up    #Single-blinded Randomised Controlled Trial
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Table 3.6 shows the details of fatty acid interventions and placebo used in included 
trials. In all studies, the intervention and placebo groups had comparable baseline 
characteristics at recruitment and also birth.  
 
Five studies administered the fatty acid supplements during pregnancy only (Dunstan, 
et al., 2003; Escamilla-Nuñez et al., 2014; Noakes et al., 2012; Olsen et al., 2008; 
Palmer et al., 2013) and, in the remaining two, fatty acid interventions were applied 
both during pregnancy and after delivery in mothers only (Furuhjelm et al., 2011) or 
in both mothers and infants (Linnamaa et al., 2010). The longest duration of 
intervention (30-32 months) was reported in the study by Linnamaa et al. (2010) and 
the shortest (2-2.5 months) by Olsen et al. (2008). Trials also differed in the timing of 
the introduction of the intervention, beginning as early as 8 weeks of gestation or as 
late as 30 weeks of gestation. 
 
The nature of the fatty acid regimen during pregnancy was different across the 
included studies: n-3 (Omega-3) PUFA was used in two studies (Dunstan, et al., 
2003a;  Furuhjelm et al., 2011; Palmer et al., 2013); Docosahexaenoic Acid (DHA) 
was used in one study (Escamilla-Nuñez et al., 2014); Blackcurrant Seed Oil (BCSO) 
was used in one study (Linnamaa et al., 2010); one study used Fish Oil (Olsen et al., 
2008) and the final study used salmon portions (Noakes et al., 2012). The composition 
of fatty acid supplements in the included studies were similar, based on presented data 
in the papers, but it was not clear how the fatty acid profiles of plasma lipids in 
pregnant women might differ between different applied fatty acids products. In all the 
included studies, the fatty acid preparations were delivered as capsules except the 
study by Noakes et al., 2012 that used Salmon portions. 
 
The diversity of comparators between studies were as follows: olive oil in three 
studies (Dunstan et al., 2003a; Linnamaa et al., 2010; Olsen et al., 2008), a mixture of 
corn and soy oil (Escamilla-Nuñez et al., 2014), mainly the omega-6 PUFA Linoleic 
Acid (LA) (Furuhjelm et al., 2011), vegetable oil (Palmer et al., 2013) and standard 
diet (Noakes et al., 2012). The choices of comparator in the Olsen et al. (2008) study 
were defined as either “olive oil” or “no treatment” and for this review all the 
analyses conducted for the fatty acid component vs. olive oil. The Noakes et al., 2012 
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study which had “standard diet” as its comparator was not included in the meta-
analysis as this was not similar in nature to the other comparators. 
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Table 3.6. Characteristics of fatty acid interventions in included trials 
Primary article  Comparable 
baseline 
characteristic  
Participants 
receiving 
intervention 
Timing of  
Intervention 
in pregnancy 
Intake  of 
intervention 
from/until
*
 
Duration of 
intervention 
(months)
**
 
Fatty Acid 
product
***
 
Placebo 
 
Mode of 
delivery 
Total daily 
dose 
Dunstan, et al., 
2003a 
Yes  Prenatally in 
mothers 
From 20wks  20wks to 
delivery 
4.5-5  N-3 PUFA Olive oil Capsule  4 (1-g) per 
day 
Olsen et al., 
2008 
Yes Prenatally in 
mothers 
Around 30wks 30wks to 
delivery 
2-2.5 Fish oil Olive oil & no 
treatment 
Gelatin 
capsule 
1-g,  
4 a day 
Linnamaa et al., 
2010 
Yes Prenatally in 
mothers & 
postnatally in 
mothers & 
infants 
Between  
8-16wks 
8-16wks to 
2yrs. postnatal 
30-32  BCSO Olive oil Capsule  3 g/day, 6 
capsules, oil 
drops in 
infants 
Furuhjelm et al., 
2011 
Yes Pre & 
postnatally in 
mothers 
From 25wks 25wks to 
3.5months 
postnatal 
7 to 7.5  Omega-3 
PUFA 
Mainly the 
omega-6 
PUFA LA
***
 
Capsule 500-mg, 
nine a day 
Noakes et al., 
2012 
Yes Prenatally in 
mothers 
20wks 20wks to 
delivery 
4.5-5 Salmon 
Portions 
Standard diet - 2 portions 
per week  
Palmer et al., 
2013 
Yes Prenatally in 
mothers 
From 21wks 21wks to 
delivery 
4-5 N-3 PUFA Vegetable oil Capsule  500 mg, 3 
per day 
Escamilla-
Nuñez et al., 
2014 
Yes Prenatally in 
mothers 
From 18 or 
22wks  
18-22wks 
until delivery 
4.5-5.5  DHA A mixture of 
corn and soy 
oil 
Capsule  400 mg, 
twice per 
day 
*Indicates total duration in mother, infant or both, whichever is applicable 
**Indicates total duration in pregnancy plus after birth either in mother only or both mother and infants, if applicable  
***DHA=Docosahexaenoic Acid, PUFA=Poly-Unsaturated Fatty Acid, BCSO=Blackcurrant Seed Oil, LA=Linoleic Acid 
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3.5.8. Risk of bias in studies of maternal fatty acid consumption during 
pregnancy and prevention of allergic diseases in the offspring 
Figure 3.13 shows the summary of risk of bias assessment in trials on fatty acid 
studies. Most of the included studies were rated as low risk of bias for most domains. 
Two studies were rated as high risk (29%) in the double blinding domain. Appendix 
3.7 shows the reviewer’s judgment of the risk of bias assessment in fatty acid studies.  
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Study author Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of Outcome 
Assessment 
Incomplete Outcome 
Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Dunstan 
(2003a) 
? + + + - + + 
Olsen (2008) ? + - + + + + 
Linnamaa 
(2010) 
+ ? + + - + + 
Furuhjelm 
(2011) 
? ? + + - + + 
Noakes 
(2012) 
+ ? - + - + + 
Palmer 
(2013) 
+ + + + + + + 
Escamilla-
Nuñez (2014) 
+ + + + + + + 
Random Sequence Generation   
 
57% 43%   
 
Allocation Concealment   
 
57% 43%   
 
Double Blinding   
 
71%   29% 
 
Blinding of Outcome 
Assessment   
 
100%    
 
Incomplete Outcome Data   
 
43%   57% 
 
Selective Outcome Reporting   
 
100%    
 
Other Sources of Bias   
 
100%    
 
 
Low risk of bias  High risk of bias   Unclear risk of bias  
 
Figure 3.13. Summary of risk of bias assessment in the included trials of fatty acids and prevention of allergy in the offspring
 116 
3.5.8.1. Random sequence generation (selection bias) 
Four studies were assessed as low risk of bias for their randomisation method. The 
remaining three studies were assessed as having an unclear risk of bias (Dunstan, et 
al., 2003a; Furuhjelm et al., 2011; Olsen et al., 2008) where it has been addressed as 
either block randomisation or generally stated as randomly assigned with no details 
on the method of randomisation.  
3.5.8.2. Allocation concealment  
The studies by Linnamaa et al. (2010) and Furuhjelm et al. (2011) were rated as 
‘unclear’ as there was no information on allocation concealment. The study by 
Noakes et al. (2012) was also rated ‘unclear’ as it was a single-blind study with no 
reference to allocation concealment. Methods for concealment of allocation were 
reported in the remaining studies and were subsequently classified as having a low 
risk of bias for allocation concealment.  
3.5.8.3. Double Blinding (performance bias) 
Two studies were deemed as high risk for performance bias. The study by Olsen et al. 
(2008) provided no information on blinding of research staff and/or participants. 
Noakes et al., (2012) trial was a single-blind study and it was not specified whether 
the participants or the research staff were blinded. The rest of the studies were 
classified as low risk for their performance bias.  
3.5.8.4. Blinding of outcome assessment (detection bias) 
The detection bias was rated as low risk in all the included fatty acid trials since the 
assessment of outcome was conducted in a blind manner. 
3.5.8.5. Incomplete outcome data (attrition bias) 
lack of completeness of data was rated as low risk in three of the included trials as the 
reasons for attrition or exclusion were comparable across the study arms. Four studies 
rated as high risk of bias (Dunstan et al., 2003a; Furuhjelm et al., 2011; Linnamaa et 
al., 2010; Noakes et al., 2012). In the study by Dunstan et al. (2003) the loss to 
follow-up and discontinuation rates due to nausea were higher in the intervention arm. 
Loss to follow-up cases due to pregnancy-related nausea and poor compliance in both 
study arms were high (>50%) in the Linnamaa et al. (2010) trial. In Furuhjelm et al. 
(2011) the minimum 15 weeks of supplementation required was not met by 23% and 
12% of women in the intervention and placebo arms respectively, and a higher loss to 
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follow-up rate was also observed in the intervention group. The study by Noakes et al. 
(2012) did not report the reasons for loss to follow-up.  
3.5.8.6. Selective outcome reporting (reporting bias) 
All the trials had reported the pre-specified outcomes in their published study protocol 
or published papers and were classified as low risk. 
3.5.8.7. Other potential sources of bias 
There were no concerns regarding any other sources of bias in the included trials and 
all were assessed as low risk. 
3.5.9. Meta-analyses of effectiveness of maternal fatty acid consumption 
during pregnancy and prevention of allergic diseases in the offspring  
Pooled results from meta-analysis in the studies that examined the effectiveness of 
fatty acid supplementations for prevention of allergic outcomes in offspring are 
presented in the following section. For some outcomes there was an insufficient 
number of studies and these have been presented descriptively. Also, the Noakes et 
al., (2012) was not included in meta-analysis, as its comparator was not similar to the 
control group in other included trials. The results from this study are described 
narratively.  
3.5.9.1. Any ‘Allergic Diseases’ as an outcome measure for fatty acid intervention 
The use of fatty-acid supplementations during pregnancy for the prevention of allergic 
diseases was assessed in three studies. Figure 3.14 shows the forest plot for fatty acids 
versus placebo in pregnant women for the prevention of allergic diseases in offspring. 
Any ‘allergic disease’ was defined differently in the included studies. These are 
described as below:  
Furuhjelm et al. (2011): Symptoms of eczema, food reaction, asthma or 
rhinoconjunctivitis were considered as clinical symptoms of allergic diseases. This 
outcome was reported as point prevalence at 2 years. 
Olsen et al. (2008): Allergic disease was defined as ‘allergic asthma, atopic 
dermatitis or allergic rhinitis’. This outcome was reported as cumulative prevalence at 
16 years. 
Palmer et al. (2013): The outcome considered was ‘allergic disease, without 
sensitisation’ and was defined as eczema, asthma, allergic rhinitis or food allergy. All 
data is based on analysis of 50 imputed datasets. This outcome was reported as 
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cumulative incidence based on 1 and 3 years assessments.  
 
A large amount of statistical heterogeneity existed between the included studies 
(χ2=5.24, P=0.07, I2=61.8 %). The result of meta-analysis did not show an association 
between maternal intake of fatty acids during pregnancy and prevention of any 
allergic diseases in the offspring (RR=0.74, 95% CI=0.45-1.22, 1,222 children). 
 
When interpreting the Forest plot, it is worth noting that the only available data for 
the Palmer et al. (2013) study (which had the largest sample size) was subject to 
multiple imputations, due to significant missing data, affecting 50 complete data sets.  
 
Figure 3.14. Forest plot of fatty acids vs. placebo for any allergic diseases 
Measure: Binary: risk ratio 
Heterogeneity: Q = 5.24; df = 2; p = 0.0729; I-squared = 61.8%; tau-squared = 0.117. 
Random effects model: 0.743 (0.451, 1.22) 
 
 
 
Outcome: Any allergic diseases Fatty acids n/N Placebo n/N 
Furuhjelm  14/54 21/63 
Olsen  6/263 10/136 
Palmer  124/368 117/338 
Subtotal 685 537 
 
The Palmer et al. (2013) study has also reported the outcome as ‘allergic disease, with 
sensitisation’. We did not pool the ‘allergic disease, with and without sensitisation’ 
together into meta-analysis in order to avoid double counting of cases with other 
allergic outcomes. We conducted a meta-analysis separately including the data for 
‘allergic disease, with sensitisation’ rather than ‘allergic disease, without 
sensitisation’ for the Palmer et al. (2013) study (forest plot not shown) and this did 
not alter the pooled result in a significant manner (RR=0.70, 95 % CI=0.45-1.1). 
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3.5.9.2. Asthma as an outcome measure for fatty acid intervention 
Four included studies measured the effect of fatty acid consumption during pregnancy 
on the prevention of asthma in offspring (Figure 3.15). The definition of asthma in the 
included trials in the meta-analysis were as below: 
Dunstan et al. (2003a): The outcome considered was ‘Asthma’ and its diagnosis was 
made in children with recurrent wheezing (3 or more episodes, at least 1 confirmed by 
a pediatrician or general practitioner). All children diagnosed with asthma had to be 
responsive to bronchodilator therapy. This outcome was reported as point prevalence 
at 1 year. 
Furuhjelm et al. (2011): The outcome considered was ‘Any asthma’. Asthma was 
defined as doctor diagnosed wheezing at least three times during the first 2 years of 
life. IgE-associated asthma was defined as asthma with the presence of IgE antibodies 
or positive SPT. This outcome was reported as cumulative incidence at 2 years.  
Olsen et al. (2008): The outcome considered was ‘Allergic asthma’ and was 
diagnosed by the DJ450 code, using the International Coding of Diseases version 10 
(ICD-10). Data were collected using the National Patient Registry (NPR), a 
mandatory national hospital discharge registry in Denmark that for many years has 
recorded virtually all discharge diagnoses for hospitalisations. This data might have 
been biased for asthma cases that did not warrant hospitalisations. This outcome 
reported as point prevalence at 16 years. 
Palmer et al. (2013): The outcome considered was ‘Asthma with sensitisation‘. 
Asthma was defined as a history of 3 or more episodes of wheeze with the episodes 
less than 6 weeks apart and/or daily use of asthma medication. This data was analysed 
by Fisher’s exact test using original data and adjusted/imputed analyses were not 
carried out due to rarity of outcomes. This outcome was reported as the cumulative 
incidence based on 1 and 3 year assessments.   
 
There was a moderate level of heterogeneity between the included trials (χ2=6.56, 
P=0.86, I
2
=54.4 %). The results of meta-analysis did not show an association between 
maternal intake of fatty acids during pregnancy for reducing the risk of asthma in 
offspring (RR=0.55, 95% CI=0.21-1.41, 1,307 children).  
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Figure 3.15. Forest plot of fatty acids vs. placebo for asthma  
Measure: Binary: risk ratio 
Heterogeneity: Q = 6.59; df = 3; p = 0.0862; I-squared = 54.5%; tau-squared = 0.495. 
Random effects model: 0.552 (0.215, 1.41) 
 
 
Outcome: Asthma Fatty acids n/N Placebo n/N 
Dunstan 2/40 6/43 
Furuhjelm 7/54 8/65 
Olsen 2/263 8/136 
Palmer 6/368 5/338 
Subtotal 725 582 
 
3.5.9.3. Eczema as an outcome measure for fatty acid intervention 
The meta-analysis on the maternal consumption of fatty acids during pregnancy and 
its effectiveness on prevention of eczema in the offspring is shown in Figure 3.16. In 
total, four studies were included in the meta-analysis. Included trials used different 
definitions of eczema but for this systematic review, all the definitions were 
considered. The definition of eczema in the included trials in meta-analysis were as 
below: 
Dunstan et al. (2003a): The outcome considered was ‘Atopic dermatitis’. The 
diagnosis of atopic eczema dermatitis syndrome was made in infants with typical skin 
lesions or physician-diagnosed eczema responsive to topical steroids. This outcome 
was reported as point prevalence at 1 year.   
Furuhjelm et al. (2011): The outcome considered was ‘Any eczema’. Eczema was 
defined as reoccurring and itching eczematous, lichenified or nummular dermatitis, 
according to the definition by Seymour in 1987. If detectable IgE antibodies or a 
positive SPT was present, it was defined as IgE-associated eczema. This outcome was 
reported as cumulative incidence at 2 years.  
Linnamaa et al. (2010):  The outcome considered was ‘Atopic eczema’. Atopic 
dermatitis was defined as a chronic or relapsing itchy dermatitis with a characteristic 
morphology and distribution, based on the Hanifin criteria. Atopic dermatitis was also 
recorded if there was a history of chronic or relapsing itchy dermatitis with a typical 
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localization. This outcome was reported as point prevalence at 2 years. 
Palmer et al. (2013): The outcome considered was ‘Eczema with sensitisation’. 
Eczema was defined according to the Hanifin criteria. IgE-associated eczema or 
atopic eczema was defined as eczema with sensitisation to at least one of the allergens 
assessed. The data is based on analysis of 50 imputed datasets. This outcome was 
reported as cumulative incidence based on 1 and 3 years assessments.  
 
Statistically, studies were moderately homogenous (χ2=5.35, P=0.14, I2=43.9%). The 
results of meta-analysis showed that there is no association between maternal intake 
of fatty acids during pregnancy for prevention of eczema in the offspring (RR=0.83, 
95% CI=0.63-1.12, 1,038 children) (Figure 3.16).  
 
Figure 3.16. Forest plot of fatty acids vs. placebo for eczema 
Measure: Binary: risk ratio 
Heterogeneity: Q = 5.35; df = 3; p = 0.148; I-squared = 43.9%; tau-squared = 0.0388. 
Random effects model: 0.836 (0.623, 1.12) 
 
 
 
Outcome: Eczema Fatty acids n/N Placebo n/N 
Dunstan  18/40 13/43 
Furuhjelm 11/54 21/65 
Linnamaa 33/85 45/92 
Palmer  51/368 64/338 
Subtotal 547 538 
3.5.9.4. Wheeze as an outcome measure for fatty acid intervention 
In total, two studies were included in a meta-analysis measuring the effect of fatty 
acid intake during pregnancy on the prevention of wheeze in the offspring (Figure 
3.17). The definition of wheeze in the included trials were as below: 
Dunstan et al. (2003a): The outcome considered was ‘Recurrent wheeze’ and was 
defined on >2 occasions. This outcome was reported as point prevalence at 1 year. 
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Escamila-Nuñez et al. (2014): The outcome considered was ‘Wheezing, maternal 
atopy and non-atopy’. This study has reported wheezing separately for ‘atopic’ and 
‘non-atopic’ mothers. We combined the two outcomes to allow for the broadest 
definition. The authors have also reported that the multivariate analysis for child’s 
sex, low birth weight and maternal education did not show a difference between 
wheezing status of children from non-atopic mothers compared to atopic mothers (p 
value=0.55). Using a clinical questionnaire, the detailed information about the 
presence or absence of signs and respiratory symptoms and the number and duration 
of episodes was provided. Symptomatic episode of wheeze was defined for each sign 
and symptom, coded as 1 for the presence of at least one symptom or sign lasting ≥3 
days or 0 otherwise. The combination of the presence of various symptoms or signs at 
the same time was also considered. This outcome was reported as point prevalence at 
1.5 years.   
 
No statistical heterogeneity was observed between the included trials (χ2=0.001, 
P=0.97, I
2
=0 %). There was no evidence that consumption of fatty acids during 
pregnancy, in atopic and non-atopic mothers, reduces the risk of wheezing in 
offspring (RR=0.97, 95% CI=0.82-1.15, 952 children).  
 
Figure 3.17. Forest plot of fatty acids vs. placebo for wheeze 
Measure: Binary: risk ratio 
Heterogeneity: Q = 0.00143; df = 1; p = 0.97; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.973 (0.823, 1.15) 
 
 
 
Outcome: Wheeze Fatty acids n/N Placebo n/N 
Dunstan 10/40 12/43 
Escamila-Nuñez 252/429 262/440 
Subtotal 469 483 
 
The Escamila-Nuñez et al. (2014) study had also reported outcomes on ‘wheezing, 
maternal atopy’ and ‘wheezing, maternal non-atopy’ and we performed meta-analyses 
including these two outcomes separately (Forest plots not shown). The analyses did 
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not substantially alter the pooled results either for children from atopic mothers 
(RR=0.88, 95% CI=0.66-1.17) or for children from non-atopic mothers (RR=1.02, 
95% CI=0.83, 1.24). 
3.5.9.5. Rhinitis as an outcome measure for fatty acid intervention 
Rhinitis was reported only in one study (Palmer et al., 2013). Another study 
(Furuhjelm et al., 2011) presented data on ‘rhinoconjunctivitis, any’ as well as ‘IgE-
mediated rhinoconjunctivitis’. Therefore no meta-analysis was performed and the data 
is presented narratively.  
 
In Palmer et al. (2013), the outcome was reported as ‘Allergic rhinitis, with 
sensitisation’. Allergic rhinitis was defined as a history of sneezing or a runny or 
blocked nose accompanied by itchy-watery eyes when there have not been symptoms 
to suggest an upper respiratory tract infection. IgE-associated asthma/allergic rhinitis 
was defined as asthma/allergic rhinitis along with sensitisation to at least one of the 
aeroallergens tested. This outcome was reported as cumulative incidence based on 1 
and 3 year assessments. The results for this outcome, based on analysis of 50 imputed 
datasets, showed that there were no differences between the n-3 LCPUFA and control 
groups in the percentage of children diagnosed with allergic rhinitis with sensitisation 
through the first 3 years of age (RR= 0.82, 95% CI=0.44–1.54). 
 
3.5.9.6. Food allergy as an outcome measure for fatty acid intervention 
In total three studies were included in a meta-analysis measuring the association 
between maternal intake of fatty acids during pregnancy and the risk of developing 
food allergy in offspring (Figure 3.18). Food allergy was defined as below: 
Dunstan et al. (2003a): Food allergy (undefined), this outcome was measured as 
point prevalence at 1 year. 
Furuhjelm et al. (2011): The outcome considered was ‘Any food reactions’. Food 
reactions were diagnosed by gastrointestinal symptoms, hives, aggravated eczema or 
wheezing following the ingestion of a certain food with recovery after food 
elimination and reoccurrence of symptoms after re-ingestion of the particular food. If 
food-specific-positive SPT or serum IgE antibodies were present, the food reaction 
was considered as IgE mediated. The outcome was reported as cumulative incidence 
at 2 years.  
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Palmer et al. (2013): The outcome considered was ‘Food allergy, with sensitisation’. 
IgE-associated food allergy was defined as a history of immediate (within 60 min) 
skin rash (hives, rash or swelling) with or without respiratory symptoms (cough, 
wheeze, stridor), gastrointestinal symptoms (abdominal pain, vomiting, loose stools) 
or cardiovascular symptoms (collapse) following ingestion of a food and sensitisation 
to the implicated food. The data is based on analysis of 50 imputed datasets. This 
outcome was reported as cumulative incidence based on 1 and 3 year assessments.  
 
A moderate level of heterogeneity was observed between the included trials (χ2=3.02, 
P=0.22, I
2
=33.8%). The results of the Forest plot did not reveal an association 
between intake of fatty acids during pregnancy and the risk of developing food allergy 
in the offspring (RR=0.73, 95% CI=0.39-1.44, 908 children). 
 
Figure 3.18. Forest plot of fatty acids vs. placebo for food allergy 
Measure: Binary: risk ratio 
Heterogeneity: Q = 3.02; df = 2; p = 0.221; I-squared = 33.8%; tau-squared = 0.113. 
Random effects model: 0.753 (0.394, 1.44) 
 
 
 
Outcome: Food allergy Fatty acids n/N Placebo n/N 
Dunstan 3/40 5/43 
Furuhjelm 6/54 16/65 
Palmer  18/368 14/338 
Subtotal 462 446 
3.5.9.7. Raised specific Immunoglobulin E (sIgE) as an outcome measure for 
fatty acid intervention 
Any positive sIgE, as the outcome of interest for this systematic review, was not 
reported in any of the included studies. Therefore we could not conduct any meta-
analysis for any positive sIgE as an outcome.  
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3.5.9.8. Positive SPT to any allergen as an outcome measure for fatty acid 
intervention 
Three studies were included in a meta-analysis measuring the effect of fatty acids 
intake during pregnancy and sensitisation, as measured by SPT in the offspring 
(Figure 3.19). Sensitisation was measured by SPT and a positive reaction was 
described in the included trials as below: 
Dunstan et al. (2003a): The outcome considered was ‘SPT, any positive’. The tests 
were performed using a standardised technique and allergen extracts (egg, milk, 
peanut, house dust mite, cat), as well as histamine as a positive control and glycerin as 
a negative control. A wheal diameter of ≥2 mm was considered positive. This 
outcome was reported as point prevalence at 1 year. 
Furuhjelm et al. (2011): The outcome considered was ‘any positive SPT’. SPTs were 
performed in the infants at 6, 12 and 24 months of age to milk, egg, wheat and cat. At 
24 months of age, timothy and birch were added to the test panel. Food allergens were 
tested prick-to-prick. A wheal diameter ≥3 mm was considered positive. The outcome 
is reported as cumulative incidence at 2 years.  
Palmer et al. (2013): The outcome considered was ‘any positive SPT’. Sensitisation 
was defined as a positive skin prick test (wheal ≥3 mm above negative control) to at 
least one of the allergens assessed. At 1 year of age, the food allergens tested were 
whole hen’s egg, cow’s milk, wheat, tuna and peanut, and the aeroallergens tested 
were ryegrass pollen, olive tree pollen, Alternaria tenuis, cat hair and house dust mite 
(Dermatophagoides farina=Der p). At 3 years of age, the same allergens were tested 
with the addition of two more foods (cashew nut and sesame seed) and one additional 
aeroallergen (house dust mite, Der P). The cow’s milk allergen extract became 
unavailable from the supplier for an extended period during the 3-year assessments 
and consequently was excluded from the definition of sensitisation at 3 years. The 
data is based on analysis of 50 imputed datasets. This outcome was reported as 
cumulative incidence based on 1 & 3 year assessments. 
Statistically, studies were largely homogeneous with no variation between studies 
(χ2=1.83, P=0.04, I2=0%). Meta-analysis results suggest that intake of fatty acids in 
pregnant women is associated with a reduction of risk of sensitisation in offspring, as 
measured by SPT to any allergens (RR=0.78, 95% CI= 0.64-0.95, 891 children).  
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Figure 3.19. Forest plot of fatty acids vs. placebo for SPT (any positive) 
Measure: Binary: risk ratio 
Heterogeneity: Q = 1.83; df = 2; p = 0.401; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.788 (0.648, 0.958) 
 
 
 
 
Outcome: Any Positive SPT Fatty acids n/N Placebo n/N 
Dunstan  9/35 14/37 
Furuhjelm 10/52 22/61 
Palmer  108/368 119/338 
Subtotal 455 436 
 
3.5.9.9. Anaphylaxis and angioedema as an outcome measure for fatty acid 
intervention 
Anaphylaxis and angioedema were defined as the outcomes of interest for this 
systematic review and these are described narratively as they have been reported in 
only one study (Dunstan et al., 2003). The results from this study showed that fewer 
children in the fish oil group developed either anaphylaxis (0/40 (fish oil) vs. 1/43 
(placebo)) or angioedema (1/40 (fish oil) vs. 5/43 (placebo)); these differences were 
not significant (P>0.05) and the small sample size limits confidence in these findings.  
 
3.5.9.10. Description of the outcomes reported in Noakes et al. 2012 study 
This study used ‘salmon portion’ (as opposed to fatty acid supplements, as utilised in 
all the other included studies) compared to ‘standard diet’ during pregnancy for 
prevention of allergic disorders in offspring. The study reported a range of pre-clinical 
and clinical outcomes measured in offspring at 6 months age. The clinical outcomes 
of the interest for this systematic review are listed in Table 3.7. The results suggest 
that the use of salmon portions in pregnant women in comparison to standard diet did 
not have an influence on the prevention of atopic dermatitis and wheeze in the 
offspring by 6 months age; however, the small sample size limits confidence in these 
findings. 
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Table 3.7. List of the reported clinical outcomes in Noakes et al., 2012 
 Control (n/N) Salmon (n/N) P value 
Atopic dermatitis  7/38  12/48  0.46 
Wheeze  7/37  11/46 0.58 
 
3.5.10. Discussion of the evidence synthesis of fatty acid consumption 
during pregnancy and prevention of allergic diseases in the offspring 
3.5.10.1. Summary of main results  
The current systematic review summarised data from seven RCTs of maternal intake 
of fatty acids during pregnancy for prevention of allergic outcomes in children, 
including a total of 2,492 children with follow-up duration ranging from 6 months to 
16 years (mean 3.7 years). Trials were at risk of bias with 29% and 57% trials rated 
high risk for detection and attrition bias respectively. Most trials had a small sample 
size and also the choice of fatty acids, control group, timing and duration of 
intervention as well as duration of follow-up was varied. The findings from this 
systematic review and meta-analysis do not provide evidence that intake of fatty acids 
during pregnancy could protect subsequent development of a number of childhood 
allergic diseases including asthma, eczema, wheeze and food allergy. However, the 
evidence does suggest that prenatal fatty acids might have a protective effect for 
developing sensitisation in offspring, as measured by SPT to any allergen (RR=0.788, 
95% CI=0.648, 0.958, 3 trials, 891 children). In general, the results from this review 
need to be considered with caution because of the heterogeneity observed between the 
studies and risk of bias.  
3.5.10.2. Overall completeness and applicability of evidence 
There was a low quality of evidence that fatty acid supplementation during pregnancy 
is not effective for prevention of several allergic manifestations in the offspring. The 
meta-analysis for the outcome of “sensitisation, measured by SPT” did not show 
statistical heterogeneity between the included trials (I
2
=0%), however the number of 
studies included limits the results. The heterogeneity between the trials limited the 
findings and random effect models were used to pool the results. Heterogeneity 
between the included trials resulted from choice of fatty acids and the dose, timing 
and duration of interventions as well as duration of follow-up and small sample size 
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in most studies. 
3.5.10.3. Quality of evidence 
Overall, the trials were at moderate to high risk of bias, for the summary of risk of 
bias assessment (Figure 3.13). Randomisation and allocation concealment were 
deemed as unclear for 43% of included studies in each domain. High loss to follow-up 
was also a major concern where 57% of studies showed a high attrition bias and might 
have largely biased the effect of intervention within these trials. In addition, a limited 
number of seven studies fulfilled the inclusion criteria for the fatty acids intervention 
group and consequently, a small number of studies contributed in the conducted meta-
analyses for most allergic outcomes.  
3.5.10.4. Strength and weakness of this systematic review for fatty acid 
consumption during pregnancy 
The key strengths and weaknesses of this systematic review for fatty acid 
consumption during pregnancy for prevention of childhood allergies are the same as 
those discussed for the probiotics intervention (see section 3.5.6.4).  
3.5.10.5 Agreement and disagreement with other reviews 
Subsequent to the start date of the present review, two further systematic reviews on 
the effectiveness of n-3 LCPUFA supplementation (either with or without arachidonic 
acid) for prevention of allergies in early childhood have been published (Best et al., 
2016; Gunaratne et al., 2015). As in the present review, these reviews had a similar 
scope examining a range of allergic diseases in children; however there are key 
differences between the present systematic review and that of Gunaratne et al., (2015) 
and Best et al., (2016). Firstly, the Gunaratne et al. (2015) review had different 
inclusion criteria where it has included studies with prenatal or only postnatal 
administration of fatty acids. The review by Best and colleagues (2016) included trials 
in which supplementation was only commenced during pregnancy and identified five 
of the trials included in the current review. The present review only included studies 
that administered fatty acids during pregnancy, a total of seven studies, regardless of 
whether the supplementation was continued postnatally or not. Secondly, in 
Gunaratne and colleagues (2015) review, individual meta-analyses were performed 
for medically diagnosed allergies with or without IgE-mediated sensitisation whereas 
the review by Best et al., (2016) only investigated IgE-mediated allergies. We 
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included the broadest definition of allergic outcomes in the meta-analyses regardless 
of being IgE-mediated or not.  Where an outcome was reported as both with and 
without sensitisation, these were not combined and the outcome reported without 
sensitisation considered. Thirdly, the reviews by Gunaratne et al. (2015) and Best et 
al., (2016) have only considered point prevalence of allergic outcomes in meta-
analyses. In the present review, the cumulative incidence where reported were 
included in the meta-analyses and if not reported, reports on point prevalence were 
considered. Also, the review by Gunaratne et al. (2015) included the earlier as well as 
the extended follow-up of a trial in some meta-analyses, while Best and colleagues 
(2016) only included the earlier follow-up report of the included trials in their meta-
analyses. The current review has selectively included the longest available follow-up 
measures in the meta-analyses.  
 
Furthermore, the review by Gunaratne et al. (2015) conducted sub-group meta-
analysis for duration of follow-up and a series of other allergic outcomes and included 
only one study in most meta-analyses. They have also not separated out the effect of 
different types of control in their analysis and included a study with a different 
comparator in the meta-analysis. The review by Best et al. (2016) did not perform 
sub-group analyses. In the present review, no sub-group meta-analyses were 
undertaken, mainly because of the small number of studies and also, one study with a 
different comparator (Noakes et al., 2012) was not included in meta-analyses and 
reported narratively. In addition, the review by Gunaratne et al. (2015) has combined 
the control groups of ‘placebo and no oil’ together for the study by Olsen et al. (2008) 
in their meta-analyses, while Best et al. (2016) review has not included this study in 
any meta-analyses. However, we have made the comparisons between the 
intervention and control group as ‘olive oil’ for Olsen et al. (2008) trial. Likewise the 
trial conducted by Linnamaa et al. (2010) is not included in the Gunaratne et al. 
(2015) and Best et al. (2016) reviews whilst we included trials that have used fatty 
acid products that are rich in n-3 LCPUFA. Therefore, the Linnamaa et al. (2010) trial 
that has used BCSO was included in our review. The composition of BCSO 
corresponds to the recommended optimal dietary intake n-3 and n-6 fatty acids with 
n-3/n-6 ratio from 1.3 to 1.4. Moreover, Gunaratne et al. (2015) have included reports 
of wheeze and asthma outcomes together and the Best et al. (2016) review did not 
conduct meta-analyses for either of these outcomes. The present review conducted 
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separate meta-analyses for wheeze and asthma in children. Finally, in the reviews by 
Gunaratne et al. (2015) and Best et al. (2016), most and all of the meta-analyses were 
conducted using a fixed-effect model. The current review, however, conducted all 
meta-analyses using a random-effect model considering all the differences between 
the included trials.  
 
The current systematic review also had a different scope and approach from the 
existing systematic reviews, as described in section 3.3.2.2. Of the two existing 
systematic reviews, one has narratively described the studies that administered n-3 
LUPUFA either prenatally or postnatally (Kremmyda et al. 2011). The review by 
Klemens and colleagues, (2011), including prenatal and postnatal trials of n-3 
LUPUFA on selected allergic outcomes, does not include the most recent trials 
(Noakes et al., 2012; Palmer et al., 2013; Escamilla-Nuñez et al; 2014). This review 
has also excluded the study conducted by Linnamaa et al. (2010). In addition we 
aimed to include the most up-to-date available follow-up data from the included trials 
in the meta-analyses; however, this was not intended in the existing reviews and 
earlier follow-up data are included in some of the conducted meta-analyses.  
 
The aforementioned detailed discussion features some key limitations in the 
previously conducted reviews on this topic, limiting the level of confidence in their 
findings. Most of the previously conducted reviews have failed to assess the evidence 
from the latest available follow-up data in the included trials of fatty acid 
interventions, administered either during pregnancy or after birth. Some of the unique 
RCTs are excluded from these reviews which limits investigating the evidence of all 
the conducted studies on this specific topic. As mentioned in section 3.5.6.4, the 
results of these reviews are also partly exposed to the risk of duplicating participants 
and, therefore, overestimating the effect of the intervention (Sterne, et al., 2011). 
 
Due to the differences in focus between the above-mentioned systematic reviews and 
the current systematic review, the ability to make meaningful comparisons between 
the findings is to some extent limited. However, where comparisons are possible these 
will now be discussed. To recap, this systematic review examined prenatal intake of 
fatty acids only (that commenced prenatally and continued postnatally) including the 
most up-to-date follow-up data from included trials in the meta-analysis, indicating 
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that fatty acids did not protect against developing any types of eczema in children. In 
contrast, the reviews by Gunaratne et al. (2015) and Best et al. (2016) showed a 
beneficial effect for atopic eczema; however, these analyses only included the earlier 
follow-up data from included trials. The results of this systematic review also did not 
support the hypothesis that fatty acids could protect against other allergic outcomes in 
offspring. Similar results are reported in other systematic reviews, although the 
approaches in the conducted meta-analyses varied to some extent. The findings of this 
systematic review also showed a protective effect for childhood sensitisation 
measured by SPT to any allergen in line with the results in the other reviews. Meta-
analyses for sensitisation to single allergens measured by SPT were not conducted in 
this systematic review, however, the reviews by Gunaratne et al. (2015) and Best et 
al. (2016) conducted meta-analyses for these outcomes and showed promising results. 
It is important to note that these meta-analyses only included a few studies and are 
subject to type II error.  
3.5.10.6. Author’s conclusion 
Implications for practice  
The evidence on prenatal fatty acids intake during pregnancy and prevention of 
allergic outcomes in children is limited, although there appears to be an association 
with reduction of childhood sensitisation. There is a need to interpret these findings 
with caution as a result of risk of bias between studies, different methods for reporting 
the outcome measures, variability of the fatty acid supplements and doses as well as 
timing and duration of intervention and diverse settings.  
Implications for research  
Taking the quantity and quality of the available evidence into account, the effect of 
fatty acids intake during pregnancy for prevention of childhood allergies needs to be 
further investigated in well-designed and executed RCTs.  
 
The timing of intervention has been varied in the conducted trials and the optimal 
timing of fatty acids intervention is an uncertainty that needs to be addressed more 
clearly in further trials. The n-3 LCPUFAs have anti-inflammatory properties that 
could alter the balance of TH1 to TH2, which is a well-recognised hallmark in allergies 
(Meydani et al., 1991; Thies et al., 2001; Trebble, et al., 2003). Therefore, it could be 
hypothesised that early introduction of fatty acids during pregnancy could promote a 
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beneficial immunomodulatory effect in the foetus as early as possible towards a 
healthy programming of the immune system. Furthermore, future trials could consider 
a differentiation between DHA to EPA ratios in fatty acid supplementation as well as 
baseline LCPUFA status in their sample. The dose and duration of intervention as 
well as the choice of control should also be addressed in future studies.  
 
Large multicentre well-executed RCTs with coherent methodology and standardised 
measures for assessing the outcomes are required in order to make stronger inferences 
for the efficacy of fatty acids intervention in pregnant women as a preventive 
approach for childhood allergies. In addition, studies should aim to minimise the 
attrition bias in their extended follow-ups. There is also a need for well-designed 
epidemiological studies from under-reported populations, since the current evidence 
originates predominantly from the developed regions. 
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3.5.11. Description of included studies of maternal food avoidance 
interventions during pregnancy and prevention of allergic diseases in the 
offspring  
A total of four included studies examined the impact of food allergen avoidance 
during pregnancy on the development of allergic disease in offspring (including a 
total of 634 children). The characteristics of the included trials and study populations 
for these studies are shown in Table 3.8. Two studies were conducted in Sweden, one 
in the United Kingdom and one in the United States (Table 3.8).  
 
In one of the studies (Lilja et al., 1989) the sample is reported as consisting of two 
groups recruited from Stockholm and Uppsala. However, in their earlier report (Lilja 
et al., 1988), they had reported that the sample for their study was recruited from 
Stockholm and Uppsala as well as Linköping and a total of four diet interventions 
were concurrently taking place in the sample. For clarification, the authors were 
contacted and the reply is pasted below (personal communication):  
“Two studies were started in Sweden around 1982-1983, one in Linköping (Falth 
Magnusson) and one in Stockholm-Uppsala (Lilja et al.,). At that time avoidance was 
the main message to prevent allergy development in childhood. 
The women in Linköping were randomly allocated to a diet during the third trimester 
completely free from egg and milk or a "normal" intake and the women in Stockholm-
Uppsala were randomly allocated to a reduced intake or a high intake of milk and 
egg. We decided to pool our data on the influence of the various maternal diets 
during late pregnancy on maternal and foetal IgG-antibody responses and on cord 
blood IgE responses in the paper published 1988 (Note: Data from 1988 paper is 
not extracted as it reports pre-clinical outcomes only). 
After the publication in 1988 we continued to include women in our studies and the 
results were published separately by Falth Magnussson and myself during the 
forthcoming years. 
Falth Magnusson has published a follow-up at 5 years of age. We have performed 
follow-ups at 5, 10 and now at 30 years of age. We will present our data from the 
follow up at 30 years of age at EAACI in Barcelona in June 2015.” 
 
Based on the author’s reply, it was concluded that subsets of women initially 
allocated to different types of food allergen avoidance were reported in the later 
reports of Lilja’s trial. This was also considered in pooling the data from this study 
and the fact that the sample reported in Lilja study (1989) were also the sub-sets of 
sample reported in the 1992 study (Fälth-Magnusson & Kjellman, 1992).  
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Also in the Lilja et al., (1989) trial, after delivery two groups naturally emerged with 
respect to reduced diet group. One group of mothers (n=25) continued their restricted 
diet during their first two months of lactation by choice, whilst the rest of the mothers 
normalised their diet. These groups were called ‘reduced A and B’ groups and no 
significant differences were found between these groups with regards to SPTs or in 
the incidence of atopic diseases. Therefore, the results in the A-group and B-group 
were considered together and presented as the reduced group.  
 
In the study conducted by Lovegrove, Hampton, & Morgan (1994), mothers allocated 
to the prophylactic-treated group were all atopic. However, mothers assigned to the 
un-restricted diet were grouped as atopic and non-atopic and allergic outcomes are 
presented separately for these groups. For this systematic review, the results from the 
atopic mothers with unrestricted diet are compared to prophylactic-treated group of 
atopic mothers.  
 
The largest sample size was reported by the study conducted by Zeiger et al., (1992), 
which included 288 mothers at recruitment, followed by Fälth-Magnusson & 
Kjellman (1992) with a total of 209 pregnant women. The smallest sample was 
observed in the pilot study conducted by Lovegrove et al. (1994) with 44 pregnant 
mothers. In all the included studies, the sample was selected from a population with a 
family history of atopy.           
 
Trials varied in their follow-up period from 1.5 years (Lilja et al., 1989 and 
Lovegrove et al., 1994) to 7 years (Zeiger et al., 1992). The data for the Zeiger et al 
(1992) study has been extracted from the report on 4 years follow-up (1992 paper) as 
the report for 7 years follow-up (Zeiger & Heller, 1995) has only presented the trends 
of allergic outcomes in children. While there was a later publication from the study by 
Lovegrove at el., (1996), only data from the 1994 report was extracted since the paper 
published in 1996 reported pre-clinical outcomes only e.g. levels of food antibodies 
and antigens in breast milk. This is also the case for the study by Lilja et al.; where 
only preclinical outcomes were reported in the 1991 report e.g. egg and milk-specific 
IgE and IgG antibodies. Therefore the clinical outcomes reported in the 1989 paper 
have been extracted for this review.  
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Table 3.8. Characteristics of included trials and study population for food avoidance interventions and prevention of allergy in offspring 
Primary article  Companion 
articles 
Country, 
enrolment 
period 
Trial 
type
*
 
Name of the 
study arms 
No. of 
particip
ants
**
 
No. at 
last  
F-U
***
 
Time 
points 
measured 
Age at 
last  
F-U 
Sample: 
high risk of 
Atopy 
Feeding 
restriction
s 
Outcomes 
reported 
 
(Lilja et al., 1989)  
 
(Lilja et al., 
1988, 1991) 
 
Sweden 
Not reported 
RCT High diet vs. 
reduced diet 
171 
mothers 
162 (79 
vs. 83) 
2, 6, 12 & 
18 months 
1.5 yrs. Yes - -Atopic eczema 
-Asthma 
-Rhinoconjunctivitis 
-Urticaria 
-SPT (egg) 
-SPT (cow’s milk) 
(Zeiger et al., 
1992) 
(Zeiger et al., 
1989; Zeiger 
& Heller, 
1995)  
the US 
Not reported 
RCT Prophylactic-
treated & 
Control 
288 
mothers 
225 
(85 vs. 
140) 
4 months, 
3, 4 & 7
##
 
yrs. 
7yrs. Yes BF 
encourage
d or infant 
formulas 
used 
-Any allergy 
-Atopic dermatitis 
-Food Allergy  
-Allergic rhinitis 
-Asthma 
-SPT (any positive) 
-SPT inhalant (any 
positive)  
-Urticaria 
(Fälth-Magnusson 
& Kjellman, 
1992)  
 
(Fälth-
Magnusson & 
Kjellman, 
1987; Fälth-
Magnusson, 
Oman, & 
Kjellman, 
1987)  
Sweden 
1983-4 
RCT
#
 Exclusion Diet 
and None-
exclusion Diet 
209 
mothers 
209 (86 
vs. 
123) 
3, 6, 12 & 
18 months 
+ 5yrs. 
5yrs. Yes - -Allergic disease 
-Atopic dermatitis 
-Any food 
intolerance 
-Rhinoconjunctivitis 
-Asthma 
-Egg intolerance 
-Fish intolerance 
-SPT (any positive) 
(Lovegrove et al., 
1994) 
(Lovegrove, 
Morgan, & 
Hamptom, 
1996) 
the UK  
1988-9 
RCT
# 
(Pilot 
study) 
Prophylactic-
treated (atopic) 
& Unrestricted-
diet (atopic & 
non-atopic) 
44 
mothers 
38 (12 
vs. 14 
vs. 12) 
6, 12 & 18 
months 
1.5 yrs. Yes Exclusive 
BF 
encourage
d with late 
start for 
solids 
-Atopic eczema 
-Severity of allergy 
-Maternal and cord 
serum β-Lg-IgG,  
α-cas-IgG and β-Lg  
+Excludes conference abstracts from which no unique data were extracted    *Randomized Controlled Trial 
**Indicates the number at randomization where recruitment has occurred prenatally   ***Follow-Up      
#Single blind study         ##at 7yrs., only the trends of outcomes are reported 
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The characteristics of food allergen avoidance interventions and the control groups in 
the included trials are presented in Table 3.9. Comparable baseline characteristics 
have been reported in all the included trials.   
 
The two Swedish studies, (Fälth-Magnusson & Kjellman, 1992; Lilja et al., 1989) had 
applied the food avoidance intervention only throughout pregnancy whilst, in the rest 
of the trials (Table 3.9) the intervention was also continued during the lactation 
period, with the longest period of intervention being 3 years postnatally in the Zeiger 
et al. (1992) study.  
 
Trials varied in the nature of food avoidance in pregnant women from complete 
avoidance of dairy as well as peanut products in the study by Zeiger et al. (1992), to 
the avoidance of dairy products and egg in the rest of the included studies. The choice 
of control group in three of the studies was ‘standard diet’ (Fälth-Magnusson & 
Kjellman, 1992; Lovegrove, Hampton, & Morgan, 1994; Zeiger et al., 1992) and one 
study used a diet which included consumption of 1 hen’s egg and 1 litre of milk daily 
as the comparator arm (Lilja et al., 1989). The latter was not included in the meta-
analysis as the control was very different to the other comparators and quite artificial. 
 
With the exception of the trial conducted by Lilja et al. (1989), all participants 
randomised to the intervention arms were prescribed substitutes including calcium, 
vitamins and also formula for their infant to compensate for the nutrient deficiency 
that could be caused by restricting egg and dairy intake. 
 
Compliance with the food allergen avoidance intervention in the included studies was 
assessed by either the mother’s daily records of their intake, or contacting women 
during the period of intervention. There was no indication of how compliance with 
the intervention was monitored in the trial by Fälth-Magnusson & Kjellman (1992).  
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Table 3.9. Characteristics of food avoidance interventions in included trials 
Primary 
article  
Comparable 
baseline 
characteristic  
Participants 
receiving 
intervention 
Timing of  
Intervention in 
pregnancy 
Intake of 
intervention  
From/until 
Duration of 
intervention 
(months)
**
 
Type of food 
intervention 
Control arm 
 
Substitutes 
prescribed (in 
Int arm) 
Lilja et al., 
1989 
Yes (but a 
significant 
higher incidence 
of atopic 
eczema and 
higher IgE 
levels before 
28wks in the 
'reduced' group) 
Pre & 
postnatally in 
mothers (after 
delivery, on 
mothers’ own 
choice) 
From 28wks 28wks to 
delivery 
2.5-3  Strictly reduced 
ingestion of egg and 
dairy products 
(milk/yoghurt/butter/che
es etc.) 
High diet 
(1 hens' egg and 
dairy products 
corresponding 
to about 1L of 
cows' milk 
daily) 
- 
Zeiger et al., 
1992 
Yes Prenatally in 
mothers & 
postnatally in 
infants 
During the last 
trimester of 
pregnancy 
3
rd
 trimester to 
3yrs. 
postnatal
*
 
36-40 Avoidance of all cow's 
milk, egg, and peanut 
products 
Standard diet 
(recommended 
by ACOG) 
1500mg daily 
prenatal 
vitamins & 
calcium 
(Fälth-
Magnusson & 
Kjellman 1992 
No (Tobacco 
exposure was 
statistically 
significant 
between the D 
& ND groups) 
Prenatally in 
mothers 
From 28wks 28wks to 
delivery 
2.5-3 Avoidance of Dairy 
Product & Egg 
(Cow's milk and egg) 
Standard diet 
(1/2 litre of 
milk/day & 3-5 
eggs/wk. 
extra calcium 
and casein 
hydrolysate 
(Nutramigen) 
supplement 
Lovegrove et 
al., 1994 
Yes Pre & 
postnatally in 
mothers 
 
From 
approximately 
36wks 
36wks to 
lactation 
period 
4.5-5 
(majority 
breast-fed by 4 
months) 
Avoidance of all milk 
and dairy products 
Standard diet 
(for pregnancy 
& lactation) 
Hypoallergenic 
complete infant 
formula, 
Peptijunioras 
required + 
1000mg Ca 
supplement 
*Mothers have continued food avoidance at different time points e.g. Late start of solids 
**Indicates total duration in pregnancy plus after birth, if applicable 
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3.5.12. Risk of bias in studies of maternal food avoidance interventions 
during pregnancy and prevention of allergic diseases in the offspring 
The summary of risk of bias of trials on food avoidance intervention studies is 
presented in Figure 3.20 In all the included studies, the allocation concealment was 
rated as unclear and all studies were rated as having a high risk of bias for their 
double blinding domain.  
 
The reviewer’s judgment on the risk of bias assessment on food avoidance 
intervention studies is shown in appendix 3.8. 
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Short Title Random 
Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources 
of Bias 
Lilja (1989) ? ? - + + + - 
Fälth-Magnusson (1992) ? ? - ? - + - 
Zeiger (1992) + ? - ? - + + 
Lovegrove (1994) ? ? - + + + ? 
 
Random Sequence Generation  
 
25% 75%   
 
Allocation Concealment  
 
  100%   
 
Double Blinding  
 
   100% 
 
Blinding of Outcome Assessment  
 
50% 50%   
 
Incomplete Outcome Data  
 
50%   50% 
 
Selective Outcome Reporting  
 
100%    
 
Other Sources of Bias  
 
25% 25% 50% 
 
 
 
Low risk of bias  High risk of bias   Unclear risk of bias  
 
Figure 3.20. Summary of risk of bias assessment in the included trials of food avoidance and prevention of allergy in the offspring 
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3.5.12.1. Random sequence generation (selection bias) 
One study was rated as having a low likelihood of selection bias (Zeiger et al., 1992), 
as they randomised the participants by using a computer system. Method of 
assignment was rated as unclear in three studies since there was no clear information 
(Fälth-Magnusson & Kjellman 1992; Lilja et al., 1989; Lovegrove et al., 1994).  
3.5.12.2. Allocation concealment  
All the food avoidance intervention trials failed to report any information for their 
allocation concealment and so were rated as having an unclear risk of bias.  
3.5.12.3. Double blinding (performance bias) 
All of the four studies were classified as having a high risk of bias, clearly stating that 
either blinding did not remain intact throughout the study or that it was not possible to 
blind the participants due to the nature of the intervention. 
3.5.12.4. Blinding of outcome assessment (detection bias) 
Only two studies described any blinding of outcome assessment and were rated as low 
risk (Lilja et al., 1989 & Lovegrove et al., 1994). The remainder were rated as unclear 
risk (Fälth-Magnusson & Kjellman 1992; Zeiger et al, 1992). 
3.5.12.5. Incomplete outcome data (attrition bias) 
Reasons for missing and/or exclusion of data were balanced across the study arms in 
two studies and therefore rated as low risk (Lilja et al., 1989 and Lovegrove et al. 
1994). Two other studies were rated as high risk of bias since, as in the trial by Fälth-
Magnusson & Kjellman (1992), some women had switched from the intervention arm 
to the control group and vice versa. The study by Zeiger et al (1992) also had a large 
rate of loss to follow-up by 4 years, largely in its intervention arm. 
3.5.12.6. Selective outcome reporting (reporting bias) 
In all the included trials, the pre-specified outcomes including the cumulative 
prevalence of allergic outcomes were reported; thus all trials were rated as low risk 
for selective outcome reporting. 
3.5.12.7. Other potential sources of bias 
Any further sources of bias within the included trials were considered and two studies 
were assessed as high risk (Fälth-Magnusson & Kjellman 1992; Lilja et al., 1989). In 
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both studies, some women decided to continue their diet during the breast-feeding 
period by choice and also some switched between the study arms. The study by 
Zeiger et al. (1992) was rated as having a low risk of bias. The study by Lovegrove et 
al. (1994) was rated as unclear as the trial was a pilot study and generously supported 
by Cow & Gate, Trowbridge, Witlshire, UK, as a commercial funding body.  
3.5.13. Meta-analyses of effectiveness of maternal food avoidance 
interventions during pregnancy and prevention of allergic diseases in the 
offspring 
Pooled results from meta-analyses in the studies that examined the effectiveness of 
food avoidance interventions during pregnancy for prevention of allergic outcomes in 
the offspring are presented in the following section. For the trial by Fälth-Magnusson 
& Kjellman (1992) the allergic outcomes at 5 years follow-up were analysed on the 
basis of compliance with diet rather than on the basis of randomisation. Also, the 
Zeiger et al. (1992) trial presented the cumulative prevalence of some outcomes by 4 
years of age only in graph format. Where possible, numbers have been calculated 
from the data presented in these graphs, although there is the potential for this to have 
introduced a small amount of error since these are estimated rather than absolute data 
and discrepancies may have arisen during rounding. It was not possible to perform 
any meta-analysis for the outcomes ‘wheeze’ and ‘positive sIgE’ as these were not 
reported in any of the included trials. The Lilja et al. (1989) study was not included in 
meta-analyses, as its comparator was not similar to the control group in other included 
trials. The results from this study are described narratively. 
3.5.13.1. Any ‘Allergic Diseases’ as an outcome measure for food avoidance 
intervention 
The effectiveness of food avoidance during pregnancy for prevention of allergic 
diseases in the offspring was assessed in two studies. Figure 3.21 shows the Forest 
plot for food avoidance versus standard diet in pregnant women for the prevention of 
allergic diseases in offspring. ‘Any allergic disease’ was defined differently in the 
included studies. These are described as below: 
Fälth-Magnusson & Kjellman (1992): The outcome considered was ‘Allergic 
diseases, definite’. Based on all available information about each child, a summarised 
classification regarding allergic disease was made by the authors. Children classified 
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as ‘allergic’ had a history that suggested allergy, verified by a positive SPT for the 
suspected allergen, and/or a diagnosis of allergic disease by a pediatrician. There is no 
information whether the outcome is calculated as point or cumulative prevalence at 5 
years.  
Zeiger et al. (1992): Any allergy was defined by phenotypes of allergy as physician 
documented lower respiratory asthma, atopic dermatitis, urticaria and allergic rhinitis 
plus sensitisation. This was reported as a cumulative prevalence at 4 years follow-up. 
 
Statistically, the studies were largely homogeneous (χ2=0.23, P=0.63, I2=0%). The 
results of meta-analysis did not support a beneficial effect for food avoidance in 
pregnant women for prevention of allergic diseases in the offspring (RR=0.99, 95% 
CI=0.73-1.35, 486 children).  
 
Figure 3.21. Forest plot of food avoidance interventions vs. standard diet for any 
allergic diseases 
Measure: Binary: risk ratio 
Heterogeneity: Q = 0.232; df = 1; p = 0.63; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.999 (0.737, 1.35) 
 
 
 
Outcome: Any allergic diseases Food Int. n/N Placebo n/N 
Falth-Magnusson 24/84 30/114 
Zeiger   32/103 62/185 
Subtotal 187 299 
 
The Fälth-Magnusson & Kjellman (1992) study has also presented data on allergic 
diseases based on parental reports of all allergies. The number of children reported by 
parents manifesting allergic diseases in the diet group vs. the non-diet group were as 
follows: no allergy (45/84 vs. 67/114), mild allergy (28/84 vs. 30/114), moderate 
allergy (10/84 vs. 17/114) and severe allergy (1/84 vs. 0/114). There were no 
significant differences between the diet and non-diet groups. The parents of seven 
children reported allergic symptoms affecting skin, eye/nose, and bronchi, three in the 
diet group and four in the non-diet group respectively. The combined evaluation of all 
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available information, assessed by the authors about each child, corresponded well to 
the parental opinion. The cases reported as ‘no allergy’ and ‘probable allergy’, as 
assessed by the authors in the diet and non-diet groups were 55/84 vs. 72/114 and 
5/84 vs. 12/114 respectively, and there were no significant differences between study 
groups. The children evaluated as having ‘definite allergy’ by authors were included 
in the meta-analysis (Figure 3.21). 
 
3.5.13.2. Asthma as an outcome measure for food avoidance intervention 
Two included studies measured the effect of food avoidance(s) during pregnancy on 
prevention of asthma in offspring (Figure 3.22). The definition of asthma prevalence 
in included studies included in the meta-analysis were as follows: 
Fälth-Magnusson & Kjellman (1992): The outcome considered was ‘Obvious 
bronchial asthma’. Parents of 52 children reported prolonged cough (>2 weeks after a 
respiratory tract infection), or wheezing upon infections, or upon physical exercise at 
least on one occasion. Parents were also offered a visit at clinic with a specialised 
pediatric allergy nurse to discuss the questionnaire replies. Further clarification was 
then sought as appropriate. Families, who declined the visit were interviewed on the 
phone. Children considered to have allergic disease, severe enough to require 
medication, were referred for a medical examination by a pediatrician. This was 
performed in 47 children referred by the nurse. To evaluate bronchial obstruction, a 
simple running exercise test was performed for 6 minutes according to the clinical 
praxis of the department. A fall in the peak expiratory flow rate of >15% was 
considered enough to verify a suspicion of asthma. This outcome was reported as 
cumulative prevalence at 5 years. 
Zeiger et al. (1992): Asthma was defined as a physician documented lower 
respiratory condition with characteristics reversible bronchospasm, occurring at least 
twice and un-associated with other anatomic, congenital, or immunologic causes. The 
outcome was reported as cumulative prevalence at 4 years.  
 
The results of the pooled analysis for asthma risk reduction in offspring following 
food avoidance intervention during pregnancy are shown in Figure 3.22. There was a 
moderate level of statistical heterogeneity between studies (χ2=1.93, P=0.16, 
I
2
=48.1%). The pooled results from included studies did not support an association 
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between food avoidance during pregnancy and prevention of asthma in the offspring 
(RR=1.09, 95% CI=0.62-1.91, 486 children). 
 
Figure 3.22. Forest plot of food avoidance intervention vs. standard diet for 
asthma 
Measure: Binary: risk ratio 
Heterogeneity: Q = 1.93; df = 1; p = 0.165; I-squared = 48.1%; tau-squared = 0.0829 
Random effects model: 1.09 (0.628, 1.91) 
 
Outcome: Asthma Food Int. n/N Placebo n/N 
Falth-Magnusson 14/84 12/114 
Zeiger  25/103 51/185 
Subtotal 187 299 
 
3.5.13.3. Eczema as an outcome measure for food avoidance intervention  
Three included studies measured the effect of food avoidance during pregnancy on 
prevention of eczema in offspring (Figure 3.23). The definition of eczema prevalence 
in included studies in the meta-analysis were as follows: 
Fälth-Magnusson & Kjellman (1992): The outcome considered was ‘Atopic 
dermatitis, adapted from the reports of the parents’. For diagnosing AD, the 
classification system proposed by Hanifin was used. This outcome was reported as 
point prevalence at 4 years follow-up. One point to consider is that there was a 
discrepancy between the numbers reported for this outcome (51 in the table and 53 
and in the text). We used the data provided in the table.  
Zeiger et al. (1992): The outcome considered was ‘Atopic dermatitis’ and was 
defined as an eczematous eruption associated with at least 3 of the following 4 criteria 
suggested by Hanifin and modified for offspring of atopic parents: i) pruritis, ii) 
typical morphology and distribution, iii) a tendency towards chronicity or recurrence, 
iv) concurrent specific-IgE. This was reported as cumulative prevalence at 4 years 
follow-up.  
Lovegrove et al. (1994): The outcome considered was ‘Allergy incidence’ which was 
defined as the occurrence of clinically diagnosed atopic eczema. The outcome was 
 145 
reported as point prevalence at 18 months. The results for atopic-diet vs. atopic 
unrestricted diet groups were considered. 
 
The results of the pooled analysis for asthma risk reduction in offspring following 
food avoidance intervention during pregnancy are shown in Figure 3.23. There was a 
moderate level of statistical heterogeneity between studies (χ2=6.35, P=0.04, 
I
2
=68.5%). The pooled results from included studies did not support an association 
between food avoidance during pregnancy for prevention of eczema in offspring 
(RR=0.96, 95% CI=0.49-1.88, 512 children). 
 
Figure 3.23. Forest plot of food avoidance intervention vs. standard diet for 
eczema 
Measure: Binary: risk ratio 
Heterogeneity: Q = 6.35; df = 2; p = 0.0419; I-squared = 68.5%; tau-squared = 0.234. 
Random effects model: 0.962 (0.492, 1.88) 
 
 
Outcome: Eczema Food Int. n/N Placebo n/N 
Falth-Magnusson 14/84 12/114 
Lovegrove  4/12 7/14 
Zeiger  15/103 39/185 
Subtotal 199 313 
 
In the study conducted by Lovegrove et al., 1994, three infants in the atopic-diet 
group inadvertently received at least one feed of commercial infant formula, derived 
from cow’s milk, shortly after delivery and developed allergic manifestations. We 
conducted another meta-analysis for this outcome in the atopic-diet group by 
excluding these children from the analysis. The result from the second meta-analysis 
showed a high heterogeneity (χ2=8.89, P=0.01, I2=77.5%) and there was no evidence 
that food avoidance protects children from developing eczema (RR=0.79, 95% 
CI=0.30-2.05) (Forest plot not shown). 
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3.5.13.4. Rhinitis as an outcome measure for food avoidance intervention  
Rhinitis was reported only in one trial (Zeiger et al., 1992), and Fälth-Magnusson & 
Kjellman (1992) reported allergic rhinoconjunctivitis. Therefore, it was not possible 
to conduct a meta-analysis for this outcome.  
 
The Zeiger et al. (1992) study defined the outcome of ‘Allergic rhinitis’ as a nasal 
condition with characteristic sneezing, itching, and/or rhinorrhea with concurrent i) 
sIgE and ii) nasal eosinophilia. This outcome was reported as cumulative prevalence 
at 4 years follow-up. Their results showed that there were no differences between the 
food allergen avoidance and standard diet groups in terms of the number of children 
diagnosed with allergic rhinitis through the first 4 years of life (43/104 vs. 24/185, 
p>0.05). 
3.5.13.5. Food allergy as an outcome measure for food avoidance intervention  
Two studies were included, which examined the effectiveness of food avoidance in 
pregnant women and prevention of food allergy in offspring (Figure 3.24). The 
definition of food allergy in the included studies, as described in the papers, were as 
follows:  
Fälth-Magnusson & Kjellman (1992): The outcome considered was ‘Food 
intolerance, to any food item’. The parents were asked about signs and symptoms of 
food intolerance and whether the child had received any medication for allergic 
disease(s). There is no information on whether the outcome reported was point or 
cumulative prevalence at 5 years.  
Zeiger et al. (1992): The outcome considered was ‘Food allergy, adverse allergic 
reactions to two or more foods’. Food allergy was defined when food-specific IgE 
occurred concurrently with symptoms consistent with: i) atopic dermatitis ii) 
urticaria/angioedema triggered at least twice by a specific food iii) gastrointestinal 
allergy (vomiting/diarrhea induced on at least two occasions by a specific food. 
DBPCFC were planned to confirm all non-anaphylactic adverse food reactions, but 
only half of these affected families agreed to undergo this procedure. The outcome 
was reported as point prevalence at 4 years. 
 
Statistically, there was no heterogeneity between the included studies (χ2= 0.33, 
P=0.56, I
2
= 0%). The result of meta-analysis indicates that there was no association 
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between food avoidance during pregnancy and prevention of food allergy in the 
offspring (RR=1.04, 95% CI=0.51-2.07, 423 children).  
 
Figure 3.24. Forest plot of food avoidance intervention vs. standard diet for food 
allergy 
Measure: Binary: risk ratio 
Heterogeneity: Q = 0.338; df = 1; p = 0.561; I-squared = 0%; tau-squared = 0. 
Random effects model: 1.04 (0.518, 2.07) 
 
 
 
Outcome: Food allergy Food Int. n/N Placebo n/N 
Falth-Magnusson 16/84 20/114 
Zeiger  1/85 3/140 
Subtotal 169 254 
 
We also conducted a separate meta-analysis including the ‘cumulative prevalence’ of 
food allergy at 4 years of age, reported in Zeiger et al. (1992) study. The results from 
the meta-analysis showed a high heterogeneity between the included studies (χ2=5.22, 
P=0.02, I
2
=80.8%) showing no effect of prenatal food allergen avoidance in 
preventing food allergies in offspring (RR=0.66, 95% CI=0.25-1.75) (Forest plot not 
shown).  
3.5.13.6. Positive Skin Prick Test (SPT) to any allergen as an outcome measure 
for food avoidance intervention  
Two studies were included in a meta-analysis measuring the effect of food avoidance 
during pregnancy and sensitisation, measured by SPT in the offspring (Figure 3.25). 
Sensitisation was measured by SPT and a positive result was described in the included 
trials as below: 
Fälth-Magnusson & Kjellman (1992): The outcome considered was ‘SPT, any 
positive’. The tests were performed according to the puncture method with a lancet 
with 1mm tip. The aeroallergens used were pasteurised cow’s milk with protein 
content and egg and milk extracts. The SPTs to milk and egg were performed in 
duplicates. Single pricks were performed to wheat, birch, timothy, cat, mites 
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(Dermatophagoides farina and D. pteronyssinus), mould (cladosporium) with Phazet. 
Histamine chloride, 10 mg/ml, as positive control. The wheal was marked on the skin 
with a filter-tipped pen and the mark was then covered with a transparent tape. The 
tape was later attached to a paper for measuring the reprint of the wheal. The SPT was 
regarded as positive when the mean wheel diameter was at least 3 mm. The outcome 
was reported as point prevalence at 5 years.  
Zeiger et al. (1992): The outcome considered was ‘SPT, multiple foods’. Skin prick 
tests were with multi-test units using the food allergens as ‘milk, egg, peanut, wheat, 
corn, soy, cod, chicken, beef and other foods incriminated in a historical adverse 
reaction and aeroallergens ‘mite, alternaria, cladosporium (hormodndrum), grass mix 
(30% Bermuda, 70% grass mix), dog and cat’. SPT allergen wheel of ≥3 mm larger 
than the saline control were considered positive. Histamine phosphate was used for a 
positive control. The outcome was reported as period prevalence at 4 years. 
 
Statistically, these studies are largely homogeneous with no variation between studies 
(χ2=0.10, P=0.74, I2=0%). The result of meta-analysis did not show an association 
between food avoidance during pregnancy and prevention of sensitisation in the 
offspring, measured by SPT to any allergens (RR=0.66, 95% CI=0.40-1.09, 443 
children).  
 
Figure 3.25. Forest plot of food avoidance intervention vs. standard diet for 
sensitisation to any allergen, measured by SPT 
Measure: Binary: risk ratio 
Heterogeneity: Q = 0.108; df = 1; p = 0.743; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.668 (0.409, 1.09) 
 
 
Outcome: Any Positive SPT Food Int. n/N Placebo 
n/N 
Falth-Magnusson 12/64 24/91 
Zeiger  7/103 21/185 
Subtotal 167 276 
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3.5.13.7. Narrative description of the results in the Lilja et al. (1989b) study 
This study by Lilja et al. (1989) used food avoidance defined by strict reduction of 
ingestion of egg and dairy products (milk/yoghurt/butter/cheese etc.), and compared 
this arm with a high diet (one hen’s egg and 1L cow’s milk daily) during pregnancy 
for prevention of allergic disorders in the offspring. The study reported pre-clinical 
and clinical outcomes measured in offspring by 18 months of age. The clinical 
outcomes of interest for this systematic review are listed in the Table 3.10. As the 
results indicate, avoidance of specific foods in pregnant women in comparison to a 
diet rich in dairy products did not influence the risk of atopic dermatitis and asthma in 
the offspring. 
 
Table 3.10. List of the reported clinical outcomes in Lilja et al (1989) 
 High diet (n/N) Reduced Food Avoidance (n/N) P value 
Atopic eczema (obvious) 10/81  14/82  >0.05  
Atopic eczema (probable) 3/81 4/82 >0.05  
Atopic eczema (possible) 14/81  5/82 >0.05  
Asthma (obvious) 1/81 1/82 >0.05  
Asthma (probable) 0/81 0/82 >0.05  
Asthma (possible) 3/81 6/82 >0.05  
 
3.5.14. Discussion of the evidence synthesis of food avoidance interventions 
during pregnancy and prevention of allergic diseases in the offspring 
3.5.14.1. Summary of main results  
The present systematic review summarised data from four RCTs of maternal food 
avoidance during pregnancy for prevention of allergic outcomes in children, including 
a total of 634 children with follow-up duration from ranging 1.5-7 years (mean 3.25 
years). Trials were at risk of bias with all trials rated as unclear for their allocation 
concealment. In addition, performance bias was high risk in all trials (100%) while 
detection bias was deemed as low (50%) and unclear (50%) risk. High attrition bias 
was also a concern in two studies (50%). All trials had a small sample size and one 
was conducted as a pilot study (Lovegrove et al., 1994). The choice of food avoidance 
was fairly similar between studies, and only one study defined a different comparator. 
The findings from this systematic review and meta-analysis do not support a 
protective effect for food avoidance in pregnant women as an intervention strategy for 
prevention of allergic diseases in children. It should be noted that the results from this 
review are not decisive because of the low quality of studies as well as high 
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heterogeneity between studies.  
3.5.14.2. Overall completeness and applicability of evidence 
No evidence was found that food avoidance during pregnancy is effective for the 
prevention of allergic disorders in the offspring. The heterogeneity between the trials 
limited the findings and random effect models were used to pool the results. 
Heterogeneity between the included trials resulted from their sample size, duration of 
intervention, choice of control and follow-up duration.  
3.5.14.3. Quality of evidence 
Overall, the trials were at high risk of bias, for the summary of risk of bias assessment 
(Figure 3.20). Randomisation was rated as unclear in three studies (75%). All studies 
were open label due to the nature of intervention, resulting in high risk of bias for 
performance. High loss to follow-up was also a major concern in two studies (50%). 
In addition, there were few studies that met the inclusion criteria for this systematic 
review of food avoidance and, as a result, a relatively small number of studies was 
included in most of the meta-analyses. 
3.5.14.4. Strength and weakness of this systematic review for food avoidance 
during pregnancy 
The key strengths and weaknesses of this systematic review for food avoidance 
during pregnancy for prevention of childhood allergies are the same as those 
discussed for the probiotics intervention (see section 3.5.6.4).  
3.5.14.5 Agreement and disagreement with other reviews 
The current systematic review had a different approach than that of the existing 
systematic review conducted by Kramer & Kakuma (2012). Firstly, the review by 
Kramer and Kakuma (2012) had different inclusion criteria where they included trials 
on maternal dietary antigen avoidance in pregnant or lactating women, excluding 
trials of multimodal interventions that included manipulation of the infant’s diet other 
than breast milk or of non-dietary aspects of the infant’s environment. Therefore they 
have excluded the study by Zeiger et al. (1992) from their review. The current review 
included trials that started food allergen avoidance only during pregnancy (and where 
continued, but not commenced postnatally). Secondly, Kramer and Kakuma (2012) 
included one study where the available information is solely based on a published 
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abstract (Appelt et al. 2004); but this study is excluded from the present review. 
Thirdly, the review by Karmer and Kakuma (2012) included the follow-up data at 18 
months for the study conducted by Fälth-Magnusson & Kjellman rather than data at 5 
years. The reviewers justified that the longer-term follow-up results in this study are 
based on diets actually followed by women, rather than those allocated by 
randomisation. We included the 5 years follow-up knowing that the women in Fälth-
Magnusson & Kjellman (1992) study were not blinded to their allocated group, and 
some switched between the groups during pregnancy and/or lactation. We agree that 
this is a breach of the study protocol and this is highlighted in the assessment of risk 
of bias. Furthermore, Kramer and Kakuma (2012) included the study by Lilja et al. 
(1989b) in their meta-analyses and in most of the analyses both the Lilja et al. (1989) 
and Fälth-Magnusson & Kjellman (1992) trials are included. We did not include the 
study by Lilja et al. (1989) in meta-analyses since the study defined a different 
comparator to the other included studies i.e. ‘high diet’ vs. ‘standard diet’. Also, the 
sample reported in this study was a sub-set of the sample from the Linköping area, 
which was the same sample reported by the Fälth-Magnusson & Kjellman trial. In 
addition, Kramer and Kakuma (2012) have performed most of the meta-analysis using 
a fixed-effect model, whereas we have conducted all the meta-analyses using a 
random-effect model reflecting all the variations between the trials. Finally, Kramer 
and Kakuma (2012) did not include the study by Lovegrove et al. (1994) in meta-
analyses since it continued into lactation and was reported on its own. This study was 
included in one relevant meta-analysis in our review  
 
The results from this systematic review on food avoidance interventions during 
pregnancy for prevention of childhood allergies, including the latest available follow-
up data from the included trials, indicated that food avoidance did not protect against 
developing allergies in the offspring i.e. any allergic diseases, asthma, eczema, food 
allergy and sensitisation. There were substantial differences between the analyses 
conducted in the present systematic review than that of the Kramer and Kakuma 
(2012) review, which makes the comparison of the findings restricted.  
3.5.14.6. Author’s conclusion 
Implications for practice  
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There is no evidence that food avoidance during pregnancy could prevent the 
development of allergic outcomes in children. The studies were very heterogeneous 
and had a high risk of bias.  
Implications for research  
In the 1980s, food avoidance of highly allergenic foods in pregnant women, 
particularly in atopic women, was believed to be the principal strategy for primary 
prevention of childhood allergies; however, this approach was mainly based on 
theories rather than evidence. This theory has been questioned during the recent 
decade(s) after trials on food elimination diet during pregnancy consistently failed to 
show a beneficial effect for prevention of childhood allergies (Fälth-Magnusson & 
Kjellman 1992; Lilja et al., 1989; Zeiger et al., 1992), accompanied by the rising trend 
of allergies and specifically higher prevalence of food allergies (Prescott, 2013). The 
open question nowadays is whether early exposure to allergenic foods in pregnancy 
could be a more effective approach for prevention of childhood allergies and 
emerging evidence from observational studies suggests this hypothesis could be true 
(Bunyavanich et al., 2014; Frazier, et al., 2014; Young, 2015). These findings provide 
an avenue for further research, exposure to allergenic foods as opposed to avoidance, 
by high-quality and well-executed trials.  
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3.5.15. Description of included studies with maternal vitamin consumption 
during pregnancy and prevention of allergic diseases in the offspring  
A total of five RCTs examined the impact of vitamin supplementation during 
pregnancy on the development of allergic diseases in offspring, including 2,456 
children. The characteristics of the included trials, their companion papers and study 
population are presented in Table 3.11. The trials were conducted across Europe in 
the United Kingdom, Netherlands and Denmark with two conducted in the United 
States. 
 
The longest follow-up period was 3 years in studies conducted by Chawes et al., 
2016; Goldring et al., 2013; Litonjua et al., 2016 and the shortest follow-up for 2 and 
1 years reported respectively in studies by Greenough, Shaheen, Shennan, Seed, & 
Poston, 2010; McEvoy et al., 2014. The largest study sample was reported in 
Greenough et al. (2010) with 2,404 mothers enrolled, followed by Litonjua et al. 
(2016) study with 880 pregnant mothers at randomisation. The smallest sample sizes 
were observed in studies conducted by Goldring et al. (2013) and McEvoy et al. 
(2014) with 180 and 179 women randomised respectively. 
 
The Chawes et al. (2016) study initially invited a larger sample of pregnant women to 
the trial and more than half declined to participate. A comparison of women who 
participated and not participated showed that participating women were characterised 
by higher prevalence of asthma, eczema and hay fever. Also, these women were more 
frequently employed as professionals and had higher income levels.  
 
The sample studied in the included trials varied and included unselected pregnant 
women
 
(Chawes et al., 2016), pregnant women with a history of atopy (Litonjua et al., 
2016), pregnant women at risk of developing pre-eclampcia (Greenough et al., 2010), 
an unselected sample from different ethnic groups (Goldring et al., 2013)
 
and smoking 
pregnant women (McEvoy et al., 2014). The most frequently reported allergic 
outcomes were wheeze and eczema. 
 
Compliance with the intervention was measured by different methods, including 
counting of returned pills, dividing the number of capsules taken by the total number 
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prescribed in a given period, electronic medication container caps and telephone calls 
during the course of pregnancy to all women in the intervention arm. 
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Table 3.11. Characteristics of included trials and study population for vitamins and prevention of allergy in offspring  
Primary article  Companion 
articles 
Country, 
enrolment period 
Trial 
type
*
 
Name and No. of 
study arms 
No. of 
participants
**
 
No. at 
last  
F-U
***
 
Time 
points 
measured 
Age at 
last  
F-U 
Sample: 
high risk 
of Atopy 
Outcomes 
reported 
 
(Greenough, et 
al., 2010)  
(Poston, 
Briley, Seed, 
Kelly, & 
Shennan, 
2006)  
Netherlands 
2003-05 
PC-
RCT 
Vitamins C & E 
supplementation 
vs. Placebo 
2,404 mothers 752 (386 
vs. 366) 
24 months 2yrs. No -Wheeze 
-Eczema 
-Asthma 
-Cough 
-Breathing 
Difficulty 
(Goldring et al., 
2013)  
(Yu, Sykes, 
Sethi, Teoh, & 
Robinson, 
2009)  
the UK 
2007-unknown 
RCT Vitamin D 
supplements  
(as a daily dose & 
single dose) vs. 
no treatment 
180 mothers 158 (56 
vs. 52 vs. 
50) 
36 months 3yrs. No -Wheeze 
-Eczema 
-Food allergy 
-Rhinitis 
-Atopy 
-URTI
#
 
-LRTI
##
 
-Inhaled 
bronchodilator 
or steroid 
(McEvoy et al., 
2014)  
McEvoy 2013 
(abstract 
conference) 
the US  
2007-11 
PC-
RCT 
Vitamin C vs. 
placebo 
179 mothers 159 (76 
vs. 83) 
Birth & 12 
months 
1yr No -Wheeze 
-Breathing 
difficulty 
(Chawes et al., 
2016)  
(Bisgaard et 
al., 2013; 
Bisgaard, 
2004)  
 
Denmark 2008-
2010 
PC-
RCT 
Vitamin D3 vs. 
placebo 
623 mothers 581 (295 
vs. 286) 
Birth & 36 
months 
3yrs No -Persistent 
wheeze 
-Asthma 
-SPT 
-sIgE 
-URTI
#
 
-LRTI
## 
-Episodes of 
lung 
symptoms 
(Litonjua et al., (Litonjua et US  PC- Vitamin D vs. 880 806 (405 Birth & 36 3yrs Yes -Asthma or 
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Primary article  Companion 
articles 
Country, 
enrolment period 
Trial 
type
*
 
Name and No. of 
study arms 
No. of 
participants
**
 
No. at 
last  
F-U
***
 
Time 
points 
measured 
Age at 
last  
F-U 
Sample: 
high risk 
of Atopy 
Outcomes 
reported 
 
2016)  al., 2014)  2009-2011 RCT placebo vs. 401) months recurrent 
wheeze   
-Eczema with 
rash 
-sIgE 
-LRTI 
-Total IgE 
(mean) 
-Sensitisation 
(aeroallergens) 
+Published data and no unique data were extracted from abstracts      *Placebo Controlled-Randomised Controlled Trial or Randomised Controlled Trial 
**Indicates the number at randomisation, where recruitment has occurred prenatally    ***Follow-Up  
#Upper Respiratory Tract Infection        ##Lower Respiratory Tract Infection 
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Table 3.12 shows the details of vitamin interventions and placebo applied in the 
included studies. Comparable characteristics have been reported in all the trials.  
 
Four studies had used the vitamin supplementation only during pregnancy from as 
early as second trimester towards the end of second trimester of pregnancy (Table 
3.12). In the trial by Chawes et al. (2016), women had started the intervention from 24 
gestation weeks and continued after delivery for 1-week. The duration of intervention 
varied from 3.5-4 months to 7.5 months within the included trials.  
 
The type of vitamin supplementations within the included studies were Vitamins C & 
E (Greenough et al., 2010), Vitamin D (Chawes et al., 2016; Goldring et al., 2013; 
Litonjua et al., 2016) and crushed Vitamin C (McEvoy et al., 2014). The Goldring et 
al. (2013) study had two intervention arms, as women were randomised either to 
receive a daily dose of ergocalciferol or a single oral dose of cholecalciferol (bolus). 
For the purpose of this systematic review, we have made the comparisons for both the 
daily dose of Vitamin D and combined Vitamin D groups. The trials by Chawes et al. 
(2016) and Litonjua et al. (2016) also supplemented women in both study arms with 
an extra 400 IU dose of multivitamin/Vitamin D3, as part of their routine care. The 
trial of Goldring et al. (2013) was originally conducted in the UK between April to 
November 2007, prior to the introduction of national guidance on Vitamin D intake 
during pregnancy in the UK in March 2008.  
 
The choice of placebo in the Greenough et al. (2010) and McEvoy et al. (2014) trials 
were microcrystalline and ground starch respectively. The choice of control in the 
Goldring et al. (2013) was “no treatment” and the study has not been included in 
meta-analysis because of the inconsistency with the other comparators. The nature of 
placebo was not stated in the two studies by Chawes et al. (2016) and Litonjua et al. 
(2016).  
 
In all trials, supplementation with vitamins significantly increased the serum 
concentration of vitamins in the intervention group compared to the control group. 
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Table 3.12. Characteristics of vitamin interventions in included trials 
Primary 
article  
Comparable 
baseline 
characteristic  
Participants 
receiving 
intervention 
Timing of  
Intervention 
in pregnancy 
Intake of 
intervention  
From/until 
Duration of 
intervention 
(months)
*
 
Vitamin product Placebo 
 
Mode of 
delivery 
Total daily 
dose 
Greenough et 
al., 2010 
Yes Prenatally in 
mothers 
From the 2
nd
 
trimester of 
pregnancy  
From the 2
nd
 
trimester of 
pregnancy to 
delivery 
6-6.5  Vitamin C & E Microcrystalline 
cellulose with 
addition of 
tartaric & citric 
acid + sunflower 
seed oil 
Tablet 1000mg Vit 
C & 400 IU 
RRR  
a-
tocopherol, 
daily 
Goldring et 
al., 2013 
Yes Prenatally in 
mothers 
From 27wks 27wks to 
delivery 
3months + 
1week 
Vitamin D 
(cholecalciferol) 
or Vitamin D 
(ergocalciferol) 
No treatment Tablet Single oral 
dose of 
200,000 IU 
(bolus) 
or 
800 IU daily  
McEvoy et al., 
2014 
Yes Prenatally in 
mothers 
Randomized 
at 22wks or 
less  
22wks to 
delivery 
4-4.5 Crushed vitamin 
C 
Ground corn 
starch 
Capsule 500 mg, 
daily 
Chawes et al., 
2016 
Yes Pre &  
postnatally in 
mothers 
From week 24  24wks to 1w 
after 
delivery 
3.5-4 + 
1week 
Vitamin D3 
(cholecalciferol) 
Tablets containing 
no active 
substance 
Tablet  2400 IU, 
twice a day 
Litonjua et al., 
2016 
Yes Prenatally in 
mothers 
Between 10-
18wks 
Between 12-
18wks 
7-7.5 Vitamin D & 
placebo  
Not mentioned Tablets 4000 IU, 
daily 
*Indicates total duration in pregnancy plus after birth, if applicable
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3.5.16. Risk of bias in studies of maternal vitamin consumption during 
pregnancy and prevention of allergic diseases in the offspring  
Figure 3.26 shows the summary of risk of bias assessment for the included trials on 
vitamin supplementations. Two studies were assessed as having high risk of bias for 
their double blinding domain whilst the allocation concealment and blinding of 
outcome assessment were ranked as low risk in all the included studies. The 
reviewer’s judgment on the risk of bias assessment on vitamin studies is shown in 
appendix 3.9. 
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Short Title Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources 
of Bias 
Greenough (2010) ? + - + - + ? 
Goldring (2013) + + - + + + + 
McEvoy (2014) ? ? + + + + + 
Chawes (2016) + ? + + + + ? 
Litonjua (2016) + + + + + + + 
 
Random Sequence Generation   
 
60% 40%   
 
Allocation Concealment   
 
60% 40%   
 
Double Blinding   
 
60%   40% 
 
Blinding of Outcome 
Assessment   100%    
 
Incomplete Outcome Data   
 
80%   20% 
 
Selective Outcome Reporting   
 
100%    
 
Other Sources of Bias   
 
60% 40%   
 
 
    
 
 Figure 3.26. Summary of risk of bias assessment in the included trials of vitamins and prevention of allergy in the offspring 
 
Low risk of bias  High risk of bias   Unclear risk of bias  
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3.5.16.1. Random sequence generation (selection bias) 
Computer generated random numbers were reported in Goldring et al. (2013) and 
Chawes et al. (2016) trials, therefore these studies were rated as having a low risk of 
bias. The study by Litonjua et al. (2016) was also rated as low risk of bias as the 
randomisation was performed by the Data Centre Coordinating, using a system that 
automates the random assignment of treatment groups to study ID numbers by 
employing stratified permuted blocks with randomly varied block sizes. The two 
other studies were assessed as having an unclear risk since they stated randomisation 
with/without blocking without any further information. 
3.5.16.2. Allocation concealment  
There is no indication of allocation concealment in McEvoy et al. (2014) and Chawes 
et al. (2016) trials and hence these were rated as unclear. All the other trials had used 
an appropriate method for concealment of allocation and were rated as having a low 
risk of bias for allocation concealment. 
3.5.16.3. Double blinding (performance bias) 
Performance bias was assessed as high risk in two trials (Goldring et al., 2013; 
Greenough, et al., 2010). In Goldring et al. (2013), it was not possible to blind 
participants or investigators as participants would know if they had no treatment, 
daily tablets or a single bolus. The staff and parents were un-blinded at the extended 
follow-up of infants at 22 months in Greenough et al. (2010). The other three studies 
were rated as low risk of bias. 
3.5.16.4. Blinding of outcome assessment (detection bias) 
All studies were rated as having low risk for their detection bias since the assessors 
were blind to the maternal allocation.  
3.5.16.5. Incomplete outcome data (attrition bias) 
The study by Greenough et al. (2010) was rated as high risk since there was a high 
rate of loss to follow-up due to no response/drop outs. Attrition bias was assessed as 
low risk in the other included trials as there were an equal number of missing values 
reported in both arms of the studies. 
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3.5.16.6. Selective outcome reporting (reporting bias) 
The pre-specified list of outcomes, in the published protocol and/or manuscript of the 
studies, have been reported; therefore all were rated as low risk. 
3.5.16.7. Other potential sources of bias 
The trial conducted by Greenough et al. (2010) was rated as unclear since the 
extended follow-up for this study was unplanned and there was an uncertainty as to 
whether participants were made aware of their allocation, and this could have 
disproportionately influenced which mothers decided to participate in the follow-up. 
All other studies were rated as low risk of bias. 
3.5.17. Meta-analyses of effectiveness of maternal vitamin consumption 
during pregnancy and prevention of allergic diseases in the offspring 
Pooled results from meta-analysis in the studies that examined the effectiveness of 
vitamin supplementation during pregnancy for prevention of allergic outcomes in 
offspring are presented in the following section. The allergic outcomes of wheeze, 
asthma, eczema and sIgE were reported in all the trials and were included in meta-
analyses. We conducted sub-group meta-analyses for this dietary group since this is 
the first systematic review of RCTs investigating the effectiveness of prenatal intake 
of vitamins on allergic outcomes in children. The sub-group meta-analyses were 
conducted for the type of vitamins and control group. The study by Goldring et al. 
(2013) was included in sub-group meta-analysis, since it defined a different 
comparator with that of the other included trials i.e. no treatment. In addition, when 
interpreting the Forest plots, it is worth noting that the only available data for the 
Chawes et al. (2016) and Litonjua et al. (2016) studies was based on ITT analysis; 
however no imputation was performed for missing data in these studies.  
3.5.17.1. Wheeze as the outcome measure for vitamin intervention 
Four included studies measured the effect of vitamin consumption during pregnancy 
for prevention of wheeze in the offspring (Figure 3.27). The outcome of “recurrent or 
persistent wheeze” included in meta-analysis and was defined differently in the 
included studies. These are described as below:  
Greenough et al. (2010): The outcome considered was “Wheeze, more than once a 
week” and was defined by asking women whether (or not) their infant had coughed 
and/or wheezed and the frequency of the cough and wheeze. The outcome was 
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reported as cumulative prevalence at 2 years of age. 
McEvoy et al. (2014): The outcome considered was “medication for wheezing” and 
was defined by respiratory questionnaire (pediatric version) with the infant’s primary 
caretaker asking presence or absence of wheezing, medication for wheezing, maternal 
smoking, and exposure to second-hand smoke. The outcome was reported as the 
cumulative prevalence through age 1 year. 
Chawes et al. (2016): The outcome considered was “Persistent wheeze” and was 
diagnosed according to a previously validated quantitative algorithm, requiring all of 
the following: i) recurrent wheeze (verified diary recordings of ≥5 episodes of 
troublesome lung symptoms [cough, wheeze, and/or dyspnea] lasting ≥3 days within 
6 months), ii) typical symptoms of asthma (e.g. exercise-induced symptoms, 
prolonged nocturnal cough, or persistent cough outside common cold), iii) need for 
intermittent bronchodilator, and iv) response to a 3-month trial of inhaled 
corticosteroids and relapse upon cessation. The outcome was reported as the 
cumulative prevalence at 3 years.  
Litonjua et al. (2016): The outcome considered was “Asthma or recurrent wheeze” 
and was defined by parental report of physician's diagnosis of asthma taken directly 
from the offspring questionnaires that was administered every three months. 
Recurrent wheeze was defined by the occurrence of at least one of the following five 
conditions: i) parental report of wheeze after child's second birthday preceded by at 
least 1 report of wheeze prior to second birthday; ii) report of child's use of asthma 
controller medication (defined as report of use of steroid inhalers or nebulizers, 
leukotriene modifiers, or steroid pills or liquids) after the second birthday, preceded 
by a report of wheeze before the second birthday; iii) 2 or more distinct parental 
reports of wheeze after the second birthday; iv) at least 1 parental report of wheeze 
and use of asthma controller medications at distinct visits, both subsequent to the 
second birthday; or v) 2 distinct reports of use of asthma controller medications after 
the second birthday. The outcome was reported as the cumulative prevalence at 3 
years. 
Statistically, there was no heterogeneity between the included studies (χ2=0.73, 
P=0.86, I
2
=0%). The result of meta-analysis demonstrated an association between 
vitamin consumption during pregnancy and the risk of developing wheeze in 
offspring (RR=0.79, 95% CI=0.66-0.95, 2,275 children). 
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Figure 3.27. Forest plot of vitamins vs. placebo for wheeze 
Measure: Binary: risk ratio 
Heterogeneity: Q = 0.736; df = 3; p = 0.865; I-squared = 0%; tau-squared = 0  
Random effects model: 0.793 (0.661, 0.95) 
 
 
 
Outcome: Wheeze
b
 Vitamins n/N Placebo n/N 
Greenough 2010 10/386 11/355 
McEvoy 2014 9/70 17/77 
Chawes 2016 47/295 57/286 
Litonjua 2016 98/405 120/401 
Subtotal 1,156 1,119 
 
3.5.17.2. Asthma as the outcome measure for vitamin intervention 
In total two studies were included in a meta-analysis measuring the effect of vitamin 
intake during pregnancy for prevention of asthma in the offspring (Figure 3.28). The 
definitions of asthma, as described in the included trials, were as follows: 
Greenough et al (2010): The outcome considered was “asthma, chest symptoms” 
(undefined) and was reported as cumulative prevalence in the first 12 months.  
Chawes et al. (2016): The outcome considered was “Asthma” and was diagnosed in 
children, as secondary endpoint fulfilling the persistent wheeze criteria. The outcome 
was reported as point prevalence at 3 years.   
 
There was a small statistical heterogeneity between the studies (χ2=1, P=0.31, 
I
2
=0.29%). The pooled results did show an association between maternal vitamin 
consumption during pregnancy and the risk of developing asthma in offspring 
(RR=0.75, 95% CI=0.53-1.05, 1,278 children).  
 
Figure 3.28. Forest plot of vitamins vs. placebo for asthma  
Measure: Binary: risk ratio 
Heterogeneity: Q = 1; df = 1; p = 0.319; I-squared = 0.29%; tau-squared = 0.000184. 
Random effects model: 0.754 (0.539, 1.05) 
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Outcome: Asthma Vitamins n/N Placebo n/N 
Greenough 2010 23/386 23/343 
Chawes 2016 32/278 47/271 
Subtotal 664 614 
 
3.5.17.3. Eczema as the outcome measure for vitamin intervention 
Three studies were included in a meta-analysis measuring the effect of vitamin intake 
during pregnancy for prevention of eczema in offspring (Figure 3.29). In the studies 
included in meta-analysis, eczema prevalence was defined as follows: 
Greenough et al. (2010): The outcome considered was “Eczema” (undefined). The 
outcome was reported as cumulative prevalence in the first 12 months.   
Chawes et al. (2016): The outcome considered was “Eczema” and was diagnosed 
according to the criteria of Hanifin including typical morphology and localisation of 
skin lesions. The outcome was reported as cumulative prevalence at 3 years.  
Litonjua et al. (2016): The outcome considered was “Eczema with rash” and was 
defined by parental report of physician’s diagnosis of eczema with rash in typical 
distribution. The outcome was reported as cumulative prevalence at 3 years. 
 
There was no heterogeneity between the included studies (χ2=0.98, P=0.61, I2=0%). 
The results of meta-analysis did not show an association between maternal vitamin 
consumption during pregnancy and the risk of developing eczema in offspring 
(RR=0.97, 95% CI=0.83-1.14, 2,139 children). 
 
Figure 3.29. Forest plot of vitamins vs. placebo for eczema 
Measure: Binary: risk ratio 
Heterogeneity: Q = 0.982; df = 2; p = 0.612; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.977 (0.837, 1.14) 
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Outcome: Eczema Vitamins n/N Placebo n/N 
Greenough 2010 98/386 86/366 
Chawes 2016 68/295 72/286 
Litonjua 2016 83/405 89/401 
Subtotal 1,086 1,053 
 
3.5.17.4. Raised specific Immunoglobulin E (sIgE) as an outcome measure for 
vitamin intervention 
Three studies were included in a meta-analysis measuring the effect of vitamin intake 
during pregnancy raised level of sIgE in offspring (Figure 3.30). The definition of a 
positive sIgE result described in the included studies were as below: 
Chawes et al. (2016): The outcome considered was “sIgE” and was defined by 
allergic sensitisation at 6 and 18 months by sIgE level of 0.35 kUA/L or higher 
against raw milk, pasteurized eggs, dogs, or cats. The outcome was reported as 
cumulative prevalence at 3 years. 
Litonjua et al. (2016): The outcome considered was “Positive sIgE tests” and was 
defined as allergen sensitisation (specific IgE to a panel of aeroallergens and food 
allergens). The outcome was reported as point prevalence at 3 years. 
 
A small level of heterogeneity was observed between the included studies (χ2=1.01, 
P=0.31, I
2
=0.98%). The results of meta-analysis did not show an association between 
maternal vitamin consumption during pregnancy and a positive sIgE in offspring 
(RR=0.95, 95% CI=0.68-1.31, 1,373 children).  
 
Figure 3.30. Forest plot of vitamins vs. placebo for positive sIgE  
Measure: Binary: risk ratio 
Heterogeneity: Q = 1.01; df = 1; p = 0.317; I-squared = 0.98%; tau-squared = 
0.000622. 
Random effects model: 0.95 (0.688, 1.31) 
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Outcome Vitamins Placebo 
sIgE n/N n/N 
Chawes 2016 34/289 22/278 
Litonjua 2016 43/405 50/401 
Subtotal 694 679 
 
We also evaluated the efficacy of vitamin intake during pregnancy for prevention of 
allergic diseases for sub-groups according to “type of vitamin” and “type of 
comparison”. 
 
3.5.17.5. Recurrent/persistent wheeze as the outcome measure in Vitamin D 
studies only  
Sub-group analyses for the type of vitamin only included trials that used Vitamin D 
during pregnancy, since there was only one study for other types of vitamins. Sub-
group analysis for studies that used “Vitamin D and applied placebo as the 
comparator” is shown in Figure 3.31. The trials were statistically homogenous 
(χ2=0.002, P=0.95, I2=0%). The results of meta-analysis showed an association 
between prenatal intake of Vitamin D and the risk of developing persistent wheeze in 
offspring (RR=0.80, 95% CI=0.66-0.97, 1,387 children).   
Figure 3.31. Forest plot of Vitamin D vs. placebo for recurrent/persistent wheeze 
Measure: Binary: risk ratio 
Heterogeneity: Q = 0.00287; df = 1; p = 0.957; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.806 (0.666, 0.976) 
 
 
 
Outcome: Wheeze-Vitamin D with Placebo Vitamin D n/N Placebo n/N 
Chawes 2016 47/295 57/286 
Litonjua 2016 98/405 120/401 
Subtotal 700 687 
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3.5.17.6. Recurrent/persistent wheeze as the outcome measure in Vitamin D 
studies versus placebo or no treatment 
Three trials that used Vitamin D and applied either “placebo or no treatment as the 
comparator” were included in a sub-group analysis (Figure 3.32). The study by 
Greenough conducted two separate analyses for combined Vitamin D (Bolus + daily) 
and daily intake and therefore, these were included separately in meta-analyses. 
The outcome considered for Goldring et al. (2013) study was “Recurrent wheezing 
(≥2 episodes of reported wheezing since birth), defined by ISAAC criteria”. The 
outcome was reported as point prevalence at 3 years. No statistical heterogeneity was 
observed between the included trials (χ2=0.61, P=0.73, I2=0%) and a beneficial 
association was shown between prenatal intake of Vitamin D and risk of developing 
persistent wheeze in the offspring (RR=0.82, 95% CI=0.68-0.988, 1,545 children). 
Figure 3.32. Forest plot of daily and/or combined Vitamin D vs. placebo or no 
treatment as the control for recurrent/persistent wheeze 
Measure: Binary: risk ratio 
Heterogeneity: Q = 0.613; df = 2; p = 0.736; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.82 (0.681, 0.988) 
 
 
 
Outcome: Wheeze-Daily/combined Vitamin D 
versus placebo & no treatment 
Vitamin D  
n/N 
Control  
n/N 
Goldring 2013 17/108 7/50 
Chawes 2016 47/295 57/286 
Litonjua 2016 98/405 120/401 
Subtotal 808 737 
 
The meta-analysis for intake of daily vitamin D only as opposed to either placebo or 
no treatment (Figure 3.33) also showed a protective effect between prenatal intake of 
vitamins and the risk of developing persistent wheeze in offspring (RR=0.812, 95% 
CI=0.673-0.98, 1,493 children). 
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Figure 3.33. Forest plot of daily Vitamin D vs. placebo or no treatment as the 
control for recurrent/persistent wheeze 
Measure: Binary: risk ratio 
Heterogeneity: Q = 0.163; df = 2; p = 0.922; I-squared = 0%; tau-squared = 0 
Random effects model: 0.812 (0.673, 0.98) 
 
 
Outcome: Wheeze-Daily Vitamin D 
versus placebo or no treatment 
Vitamin D  
n/N 
Control  
n/N 
Goldring2013 7/50 8/56 
Chawes 2016 47/295 57/286 
Litonjua 2016 98/405 120/401 
Subtotal 750 743 
 
3.5.18. Discussion of the evidence synthesis of vitamin consumption during 
pregnancy and prevention of allergic diseases in the offspring 
3.5.18.1 Summary of main results 
This systematic review summarised data from five RCTs of maternal intake of 
vitamins for prevention of childhood allergic diseases, including a total of 2,456 
children with follow-up duration ranging from 1-3 years (mean 2.4 years). The studies 
were at risk of bias with 40% rated as unclear and a high risk of bias for allocation 
concealment and performance respectively. Studies were also varied for the type and 
dose of vitamin supplemented, duration of follow-up and their sample size. The 
findings from this systematic review and meta-analysis do not provide evidence of a 
protective association between intake of vitamins during pregnancy and subsequent 
development of a number of allergic manifestations including asthma, eczema and 
sensitisation to allergens as measured by sIgE. However, there appeared to be an 
effect for recurrent wheeze. The meta-analysis of four studies showed a significantly 
reduced risk of developing recurrent wheeze in offspring (RR=0.79, 95% CI=0.66-
0.95, 2,275 children). These results need to be interpreted with caution because of the 
risk of bias, heterogeneity observed between studies as well as small number of 
studies that contributed to the meta-analyses. 
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3.5.18.2. Overall completeness and applicability of evidence 
There was a low level of evidence that vitamin supplementation during pregnancy is 
effective for prevention of a number of allergic outcomes in the offspring. The meta-
analyses for “recurrent wheeze” were also limited by the number of studies included 
and also a small sample size in most trials. The heterogeneity between the trials 
limited the findings and random effect models were used to pool the results. 
Heterogeneity between studies originated from varied types and dose of vitamins, 
different timing and duration of interventions, as well as the follow-up duration and a 
sample size. Trials also used different methods for measuring and reporting allergic 
outcomes.  
3.5.18.3. Quality of evidence 
Overall, the trials were at moderate to high risk of bias, for the summary of risk of 
bias assessment (Figure 3. 26). Some studies were rated as unclear or high risk of bias 
for individual quality domains. Un-blinded detection bias and high loss to follow-up 
were judged in one study in each domain (20%). Also, the small number of studies 
and participants that contributed to the meta-analyses might have downgraded the 
quality of body of evidence. 
3.5.18.4. Strength and weakness of this systematic review for vitamin 
consumption during pregnancy 
The results from this unique systematic review provided an overview of the current 
body of literature on the effectiveness of prenatal intake of vitamins and the risk of 
developing allergic diseases in the offspring. Following an a priori published protocol, 
we used a comprehensive search strategy that allowed for a complete cover of all the 
relevant literature through citation databases, trial registries and conference 
proceedings, identifying five RCTs with a total of 2,456 children. Furthermore, we 
were interested in any reported allergic outcomes from these trials; however a limited 
number of allergic diseases were reported in included trials, mostly reporting the 
pulmonary function outcomes.  
 
The limitation of our systematic review stems from the limitations of the included 
trials. We were unable to perform any meta-analyses on the timing or dose of 
intervention and study populations due to a relatively small number of trials that could 
contribute.  
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3.5.18.5. Agreement and disagreement with other systematic reviews or studies 
This is the first systematic review and meta-analysis of RCTs that investigated the 
association between prenatal intake of vitamins and the risk of developing allergic 
diseases in the offspring. The results however, are in line with observational studies 
that have typically reported a beneficial effect of higher intake of Vitamin D during 
pregnancy on allergic outcomes (Allan, Kelly, & Devereux, 2010; Nurmatov, 
Devereux, & Sheikh, 2011; Palmer, Sullivan, Skeaff, Smithers, & Makrides, 2015).  
3.5.18.6. Author’s conclusion 
Implications for practice 
The current body of evidence suggests that there is an association between prenatal 
supplementation of Vitamin D and prevention of recurrent/persistent wheezing in 
children. However the certainty of evidence is low due to the number of studies and 
discrepancies between studies. There is a lack of evidence for the effect of prenatal 
intake of vitamins and developing other allergic outcomes. 
 
Implications for research  
Taking the quantity and quality of the available evidence into account, the effect of 
vitamins intake during pregnancy for prevention of childhood allergies needs to be 
further investigated in large well-designed and executed RCTs.  
 
Timing of intervention is a key factor that needs to be further investigated. In all trials 
the intervention was started in the second trimester in pregnancy. However, the 
development of the lungs begins in the first trimester in pregnancy and Vitamin D 
plays an immunomodulatory role in the development of the lung and immune system 
(Henderson & Warner, 2012). Therefore the interventions might have commenced too 
late in pregnancy, or used too low dose of Vitamin D to have a beneficial impact on 
lung development. Furthermore, the studies recruited different types of population, 
which limits the generalisability of the studies. Baseline levels of Vitamin D vary in 
different geographical areas (Kimlin, Olds, & Moore, 2007), and this issue has not 
been addressed in the conducted trials. Well-designed trials are necessary to address 
all these possible confounders among different populations (Karras et al., 2015). 
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It is also possible that the follow-up periods of the studies for this review have been 
too short to detect other allergic outcomes. For example, wheezing is known as a 
primary symptom of asthma in early childhood (Stevens, Turner, Kuehni, Couriel, & 
Silverman, 2003). About 40% of childhood wheeze will persist later in life, and will 
eventually develop into asthma by 6 years of age (Martinez et al., 1995), indicating 
that the majority of wheeze during infancy is in fact acute respiratory infection. 
Therefore, extended follow-up of these trials could help to provide a clearer answer as 
to whether the Vitamin D intervention is beneficial for asthma prevention.  
 
There were also some limitations in the design of studies. For example, the trials were 
statistically underpowered to detect an effect for their primary and/or secondary 
outcome measures. Significant differences were only observed for some of the 
secondary outcomes as “at least 1 episode of wheezing” (McEvoy et al., 2014), 
“episodes of troublesome lung symptoms” (Chawes et a., 2016) and “positive sIgE” 
(Litonjua et al., 2016) and trials failed to show a beneficial effect for primary allergic 
outcomes such as wheeze and asthma in children. Also, the trials used different doses 
of vitamins during pregnancy. The dose of Vitamin D varied between 800-4000IU 
and doses of Vitamin C and/or E, varied between 500-1000mg. It is possible that 
lower doses of vitamins may have failed to reach the desirable level of 25-
hydroxyvitamin D or antioxidants in pregnant women to have an influential effect on 
the foetal immune programming and lung function (Holick, 2007; Litonjua & Weiss, 
2007; Yurt et al., 2014). However this is refuted by studies which have reported a 
similar size using higher doses of Vitamin D (Chawes et al., 2016; Litonjua et al., 
2016). Safety and efficacy of Vitamin D supplementation during pregnancy is 
addressed in a RCT and it showed that a 4000IU dose of Vitamin D was a safe 
approach and is necessary to optimise the circulating concentration of 25-hydroxy 
Vitamin D levels to ≥ 80nmol/L (Hollis, Johnson, Hulsey, Ebeling, & Wagner, 2011). 
There is limited evidence on the safety of Vitamins C and E intake at any stage of 
pregnancy; however the Institute of Medicine’s Food and Nutrition Board have set an 
upper limit of 2000mg and 1000mg per day for Vitamins C and E ingestion 
respectively during pregnancy in the United States (Institute of Medicine, 2000).  
 
Moreover, the role of maternal consumption of vitamins during pregnancy on the risk 
of developing other allergic outcomes and sensitisation needs to be investigated in 
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larger well-designed trials. Human in vitro studies suggest that antioxidants e.g. 
Vitamins A, C, D and E can improve immune function in human (Utsugi et al., 2003).  
3.6. Round-up conclusion of the chapter 
The current body of evidence in terms of quantity as well as quality of the conducted 
RCTs makes the strength of the current findings fairly unreliable and underscores the 
importance of prenatal intake of dietary interventions for prevention of most allergic 
outcomes in the offspring. Large well-designed and well executed nutritional 
intervention studies that could target pregnant women in pre-pregnancy and as early 
as in pregnancy could provide a better understanding of the role of nutrition immune 
programming and its role for the prevention of childhood allergic disorders. It is 
advised that nutritional trials ought to consider clearly defined rules and objectives in 
their design such as measurement of basal nutrient status and the change following the 
intake of intervention, enabling to validly test the hypothesised association(s) 
(Heaney, 2014). 
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Chapter 4: The effectiveness of maternal nutritional/dietary 
interventions during pregnancy and risk of developing 
obesity in the offspring: systematic reviews and meta-
analyses 
4.1. Overview of the chapter  
This chapter presents systematic reviews of literature describing the most recent 
available evidence from randomised controlled trials on the effectiveness of maternal 
dietary interventions during pregnancy for the prevention of obesity in offspring. 
Dietary interventions explored include fatty acids, pro/prebiotics, low glycemic index, 
lifestyle change and vitamins/supplements. The methodology section outlines: how 
the comprehensive literature search was conducted, the eligibility criteria used to 
assess studies against the defined inclusion criteria, and the techniques used for 
assessing the quality of included studies. The results are sectioned according to the 
intervention type and risk of bias (ROB) assessment. Where possible, the effect of 
outcomes have been presented using meta-analyses and where not possible, through 
narrative description. For each intervention type, discussion sections summarise the 
findings from this systematic review, making comparisons with the current literature 
and defining areas for further research.  
4.2. Objectives 
To conduct systematic reviews assessing the effectiveness of maternal dietary 
interventions during pregnancy on the prevention of obesity in offspring 
4.3. Methods and protocol for the systematic reviews  
With the exception of the included outcomes, the protocol developed for assessing the 
efficacy of prenatal dietary interventions during pregnancy on allergic outcomes in 
offspring was utilised for this systematic review (appendix 3.1). Hence, the methods 
for conducting this systematic review have already been described in Chapter 3, but 
where appropriate, additional details are described below.  
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4.3.1. Criteria for considering studies for review 
4.3.1.1. Types of studies 
Please refer to section 3.3.1.1 in Chapter 3  
4.3.1.2. Types of participants 
Please refer to section 3.3.1.2 in Chapter 3 
4.3.1.3. Types of interventions 
Studies reporting one or more of the following interventions during pregnancy were 
included:  
a. Fatty acid supplementations 
b. Pro/prebiotic supplementations 
c. Food-based dietary advice (promoting a healthy diet) alone or in combination 
with supervised exercise/physical activity i.e. low glycemic (LG) index diet, 
lifestyle change (nutritional counselling) 
d. Vitamin/multivitamin, micronutrients and minerals (will be mentioned as 
vitamins hereafter) 
Trials were also included if the intervention(s) had been extended after pregnancy 
either in breast-feeding mothers, the infants or both. Studies within each of the above 
mentioned interventions were grouped under a common type of intervention i.e. any 
fatty acids, pro/prebiotics, LG index diet, life-style change or vitamins, regardless of 
their specific applied intervention. 
4.3.1.4. Outcomes of interest 
Trials were included if they had reported obesity as an outcome, either as a primary or 
secondary endpoint, in the offspring from infancy to adulthood. The primary and 
secondary outcome measures were defined by body composition outcomes.  
4.3.2. Search strategy for identification of studies 
A comprehensive search strategy, including all the relevant synonyms for the main 
concepts, was developed covering the main bibliographic databases (see appendix 
4.1). 
4.3.2.1. Electronic searches 
Please refer to section 3.3.2.1 in Chapter 3 
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4.3.2.2. Searching other sources of evidence 
References of all identified studies and key systematic reviews in this area were 
checked for potentially relevant studies not identified by the above search strategy. To 
date, there are five systematic reviews that have evaluated the use of prenatal and/or 
postnatal fatty acids for the prevention of obesity in offspring. Three systematic 
reviews did not perform meta-analyses (Campoy, Escolano-Margarit, Anjos, 
Szajewska, & Uauy, 2012; Muhlhausler, Gibson, & Makrides, 2010; Rodriguez, 
Iglesia, Bel-Serrat, & Moreno, 2012) and narratively described the effectiveness of 
prenatal and/or postnatal supplementation with n-3 LCPUFA on an infant’s body 
composition. Another systematic review (Imhoff-Kunsch, Briggs, Goldenberg, & 
Ramakrishnan, 2012) included RCTs that used prenatal n-3 LCPUFA, in high and 
low risk pregnancies, and investigated the influence of the intervention on maternal, 
neonatal and child health at birth only.  The most recent systematic review by 
Stratakis (Stratakis, Gielen, Chatzi, & Zeegers, 2014) included both prenatal and post-
natal RCTs that used n-3 LCPUFA and conducted meta-analyses and sub-group 
analyses only for BMI. In the present systematic review, we included RCTs that 
involved only prenatal intake of fatty acids (as well as those in which intake 
continued postnatally) and considered a range of the reported outcomes on obesity.  
 
There are also systematic reviews that evaluated the effectiveness of ‘lifestyle 
interventions’ or ‘dietary counselling in combination with physical activity’ during 
pregnancy, considering only maternal outcomes such as gestational weight gain and 
obstetrics outcomes e.g. birth weight, small for gestational age (SGA) or large for 
gestational age (LGA) (Campbell, Johnson, Messina, Guillaume, & Goyder, 2011; 
Dodd, Grivell, Crowther, & Robinson, 2010; Gardner, Wardle, Poston, & Croker, 
2011; Muktabhant, Lawrie, Lumbiganon, & Laopaiboon, 2015; Ronnberg & Nilsson, 
2010; Skouteris et al., 2010; Streuling, Beyerlein, & von Kries, 2010; Sui, Grivell, & 
Dodd, 2012; Tanentsapf, Heitmann, & Adegboye, 2011; Thangaratinam et al., 2012) 
No systematic reviews to date investigated the longer-term efficacy of life-style 
interventions for prevention of childhood obesity. When this review was conducted, 
there were also no published systematic reviews for prevention of childhood obesity 
for probiotics, LG index diet and vitamin interventions. 
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The uniqueness of the present systematic review is therefore that it aims to explore a 
variety of the dietary interventions that have only commenced during pregnancy, and 
to investigate the effectiveness of these interventions for prevention of a range of 
reported obesity outcomes in the offspring.  
4.3.3. Data collection and analysis 
4.3.3.1. Selection of studies 
Please refer to section 3.3.3.1 in Chapter 3. The relevant appendices are 4.2 and 4.3.  
4.3.3.2. Data extraction and management  
Please refer to section 3.3.3.2 in Chapter 3. Where relevant, changes were made in the 
data extraction such as type of studied sample, detailed information about type of 
intervention (fatty acids, probiotics, LG index, lifestyle change and vitamins) and the 
reported outcomes (appendix 4.4).  
4.3.4. Assessment of risk of bias in included studies 
Please refer to section 3.3.4 in Chapter 3. 
4.3.4.1. Measurement of treatment effect 
Please refer to section 3.3.4.1 in Chapter 3.  
4.3.4.2. Unit of analysis issues 
Please refer to section 3.3.4.2 in Chapter 3.  
4.3.4.3. Handling missing data 
Please refer to section 3.3.4.3 in Chapter 3. Studies that performed ITT analysis are 
also identified in the table of characteristics of included studies (Table 4.2).  
4.3.4.4. Assessment of heterogeneity 
To measure statistical heterogeneity between effect sizes of included studies, within 
each umbrella intervention group and for each obesity outcome separately, we used 
visual inspection of forest plots and also the χ2 test for heterogeneity with a P Value 
<0.05 (Deeks, et al., 2001). I
2 
statistics were used to quantify the amount of possible 
variability in effect estimates that is due to heterogeneity rather than chance (I
2 30 
moderate heterogeneity, I
2 ≥75 considerable heterogeneity). Moreover, studies with 
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a similar comparator within each umbrella intervention group were grouped to run 
meta-analyses. 
 
With regards to clinical heterogeneity, two key issues were considered. Firstly, the 
crude data for any reported obesity outcomes from the included trials were extracted. 
The following outcomes were considered for this systematic review (Table 4.1). 
  
Table 4.1.  List of the outcomes of interest for this systematic review 
Main Obesity outcomes  Comments  
Body Mass Index (BMI) Latest available follow-up data 
BMI-Z score Latest available follow-up data 
Weight (kg) Latest available follow-up data 
Height (cm) Latest available follow-up data 
Length (cm) Latest available follow-up data 
Skin Fold Thickness (SFT) Latest available follow-up data 
Obesity Latest available follow-up data 
Overweight Latest available follow-up data 
 
Secondly, the longest follow-up measures, where available, were selected for this 
systematic review and entered in the meta-analyses. Moreover, where reported, 
cumulative prevalence/incidence were included in meta-analyses and if not reported, 
point prevalence(s) were considered. Sub-group meta-analyses were conducted where 
there were an adequate number of studies that could contribute in meta-analysis for 
the following criteria: 
a. Type of the comparator 
b. Length of follow-up  
4.3.4.5. Assessment of reporting biases 
Every effort was made to identify unpublished studies through searching abstracts and 
ongoing trials databases as described in section 3.3.2. Publication bias was not 
evaluated since the number of studies within each intervention group were less 
than10.  
4.3.4.6. Data synthesis  
This section compares with the 3.3.4.6 section in Chapter 3, with the exception of one 
minor change regarding the nature of extracted data. Continuous data were entered as 
means and standard deviations.  
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4.4. Changes to the protocol  
There were five changes made to the protocol during the conduct of the review. 
Firstly, we stated in the protocol that studies with a maximum follow-up duration of 
18 years will be included. However, there was an exception to this in that we included 
a study with a follow-up period of 19 years in the current systematic review, and the 
effect of duration of follow-up on obesity outcomes in children was assessed in sub-
group analyses. 
 
Secondly, in the protocol for this review, it was initially stated that in trials with 
multiple intervention groups, data for the control group would be used for each 
intervention group comparison and the weight assigned to the control group will be 
reduced by dividing the number of participants in the control group by the number of 
intervention groups. However, for more clarity, and as recommended by the Cochrane 
Collaboration (Higgins
 
et al., 2011), it was decided to pool the data for each 
intervention arm for different probiotic strains only, and make the comparison for the 
pooled probiotic intervention arm versus the control group. So, the weight assigned to 
the intervention group was considered as the total number of participants in 
intervention arms divided by the number of participants in the control group. It is 
important to add that we did not pool the data for different intervention arms in fatty 
acids studies versus the control group, since the individual intervention arms were 
entirely different in their nature. Therefore only the data for the fatty acids (fish oil) 
intervention arm was considered as opposed to the control group for this systematic 
review. 
 
Thirdly, there were some cases for which we included the data on an earlier available 
follow-up point in meta-analyses since this could allow a more consistent outcome 
measure assessment across a number of the included studies. For example, where 
there were outcomes reported at 7 and 10 year follow-up points in a study that used 
probiotics as an intervention, the 7 years follow-up data was included in meta-
analyses since it was closer to the follow-up points in the other included studies.  
 
Additionally, due to the discrepancies observed between the included studies (e.g. 
differences in primary and secondary endpoints, different comparators) as well as the 
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small number of studies that met the inclusion criteria in the dietary groups, it was 
decided not to perform detailed sub-group meta-analyses for the duration of 
intervention, specific type of consumed dietary products and 
dosage/frequency/delivery mode of intervention. 
 
Lastly, it was intended to use the per-protocol analysis for conducting all the meta-
analyses; however this was not possible for a few papers as the ITT was the only 
available data. In these cases the reported data were used in performing meta-
analyses. 
 
4.5. Results 
4.5.1. Studies identified through searches and total included studies 
Searches of electronic databases were initially carried out between November and 
December 2014 and updated by the end of January 2016. The searches yielded a total 
of 10,127 references. As specified in the protocol, removal of duplicates and non-
relevant studies (6,834) from the 6,898 included studies for screening the title and 
abstract left 65 papers for further consideration. Of the remaining 65 references, 22 
were excluded after closer inspection showed that they had either reported an 
inappropriate study outcome or had inappropriate study design/participants.  
 
Full-text screening of the remaining 43 papers showed that they were either a study 
protocol (n=4) or earlier published reports of the included studies (n=21). These 
earlier reports, hereafter referred to as ‘linked records/companion papers’, were used 
to extract any relevant data of the initial trial, if required. Supplementary searches 
from other databases identified one extra paper. As a result, a total number of 19 
studies were included in this systematic review. The PRISMA flow diagram is shown 
in Figure 4.1.  
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Figure 4.1. PRISMA flowchart for the literature review strategy-Obesity 
outcomes 
 
The list of the included studies that met the inclusion criteria for this systematic 
review, by intervention type, is shown in Table 4.2. All trials were in English and had 
been carried out in various countries across the world. The descriptive findings, risk 
of bias assessment and effects of interventions are structured by intervention in the 
following sections.  
 
	
	
	
 
 
	
	 	
	
	
	 	
		 	
	
	
	
		
	 	
	
	
	
	
	
	
*
To supplement the electronic searching, the reference lists of papers selected for full text screening as well as 
key systematic reviews on the topic were scrutinised to identify any further studies. 
**
Earlier reports/papers of the trials included in the systematic reviews and were used for data extraction if 
required	
*
Additional papers 
identified (n=1) 
Full texts considered for data extraction 
(n=19) 
Papers selected for further 
screening on abstract 
(n=65) 
Papers excluded (n=22): 
Inappropriate Study 
outcome (n=11) 
Inappropriate Study 
design (n=7) 
Inappropriate 
Participants (n=4) 
Papers selected for full-text 
screening (n=43) 
 
Papers excluded 
following further 
screening (n=25): 
Study protocol (n=4) 
Linked record (n=21)
**	
 
 
Records identified 
through database 
searching 
(total=10,127):   
MEDLINE (n=2,321) 
COCHRANE  
(n=2,880) 
SCOPUS (n=4,926),  
OTHER 
DATABASES, as 
specified in the 
protocol (n=0) 
 
Records excluded (total=3,229): 
Reviews/Meta-analysis/Protocols 
(n=3,216) 
Guidelines (n=12) 
Magazines (n=1) 
Original studies included for screening 
the title and abstracts, as specified in 
the protocol (n=6,898) 
Papers excluded 
(n=6,834): 
Non-relevant, 
non-randomised 
& inappropriate 
populations  
(n=6,811)  
Duplicates 
(n=23) 
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It is important to note that studies which used vitamin/micronutrients, including one 
study using protein-energy supplements, were conducted in developing countries 
aiming to boost the growth standards of infants at birth. These studies met the 
inclusion criteria for this systematic review and were therefore included in the review; 
however, their results are only described narratively in a separate section and no 
meta-analyses were conducted for this intervention group. 
  
Table 4.2. List of the included studies 
Fatty Acids 
Interventions 
AOD ITT LG index diet Interventions AOD ITT 
Helland 2008 ✓ NI Louie 2015 ✓ NI 
Dunstan 2008 ✓ NI Horan 2016 ✓ NI 
Campoy 2011 ✓ NI    
Rytter 2011 ✓ NI Life-style change Interventions 
Stein 2015 ✓ NI Tanvig 2015 ✓ NI 
Bergmann 2014 - ✓ Rauh 2015 ✓ NI 
Brei 2016 ✓ NI    
Probiotics Interventions Vitamins/Micronutrients/Protein-energy Supp. 
Kuitunen 2009 ✓ NI Roth 2013 ✓ NI 
Luoto 2010 ✓ - Stewart 2009 ✓ NI 
Abrahamsson 2013 ✓ NI Vaidya (2008) ✓ ✓ 
Wickens 2013 ✓ ✓ Hawksworth 2008 ✓ ✓ 
*For studies with data available on both observed and ITT analysis, the observed data are included in meta-analysis.  
Ante. AOD=Analysis on the Observed Data; ITT=Intention to Treat Analysis, some trials have conducted the ITT only for 
certain outcomes; NI=No information 
 
4.5.2. Presentation of the results 
The meta-analyses for assessing the effect of intervention are structured by 
intervention type. Within each intervention category, studies are grouped and assessed 
for the clinical outcome(s) of interest for this systematic review. Detailed descriptions 
of the outcomes included in the meta-analyses are also presented. As described in 
section 4.3.4.4, meta-analyses were conducted using a random effect model and 
where relevant, sub group analyses have been conducted in different dietary 
intervention groups.  
4.5.3. Description of included studies of maternal fatty acid consumption 
during pregnancy and prevention of obesity in the offspring 
Of the 19 included trials, 7 (with a total of 1,647 children) examined the impact of 
fatty acid interventions on the development of obesity in offspring. The detailed 
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characteristics of the included trials, their companion papers and study population are 
shown in Table 4.3. One study was multi-centre in Germany, Spain and Hungary; two 
studies were conducted in Germany and the rest in Australia, Norway, Denmark and 
Mexico. 
 
It is worth noting that most of the trials were primarily designed to investigate other 
outcomes in children such as neurological development, and using post-hoc analyses, 
they also reported growth measures in the offspring (Bergmann et al., 2012; Campoy 
et al., 2011; Dunstan, Simmer, Dixon, & Prescott, 2008; Gonzalez-Casanova et al., 
2015; Helland et al., 2008; Rytter et al., 2011). The study by Brei (Brei et al., 2016) 
was the first trial designed to evaluate the effectiveness of prenatal n-3 LCPUFA 
supplementation on infant’s body composition. 
 
The longest follow-up period was 19 years, in the study conducted by Rytter et al. 
(2011), followed by 7 years follow-up in the study by Helland et al. (2008). The 
shortest follow-up period was 2.5 years, in the study conducted by Dunstan et al 
(2008). The largest study sample was reported in Gonzalez-Casanova et al. (2015) 
with 1,094 mothers enrolled followed by Rytter et al. (2011) involving 533 pregnant 
mothers. The smallest sample sizes were found in studies conducted by Dunstan et al. 
(2008) and Bergman et al. (2012) with 98 and 144 mothers randomised at recruitment 
respectively. 
 
With the exception of the study conducted by Dunstan and colleagues (2008) that 
enrolled atopic women in their trial, the remainder recruited healthy pregnant women 
with non-complicated pregnancies and most frequently reported outcomes were BMI, 
weight, and height.  
 
Compliance with the intervention was assessed by a variety of methods, including the 
number of fatty acids capsules ingested, divided by the number the participant should 
have ingested multiplied by 100, standardised questionnaires at gestation, the 
percentage of the total number of capsules expected to be consumed and measuring 
fatty acids levels in erythrocytes at 30 and 37 gestational week and 6 weeks 
postnatally. Two studies did not report the method of measuring adherence to the 
intervention (Bergmann et al., 2012; Helland et al., 2008). 
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Table 4.3. Characteristics of the included trials and study population of fatty acids and prevention of obesity 
Primary 
article  
Companion articles
+
 Country, 
enrolment 
period 
Trial 
type
*
 
Study 
intervention & 
comparator 
No. of 
participants
**
 
No. at last  
F-U
***
 
Time points 
measured 
Age at 
last  
F-U 
Sample: high or 
low risk  
Outcomes reported 
 
(Helland et 
al., 2008) 
(Helland et al., 2001)  Norway  
1994-96 
PC-
RCT 
N-3 FA & 
control 
 
Pregnancy: 
590  
Birth: 341  
143: 82 vs. 
61 
Birth, 6 & 9 
months, 4 & 
7yrs 
7yrs. Healthy women -BMI (kg/m
2
) 
-Weight (Kg) 
-Height (cm) 
 
(Dunstan, et 
al., 2008)  
(Dunstan et al., 2003; 
Dunstan, et al., 2004) 
Australia  
2000-2001 
PC-
RCT 
Fish oil & olive 
oil 
98 mothers 72: 33 vs. 
39 
Birth, 2.5yrs 2.5yrs. Women with 
allergic disease 
-Weight  
-Height 
(Campoy et 
al., 2011) 
(Decsi, Campoy, & 
Koletzko, 2005; 
Escolano-margarit, 
Ramos, & Beyer, 
2011; Krauss-
Etschmann et al., 
2007)  
Germany 
Spain 
Hungary 
2001-03 
PC-
RCT 
Fish-oil vs. 
FO+5MTHF
#
 
vs. 5-MTHF vs. 
Placebo  
 
311 mothers 154: 37 vs. 
37 vs. 35 
vs. 45 
Birth, 4 & 
6.5yrs  
6.5yrs. Healthy women 
 
-BMI (kg/m
2
) 
(Rytter et 
al., 2011)  
 
(Olsen et al., 1992) Denmark  
1989-90  
PC-
RCT 
Fish Oil vs. 
either Olive oil 
or No oil 
 
533 mothers 243: 108 
vs. 63 vs. 
72 
 
19yrs. 19yrs. Non complicated 
pregnancies + no 
allergy to fish 
-BMI (kg/m2)  
-Waist (cm) 
-Insulin (pmol/L) 
-Blood glucose (mmol/L) 
-Hb A1c fraction (%) 
-HOMA-IR 
-Leptin (lg/L) 
-Adiponectin (microg/L) 
-IGF-I (microg/L) 
-hs-CRP (mg/L) 
(Bergmann 
et al., 2012)  
(Bergmann et al., 
2007; Bergmann et 
al., 2008) 
 
Germany, 
Berlin  
2000-02 
PC- 
RCT 
Fish oil + 
Vit/Min + FOS
$
 
vs.  
two controls 
144 mothers 115: 41 vs. 
74 (DHA 
vs. pooled 
control 
groups) 
1, 3, 21 
months & 
6yrs 
6yrs. Healthy pregnant 
Caucasian women 
 
-Weight (Kg) 
-Height (cm) 
-BMI (kg/m2) 
-BMI Z-score 
-Sum 4 SFT [mm]  
-Head Circumference 
(cm) 
(Gonzalez- (Ramakrishnan et al., Mexico  PC- DHA & placebo 1,094 mothers 802: 403 1, 3, 6, 9, 5yrs. Non complicated -BMI Z-score  
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+Published data and conference presentations, no unique data were extracted from conference abstracts           *Placebo Controlled-Randomised Controlled Trial 
**Indicates the number at randomisation, where recruitment has occurred prenatally            ***Follow-up 
#Methyl tetra-hydro folic                  $Fructo-oligosaccharide 
†Published on May 2016 and data for 5years follow-up was obtained from personal communication with author, following the update of search strategy on January 2016  
Casanova et 
al., 2015) 
 
2010; Stein et al., 
2011) 
 
2005-07 RCT vs. 399  12,18months 
& 5yrs. 
pregnancies -Weight (Kg) 
-Height (cm) 
-Height for age z-score 
-Weight for age z-score 
(Brei et al., 
2016)
†
 
(Hauner et al., 2012) 
(Brunner et al., 2013) 
(Much et al., 2013)  
(Brunner et al., 2015) 
Germany, 
Munich   
2006-09 
RCT Fish oil & 
control  
208 mothers 118: 61 vs. 
57  
4months, 1, 
2 & 5 years 
5yrs. Healthy women -Weight (Kg) 
-Head Circumference 
(cm) 
-Height (cm) 
-BMI percentile 
-Sum 4 SFT [mm] 
-Arm circumference (cm) 
-Waist (cm) 
-Ponderal index (kg/me3) 
-Biceps [mm] 
-Triceps [mm] 
-Subscapular [mm] 
-Suprailiacal [mm] 
-Body fat [%] 
-Fat mass [g] 
-Lean Body Mass [g] 
-Subscapular/triceps-
Ratio 
-Trunk-to-total SFT [%] 
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Table 4.4 shows the details of the fatty acid interventions and placebo used in 
included trials. In all studies the intervention and placebo groups had comparable 
baseline characteristics at recruitment. It is worth noting that the Helland et al. (2008) 
study reported mean age of the mothers receiving cod liver oil was, by chance, 1 year 
higher than the age of the mothers receiving corn oil (p≤0.01).  
Three studies administered fatty acids supplements solely during pregnancy (Dunstan 
et al., 2008; Gonzalez-Casanova et al., 2015; Rytter et al., 2011). Whereas in the 
remainder, fatty acid interventions were continued after pregnancy either in mothers 
only or in infants (Table 4.4). The starting time of intervention varied in the trials, 
beginning as early as 15 weeks of gestation (Brei et al., 2016) or as late as week 30 of 
gestation (Rytter et al., 2011) with the longest duration of intervention being 10-10.5 
months (Campoy et al., 2011), and the shortest 2-2.5 months (Rytter et al., 2011).  
 
With the exception of one study that only used algal DHA (Gonzalez-Casanova et al., 
2015), all other studies used a combination of EPA and DHA together. In the study by 
Campoy et al., (2011) vitamin and mineral supplements were also used along with the 
fatty acid component. Furthermore, Brei et al., 2016 provided women with fatty acid 
intervention as well as nutritional counseling, focused on normalising the 
consumption of n-6 fatty acid (AA) to a moderate level of intake (90 mg AA per day).  
The fatty acid preparations were delivered as capsules in four of the studies (Brei et 
al., 2016; Dunstan, et al., 2008; Gonzalez-Casanova et al., 2015; Rytter et al., 2011), 
with a further two using milk-based supplements (Bergmann et al., 2012; Campoy et 
al., 2011;) and another study providing oil preparations (Helland et al., 2008).  
 
The choices of intervention in the Campoy et al. (2011) study were defined within 
three categories: modified fish oil plus vitamin and mineral, fish oil plus 5-
methyltetrahydrofolic (MTHF) and 5-MTHF only. In this systematic review, we have 
only considered modified fish oil component plus vitamin and mineral as the 
intervention arm compared to placebo. 
 
In addition, the diversity of comparators between studies were as follows: corn oil 
(Helland et al., 2008), a mixture of corn and soy oil (Gonzalez-Casanova et al., 2015), 
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olive oil (Dunstan et al., 2008; Rytter et al., 2011), basic vitamin and mineral 
(Bergmann et al., 2012), standard diet (Brei et al., 2016) and no information in one 
study (Campoy et al., 2011). The Bergmann et al. (2012) study originally defined 
either ‘basic vitamin plus mineral’ or ‘prebiotic FOS’ as the comparators and at 6 
years follow-up, the authors presented the data for the combined control groups 
versus fatty acids component. The study by Rytter et al. (2011) also had the choice of 
either ‘olive oil’ or ‘no oil’ and for the purposes of this systematic review, we 
considered the fatty acids versus ‘olive oil’ in the meta-analysis.  
 
The study by Brei et al. (2016) that introduced ‘standard diet’ as its comparator, was 
included in sub-group meta-analysis, since this was not similar in nature to the other 
comparators. 
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Table 4.4. Characteristics of fatty acid interventions in the included trials 
Primary 
article  
Comparable 
baseline 
characteristic  
Participants 
receiving 
intervention 
Timing of  
Intervention 
in pregnancy 
Intake of 
Intervention 
from/until
*
 
Duration of 
intervention 
(months)
**
 
Fatty acids 
product
***
 
Placebo/ 
Control 
 
Mode of 
delivery 
Total daily 
dose 
Helland et 
al., 2008 
No Mean age of the 
mothers receiving 
cod liver oil was, 
by chance, 1 year 
higher than the age 
of the mothers 
receiving corn oil 
Prenatally & 
postnatally-in 
mothers 
From 18 wks. 18 wks. to 3 
months 
postnatal 
8-8.5  Cod liver oil 
(1183 mg/10 mL 
of DHA, 803 
mg/mL of EPA; 
20:5N-3) & a total 
of 2494 mg/10 
mL of n-3 PUFAs  
Corn oil 
contained 
4747 mg/10 
mL of LA & 
92 mg/10 
mL of ALA 
Oil (no 
information) 
10mL/day 
 
Dunstan et 
al., 2008 
Yes, although 
mothers in the Int. 
group were slightly 
younger (p=0.047) 
Prenatally  From 20 wks. 20 wks. to 
birth 
4.5-5 Fish oil: 1.1g 
EPA (20:5n-3) 
and 2.2g DHA per 
day 
Olive oil 
containing 
2.7g n-9 
oleic acid  
Capsule Four 1gr/day 
Campoy et 
al., 2011 
Yes Prenatally & 
postnatally-in 
infants  
From 22 wks. 22 wks. to 6 
months 
postnatal 
10-10.5  Modified Fish Oil 
(500mg 
DHA+150mg 
EPA) & Vit+Min  
Fish Oil + 
5-MTHF
#
  
OR  
5-MTHF OR 
Placebo 
(nature not 
identified) 
Milk-based 
supplement 
sachets 
15gr one 
daily dose 
 
Rytter et al.,  
2011 
Yes Prenatally 
only 
At 30 wks. 30 wks. to 
delivery 
2-2.5 Fish oil (32% 
EPA & 23% 
DHA, together 
with 2 mg 
tocopherol/mL 
added to prevent 
auto oxidation of 
EPA & DHA, 
corresponding to 
~2.7g marine n-3 
PUFA/d 
Olive oil 
(72% oleic 
acid & 12% 
linoleic acid) 
 
Capsule  Four 1-g/day  
 
Bergman et Yes Prenatally & From 21-37 21-37 wks. & 4-7 (longer 0.6 fish oil (200 1) Basic Flavored & 0.6 g Fish oil 
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Primary 
article  
Comparable 
baseline 
characteristic  
Participants 
receiving 
intervention 
Timing of  
Intervention 
in pregnancy 
Intake of 
Intervention 
from/until
*
 
Duration of 
intervention 
(months)
**
 
Fatty acids 
product
***
 
Placebo/ 
Control 
 
Mode of 
delivery 
Total daily 
dose 
al., 2012 postnatally-in 
mothers 
wks. 3 months 
postnatal 
(optional) 
period for 
women who 
continued 
participation 
after 
delivery) 
mg DHA+60 mg 
EPA) 
Vit/Min  
2) Prebiotic 
FOS
$
 (to 
promote a 
favorable 
gut flora) 
acidified 
milk-based 
supplement 
(containing 
200mg 
DHA) + 4.5 
g FOS + 
Vit/Min (a 
skim milk-
based, 
acidified 
liquid in a 
200ml tetra 
box), daily 
Gonzalez-
Casanova et 
al., 2015 
Yes, maternal 
height was slightly 
higher in the 
placebo group 
(p=0.06) 
Prenatally 
only 
From wk. 18-
20 
From  
18-20 wks. to 
delivery 
5-5.5 Algal DHA Corn-soy oil 
blend, not 
containing 
any DHA or 
other (n-3) 
fatty acids 
Capsule  400mg (2 
capsules 
taken at the 
same time) 
 
Brei et al., 
2016 
Yes Prenatally & 
postnatally-in 
mothers 
From 15 wks. 15 wks. to 4 
months 
postnatal 
9.5-10 + 
1week 
N-3 LCPUFA 
[1,020 mg (DHA) 
&180 mg (EPA)]  
Standard 
diet 
Capsule 1200mg/day 
*Abbreviations: WKS= weeks, MON= months 
**Indicates total duration in pregnancy plus after birth either in mothers only or both mother and infant, if applicable  
***DHA=Docosahexaenoic acid, EPA=Eicosapentaenoic acid 
#Methyltetrahydrofolic   
$Fructo-oligosaccharide
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4.5.4. Risk of bias in studies of maternal fatty acid consumption during 
pregnancy and prevention of obesity in the offspring 
The summary of risk of bias in trials on fatty acid studies is presented in Figure 4.2. 
The reviewer’s judgment for the risk of bias assessment of fatty acid studies is shown 
in appendix 4.5. 
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Short Title Random Sequence 
Generation 
Allocation 
Concealment 
Double 
Blinding 
Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources 
of Bias 
Helland (2008) + ? ? ? - + + 
Dunstan (2008) ? + + + + + + 
Campoy (2011) ? - + ? - + ? 
Rytter (2011) ? + - + - + + 
Bergmann (2012) + ? ? + + + ? 
Gonzalez-Casanova (2015) ? + + + - + + 
Brei (2016) + ? - - - + ? 
 
Random Sequence Generation   
 
43% 57%   
 
Allocation Concealment   
 
43% 43% 14% 
 
Double Blinding   
 
43% 28.5% 28.5% 
 
Blinding of Outcome 
Assessment   57% 29% 14% 
 
Incomplete Outcome Data   
 
29%   71% 
 
Selective Outcome Reporting   
 
100%    
 
Other Sources of Bias   
 
57% 43%   
 
 
 
Low risk of bias  High risk of bias   Unclear risk of bias  
 
Figure 4.2. Summary of risk of bias assessment in the included trials of fatty acids and prevention of obesity in the offspring 
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4.5.4.1. Random sequence generation (selection bias) 
Of the seven included trials, three studies were assessed as having a low likelihood of 
selection bias (Bergmann et al. 2012; Brei et al., 2016; Helland et al., 2008) as the 
treatment allocation in these studies was carried out using a computer generated 
randomisation system. The risk of selection bias in the remaining studies was unclear 
as they had either not reported their method of randomisation or just stated that they 
had used block randomisation with no further information. 
4.5.4.2. Allocation concealment  
The allocation concealment was rated as high risk in the Campoy et al. (2011) trial 
since the randomisation numbers were provided in envelopes left in a closed box for 
each participating centre. The method of allocation concealment was not clear in three 
of the studies (Bergmann et al., 2012; Brei et al., 2016; Helland et al., 2008). The 
remainder kept the allocation concealed from the staff involved with the study 
(Dunstan et al., 2008; Gonzalez-Casanova et al., 2015; Rytter et al, 2011).   
4.5.4.3. Double blinding (performance bias) 
The specific intervention in the study conducted by Brei et al. (2016) did not allow a 
double-blind design and therefore, the study was rated as having a high risk of bias. 
The study by Rytter et al. (2011) was also deemed as high risk for performance bias 
since women would know if they were in one of the study’s control groups, as they 
would not receive any tablets. 
 
A further two studies gave no indication of blinding, of either staff or participants, 
and were recorded as having an unclear risk (Bergmann et al., 2012; Helland et al., 
2008). The final three studies (Campoy et al., 2011; Dunstan et al., 2008; Gonzalez-
Casanova et al., 2015) stated that their trial was double-blinded by keeping the codes 
blinded to research staff throughout the study and also by ensuring an equal 
appearance and smell for the intervention and placebo supplementations. 
4.5.4.4. Blinding of outcome assessment (detection bias) 
The study by Brei et al. (2016) was rated as having high risk of bias for blinding of 
outcome assessment, since the research staff who assessed SFT and infant growth 
were not blinded to study-group allocation. Two studies were rated as unclear for the 
blinding of outcome assessment (Campoy et al., 2011; Helland et al., 2008), as there 
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was no clear information about whether the staff or participants were blinded at the 
time of assessment, the remainder were rated as low risk of bias (Bergmann et al., 
2012; Dunstan et al., 2008; Gonzalez-Casanova et al., 2015; Rytter et al., 2011).  
4.5.4.5. Incomplete outcome data (attrition bias) 
Completeness of data was ranked as high risk in five studies (Brei et al., 2016; 
Campoy et al., 2011; Helland et al., 2008; Gonzalez-Casanova et al., 2015; Rytter et 
al., 2011). One study had a high loss to follow-up and did not specify the reasons for 
missing participants (Brei et al., 2016). The study by Helland et al. (2008) had a high 
loss to follow-up with higher non-compliance rate in the intervention group. 
Similarly, high loss to follow-up was also reported in Campoy et al. (2011), Rytter et 
al. (2011) and Gonzalez-Casanova et al. (2015) trials with a higher rate being 
observed in the study by Rytter et al. (2011). The rest of the studies were rated as low 
risk of bias since a high proportion of their sample participated in the follow-up 
assessment (Bergmann et al., 2012; Stein et al., 2011).  
4.5.4.6. Selective outcome reporting (reporting bias) 
All the pre-specified outcomes listed in the published papers were reported and 
consequently all the included trials were deemed to have a low risk of bias.  
4.5.4.7. Other potential sources of bias 
Each included study was assessed for other factors that might contribute to additional 
risk of bias. Three studies were rated as unclear for further risk of bias (Bergmann et 
al., 2012; Brei et al., 2016; Campoy et al., 2011) since there was no information 
regarding whether the participants have consumed the fatty acid supplement after the 
termination of the intervention. The remaining studies were classified as low risk for 
any further bias. 
 
4.5.5. Meta-analyses of effectiveness of maternal fatty acid consumption 
during pregnancy and prevention of obesity in the offspring 
Pooled results from meta-analyses in the studies that examined the effectiveness of 
maternal fatty acid supplementations during pregnancy and the prevention of obesity 
in offspring are presented in the following section. It is worth noting that the ITT 
analysis was only available data in Bergmann et al. (2012) study and hence, these are 
included in the meta-analyses. Also, the study conducted by Brei et al., (2016) is 
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included in sub-group analyses since it had a different comparator to other included 
studies. Furthermore, length as an outcome of interest for this review was not reported 
in the trials. 
4.5.5.1. BMI as an outcome for fatty acid intervention 
The effectiveness of fatty acid products during pregnancy on BMI in the offspring 
was assessed in four studies. Figure 4.3 shows the Forest plot for fatty acids versus 
placebo in pregnant women for BMI in offspring. The measurement of BMI was 
described differently in the included studies as below: 
Bergmann et al. (2012): Length and weight of the children were measured by 
standardised methods using Harpenden measuring boards, small measuring tapes and 
calibrated Seca balances; BMI was calculated accordingly. This outcome was 
reported as point prevalence at 6 years.  
Campoy et al. (2011): The outcome considered was “BMI, as the secondary 
endpoint” (undefined). This outcome was reported as point prevalence at 6.5 years.   
Helland et al. (2008): Growth data as length and weight were measured at follow-up 
assessment, along with intelligence testing, and the method of measuring the growth 
outcomes is not defined. This outcome was reported as point prevalence at 7 years.  
Rytter et al. (2011): Anthropometric measures were taken through a self-
administered web-based questionnaire and those who did not answer were invited for 
a physical examination. The method of measurement was not defined. The outcome 
was reported as point prevalence at 19 years.  
Statistically, these studies were largely homogeneous, with no variation between 
studies attributable to heterogeneity as opposed to sampling error (χ2=1.53, p=0.67, 
I
2
=0%). The result of meta-analysis did not show an association between maternal 
intake of fatty acids during pregnancy and BMI in the offspring (Mean Difference 
(SMD)=0.013, 95% CI=-0.16-0.18; 520 children) (Figure 4.3).  
Figure 4.3. Forest plot of fatty acids vs. placebo for BMI 
Measure: Continuous: d (Hedges g) 
Heterogeneity: Q = 1.53; df = 3; p = 0.675; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.0136 (-0.162, 0.189) 
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A sub-group analysis was also conducted including only the studies with similar 
duration of follow-up (Campoy et al., 2011; Bergmann et al., 2012; Helland et al., 
2008). The results did not yield a significant effect (SMD=0.04, 95% CI=-0.18-0.25, 
337 children) (Forest plot not shown). 
4.5.5.2. BMI-Z as an outcome measure for fatty acid intervention 
Two included studies measured the effect of fatty acids products consumption during 
pregnancy on BMI-Z in offspring (Figure 4.4). The definition of the outcome in the 
included studies was as below:  
Bergmann et al. (2012): The outcome considered was ‘Z-BMI’. The BMIs of the 
children from birth to 6 years were standardised with age-specific means of the World 
Health Organisation (WHO) multicentre growth reference study. This outcome was 
reported as point prevalence at 6 years. 
Gonzalez-Casanova et al. (2015): The outcome considered was ‘BMI-Z’. BMI was 
computed by calculating age at measurement from the date of birth, and then 
converted to age-specific Z-scores using the 2006 WHO reference standards. This 
outcome was reported as point prevalence at 5 years. 
The studies were statistically homogeneous, with no variation between studies 
(χ2=0.34, p=0.55, I2=0%). The result of meta-analysis did not show an association 
between maternal intake of fatty acids during pregnancy and BMI Z-score in the 
offspring (Mean Difference (SMD)=0.0142, 95% CI=-0.11-0.14, 917 children) 
(Figure 4.4). 
Outcome:  BMI Fatty acids  Mean (SD) Placebo  Mean (SD) 
Bergmann (n=41/74) 15.7 (1.5) 15.5 (1.3) 
Campoy (n=37/45) 17.23 (2.92) 16.82 (2.30) 
Helland (n=82/61) 16.4 (1.7) 16.3 (1.7) 
Rytter  (n=108/72) 22.5 (3.5) 22.6 (3.8) 
Subtotal (n=268/252)   
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Figure 4.4. Forest plot of fatty acids vs. placebo for BMI-Z 
Measure: Continuous: d (Hedges g) 
Heterogeneity: Q = 0.347; df = 1; p = 0.556; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.0142 (-0.116, 0.144) 
 
 
 
 
 
 
4.5.5.3. Weight as an outcome measure for fatty acid intervention 
Three included studies measured the effect of fatty acid products consumption during 
pregnancy on weight in offspring (Figure 4.5). The definition of the outcome in the 
included studies was as below: 
Bergmann et al. (2012): Weight (method of measurement undefined), this outcome 
was reported as point prevalence at 6 years. 
Dunstan et al. (2008): Weight (method of measurement undefined), this outcome was 
reported as point prevalence at 2.5 years. 
Gonzalez-Casanova et al. (2015): Weight (to the nearest 10gr) was measured using a 
Tanita scale. This outcome was reported as point prevalence at 5 years. 
Helland et al. (2008): Weight (method of measurement undefined), this outcome was 
reported as point prevalence at 7 years. 
 
The studies were statistically homogeneous (χ2=0.97, p=0.80, I2=0%). The result of 
meta-analysis did not show an association between maternal intake of fatty acids 
during pregnancy and weight in the offspring (SMD=-0.01, 95% CI=-0.13-0.10; 934 
children).   
  
Outcome:  BMI-Z Fatty acids  Mean (SD) Placebo  Mean (SD) 
Bergmann (n=41/74) 1.02 (0.09) 1.01 (0.08) 
Gonzalez-Casanova  
(n=403/399) 
0.1 (1.1) 0.1 (1.1) 
Subtotal (n=444/473)   
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Figure 4.5. Forest plot of fatty acids vs. placebo for weight 
 
Measure: Continuous: d (Hedges g) 
Heterogeneity: Q = 0.974; df = 3; p = 0.808; I-squared = 0%; tau-squared = 0. 
Random effects model: -0.0142 (-0.131, 0.103) 
 
 
Outcome: Weight Fatty acids Mean (SD) Placebo Mean (SD) 
Bergmann (n=41/74) 22.4 (3.1) 22.3 (2.9) 
Dunstan (n=33/39) 14.5 (2.0) 14.1 (2.0) 
Gonzalez-Casanova 
(n=369/370) 
10.4 (1.1) 10.4 (1.2) 
Helland (n=82/61) 26.8 (4.1) 27.0 (4.1) 
Subtotal (n=525/409)   
 
In addition, an additional analysis was conducted including the study conducted by 
Brei et al. (2016), which defined “standard diet” as its comparator. The outcome in 
this study was measured as below: 
Brei et al. (2016): The weight was measured to the nearest 100g using a standard flat 
scale (Seca Clara 803), with the child in a standing position. The outcome was 
reported as point prevalence at 5 years. 
 
As Figure 4.6 shows, the studies were largely homogenous (χ2=2.85, p=0.58, I2=0%). 
The meta-analysis did not alter the results greatly, indicating that there was no 
association between prenatal fatty acid supplementation during pregnancy and weight 
in the offspring (SMD=0.010, 95% CI=-0.101-0.12, 1,183 children).  
 
Figure 4.6. Forest plot of fatty acids vs. control for weight 
 
Measure: Continuous: d (Hedges g) 
Heterogeneity: Q = 2.85; df = 4; p = 0.583; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.0106 (-0.101, 0.122) 
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4.5.5.4. Height as an outcome measure for fatty acid intervention 
The meta-analysis on the maternal consumption of fatty acids during pregnancy and 
its effectiveness on height in the offspring is shown in Figure 4.7. In total, four studies 
were included in the meta-analysis. The outcome considered within the included 
studies were as below: 
Bergmann et al. (2012): Height (method of measurement undefined), this outcome 
was reported as point prevalence at 6 years. 
Dunstan et al. (2008): Height (method of measurement undefined), this outcome was 
reported as point prevalence at 2.5 years. 
Gonzalez-Casanova et al. (2015): Heigth (to the nearest 1mm) was measured using a 
Seca stadiometer. This outcome was reported as point prevalence at 5 years. 
Helland et al. (2008): Height (method of measurement undefined), the outcome was 
reported as point prevalence at 7 years.  
Statistically, these studies were largely homogeneous, with no variation between 
studies attributable to heterogeneity (χ2=1.51, p=0.68, I2=0%). The result of meta-
analysis did not show an association between maternal intake of fatty acids during 
pregnancy and height in the offspring (SMD=-0.042, 95% CI=-0.159-0.07; 1,069 
children) (Figure 4.7). 
 
Outcome:  Weight Fatty acids Mean (SD) Placebo Mean (SD) 
Bergmann (n=41/74) 22.4 (3.1) 22.3 (2.9) 
Brei (n=58/56) 19.2 (3.0) 18.4 (3.2) 
Dunstan (n=33/39) 14.5 (2.0) 14.1 (2.0) 
Gonzalez-Casanova  
(n=369/370) 
10.4 (1.1) 10.4 (1.2) 
Helland (n=82/61) 26.8 (4.1) 27.0 (4.1) 
Subtotal (n=583/600)   
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Figure 4.7. Forest plot of fatty acids vs. placebo for height 
Measure: Continuous: d (Hedges g) 
Heterogeneity: Q = 1.51; df = 3; p = 0.68; I-squared = 0%; tau-squared = 0. 
Random effects model: -0.0421 (-0.159, 0.0751) 
 
 
 
Outcome: Height Fatty acids Mean (SD) Placebo Mean (SD) 
Bergmann (n=41/74) 119.2 (5.3) 119.6 (4.6) 
Dunstan (33/39) 93.8 (3.8) 93.3 (4.6) 
Gonzalez-Casanova 
(n=369/370) 
108.3 (4.4) 108.4 (4.5) 
Helland (n=82/61) 127.5 (5.5) 128.6 (5.0) 
Subtotal (n=525/544)   
 
A sub-group analysis was also conducted including the study conducted by Brei et al. 
(2016) that defined “standard diet” as its comparator. The outcome in this study was 
defined as below: 
Brei et al. (2016): Height was measured to the nearest 0.5cm using a stadiometer, 
with the child in a standing position. The outcome was reported as point prevalence at 
5 years. 
 
As Figure 4.8 shows, there was moderate level of heterogeneity between the studies 
(χ2=5.17, p=0.27, I2=22.6%). The meta-analysis did not alter the results greatly, 
indicating the result of meta-analysis did not show any association between maternal 
intake of fatty acids during pregnancy and height in the offspring (SMD=0.001, 95% 
CI=-0.147-0.15, 1,183 children).  
 
Figure 4.8. Forest plot of fatty acids vs. control for height 
Measure: Continuous: d (Hedges g) 
Heterogeneity: Q = 5.17; df = 4; p = 0.27; I-squared = 22.6%; tau-squared = 0.00701. 
Random effects model: 0.00157 (-0.147, 0.151) 
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Outcome: Height Fatty acids Mean (SD) Placebo Mean (SD) 
Bergmann (n=41/74) 119.2 (5.3) 119.6 (4.6) 
Brei (n=58/56) 112.2 (4.8) 110.7 (4.0) 
Dunstan (33/39) 93.8 (3.8) 93.3 (4.6) 
Gonzalez-Casanova 
(n=369/370) 
108.3 (4.4) 108.4 (4.5) 
Helland (n=82/61) 127.5 (5.5) 128.6 (5.0) 
Subtotal (n=583/600)   
 
4.5.5.5. Sum of SFT as an outcome measure for fatty acid intervention 
The outcome measure as a sum of SFT in children was measured in two of the 
included studies (Bergmann et al., 2012 and Brei et al., 2016), which have introduced 
different comparators as “placebo” and “standard diet” respectively. A meta-analysis 
was performed including these two studies investigating the effect of prenatal intake 
of fatty acids on sum of SFT in the offspring (Figure 4.9). Measurement of the 
outcome in the included trials was described as below: 
Bergmann et al. (2012): The outcome considered was ‘sum of SFT (mm)’. SFT was 
measured with a Holtain caliper at the mid tricipital, the subscapular, and the 
suprailiac measuring point. This outcome was reported as point prevalence at 6 years. 
Brei et al. (2016): SFTs, as a primary outcome, was measured in triplicate with the 
use of a Holtain caliper at four different body sites on the left body axis: triceps, 
biceps, subscapular and suprailiac. Measurements were performed at 2, 3, 4 and 5 
years of age at the study centre or at the family’s home. For each site, the mean of the 
three measurements was used for the SFT value and the sum of the 4 SFTs was 
calculated. This outcome was reported as point prevalence at 5 years. 
 
The studies were largely heterogeneous (χ2=2.67, P=0.10, I2=62.6%). The result of 
meta-analysis did not show an association between maternal intake of fatty acids 
during pregnancy and SFT in the offspring (SMD=0.09, 95% CI=-0.33-0.53, 227 
children) (Figure 4.9).  
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Figure 4.9. Forest plot of fatty acids vs. control for sum of SFT 
Measure: Continuous: d (Hedges g) 
Heterogeneity: Q = 2.67; df = 1; p = 0.102; I-squared = 62.6%; tau-squared = 0.062. 
Random effects model: 0.0968 (-0.339, 0.533) 
 
 
 
Outcome: Sum of SFT Fatty acids Mean (SD) Placebo Mean (SD) 
Bergmann (n=41/74) 23.2 (7.1) 21.1 (6.1) 
Brei (n=57/55) 23.9 (4.7) 24.5 (5.0) 
Subtotal (n=98/129)   
 
4.5.6. Discussion of the evidence synthesis of maternal fatty acid 
consumption during pregnancy and prevention of obesity in the offspring 
4.5.6.1. Summary of main results 
This systematic review summarised data from seven RCTs of prenatal intake of fatty 
acids for prevention of childhood adiposity that included a total of 1,647 children with 
follow-up ranging from 1.5 to 19 years (mean 7.28 years). Method of allocation 
concealment was rated unclear in three studies, with one study judged as high risk. 
Also, over half of the studies (71%) were deemed as high risk for loss to follow-up. 
The findings from this systematic review and meta-analysis do not provide evidence 
of a protective association between intake of fatty acids during pregnancy and 
subsequent development of a number of obesity measures in children including BMI, 
BMIZ, weight, height, length, sum of SFT. These results, however, need to be 
considered with caution due to the risk of bias in the trials, limited number of studies, 
a small sample size in most studies, and the statistical heterogeneity observed for 
some outcomes i.e. height and SFT.  
 
It is also worth mentioning that with the exception of the study by Brei et al., (2016), 
the other five included trials were primarily designed to assess outcomes other than 
obesity in childhood, and reported growth measures as their secondary outcomes in 
further follow-up assessments. In an open label trial, Brei and colleagues (2016) 
applied a combined intervention approach of fish oil capsules and AA-balanced diet 
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(ratio of n-6/n-3) during pregnancy, and introduced a number of measures for 
adiposity outcomes such as mean of SFT and fat distribution in infants by 5 year of 
age. Data from this trial did not demonstrate a significant difference between the 
study arms for adiposity outcomes in children. It is important to note that the study 
had a high non-participation rate at the 5 years follow-up. 
4.5.6.2. Overall completeness and applicability of evidence 
No evidence was found that fatty acid supplementation during pregnancy is effective 
for the prevention of adiposity in the offspring. The heterogeneity between the trials 
limited the findings and random effect models were used to pool the results. 
Heterogeneity between studies originated from varied dosage and timing of 
intervention, variability of comparators, different methods for reporting the outcome 
measures across studies, diverse locations/settings and the follow-up duration. One 
study (Gonzalez-Casanova et al., 2015) also used DHA, isolated from algal, which 
may act differently from fish oil. It was not possible to conduct stratified analyses for 
the type, dosage and timing of intervention to explore the differences caused by the 
relatively small number of trials in each group. In addition, although most studies 
recruited a relatively large sample, only a small number of participants were 
approached at their follow-up. 
4.5.6.3. Quality of evidence 
Overall, the trials were at moderate to high risk of bias, for the summary of risk of 
bias assessment (Figure 4.2). A large proportion of studies were rated as unclear in 
many risk of bias domains, and some had high risk of bias for individual quality 
domains (Figure 4.2). High loss to follow-up was the main concern in five of the 
included trials (71%) and the number of studies and participants contributing to the 
meta-analyses is also an issue that might downgrade the quality of the body of 
evidence.  
4.5.6.4. Strength and weakness of this systematic review for fatty acid 
consumption during pregnancy 
The main distinction of this systematic review is that it includes only trials that started 
intake of fatty acids during pregnancy, thus, crucially, enabling us to isolate the effect 
of prenatal intake of fatty acids for prevention of childhood obesity. An additional 
strength is that the systematic review followed an a priori published protocol, using a 
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comprehensive search strategy that allowed complete coverage of all the relevant 
literature including citation databases, trial registries and conference proceedings. 
Moreover, a range of obesity measures were the focus of the present review and the 
most up-to-date results from the trials, reported as the longest available follow-up 
data, are included in the meta-analyses.  
 
A limitation of the review is that we made some changes to the protocol. Sub-group 
analyses were not conducted as planned for the type, duration and dosage of 
intervention, owing to the small number of studies that could contribute in meta-
analysis. Nevertheless, the established methodological guidelines from the protocol 
were largely followed, and there was a clear rational for deviations from the protocol. 
As a consequence of these changes, data were pooled from trials conducted in diverse 
populations, initially designed to account for the different outcome and quality of 
studies. It is worth noting that sub-group analyses conducted in the current systematic 
review might be susceptible to type II errors due to relatively small sample sizes in 
trials; however no statistical heterogeneity was introduced in most of the meta-
analyses conducted. Furthermore, the limited number of studies did not allow formal 
assessment for publication bias. 
4.5.6.5. Agreement and disagreement with other reviews 
As described in section 4.3.2.2, there have been few systematic reviews for the use of 
fatty acids during pregnancy for prevention of childhood obesity. Most of these 
provided a narrative description of the included studies, with the exception of one 
meta-analysis that reported maternal and neonatal outcomes at birth only (Imhoff-
Kunsch et al., 2012). One systematic review and meta-analyses by Stratakis and 
colleagues (2014) focused on longer-term adiposity outcomes in children and used 
different inclusion criteria from the current review in terms of the timing of 
intervention where they included studies that administered fatty acids supplements 
prenatally and/or exclusively in lactation. They also defined a few obesity outcomes 
and conducted the meta-analyses only for BMI with subgroup analyses for age groups 
(<5, 6-12 and >13 years) and the timing of intervention i.e. pregnancy, pregnancy and 
lactation, lactation. In addition, Stratakis and colleagues included BMI in units of 
either kg/m
2
 or z-score in the meta-analyses. Our systematic review provides an 
update with that of Startakis et al. (2014), and although our results are not directly 
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comparable with their review, the current findings are in agreement with the previous 
review that concludes fatty acid supplementation during pregnancy does not protect 
against adiposity-related measures in children. Similarly, they have also reported 
methodological shortcomings including number of studies, small sample sizes and 
attrition bias. 
4.6.5.6. Author’s conclusion 
Implications for practice 
The results of the current systematic review do not provide an evidence for the 
prevention of obesity in the offspring by prenatal fatty acid intake when compared 
with placebo/no treatment. Due to the high heterogeneity between studies along with 
small sample size and large attrition at follow-ups, the effects of fatty acid 
supplementation during pregnancy for prevention of childhood adiposity in long-term 
remains unclear.  
Implications for research  
Taking the volume and quality of the available evidence into account, the effect of 
prenatal intake of fatty acids for prevention of childhood obesity needs to be further 
investigated in large, high quality RCTs. Given that only one included study had been 
established to explicitly examine the effect of prenatal consumption of fatty acids on 
obesity in offspring, such RCTs need to be dedicated trials designed specifically to 
examine this question. Trials should also consider the effect of n-6/n-3 ratio in the 
dietary intervention and rather than increasing n-3 LC-PUFA in isolation to determine 
the role of the balance of fatty acid intake in maternal diet. Using combined methods 
of anthropometric and SFT measurements as well as more precise measures such as 
MRI and ultrasound will also allow for more accurate estimation of adipose tissue 
deposition in children.  
 
The optimal timing of fatty acid intervention is another key factor that needs to be 
further investigated. The first appearance of adipocytes in the human foetus occurs in 
second trimester of pregnancy, between 14-16 weeks of gestation (Ailhaud & Hauner, 
2004). Further research is required to determine the critical window for programming 
of offspring adipose tissue. Baseline level of DHA in pregnant women, type and 
optimal dose of LC-PUFA, as well as the choice of control regimens, are elements 
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that need to be considered in further trials. More importantly, additional rigorous 
strategies are needed to minimise the low participation rate at follow-up assessments.  
Recruiting fewer participants or high attrition rates in interventions with ω-3 PUFAs 
could lead to significantly varied findings and thus bias in impact of fatty acids, as 
highlighted in a recent study (Yelland, Makrides, McPhee, Quinlivan, & Gibson, 
2016). Therefore, significant research by conducting longitudinal studies with 
adequate sample size and repeated measurements is required to provide a strong 
evidence with which to determine the effect of fatty acids intake during pregnancy on 
obesity in offspring 
 
One might also argue that the existing evidence is applicable only to the populations 
in which these studies were undertaken. Given that the majority of the studies were 
conducted in developed countries, it remains a priority to also understand the 
effectiveness of these interventions for childhood obesity among the underreported 
populations. 
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4.5.7. Description of included studies of maternal probiotic consumption 
during pregnancy and prevention of obesity in the offspring  
In total four studies (with a total of 1,610 children) examined the impact of probiotic 
supplementation during pregnancy on the development of obesity in offspring. The 
characteristics of the included trials, their companion papers and study population are 
presented in Table 4.5. Studies were conducted in Finland, Denmark, Sweden and 
New Zealand.  
 
Only one study was specifically designed to investigate the impact of perinatal 
probiotic intervention on the development of overweight and obesity in children and 
reported the 10 year follow-up of the original study (Luoto, Kalliomäki, Laitinen, & 
Isolauri, 2010). In contrast, the other included studies were originally planned to 
investigate the effect of maternal supplementation with probiotics during pregnancy 
on developing allergic diseases in offspring and additionally reported the 
anthropometric/growth measures of children in their extended follow-up along with 
the allergic outcomes.  
 
One study used a combination of a probiotic and a prebiotic in pregnant women 
(Kuitunen, et al., 2009) and the remainder applied probiotics only (Abrahamsson et 
al., 2013; Luoto et al., 2010; Wickens et al., 2013). All studies selected their study 
sample from families with a reported history of atopic diseases. 
The longest follow-up period was 10 years, in the study conducted by Luoto et al. 
(2010), followed by 7 and 6 years in the studies by Abrahamsson et al. (2013) and 
Wickens et al. (2013) respectively. The largest study sample was reported in Kuitunen 
et al. (2009) with 1,223 mothers enrolled followed by Wickens et al. (2013) with 511 
pregnant mothers at enrolment. The smallest sample size was observed in study 
conducted by Luoto et al. (2010) with 159 mothers randomised at recruitment. 
 
Compliance with the treatment was assessed by interviews/stool examination and 
counting of unused supplements. Method of adherence to intervention was not 
reported in the study conducted by Luoto et al. (2010).  
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Table 4.5. Characteristics of the included trials and study population of probiotics and prevention of obesity 
Primary article  Companion 
articles
+
 
Country, 
enrolment 
period 
Trial 
type
*
 
Study 
intervention & 
comparator 
No. of 
participants
**
 
No. at last 
F-U
***
 
Time 
points 
measured 
Age at 
last  
F-U 
Sample: high 
risk of Atopy 
Outcomes 
reported 
 
(Kuitunen, et 
al., 2009)  
(Kukkonen et al., 
2007, 2008; 
Kukkonen, 
Nieminen, Poussa, 
Savilahti, & 
Kuitunen, 2006a)  
Finland 
2000-03 
PC-
RCT 
Mixed Probiotic 
& placebo 
1,223 mothers 891 (445 
vs. 446) 
3, 6, 12, 24 
months 
5yrs. 
5yrs. Yes -Weight (kg) 
-Height (cm) 
(Luoto, et al., 
2010)  
(Luoto, Laitinen, 
Nermes, & Isolauri, 
2010)  
Denmark  
no 
information 
PC-
RCT 
Two Probiotics 
supplement & 
control 
159 mothers 113: 59 vs. 
54 
3, 6, 12 & 
24 months; 
4, 7 & 
10yrs 
10yrs. Yes -BMI (kg/m
2
) 
-Obesity 
-Overweight 
(Abrahamsson,  
et al., 2013)  
(Abrahamsson et 
al., 2007; Böttcher, 
et al., 2008; 
Forsberg, et al., 
2014)  
Sweden  
2001-03 
PC-
RCT 
Lactobacillus 
reuteri & 
placebo 
 
 
232 mothers 
 
 
184 (94 vs. 
90) 
2 & 7 yrs. 7yrs. 
 
 
Yes -Weight (kg) 
-Height (cm) 
 
 
(Wickens et al., 
2013)  
(Dekker et al., 
2009; Prescott et 
al., 2008; Wickens 
et al., 2008, 
Wickens et al., 
2012) 
New 
Zealand 
2004-05  
 
PC-
RCT 
 
2 diff mixed 
probiotic arms 
& placebo 
511 mothers 422(134 
vs. 144 vs. 
144) 
2, 4 & 
6yrs. 
6yrs. Yes -BMI (kg/m
2
) 
-Obesity 
-Overweight 
+Published data and conference presentations, No unique data were extracted from conference abstracts          
*Placebo Controlled-Randomised Controlled Trial 
**Indicates the number at randomisation, where recruitment has occurred prenatally           
***Follow-up
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Table 4.6. shows the details of the probiotic interventions and placebo used in 
included trials. In all studies the intervention and placebo groups had comparable 
baseline characteristics at recruitment and also at birth. It is worth noting that the 
Abrahamsson et al. (2013) study reported higher antibiotic prescription during the 
first year of life in the intervention vs. placebo group (p=0.03).  
 
In all studies, the probiotic interventions were continued after pregnancy either in 
mothers only or with both mothers and their infants for a period of time (Table 4.6). 
The longest duration of intervention was 25 months (Wickens et al., 2013) and the 
shortest was 6.5-7 months (Kuitunen et al., 2009 & Luoto et al., 2010). In one study, a 
single strain of probiotics was used as the intervention (Abrahamsson et al., 2013) 
whereas a mixed strain of probiotics was employed in the other included studies. For 
the purpose of this systematic review, all the probiotic intervention studies, whether 
they have used mixed or single strains of probiotics, have been grouped together 
under one umbrella as “any probiotics”.  
 
One study included two active intervention trial arms by employing different mixed 
strains of probiotics in each intervention group and comparing these with a placebo 
(Wickens et al., 2013). For reporting purposes and as recommended by the Cochrane 
Handbook (Higgins
 
et al., 2011b), data from the two different active intervention arms 
were pooled when entered into meta-analysis. On a request for the anthropometric 
measures from the author, the combined data for intervention arms were also sought.  
 
All studies used placebo as their comparator/control. Probiotic preparations included 
capsules and oil drops. In the study by Luoto et al. (2010), participants of both 
probiotic and placebo groups also received an intensive dietary counseling 
intervention at every study visit by a nutritionist. Women were advised to follow a 
diet complying with current recommendations, combined with conventional food 
products with favourable fat and fibre contents for use at home. 
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Table 4.6. Characteristics of probiotic interventions in the included trials for prevention of obesity 
Primary article  Comparable 
baseline 
characteristic  
Participants 
receiving 
intervention 
Timing of  
Intervention in 
pregnancy 
Intake of 
intervention 
from/until
*
 
Duration of 
intervention 
(months)
**
 
Probiotic 
organism
***
 
Placebo 
 
Mode of 
delivery 
Total daily 
dose (colony 
forming 
units) 
Kuitunen et al., 2009 Yes Prenatally and 
postnatally in 
infants 
From 36wks. of 
gestation 
6 months 
postnatal 
6.5-7 LC705 +  
LC705 +bb99 + 
Pf 
Micro-
crystalline 
cellulose 
Capsule 5 × 10
9
,
 
5 × 
10
9
, 2× 10
8
, 
2 × 10
9
 
CFU/day, 
twice a day 
Luoto  et al.,  
2010 
Yes  Prenatally & 
postnatally in 
mothers & 
infants 
4wks before 
expected 
delivery 
34-36wks. to 
6 months 
postnatal 
6.5-7  LGG & BBL  
+ intensive 
dietary 
counseling 
Microcrystal
line 
cellulose & 
dextrose 
anhydrate 
Capsule  10
10
 per day 
each strain 
Abrahamsson et al., 
2013 
Yes, higher 
Antibiotic 
prescription 
during the first 
year of life in 
Int. vs. placebo 
in 1
st
y of life 
Prenatally and 
postnatally in 
infants 
From 36+0 wks. 36 wks. to 
12 months 
postnatal 
12.5-13  L. reuteri Same oil 
without any 
bacteria 
Oil drops 1 × 10
8
 
CFU/day, 
5 drops daily 
Wickens et al., 2013 Yes Prenatally & 
postnatally in 
mothers & 
infants 
From 35wks. 
gestation 
35wks to 
2yrs. 
postnatal 
25-25.5 BA HN019 or L 
rhamnosus 
HN001 
Dextran, 
salt, and a 
yeast extract 
Capsule 
9 × 10
9
,
 
6 × 
10
9 
CFU/day, 
daily 
*Indicates total duration in mother, infant or both, whichever is applicable 
**Indicates total duration in pregnancy plus after birth either in mother only or both mother and infants, if applicable  
***DHA=Docosahexaenoic Acid, PUFA=Poly-Unsaturated Fatty Acid, BCSO=Blackcurrant Seed Oil, LA=Linoleic Acid 
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4.5.8. Risk of bias in studies of maternal probiotic consumption during 
pregnancy and prevention of obesity in the offspring 
Figure 4.10 shows the summary of risk of bias assessment in trials of probiotic 
studies. Appendix 4.6 shows the reviewer’s judgment of the risk of bias assessment 
for probiotic studies.  
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Short Title Random 
Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources 
of Bias 
Kuitunen (2009) + + + ? ? ? + 
Luoto (2010) ? ? + + ? + ? 
Abrahamsson 
(2013) 
? + - - - ? - 
Wickens (2013) + + - + - ? + 
 
Random Sequence Generation   
 
50% 50%   
 
Allocation Concealment   
 
75% 25%   
 
Double Blinding   
 
50%   50% 
 
Blinding of Outcome 
Assessment   50% 25% 25% 
 
Incomplete Outcome Data   
 
  50% 50% 
 
Selective Outcome Reporting   
 
25% 75%   
 
Other Sources of Bias   
 
50% 25% 25% 
 
 
 
Low risk of bias  High risk of bias   Unclear risk of bias  
 
Figure 4.10. Summary of risk of bias assessment in the included trials of probiotics and prevention of obesity in the offspring 
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4.5.8.1. Random sequence generation (selection bias) 
Two studies were rated as low risk of bias for their randomisation method (Kuitunen 
et al., 2009; Wickens et al., 2013). The remaining two studies were assessed as having 
an unclear risk of bias (Abrahamsson et al., 2013; Luoto et al., 2010) where it has 
been generally stated as randomly assigned with no details on the method of 
randomisation.  
4.5.8.2. Allocation concealment  
The study by Luoto et al. (2010) was rated as ‘unclear’ as there was no information on 
how participants were allocated. Methods for concealment of allocation were reported 
in the remaining studies (Abrahamsson et al., 2013; Kuitunen et al, 2009; Wickens et 
al., 2013) and were subsequently classified as having a low risk of bias for allocation 
concealment.  
4.5.8.3. Double Blinding (performance bias) 
There was no blinding of either staff or participants at the time of extended follow-up 
in two studies (Abrahamsson et al., 2013; Wickens et al., 2013). The rest of the 
studies were classified as low risk for their performance bias.  
4.5.8.4. Blinding of outcome assessment (detection bias) 
One study was rated as having high risk of bias for blinding of outcome assessment 
(Abrahamsson et al., 2013), as the extended follow-up study was only single-blinded 
to the investigator(s). One study was rated as unclear for the blinding of outcome 
assessment (Kuitunen et al., 2009) and the remainder were classified as low risk 
(Luoto et al., 2010; Wickens et al., 2013). 
4.5.8.5. Incomplete outcome data (attrition bias) 
Completeness of data was ranked as high risk in two studies. One study had a high 
loss to follow-up and did not specify the reasons for missing participants 
(Abrahamsson et al., 2013) and the study by Wickens et al. (2013) used imputed 
analysis for a number of the reported outcomes. Two studies (Kuitunen et al., 2009; 
Luoto et al., 2010) were rated as unclear as they did not specify the reasons for loss to 
follow-up. 
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4.5.8.6. Selective outcome reporting (reporting bias) 
Three studies were rated as unclear since the original study was primarily designed to 
assess allergic outcomes in children (Abrahamsson et al., 2013; Kuitunen et al., 2009; 
Wickense et al., 2013) and there is no indication in the manuscript as to whether the 
anthropometric measures are defined as the secondary outcomes. The study by Luoto 
et al. (2010) specified the obesity measures as primary outcomes in their 
protocol/manuscript and was classified as low risk of bias. 
4.5.8.7. Other potential sources of bias 
There were no concerns regarding any other sources of bias in two of the included 
trials which were therefore assessed as low risk (Kuitnen et al., 2009; Wickens et al., 
2013).  One study was rated as being at high risk of further bias (Abrahamsson et al., 
2013) since the participants reported that they continued to consume the study 
intervention product after delivery despite this not being part of the study protocol. 
The study by Luoto et al. (2010) was rated as having an unclear risk of bias since 
there is no information whether children in the intervention group have consumed the 
probiotics after the study termination. 
4.5.9. Meta-analyses of effectiveness of maternal probiotic consumption 
during pregnancy and prevention of obesity in the offspring  
Pooled results from meta-analysis in the studies that examined the effectiveness of 
probiotic supplementations for the prevention of obesity in offspring are presented in 
the following section. Since the studies were inconsistent for the reported outcomes 
on anthropometric measures, all four authors were contacted requesting ‘Mean 
(Standard Deviation (SD))’ of growth outcomes i.e. crude/unadjusted BMI, weight, 
height. Two authors (Abrahamsson 2013; Kuitunnen 2009) did not provide the 
requested data. One author provided only the unadjusted BMI at different follow-up 
time points (Luoto et al., 2010). Wickens et al. (2013) contributed data on BMI, 
weight and height for individual intervention arms and also, as requested, for 
combined intervention arms. For this systematic review, the data for combined 
probiotic intervention arms were included in meta-analyses. It is worth noting that in 
the study by Wickens et al. (2013), there were no significant statistical differences in 
the reported anthropometric measures for individual probiotic arms. Furthermore, the 
study by Luoto et al. (2010) reported the anthropometric measures at 2, 4, 7 and 10 
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years and the follow-up data at 7 years was included in meta-analyses as it is more 
comparable to the reported follow-up times in the other included studies. Data on 
anthropometric measures at 10 years follow-up for this study are reported separately. 
The definition of the outcomes included in individual meta-analysis is presented in 
the following sections. 
4.5.9.1. BMI as an outcome measure for probiotic intervention 
The effectiveness of probiotic supplementations during pregnancy on BMI in children 
was assessed in three studies. Figure 4.11 shows the forest plot for probiotics versus 
placebo in pregnant women on BMI in offspring. Measurement of BMI in the 
included studies was described as below:  
Luoto et al. (2010): The outcome considered was “BMI, crude”. The BMI (in kg/m
2
) 
was calculated as weight in kilograms divided by height in meters squared and 
approximated to one decimal place. This outcome was reported as point prevalence at 
7 years.  
Wickens et al. (2013): The outcome considered was “BMI, combined probiotic 
arms”. BMI was defined as weight (kg)/height (m
2
). This outcome is reported as point 
prevalence at 6 years.  
Statistically, the studies were largely homogenous (χ2=0.002, P=0.95, I2=0%). The 
result of meta-analysis did not show an association between maternal intake of 
probiotics during pregnancy and BMI in the offspring (SMD=0.01, 95%CI=-0.17-
0.19, 480 children). 
 
Figure 4.11. Forest plot of probiotics vs. placebo for BMI 
Measure: Continuous: d (Hedges g) 
Heterogeneity: Q = 0.00278; df = 1; p = 0.958; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.0104 (-0.176, 0.197) 
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Outcome: BMI Probiotics Mean (SD) Placebo Mean (SD) 
Luoto (n=54/59) 16.88 (2.04) 16.84 (2.09) 
Wickens (n=245/127) 15.88 (1.38) 15.87 (1.20) 
Subtotal: (n=299/181)   
 
4.5.9.2. Weight as an outcome measure for probiotic intervention 
Three included studies measured the effect of probiotic consumption during 
pregnancy on weight in offspring (Figure 4.12). Weight was measured as described 
below: 
Abrahamsson et al. (2013): The outcome considered was ‘Weight (kg), mean (SD)’, 
undefined. This outcome is reported as point prevalence at 7 years. The authors 
presented “weight, mean (95% CI)” and the SD was calculated from 95% CI using the 
formula below, as detailed in the Cochrane handbook (Higgins & Deeks 2011):  
SD= √N × (upper limit – lower limit) / 3.92 
Kuitunen et al. (2009): The outcome considered was ‘Weight (kg), mean (SD)’, 
undefined. The percentage of national reference in the intervention and placebo 
groups was also reported as 2.64 (9.18) and 1.58 (8.71) respectively. This outcome 
was reported as point incidence at 5 years.  
Wickens et al. (2013): The outcome considered was ‘Weight (kg), mean (SD)’ for 
combined probiotic groups, undefined. This outcome was reported as point 
prevalence at 6 years. 
There was no statistical heterogeneity between the included trials (χ2=0.35, P=0.83, 
I
2
=0 %). The result of meta-analysis did not show an association between maternal 
intake of probiotics during pregnancy and weight in the offspring (SMD=0.06, 95% 
CI=-0.03-0.17, 1,421 children).  
 
Figure 4.12. Forest plot of probiotics vs. placebo for weight 
Measure: Continuous: d (Hedges g) 
Heterogeneity: Q = 0.353; df = 2; p = 0.838; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.0659 (-0.0396, 0.171) 
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Outcome: Weight Probiotic Mean (SD) Placebo Mean (SD) 
Abrahamsson (n=81/77) 25.4 (3.9) 25.5 (4.7) 
Kuitunen (n=445/446) 19.7 (2.6) 19.5 (2.5) 
Wickens (n=245/127) 22.61 (3.00) 22.39 (2.83) 
Subtotal (n=771/650)   
 
4.5.9.3. Height as an outcome measure for probiotic intervention 
The meta-analysis on the maternal consumption of probiotics during pregnancy and 
their effectiveness on height in the offspring is shown in Figure 4.13. In total, three 
studies were included in the meta-analysis. Measurement of height in the included 
trials was as below: 
Abrahamsson et al. (2013): The outcome considered was ‘Height (cm), mean (SD)’, 
(undefined). This outcome was reported as point prevalence at 7 years. The authors 
presented “height, mean (95% CI)” and SD was obtained from 95% CI as stated in 
section 4.5.9.2. This outcome was reported as point prevalence at 7 years.   
Kuitunen et al. (2009): The outcome considered was ‘Height (cm), mean (SD)’, 
(undefined). Also, the SD of national reference in the intervention and placebo groups 
was reported as 0.38 (0.99) and 0.38 (0.99) respectively. This outcome was reported 
as point incidence at 5 years. 
Wickens et al. (2013):  The outcome considered was ‘Height (cm), mean (SD)’ for 
combined probiotic groups (undefined). This outcome was reported as point 
prevalence at 6 years. 
 
Statistically, studies were largely homogenous (χ2=0.76, P=0.68, I2=0%). The result 
of meta-analysis did not show an association between maternal intake of probiotics 
during pregnancy and height in the offspring (SMD=0.03, 95% CI=-0.07-0.14, 1,421 
children) (Figure 4.13).  
 
Figure 4.13. Forest plot of probiotics vs. placebo for height 
Measure: Continuous: d (Hedges g) 
Heterogeneity: Q = 0.768; df = 2; p = 0.681; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.035 (-0.0704, 0.14) 
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Outcome: Height Probiotic Mean (SD) Placebo Mean (SD) 
Abrahamsson (n=81/77) 124.7 (5.05) 124.2 (5.59) 
Kuitunen (n=445/446) 111 (6.6) 111 (6.3) 
Wickens (n=245/127) 119.12 (5.30) 118.59 (5.17) 
Subtotal (n=771/650)   
 
4.5.9.4. Obesity as an outcome measure for probiotic intervention 
In total two studies were included in a meta-analysis measuring the effect of probiotic 
intake during pregnancy on obesity in the offspring (Figure 4.14). Measurement of 
obesity in the included trials was as below: 
Luoto et al. (2010): The outcome considered was ‘Obesity, number (%)’. The weight 
status, in calculating BMI, was established by the International Obesity Task Force 
criteria for overweight and obesity, which identifies BMI values for each age 
associated with a predicted BMI of 25 or 30 at the age of 18 years. Obesity at 7 years 
was defined according to the international cut-off values 20.51 kg/m
2
 for girls and 
20.63 kg/m
2
 for boys. This outcome was reported as point prevalence at 7 years. 
Wickens et al. (2013): The outcome considered was ‘ Obesity, number (%)’ and was 
defined with gender and age-specific cut-off values. This outcome was reported as 
point prevalence at 6 years.   
 
A moderate level of statistical heterogeneity was observed between the included trials 
(χ2=2.26, P=0.13, I2=55.7%). The result of meta-analysis did not show an association 
between maternal intake of probiotics during pregnancy and developing obesity in the 
offspring (RR=0.38, 95% CI=0.03-3.91, 485 children).  
 
Figure 4.14. Forest plot of probiotics vs. placebo for obesity 
Measure: Binary: risk ratio 
Heterogeneity: Q = 2.26; df = 1; p = 0.133; I-squared = 55.7%; tau-squared = 1.72. 
Random effects model: 0.38 (0.0369, 3.91) 
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Outcome: Obesity Probiotic n/N Placebo n/N 
Luoto  4/54 4/59 
Wickens  0/245 3/127 
Subtotal 299 186 
 
4.5.9.5. Overweight as an outcome measure for probiotic intervention 
In total two studies were included in a meta-analysis measuring the effect of probiotic 
consumption during pregnancy on overweight in offspring (Figure 4.15). 
Measurement of overweight in the included trials was defined as below: 
Luoto et al. (2010): The outcome considered was ‘Overweight, number (%)’. The 
weight status, in calculating BMI, was established by the International Obesity Task 
Force criteria for overweight and obesity, which identifies BMI values for each age 
associated with a predicted BMI of 25 or 30 at the age of 18 years. At 7 years, a child 
was considered overweight if the BMI exceeded the international cut-off value for 
overweight, 17.92 kg/m
2
 for boys, and 17.75 kg/m
2
 for girls.  This outcome was 
reported as point prevalence at 7 years. 
Wickens et al. (2013): The outcome considered was ‘Overweight, number (%)’ and 
was defined with gender and age-specific cut-off values. This outcome was reported 
as point prevalence at 6 years.   
 
The studies were statistically largely homogeneous (χ2=0.70, P=0.4, I2=0%). The 
result of meta-analysis did not show an association between maternal intake of 
probiotics during pregnancy and being overweight in the offspring (RR=0.76, 95% 
CI=0.45-1.27, 485 children). 
 
Figure 4.15. Forest plot of probiotics vs. placebo for overweight 
Measure: Binary: risk ratio 
Heterogeneity: Q = 0.709; df = 1; p = 0.4; I-squared = 0%; tau-squared = 0. 
Random effects model: 0.76 (0.457, 1.27) 
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Outcome: Overweight   Probiotic n/N Placebo n/N 
Luoto  11/54 16/59 
Wickens  17/245 9/127 
Subtotal 299 186 
 
4.5.9.6. Reported outcomes of obesity in the study by Louto 2010 at 10 years 
follow-up 
This study followed up children until 10 years of age, reporting the adjusted mean 
(95% CI) difference of BMI, obesity and overweight as well as overall comparison of 
these adiposity measures across 2-10 years of follow-ups. There were no statistically 
significant differences for obesity measures between the groups either at 10 years or 
overall comparisons. The results are presented in the below table. 
 
Table 4.7. List of the reported obesity outcomes in Louto et al. (2010) study at 10 
years follow-up 
 Probiotic (n=54) Placebo (n=59) P.value  
BMI (kg/m
2
) at 10yrs, Mean (95% CI) 17.96 (17.26–18.67)  17.73 (17.06–18.41)  0.643  
BMI (kg/m
2
), Overall (54/58)  16.74 (1.61)  16.81 (1.62)  0.806  
Overweight, N (%) 13 (24.1)  12 (20.3)  0.449  
Overweight ≥once, N (%) 14 (25.9)  19 (32.2)  0.576  
Obesity, N (%) 3 (5.6)  3 (5.1)  - 
Obesity ≥once, N (%) 5 (9.3)  6 (10.2)  0.939 
  
4.5.10. Discussion of the evidence synthesis of maternal probiotic 
consumption during pregnancy and prevention of obesity in the offspring 
4.5.10.1. Summary of main results 
This systematic review summarised data from four RCTs of prenatal intake of 
probiotics for the prevention of childhood adiposity including a total of 1,610 children 
with follow-up ranging from 6.5 to 10 years (mean 7 years). One study was rated 
unclear for the method of allocation concealment (25%) and performance bias was 
judged as high risk in two studies (50%). Two studies also were assessed as unclear 
(25%) and high risk (25%) respectively for the detection bias domain. In addition, 
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half of the studies (50%) were deemed as high risk for loss to follow-up. The findings 
from this systematic review and meta-analysis do not provide evidence that prenatal 
intake of probiotics protects against developing childhood obesity. These results, 
however, need to be considered with caution due to the risk of bias in included trials, 
the limited number of studies and the small sample size in most studies.  
 
It is worth noting that with the exception of one study conducted by Luoto et al., 
(2010), the others were primarily designed to assess outcomes other than adiposity in 
childhood, and reported growth measures as their secondary outcomes in further 
follow-up assessments. In the study by Luoto and colleagues (2010), women in both 
study arms also received intensive nutritional counseling complying with current 
recommendations for healthy fat and fibre content. Despite this, there was not a 
significant difference between the probiotic and placebo groups for the adiposity 
measures at any of the follow-ups.  
4.5.10.2. Overall completeness and applicability of evidence 
No evidence was found that prenatal intake of probiotic is effective for the prevention 
of adiposity in the offspring. The heterogeneity between the trials limited the findings 
and random effect models were used to pool the results. Heterogeneity between 
studies originated from varied types and dosage of probiotics, sample size, duration of 
intervention, different methods for reporting the outcome measures across studies and 
diverse locations/settings. Three studies used mixed strains of probiotics and the other 
a single probiotic strain. Due to the relatively small number of trials, it was not 
possible to test for differences originating from the type, dosage and duration of 
intervention. Moreover, attrition bias was an issue in two trials and one study used 
imputed analysis. 
4.5.10.3. Quality of evidence 
Overall, the trials were at moderate to high risk of bias, summary of risk of bias 
assessment in probiotic studies (Figure 4.10). A large proportion of studies rated as 
unclear on many risk of bias domains and some having a high risk of bias for 
individual quality domains. High loss to follow-up was a leading concern in two of 
the included trials (50%). Also the number of studies and participants contributed in 
meta-analyses might downgrade the quality of the evidence.  
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4.5.10.4. Strength and weakness of this systematic review for probiotic 
consumption during pregnancy 
The main strengths and weaknesses of the current systematic review are discussed in 
section 4.5.6.4.  
4.5.10.5. Agreement and disagreement with other reviews 
This is the first systematic review and meta-analysis undertaken to examine the 
efficacy of prenatal consumption of probiotics for prevention of the long-term 
adiposity in children.  
4.6.10.6. Author’s conclusion 
Implications for practice 
The results of the current systematic review do not support the hypothesis that 
supplementation of pregnant women with probiotics could prevent obesity in the 
offspring. Given the high heterogeneity between studies and attrition bias, along with 
small number of studies, the efficacy of probiotics intake during pregnancy for 
prevention of childhood adiposity in long-term remains unclear.  
 
Implications for research  
Taking the volume and quality of the available evidence into account, there is 
insufficient evidence as to whether prenatal probiotic intake could prevent the 
development of obesity in children. The efficacy of the intervention on childhood 
obesity needs to be addressed in further, large and high quality RCTs with coherent 
methods. Given that only one of the studies included had been established to 
explicitly examine the effect of prenatal consumption of probiotics on obesity in 
offspring, such RCTs need to be dedicated trials designed specifically to examine this 
question. Combined interventions of maintaining balanced nutrition and probiotic 
supplementation during pregnancy will also provide more validated means for the 
efficacy of probiotics, particularly in obese women who are at high risk of developing 
GDM.  
 
The type of probiotic’ strain as well as their required dosage are key elements for 
consideration in future trials. Such studies should also consider measurement of 
obesity in children using a number of techniques including anthropometric 
measurements as well as adipose distribution such as fat mass, SFT. There is also a 
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need for well-designed epidemiological studies from under-reported populations, 
since the current evidence originates dominantly from the developed regions.   
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4.5.11. Description of included studies of maternal LG index diet during 
pregnancy and prevention of obesity in the offspring  
A total of two included studies examined the impact of LG index diet during 
pregnancy on the development of obesity in offspring (including a total of 338 
children). The characteristics and study population of these trials are shown in Table 
4.8. The studies were conducted in Australia and Ireland.  
 
The study conducted by Horan (Horan et al., 2016) had a large sample size of 800 
women at recruitment and the study by Louie (Louie, Markovic, Ross, Foote, & 
Brand-Miller, 2015) involved 99 pregnant women at randomisation. One trial 
followed up the children up to 3 months of age (Louie et al., 2015) and the study by 
Horan et al. (2016) completed the follow-up by 6 months of age. The studies included 
women with a diagnosis of gestational diabetes mellitus (Louie et al., 2015) and 
women with a history of macrosomic baby (Horan et al., 2016).  
 
There were substantial differences in the reported outcomes of the two studies. The 
study conducted by Louie et al. (2015) reported only the adjusted measures of weight 
and length in children, whereas a variety of anthropometric outcome measures were 
reported by Horan et al. (2016) study. 
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Table 4.8. Characteristics of the included trials and study population of LG index diet and prevention of obesity 
Primary 
article  
Companion 
articles
+
 
Country, 
enrolment 
period 
Trial 
type
*
 
Name of the 
study arms 
No. of 
participants
**
 
No. at 
last  
F-U
***
 
Time 
points 
measured 
Age at last  
F-U 
Sample: high 
risk or low risk 
Outcomes reported 
 
(Louie, et 
al., 2015) 
(Kizirian et al., 
2013; Louie et 
al., 2011; 
Markovic
†
 et al., 
2016)  
 
Australia  
2008-10 
RCT LG index & 
(HF) 
High-fibre 
moderate-GI 
diet 
99 mothers 58: 33 
vs. 25 
 
Birth & 3 
months 
3 months 
 
Diagnosed with 
GDM
#
 
-Weight for age percentile 
(kg) 
-Length for age percentile 
(cm)  
 
 
(Horan et 
al., 2016)  
(Donnelly, 
Walsh, Byrne, 
Molloy, & 
McAuliffe, 
2015; Horan, 
McGowan, 
Gibney, 
Donnelly, & 
McAuliffe, 
2014; 
McGowan, 
Walsh, Byrne, 
Curran, & 
McAuliffe, 
2013; Walsh, 
McGowan, 
Mahony, Foley, 
& McAuliffe, 
2012; Walsh, 
Mahony, Foley, 
& Mc Auliffe, 
2010)  
Ireland  
2007-2011 
RCT LG index & 
usual 
antenatal 
care 
800 mothers 280: 
138 vs. 
142 
Birth & 6 
months 
6 months History of 
macrosomic 
baby 
-Weight (kg) 
-Weight-for-length z-score 
-Weight-for-age z-score 
-Length (cm) 
-Length-for-age z-score 
-BMI z-score 
-Sum of SFT 
-Mid-upper-arm circum.## 
-Triceps skinfold-for-age z-
score 
-Subscapular skinfold-for-age 
z-score  
-Abdominal circum. 
-Chest circum. 
-Hip circum. 
-Thigh circum. 
-Biceps skinfold 
-Thigh skinfold 
-Sum triceps & subscapular 
skinfolds 
-Triceps: subscapular skinfold 
ratio 
-Waist: Hip circum. ratio 
-Hip circum. length ratio 
+Published data & conference presentations, no unique data extracted from conference abstracts  *Randomised Controlled Trial **Indicates the No. at randomisation, where recruitment has occurred prenatally  
***Follow-up               †only birth outcomes reported in 2016 paper                                     #Gestational Diabetes Mellitus   ##Circumference 
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The characteristics of LG index diet interventions and the control groups in the 
included trials are presented in Table 4.9. Comparable baseline characteristics have 
been reported in the included trials. Both included studies applied the intervention 
only throughout pregnancy, from the third (Louie et al., 2015) and second trimester of 
pregnancy (Horan et al., 2016).  
 
In the study conducted by Louie et al. (2015), women attended at least three face-to-
face visits with the study dietician, scheduled to coincide with regular antenatal visits, 
and were advised to have a LG index target of ≤50. The intervention in Horan et al. 
(2016) study involved a dietary education session lasting 2hrs, in groups of 2-6 
women with the research dietician. Women were advised on: a) general healthy eating 
guidelines for pregnancy, following the food pyramid; b) the definition, concept, and 
rationale on GI for use in pregnancy. Women were encouraged to choose as many low 
GI foods as possible and to exchange high GI carbohydrates for low GI alternatives 
and received written resources about low GI foods. The recommended low GI diet 
was caloric balance, meaning women were not advised to reduce their total caloric 
intake but the source of calorie in their diet. The research dietician met with the 
patients at 28 and 34 weeks’ gestation for reinforcement of the low GI diet and to 
answer any dietary queries. 
 
In the trial by Louie et al. (2015) women were supplemented in both study arms, as 
appropriate by the treating endocrinologist, by iron and iodine since the study diet 
could provide all essential nutrients other than the two minerals. Women in the study 
conduced by Horan et al. (2016) did not receive any supplementation. 
 
The Louie et al. (2015) trial assessed dietary compliance during the intervention 
period, every 2–3 weeks with an approval from multiple-pass 24-h recalls, and where 
the subject’s diet deviated from the assigned diet, they were encouraged to choose 
more foods that conformed to their assigned diet. A 3-day food record was also 
completed at the end of the intervention and its results showed a six-unit difference in 
dietary GI index between the two groups (intervention vs. control: 47/53; P < 0.001). 
The Horan et al. (2016) study assessed the adherence to the LG index diet, at the 34 
weeks antenatal visit, using a five point Likert-type scale (1=“I followed the 
recommended diet all of the time”; 5=“I followed the recommended diet none of the 
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time”). In addition, acceptability of the diet was assessed using a 6-item questionnaire 
and 68% of women generally or strongly agreed that the diet was easy to follow. 
Women also completed 3-day food diaries in each trimester of pregnancy to define 
their glycemic index and glycemic load and at the third trimester, a lower glycemic 
index [56 (3.8) vs. 57.7 (3.9)] as well as glycemic load [127.1 (30.4) vs. 139.9 (37.5)] 
was observed in the intervention group compared to the control women.  
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Table 4.9. Characteristics of LG index diet interventions in the included trials for prevention of obesity 
Primary 
article  
Comparable 
baseline 
characteristic  
Participants 
receiving 
intervention 
Timing of  
Intervention in 
pregnancy 
Intake of 
intervention  
From/until
*
 
Duration of 
intervention 
(months)
**
 
Type of food 
intervention 
Control arm 
 
Substitutes 
prescribed (in 
both arms) 
Louie et al., 
2015 
Yes (At 
baseline, 
subjects in the 
LGI group had 
significantly 
higher 2hrs  
post-load blood 
glucose levels
  
Prenatally 
only 
29wks. 29wks. to 
delivery 
2 months & 
3wks 
Healthy diet containing: 
protein (15–25%), fat 
(25–30%), carbohydrate 
(40–45%) & an LGI 
target ≤50 
Diet with high-
fibre content & 
moderate GI 
Iron and iodine  
Supplemented 
as appropriate 
by the treating 
endocrinologist  
 
Horan et al., 
2016 
Yes  Prenatally 
only 
14wks. 14wks. to 
delivery 
6-6.5 LG index diet under 
dietetic supervision  
No dietary 
intervention 
- 
*Mothers have continued food avoidance at different time points e.g. Late start of solids 
**Indicates total duration in pregnancy plus after birth, if applicable 
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4.5.12. Risk of bias in studies of maternal LG index diet during pregnancy 
and prevention of obesity in the offspring 
The summary of risk of bias of trials on LG index diet is presented in Figure 4.16. 
The reviewer’s judgment for the risk of bias assessment of LG index diet studies is 
shown in appendix 4.7. 
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Short 
Title 
Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Horan 
2016 
+ ? - ? - + - 
Louie 
(2013) 
+ ? ? ? - + ? 
 
Random Sequence Generation   
 
100%    
 
Allocation Concealment   
 
  100%   
 
Double Blinding   
 
  50% 50% 
 
Blinding of Outcome 
Assessment     100%   
 
Incomplete Outcome Data   
 
   100% 
 
Selective Outcome Reporting   
 
100%    
 
Other Sources of Bias   
 
  50% 50% 
 
 
Low risk of bias  High risk of bias   Unclear risk of bias  
 
Figure 4.16. Summary of risk of bias assessment in the included trials of LG index diet and prevention of obesity in the offspring 
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4.5.12.1. Random sequence generation (selection bias) 
Both studies were rated as having a low likelihood of selection bias as they 
randomised the participants by using a computer system.  
4.5.12.2. Allocation concealment  
One study failed to report the method of allocation (Louie et al., 2015) and so was 
rated as having an unclear risk for allocation concealment. In the study by Horan et al. 
(2016) the research staff were involved in the randomisation process, using opaque 
sealed envelopes and was rated as having unclear risk of bias.  
4.5.12.3. Double blinding (performance bias) 
The study conducted by Horan et al. (2016) was rated as high risk of bias since it is 
stated that the staff and obstetricians were blind to the intervention although the 
participants were aware of the type of intervention. The study by Louie and 
colleagues (2015) was classified as having an unclear risk of bias, since it did not 
provide any information on blinding of the research staff or the participants.  
4.5.12.4. Blinding of outcome assessment (detection bias) 
The two included studies were rated as unclear risk of bias since they did not give an 
indication whether the measurements were conducted in a blinded fashion.  
4.5.12.5. Incomplete outcome data (attrition bias) 
A high rate of loss to follow-up was observed in the included studies and both failed 
to report the reasons for missing and were therefore rated as high risk. 
4.5.12.6. Selective outcome reporting (reporting bias) 
In both included trials, the pre-specified outcomes of obesity were reported; thus the 
trials were rated as low risk for selective outcome reporting. 
4.5.12.7. Other potential sources of bias 
Other sources of bias in both the included trials were considered and one study was 
assessed as high risk (Horan et al., 2016), as no detailed dietary data was collected at 
6 months postpartum. Therefore, there is no information regarding whether women 
continued the low GI diet or had reverted to pre-pregnancy dietary habits. The study 
by Louie et al. (2015) was rated as unclear risk, since women were encouraged to 
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continue their assigned diet after delivery; however the post-partum diet was not 
formally assessed and women may have reverted to their habitual eating pattern.  
4.5.13. Meta-analyses of effectiveness of maternal LG index diet during 
pregnancy and prevention of obesity in the offspring 
The type and method of measuring the obesity-related outcomes in the two included 
studies for LG index diet were not similar.  Therefore it was not possible to perform 
meta-analysis and the reported outcomes of interest for the current systematic review 
are described narratively in the following sections. 
4.5.13.1. Narrative description of the results in the Louie et al. (2015) study 
The study of Louie et al. (2015) reported adjusted adiposity-related measures in 
offspring by 3 months of age, listed in the table (4.10). The percentiles of the 
outcomes measured (weight for age, length for age and weight for length) were based 
on the Centers for Disease Control and Prevention growth charts and the reported 
outcomes were also adjusted for breast-feeding status (exclusive vs. non-exclusive). 
The outcome reported (weight gain per day) was adjusted for both breast-feeding 
status and gender. The results of this study indicated that LG index diet in pregnant 
women in comparison to a diet high in fibre did not have an influence on the obesity-
related outcomes in children. 
 
Table 4.10. List of the reported obesity outcomes in Louie et al. (2015) study 
 LG index (n=31) 
Mean (95% CI) 
High-Fibre (n=21) 
Mean (95% CI) 
P value 
Weight for age percentile  69.6 (60.5–78.8) 68.0 (56.9–79.1) 0.72 
Length for age percentile  47.9 (38.6–57.2) 48.1 (36.9–59.3)  
 
0.97  
Weight for length percentile  72.4 (61.2–83.6)  64.6 (51.0–78.1)  0.51  
Weight gain per day (g)  32.6 (29.9–35.4) 31.4 (27.5–35.3) 0.52  
 
4.5.13.2. Narrative description of the results in the Horan et al. (2016) study 
Horan et al. (2016) reported a range of adiposity-related measures in offspring by 6 
months of age, listed in the below table. WHO growth standards were used to convert 
the infant measurements to z-scores, which are adjusted for infant age and gender. At 
6 months, there were no differences in any infant anthropometric measures between 
the control (routine care) and intervention (LG index diet) groups (Table 4.11). 
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Table 4.11. List of the reported obesity outcomes in Horan et al. (2016) study 
 LG index (n=138)  
Mean (SD) 
Routine care (n=142)  
Mean (SD) 
P. value 
Weight-for-Length z-score 0.34 ±1.90 0.1241± 1.05  0.24 
Weight (kg)  8.61 ±1.77 8.34 ±1.09 0.12 
Weight-for-age z-score 0.93 ±1.59  0.65 ±1.00 0.07 
Length 70.02 ±3.36 69.62 ±2.90 0.28 
Length-for-age z-score  1.39±1.39 1.17 ±1.09 0.15 
BMI-for-age z-score  0.20 ±1.95 -0.0109 ±1.05 0.26 
Triceps skinfold-for-age  
z-score (Total=217)
*
 
0.08 ±1.11 -0.0175 ±1.16 0.53 
Subscapular skinfold-for-age z-
score (Total=218)
*
 
0.73±1.05 0.41 ±1.24 0.051  
Sum of all skinfolds 
(Total=217)
 *
 
38.61 ±5.47 37.76 ±6.24  0.286  
*Reported for a sub-sample and the numbers in each group are not specified 
 
This study however, showed that maternal GI index in third trimester of pregnancy 
was positively associated with triceps skinfold thickness for age-z-score and biceps 
skinfold thickness at 6 months (p=0.003). 
4.5.14. Discussion of the evidence synthesis of maternal LG index diet 
during pregnancy and prevention of obesity in the offspring 
4.5.14.1 Summary of main results 
This systematic review summarised data from two RCTs that evaluated the efficacy 
of a LG index diet during pregnancy on adiposity outcomes in children. The review 
included a total of 338 children with the follow-up duration from three to six months 
(mean 4.5 months). Allocation concealment was rated as unclear in both studies and 
detection bias was judged as either unclear or high in each of the studies. 
Furthermore, there was a high rate of loss to follow-up in both studies. It was not 
possible to conduct any meta-analyses due to the various outcomes reported in these 
studies and therefore, the findings were described narratively. Neither study provides 
evidence for a protective association between LG index diet during pregnancy and 
subsequent development of childhood adiposity. It is worth mentioning that both 
studies had a high risk of bias, particularly for loss to follow-up domain.  
4.5.14.2. Overall completeness and applicability of evidence 
It is important to note that only two RCTS were included in this systematic review 
and there was a low quality of evidence from individual studies that LG index diet 
during pregnancy is effective for the prevention of adiposity in the offspring. There 
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was a high heterogeneity between the two trials in terms of timing of intervention, 
different controls and varied reported outcomes. It was not possible to conduct any 
meta-analyses due to the varied adiposity outcomes reported in the studies. In both 
studies, an insufficient number of women were followed up. The study by Horan et 
al., (2016) reported that only 35% of women (280 out of 800 recruited) returned for 
the follow-up assessment at 6 months. Louie and colleagues (2015) enrolled a smaller 
sample and 59% of women originally recruited (58 out of 99) were approached for the 
follow-up assessment at three months.  
4.5.14.3. Quality of evidence 
Overall, the trials were at high risk of bias, for the summary of risk of bias assessment 
(Figure 4.16). Both studies were rated as either unclear or high risk of bias for most 
individual quality domains and attrition bias was also a main issue in both studies.  
4.5.14.4. Strength and weakness of this systematic review for LG index diet 
during pregnancy 
The main strengths and weaknesses of the current systematic review are discussed in 
section 4.5.6.4. It is important to add that, due to the small number of LG index diet 
intervention studies that met the inclusion criteria for this systematic review and also 
inconsistencies between the reported outcomes, it was not possible to perform meta-
analysis and data were described narratively.  
4.5.14.5. Agreement and disagreement with other reviews 
This is the first systematic review of RCTs that narratively described the efficacy of 
applying a LG index diet during pregnancy for the prevention of childhood obesity in 
the long-term.  
4.6.14.6. Author’s conclusion 
Implications for practice 
The available evidence does not support the hypothesis that LG index diet in pregnant 
women can protect against developing childhood adiposity. Since only two studies 
fulfilled the inclusion criteria and the observed variability between the reported 
outcomes did not warrant meta-analyses, it remains an open question whether LG 
index diet during pregnancy would prevent developing childhood obesity in the long-
term.  
 234 
Implications for research  
The quantity and quality of the current evidence indicates that the efficacy of LG 
index, as a prenatal dietary strategy, needs to be examined in further large well-
designed RCTs. In addition, more consistent approaches are required for reporting the 
adiposity outcomes using combined methods of anthropometric and fat distribution 
measurements.  
 
The optimal timing of LG index diet intervention is additionally an important element 
that needs to be addressed in future trials, since intervention as early as pre-pregnancy 
could deter either the extra or accelerated weight gain in pregnant women, particularly 
in those who are already obese or at high risk of developing GDM. The choice of 
control is also an important factor in interventional studies of this nature since it is 
generally hard to control in a double blind manner, and could potentially bias 
assessment of outcomes in the study arms. A practical approach could be to introduce 
a representative sample of pregnant women from the general population as the control 
or allocate independent participating centres for recruiting women into the 
intervention and control arms of the study.  
 
Maintaining compliance with the recommended diet during pregnancy is clearly a 
major challenge. Food diaries provide the best subjective estimate of regular intake of 
food items, however participants may inaccurately report or inadvertently change 
their dietary habits while keeping a dietary record. Evidence from studies on LG 
index diet in pregnant women has shown that women had poor adherence to dietary 
change post-partum and reverted to their pre-intervention dietary intake (Fehler, 
Kennedy, & McCargar, 2007; Moses, Luebke, Petocz, & Brand-Miller, 2007; Stage, 
Ronneby, & Damm, 2004). Therefore, measuring of adherence to intervention using 
more rigorous methods such as biochemical parameters is recommended in future 
studies. More importantly, high attrition bias in both studies included in this review 
suggests that their results could have been biased by an unrepresentative sample of 
women originally recruited and thus the real efficacy of the intervention might have 
been underestimated. In both trials, women in the intervention arm had a significant 
lower glycemic index compared to the control group by third trimester of pregnancy, 
denoting the efficacy of intervention and in the mean time, adds weight to the 
importance of reducing loss to follow-up. Therefore, conducting longitudinal studies 
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prior to or as early as possible in pregnancy, with adequate sample size, is required to 
provide strong evidence with which to determine the effect of LG index diet during 
pregnancy on childhood obesity. 
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4.5.15. Description of included studies of maternal life-style change during 
pregnancy and prevention of obesity in the offspring  
Two studies were grouped as lifestyle change, including a total of 375 children. The 
characteristics of the included trials, their companion papers and study population are 
presented in Table 4.12.  
 
The included studies recruited a sample of 360 (Tanvig et al., 2015) and 250 (Rauh, 
Günther, Kunath, Stecher, & Hauner, 2015) of pregnant women at randomisation. The 
duration of follow-up were reported by 2.5-3 years (Tanvig et al., 2015) and 10-12 
months (Rauh, et al., 2015). The studied samples were selected of obese women 
(Tanvig et al., 2015) and unselected women (Rauh, et al., 2015). The study conducted 
by Tanvig et al. (2015) also included an external reference group of lean mothers and 
their offspring for comparisons of offspring from their study arms with this group. 
 
Great differences were observed between the studies for the reported obesity 
outcomes in children. A range of obesity outcomes were reported in the study 
conducted by Tanvig et al. (2015), whereas Rauh and colleagues (2015) only reported 
weight as the outcome in children. 
 
 
 
 
 237 
Table 4.12. Characteristics of the included trials and study population of life-style change interventions and prevention of obesity 
Primary 
article  
Companion 
articles
+
 
Country, 
enrolment 
period 
Trial 
type
*
 
Name of the 
study arms 
No. of 
participants
**
 
No. at 
last  
F-U
***
 
Time 
points 
measured 
Age at last  
F-U 
Sample: high 
risk or low risk 
Outcomes reported 
 
(Tanvig et 
al., 2015)  
(Tanvig, 2014;  
Tanvig et al., 
2014)  
 
Denmark   
2007-10 
RCT Life style Int. 
& control 
(routine care) 
360 mothers 150: 77 
vs. 73 
Birth & 
2.5-3yrs. 
2.5-3yrs. 
 
Obese women  -Weight (Kg) 
-Height (cm) 
-BMI (kg/m
2
) 
-BMI–Z score 
-Obese/Overweight 
-Triceps (mm) 
-Sub-scapular (mm) 
-Body fat 
-Fat mass 
-Lean Body mass 
-Abdominal 
circumference 
-Hip 
-AC/Hip ratio  
-Total fat  
(Rauh, et 
al., 2015) 
Rauh 2013 
Rauh 2014 
Kunath 2014 
(abstract) 
Munich, 
Germany 
2010-11 
RCT Life style & 
control 
250 mothers 220 
(childre
n): 150 
vs. 70 
4 & 12 
months 
10-12 
months 
Unselected  -Weight (kg) 
 
+Published data and conference presentations, no unique data were extracted from conference abstracts          *Randomised Controlled Trial 
**Indicates the No. at randomisation, where recruitment has occurred prenatally        ***Follow-up   
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Table 4.13 shows the details of lifestyle change interventions and control groups 
applied in the included trials. Comparable baseline characteristics have been reported 
in the trial conducted by Tanvig et al. (2015); although in the study conducted by 
Rauh et al. (2015) a higher proportion of overweight and obese women were reported 
in the control group (31% vs. 16%) which resulted in a significantly higher self-
reported weight and BMI before pregnancy in the control group compared to the 
intervention group.  
 
The lifestyle intervention in the Tanvig et al. (2015) trial consisted of dietary 
counseling and physical activity. The dietary history, weight and level of activity of 
women in the intervention group were evaluated and then they received four 
individual dietary counselling sessions by trained dieticians aiming to limit their 
gestational weight gain by 5kg. The physical activity plan encouraged women to be 
physically active for 30-60 minutes daily and also a closed aerobics class was 
arranged with a physiotherapist for an hour a week. Women also participated in group 
sessions 4-6 times during pregnancy along with the physiotherapist, where using the 
inspired coaching methods, the aim was to improve women’s integration of physical 
activity in pregnancy and daily life. In addition, women were provided with a free, 
fulltime membership to a fitness centre with access to all types of aerobic classes and 
weight training. The intervention in the study conducted by Rauh et al. (2015) 
involved two individual counselling sessions by trained researchers at the 20
th
 and 
30
th
 gestational week comprising of three components: healthy diet, advice on 
physical activity and weight monitoring using IOM recommendations for GWG.    
 
The study conducted by Tanvig et al. (2015) assessed compliance with both the 
dietary counselling sessions and physical component by participation rate. Women 
were also asked whether participation in the study resulted in more healthy eating 
habits. A good compliance rate was reported where 92% of women attended all their 
dietary counseling sessions with 98% completing at least three sessions and 85% also 
believed that the study enhanced their dietary habits. Compliance with the physical 
component of the intervention was reported as 10.4 hours for attending the 20 aerobic 
classes and 78% also undertook leisure time sporting activities along with the aerobic 
classes. At the same time, 21% of women in the control group reported having 
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healthier eating habits following participation in the study and, 65% reported some 
type of sporting leisure activities.  
 
The Rauh et al. (2015) trial measured compliance with the nutritional counselling by 
assessing dietary intake during pregnancy using 7-day dietary records, at 16-18 
(baseline), 26-28 and 36-38 weeks of gestation in the intervention group. The dietary 
intake of women in the control group was also measured at baseline and third 
trimester of pregnancy. Level of physical activity was assessed in women of both 
groups by the long version of International Physical Activity Questionnaire (IPAQ) 
(Carig, et al., 2003) at the three time points in pregnancy as above. The study did not 
report how the dietary pattern and level of physical activity differed between the two 
study groups at the end of the intervention. 
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Table 4.13. Characteristics of life-style change interventions in the included trials for prevention of obesity 
Primary 
article  
Comparable 
baseline 
characteristic  
Participants 
receiving 
intervention 
Timing of  
Intervention in 
pregnancy 
Intake of 
intervention  
From/until
*
 
Duration of 
intervention 
(months)
**
 
Type of nutrition 
intervention 
Control arm 
 
Substitutes 
prescribed (in 
both arms) 
Tanvig et al., 
2015 
Yes  Prenatally 
only 
10-14wks 10-14wks to 
delivery 
6-7.5 Dietary counseling+ 
Physical activity  
Routine 
obstetric care 
- 
 
Rauh et al., 
2015 
No, Higher 
weight and 
BMI, before 
pregnancy was 
reported in the 
control group  
Prenatally 
only 
At 20
th
 & 30
th
 
gestational wks. 
Individual 
counseling at 
20
th
 & 30
th 
wks. 
2.5-5 Individual nutrition 
counseling+ physical 
activity+ weight 
monitoring 
Routine prenatal 
care 
- 
*Indicates total duration in pregnancy plus after birth, if applicable
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4.5.16. Risk of bias in studies of maternal life-style change during 
pregnancy and prevention of obesity in the offspring  
The summary of risk of bias of trials on life-style change is presented in Figure 4.17. 
The reviewer’s judgment for the risk of bias assessment of life-style change studies is 
shown in appendix 4.8. 
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Short 
Title 
Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Rauh 
2015 
+ + - - - + ? 
Tanvig 
(2015) 
+ ? - + - + ? 
 
Random Sequence Generation   
 
100%    
 
Allocation Concealment   
 
50% 50%   
 
Double Blinding   
 
   100% 
 
Blinding of Outcome 
Assessment   
 
50%   50% 
 
Incomplete Outcome Data   
 
   100% 
 
Selective Outcome Reporting   
 
100%    
 
Other Sources of Bias   
 
  100%   
 
 
 
Low risk of bias  High risk of bias   Unclear risk of bias  
 
Figure 4.17. Summary of risk of bias assessment in the included trials of life-style change and prevention of obesity in the offspring 
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4.5.16.1. Random sequence generation (selection bias) 
Both studies used a computer-generated randomisation table and were, therefore, 
rated as low risk of bias. It is worth adding that randomisation in Rauh et al. (2015) 
trial was conducted at cluster level rather than individuals i.e. gynaecological 
practices.  
4.5.16.2. Allocation concealment  
In the study by Rauh et al. (2015), a researcher that was not involved in the study 
design performed the randomisation and the study was rated as having a low risk of 
bias for allocation concealment. The study by Tanvig et al. (2015) was rated as having 
an unclear risk of bias since the study involved a doctor and research midwife in 
enrolment and women themselves picked up their randomisation number from a 
basket, with no detail how the numbers were presented.  
4.5.16.3. Double blinding (performance bias) 
In both of the included studies, neither the study staff nor the participants were 
blinded to the study intervention and studies were rated as high risk of bias. 
4.5.16.4. Blinding of outcome assessment (detection bias) 
The Rauh et al. (2015) trial was open label due to the nature of the intervention and 
was rated as high risk. In the study by Tanvig et al. (2015), the outcome assessor was 
blinded to the RCT intervention and was rated as low for detection bias. 
4.5.16.5. Incomplete outcome data (attrition bias) 
Both studies were rated as having a high risk of attrition bias. In the Rauh et al. (2015) 
study, due to the higher participation rate, there was an unequal group size between 
the intervention and control groups at recruitment with the number of participants 
doubled in the intervention arm (83 vs. 167). A higher attrition bias was observed for 
the control group at the follow-up assessment where 78% and 88% (65 vs. 148) of 
women were approached in the standard care and intervention groups respectively. 
The trial by Tanvig et al. (2015) approached less than 50% of women in the follow-up 
assessment and reason(s) for attrition are not stated. 
4.5.16.6. Selective outcome reporting (reporting bias) 
The pre-specified outcomes are reported in both studies and thus rated as low risk of 
bias. 
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4.5.16.7. Other potential sources of bias 
Any other sources of bias were assessed in the included studies and both were rated as 
high risk of bias since there was no information whether women in the intervention 
arm adhered to their healthy dietary advice or physical activity component after 
delivery.  
4.5.17. Meta-analyses of effectiveness of maternal life-style change during 
pregnancy and prevention of obesity in the offspring 
Only one outcome, defined as “weight” was reported in common in the two included 
studies. A meta-analysis for the outcome measure as “weight” yielded a great level of 
heterogeneity between the included studies (χ2=6.55, p=0.01, I2=84.7%) (Forest plot 
is not shown). Therefore, the results from these studies are reported narratively in the 
following sections. 
4.5.17.1. Narrative description of the results of the Tanvig et al. (2015) study  
The study of Tanvig et al. (2015) reported a range of adiposity-related outcomes in 
offspring by 2.8 years, listed in the table below (4.14). Weight and height (to the 
nearest 0.1) were measured using a digital weight and portable stadiometer 
respectively. A Harpenden skinfold calliper was used to measure triceps and 
subscapular skinfold thickness to the nearest 0.1 mm. BMI-Z was reported based on 
age and sex-specific Danish standards. Overweight and obesity were classified as one 
outcome due to the small number of children and were identified using the IOTF 
criteria. The results showed that lifestyle intervention, including dietary advice, 
coaching and exercise during pregnancy compared to routine obstetric care did not 
have an influence on the obesity-related measures in offspring.   
 
Table 4.14. List of the reported obesity outcomes in Tanvig et al. (2015) study 
 Lifestyle change 
(n=82) Mean (SD)  
Routine obstetric care  
(n=75) Mean (SD)  
P. value 
Weight (kg) 14.7±1.64 14.4±1.63  >0.05 
Height   (cm)  94.6±3.42 94.6±3.52 >0.05 
BMI 16.4±1.3  16.1±1.2 >0.05 
BMI-Z 0.06±1.05 -0.18±1.70 >0.05 
Overweight/obese ((No.) 9 (10.9%) 5 (6.7%) >0.05 
Triceps skinfold thickness 8.3±1.68 8.3±1.96 >0.05 
Subscapular skinfold thickness  6.1±1.58 6±1.09 >0.05 
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4.5.17.2. Narrative description of the results of the Rauh et al. (2015) study  
The study conducted by Rauh et al. (2015) only reported weight in the offspring, as 
the outcome of interest for the current systematic review, measured at different time 
points up to 10-12 months of age. Women were asked for the weight development of 
their children as assessed by the paediatricians at the routine check-ups. The results of 
the unadjusted analysis showed a significant association between the weight of 
children, between 10-12 months, as infants born to mothers in the intervention group 
weighed less than control group infants (9.382±0.93 vs. 9.736±0.99, p=0.01). 
However the effect disappeared in an adjusted analysis for practice (random factor), 
maternal age, pre-pregnancy BMI, infant age at follow-up and birth weight (p=0.099). 
Also, adjusting the model for an added variable as “breastfeeding duration” did not 
show a statistical significant difference between the two groups (p=0.14). 
4.5.18. Discussion of the evidence synthesis of maternal life-style change 
during pregnancy and prevention of obesity in the offspring 
4.5.18.1. Summary of main results 
This systematic review summarised data from two RCTs that evaluated the efficacy 
of a life-style change during pregnancy on adiposity outcomes in children. The review 
included a total number of 375 children with follow-up duration ranging from 10-12 
months to 2.5-3 years (mean 20-24 months). Method of allocation concealment was 
rated as low (50%) and unclear (50%) in the included studies. In both studies, staff 
and participants were aware of the allocation assignment and additionally, detection 
bias was judged as high in one study. High rate of loss to follow-up was reported in 
the included studies. Substantial statistical heterogeneity was observed in the meta-
analysis conducted for “weight” as the only outcome reported in common in both 
studies. It was not possible to conduct any other meta-analyses due to inconsistency 
between the reported outcomes and, therefore, the findings were described 
narratively. Findings from each individual study do not provide evidence that life-
style change during pregnancy, consisting of dietary counselling and physical activity 
components, could be beneficial in subsequent development of childhood adiposity.  
4.5.18.2. Overall completeness and applicability of evidence 
It is important to note that only two RCTS were included in this systematic review 
and there was a low quality of evidence from individual studies that life-style change 
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during pregnancy could be beneficial for prevention of adiposity in the offspring. 
There was a high heterogeneity between the two trials in terms of the study sample 
(obese vs. unselected), timing and duration of intervention, duration of follow-up, 
using varied methods for measurement of obesity outcomes and diverse reported 
outcomes as well as measurement of compliance with the intervention. The only 
conducted meta-analysis showed a high statistical heterogeneity between studies and 
it was not possible to conduct any other meta-analyses because of the diverse 
adiposity outcomes reported in studies. High loss to follow-up was also a concern in 
the studies. In the study conducted by Tanvig and colleagues (2015), less than 50% of 
women were included in the follow up assessment. The study by Rauh et al. (2015) 
approached 88% of women in the intervention group but 78% in the control. Since the 
number of participants in the control group was half of the intervention group at 
recruitment, the lower rate of follow-up in the control arm was a major problem. A 
higher proportion of women in the control group of this study, with a significant 
difference (31% vs. 16%), also tended to be obese at recruitment. 
4.5.18.3. Quality of evidence 
Overall, the trials were at high risk of bias, as shown in Figure 4.17 for the summary 
of risk of bias assessment. Both studies were mainly rated as high risk of bias for most 
individual quality domains.  
4.5.18.4. Strength and weakness of this systematic review for life-style change 
during pregnancy 
The main strengths and weaknesses of the current systematic review are discussed in 
section 4.5.6.4. However, specifically in relation to the life-style change as an 
intervention, it is important to add high statistical heterogeneity was observed in the 
one meta-analysis conducted and because of the inconsistencies between the reported 
outcomes in studies, it was not possible to perform any more meta-analysis and data 
were described narratively.  
4.5.18.5. Agreement and disagreement with other reviews 
This is the first systematic review of RCTs to asses the efficacy of life-style change 
intervention during pregnancy, using a narrative approach, for the prevention of 
childhood obesity in the long-term.  
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4.6.18.6. Author’s conclusion 
Implications for practice 
Current data does not provide evidence that life-style change, as an intervention 
during pregnancy, can protect against developing childhood adiposity; however the 
evidence is not conclusive. There were a small number of studies included and the 
observed variability between reported outcomes did not allow for conducting detailed 
meta-analyses, so it remains uncertain whether life-style change in pregnancy would 
be a beneficial preventive approach against developing childhood obesity in the long-
term.  
Implications for research  
The quantity and quality of the current evidence signifies that the efficacy of life-style 
change needs to be assessed in further large well-designed RCTs. In addition, more 
consistent approaches are required for reporting the adiposity outcomes using 
combined methods of anthropometric and fat distribution measurements.  
 
The ideal timing of life-style change interventions is also an important area that needs 
to be precisely addressed in future studies. A recent study has flagged inappropriate 
timing of the life-style interventions during pregnancy i.e. late onset as the main 
concern that these trials have failed to control maternal, and more specifically foetal 
overgrowth (Catalano & DeMouzon, 2015). Catalano & deMouzon (2015) reasoned 
that since the metabolic conditioning programmes the placental function and gene 
expression in the first trimester of pregnancy, the interventions need to commence 
prior to conception to normalise metabolic conditioning in women and thus, to 
decrease the related complications in infants. Furthermore, blinding of staff and 
participants in studies of this nature is difficult and the fact that the participants were 
aware of their group allocation in the included studies in this review might have partly 
minimised the participation rate, particularly among the women in control group. 
Tanvig and colleagues (2015) also included an external reference group of lean 
mothers in their study, which could be a practical strategy in future trials.  
 
Maintaining compliance with the recommended dietary advice as well as physical 
activity during pregnancy is a key issue and highlights the importance of maintaining 
women’s motivation throughout the intervention. More importantly, high attrition bias 
in the included studies suggests that their results could have been biased by an 
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unrepresentative sample of women and thus the real efficacy of life-style intervention 
might have been underscored.  Significant research by conducting longitudinal studies 
with early onset, prior to pregnancy, and adequate sample size is required to provide 
strong evidence with which to determine the effect of life-style change during 
pregnancy on obesity in children. It is worth adding that reasons for non-participation 
in life-style change interventional studies have been investigated. Findings from one 
study in Norway showed that this group are usually content with their personal 
nutrition and fitness plan, they are younger, with a higher educational status and also 
smoke (Sagedal, 2014). In contrast, the results of another study in Denmark indicated 
that non-participants were at an educational level comparable to the participants, and 
tended to be younger, had lower parity, were more frequently non-smokers and either 
married or cohabiting with their partner (Gesche, Renault, Nørgaard, & Nilas, 2014). 
In both of these studies, participants and non-participant women had comparable 
BMI. These findings highlight the importance of cultural differences when designing 
community-based studies aiming to make behavioural modifications at the population 
level.  
4.6. Round-up conclusion 
The role of environmental factors in developing many chronic diseases is well-
documented and early life nutritional interventions provide a window of opportunity 
for longer-term health in the offspring. The current body of evidence underscores the 
importance of dietary and life-style interventions during pregnancy for the prevention 
of childhood obesity. These findings, however, are not conclusive due to the small 
number of studies included in most intervention groups and also, great heterogeneity 
observed between the included studies. Well-designed high-quality studies, with early 
onset prior to pregnancy or the first trimester of pregnancy, need to address the 
hypothesised effect of nutritional interventions during pregnancy for prevention of 
adiposity in children. It is advised that nutritional trials should establish defined rules 
and objectives in their design such as measurement of basal nutrient status and the 
change following the intake of intervention to allow valid testing of the hypothesised 
association(s) (Heaney, 2014). 
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4.7. Description of included studies of maternal vitamin/micronutrient 
consumption during pregnancy and boosting growth standards in the 
offspring 
Following the search strategy for this systematic review, a sub-group of studies were 
identified that supplemented pregnant women with vitamins/micronutrients. Further 
investigation of these studies revealed that these trials were all conducted in 
developing countries and were initially intended to enhance foetal birth weight rather 
than prevention of obesity-adiposity. Further follow-up assessments in these studies 
have also investigated the efficacy of the prenatal intervention on boosting childhood 
growth standards i.e. patterns of linear growth and body size. It was decided to only 
present the descriptive findings for this dietary group in the following sub-section, as 
the goal of these trials was originally different from the defined aim in these 
systematic reviews i.e. boosting growth standards rather than prevention of obesity, 
and risk of bias assessment and meta-analyses were not conducted.  
 
Four studies were grouped as vitamins/micronutrient, including 3,040 children. The 
characteristics of the included trials, their companion papers and study population are 
presented in Table 4.15. Two studies were conducted in Nepal, one in Bangladesh and 
one in Gambia. Two studies were community-based involving cluster randomisation 
of villages including women of childbearing age (Hawkesworth, Prentice, Fulford, & 
Moore, 2008; Stewart, Christian, LeClerq, West, & Khatry, 2009).  
 
The longest follow-up period was 11-17 years, in the study conducted by Hawksworth 
et al. (2008), and followed by 6-8 years in the study by Stewart et al. (2009). The 
shortest follow-up period was reported in the Roth et al. (2013) study. The largest 
study sample was reported in Stewart et al. (2009) with 4,998 mothers enrolled 
followed by Hawksworth et al. (2008) with 1,460 pregnant mothers at enrolment. The 
smallest sample size was observed in the study conducted by Roth et al. (2013) with 
160 mothers randomised at recruitment. 
 
Compliance with the treatment was assessed using a variety of methods as 
discrepancy estimate method (providing participants with a varying quantity), 
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monitoring and recording by research team staff and number of doses received 
divided by number of doses scheduled times 100.  
 
The outcome measures in the studies by Hawksworth et al. (2008) and Roth et al. 
(2013) were presented by child gender only. All studies reported detailed 
anthropometric measures in children to assess as to whether the maternal intervention 
improved the body composition in children later in life. 
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Table 4.15. Characteristics of the included trials and study population of vitamins/micronutrients for improving growth measures in 
children 
Primary 
article  
Companion 
articles
+
 
Country, 
enrolment 
period 
Trial 
type
*
 
Name and 
No. of study 
arms 
No. of 
participants
**
 
No. at last  
F-U
***
 
Time points 
measured 
Age at 
last  
F-U 
Sample Outcomes reported 
 
(Vaidya et al., 
2008)  
(Osrin et al., 
2005) 
Nepal  
2002-03 
RCT Multiple 
micronutrient 
supplement vs. 
routine iron & 
folic acid 
supplements 
1,200 
mothers 
917: 462 
vs. 455 
Birth & 
2.5yrs 
2.5yrs. Unselected  -Head Circumference 
(cm)   
-Weight (Kg)   
-Height  (cm)   
-Chest circumference 
(cm)   
-BMI (kg/me2) 
-Hip circumference 
(cm) 
-Waist circumference 
-Mid-upper-arm-
circumference 
(Hawkesworth
, et al., 2008)  
 
(Ceesay et 
al., 1997)  
Gambia   
1989-1994 
CRT Protein-
supplement 
energy & 
control  
 
1,460 
women 
leading to 
2047 
singleton 
live births 
1,317: 630 
vs. 687 
children 
measured 
Birth & 11-
17yrs. 
11-17 
yrs. 
 
Undernouris
hed women 
 
-Height, cm  
-Weight, kg  
-BMI, kg/m 
-Body fat 
-Trunk fat  
-Fat Mass Index 
(kg/m4 ) 
-Fat Free Mass Index 
(kg/m3)  
(Stewart, et 
al., 2009)  
(Christian et 
al., 2003)  
Nepal  
1998-2001 
CRT 4 Int. arms as: 
Folic acid or 
Folic acid + 
iron or Folic 
acid 
+iron+zinc or 
Multiple 
4,998 
mothers 
658 vs. 
674 vs. 
708 vs. 
749 
vs. 735 
Birth & 6-
8yrs. 
6-8yrs. Community 
trial (from 
30 villages) 
-Weight (Kg) 
  -Height (cm)   
-Arm circumference 
(cm)   
-Waist circumference 
(cm)   
-BMI (kg/m
2
) 
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Micronutrients 
& Control 
  -Subscapular [mm]   
-Sum 4 SFT [mm] 
-Triceps skinfold 
thickness 
-Subscapular skinfold 
thickness 
-Arm fat area 
-Arm muscle area 
-Height-for-age-z-score 
-Weight-for-age-z-
score 
-BMI-for-age-z-score 
(Roth, 
Perumal, Al 
Mahmud, & 
Baqui, 2013) 
 
(Roth, et al., 
2013)  
Bangladesh  
2010-11 
PC-
RCT 
Vitamin D & 
Placebo 
160 mothers 148: 72 vs. 
76 
Birth, 1, 2, 
4, 6, 9 &12 
months 
1yr Unselected  -Weight (Kg) 
-Length (cm) 
-Head circum. 
-Femur length 
-Length-for-age-z-
score 
-Weight-for-age-z-
score 
-Weight-for-length-z-
score 
-Head circumference-
for-age-z-score 
+Published data and conference presentations, no unique data were extracted from conference abstracts        
*Placebo-controlled Randomised Controlled Trial or Randomised Controlled Trial or Cluster Randomised Trial  
**Indicates the number at randomisation, where recruitment has occurred prenatally  
***Follow-up   
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Table 4.16 shows the details of vitamin/micronutrient interventions and control 
applied in the included studies. Comparable characteristics have been reported in two 
trials. In the study by Stewart et al. (2009), small differences were observed in ethnic 
composition and land holding and women in the control group also weighed slightly 
less. The study by Roth et al (2013) reported mothers in the Vitamin D group had a 
higher level of education, although this difference was not statistically significant.  
 
All studies applied the intervention during pregnancy only (Table 4.16). The longest 
duration of intervention was reported in the studies conducted by Vaidya et al. (2008 
and Stewart et al. (2009) for 5-7 and 6.5-7 months respectively and the shortest 
follow-up period was 2.5-3 months (Roth et al., 2013). One study supplemented 
women with multiple micronutrients (Vaidya et al., 2008), whereas the study by 
Stewart et al. (2009) defined four different intervention arms including multiple 
micronutrients. The study by Hawksworth et al. (2008) used protein-supplement 
energy biscuits as the intervention and in the study by Roth et al. (2013) women in the 
intervention group were supplemented with vitamin D. 
 
The nature of control varied between studies. The control group was defined as the 
routine care, as iron and folic acid, in the study by Vaidya et al. (2008), Vitamin A 
alone in Stewart et al. (2009) study, miglyol oil in the study by Roth et al. (2013) and 
no treatment in Hawksworth et al. (2008) study. Women in the control group in 
Hawksworth et al. (2008) received the protein-energy supplement for 20 weeks after 
delivery. Vitamin/supplement preparations included capsules and oil drops. 
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Table 4.16. Characteristics of vitamin/micronutrient interventions in the included trials for improving growth measures 
Primary article  Comparable 
baseline 
characteristic  
Participants 
receiving 
intervention 
Timing of 
intervention 
in pregnancy 
Intake of 
intervention  
From/until
*
 
Duration of 
intervention 
(months)
**
 
Vitamin &/or 
Micronutrient 
product 
Placebo/ 
Control 
 
Mode of 
delivery 
Total daily 
dose 
Vaidya et al., 
2008 
Yes Prenatally 
only 
Between 12- 
20 completed 
wks. 
<20 wks. to 
delivery 
5-7 Vitamins A, E, D, 
B1, B2, niacin, 
B6, B12, folic 
acid, C + iron, 
zinc, copper, 
selenium, iodine 
Current 
nationally 
advised 
tablets (iron 
60 mg & 
folic acid 
400 μg) 
Tablet  Recommended 
daily allowance 
of 15 vitamins 
& minerals 
 
Hawkesworth et 
al.,  
2008 
Yes  
(Cluster 
randomization) 
Prenatally 
only 
20wks 20 wks. to 
delivery 
4.5-5 Biscuits 
containing roasted 
ground-nuts, rice 
flour, sugar, and 
groundnut oil 
No 
treatment, 
supplement 
provided for 
20wks after 
delivery 
N/A Two biscuits: of 
4,250 kJ energy, 
22g protein, 56g 
fat, 47mg 
calcium & 
1.8mg iron 
Stewart et al., 
2009 
Yes 
Except for small 
differences in 
ethnic 
composition & 
land holding + 
women in the 
control group 
weighed slightly 
less 
Prenatally 
only 
11.2-11.6  11wks. to 
delivery 
6.5-7 Folic acid or folic 
acid + iron or 
folic acid + iron + 
zinc or multiple 
micronutrients 
containing folic 
acid, iron, zinc, 
11 vitamins & 
minerals
***
 
Vitamin A 
alone (1000 
μg) 
Caplet  Folic acid 
400μg, iron 
60mg, zinc 
30mg, 10mg 
Vit. D, 10mg 
Vit. E, 1.6mg 
thiamine, 1.8mg 
riboflavin, 
20mg niacin, 
2.2mg Vit. B6, 
2.6μg Vit. B-12, 
100mg Vit. C, 
65 μg Vit. K, 
2.0 mg Cu, 
100mg Mg 
Roth et al.,  
2013 
Yes 
Mothers in 
Prenatally 
only 
From 26 & 
<30 wks. 
Between 26-
<30 wks. to 
2.5-3 Vitamin D3 
(cholecalciferol) a 
Miglyol oil 
812 
Oil (the 
vehicle 
35,000 IU/wk 
 255 
Vitamin D 
group had 
higher education 
level 
 
delivery high-
concentration 
(20,000 IU D3 per 
mL) liquid 
formulation 
used in 
Vigantol 
Oil) 
 
*Indicates total duration in mother, infant or both, whichever is applicable         **Indicates total duration in pregnancy plus after birth, if applicable  
***All supplements were given with 1000 μg retinol equivalent
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Chapter 5: Assessing quality of maternal diet during 
pregnancy and infant feeding behaviours and their 
associations with infant birth weight Z-score and weight/age 
at 6 months of age  
5.1. Overview of the chapter  
This chapter describes a cohort study examining the quality of the diet in women 
during pregnancy as well as infant feeding behaviour and their associations with 
infants’ birth weight Z-scores and weight/age at 2-3 and 6 months of age. Women 
completed a validated Food Frequency Questionnaire in the last trimester of 
pregnancy (FFQ-P) and data on infant feeding behaviour was collected using a Milk 
Diary (MD) between 2-3 months of infant age. Data on infant weight were collected 
at 2-3 and 6 months follow-ups. The questionnaires used will be described and their 
choice justified. The results are presented and discussed in relation to the role of the 
quality of maternal diet and infant feeding behaviours and any implications the 
findings may have.  
5.2. Objectives 
a. To determine dietary quality of pregnant women during pregnancy and its 
association with birth weight Z-score  
b. To determine the duration, number of feeds and volume of breast-feeding in 
infants and their associations with the weight/age of the infant at 2-3 and 6 
months 
c. To determine the timing of introduction of formula feeding, the volume 
consumed and number of feeds and their associations with the weight/age of 
the infant at 2-3 and 6 months 
d. To determine weight/age differences of breast-fed, formula-fed and partially 
breast-fed infants at 2-3 and 6 months 
e. To determine predictors of weight/age at 2-3 and 6 months age (infant feeding 
behaviour, maternal diet during pregnancy, age of introduction of solids). 
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5.3. Rationale for the choice of questionnaires 
Questionnaires were selected if they had been validated in the target group and they 
were relevant for the study age group. In addition, the time needed to complete the 
questionnaires was considered. The following section provides detailed description of 
these questionnaires and the rationale for their choice. 
5.3.1. Measuring maternal dietary intake  
Measuring dietary intake, synonymous with dietary diversity or dietary variety, is 
defined by a simple count of foods or food groups consumed over a given reference 
period (Ruel, 2003). The assumption is that dietary variety and dietary quality are 
closely linked (Ruel, 2003); therefore measuring dietary variety offers an alternative 
for the nutritional quality and balance of food groups in the diet.  
 
A number of methods have been developed for assessment of dietary intakes such as 
24-hour dietary recall, food diary and Food Frequency Questionnaires (FFQs). It 
should be stressed that all methods have some limitations since eating is a complex 
behaviour influenced by a number of factors. When choosing a dietary assessment 
tool it is important to match the tool to the research question. For example food 
records, as a gold standard, provide detailed information on nutritional intake; 
however when data on usual intake or dietary patterns is required a FFQ could 
provide more accurate information over a period of time.  
 
In this PhD study, a FFQ was used since the objective of the study was to measure 
overall dietary intake of women during pregnancy as opposed to quantifying 
nutritional intake. FFQs could be administered to provide data on overall habitual 
diet over time, minimising the degree of dietary recall required. There are a number 
of FFQs specifically designed to measure defined outcomes in pregnant women, 
adults and children. Cohort studies commonly use variations of the FFQ to assess 
dietary intake in populations (Siri-tarino, Sun, Hu, & Krauss, 2010). A systematic 
review on the validity and reliability of self-reported measures of foods and nutrients 
in pregnancy showed that FFQs had adequate validity in comparison to biomarkers, 
24-hour recall and food records (Vézina-Im & Robitaille, 2014). The results of this 
review show that FFQs are validated and reliable measures for assessing dietary 
patterns in pregnant women. The questionnaire administered in this PhD project 
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(appendix 5.1) was an amended version of the Southampton Women’s Survey FFQ 
in pregnancy (Robinson, Godfrey, Osmond, Cox, & Barker, 1996). The main reason 
for selecting this particular questionnaire was because it was developed using the 
food lists from the UK. It has been validated in a group of pregnant women against a 
four-day weighed food diary in a geographical population similar to this study 
population. The original questionnaire was semi-quantitative (asking respondents to 
report food portion sizes in addition to frequency intake) and for this study, the 
portion sizes were removed since nutritional intake was not being assessed. 
Therefore, the questionnaire only asked for the frequency of intake and consisted of a 
list of 100 foods and drinks, divided into subcategories. The food list was also 
adapted, by input from a dietician, to reassure acceptable accuracy of dietary 
assessment. This was done by removing some unpopular/uncommon items e.g. 
haggis and adding some more common foods and drinks e.g. pizza/quiches/cheese 
flans, green tea. The subcategories of food and drinks were: starch and carbohydrate 
(13 foods), vegetables (17 items), fruits (11 items), drinks (10 items), meat and 
substitute (15 foods), fish (four items), egg and dairy (nine items), sweet and 
miscellaneous foods (17 items) and fat consumed separately as spreading, frying and 
other oil (three open questions to specify the type). Also, there was an additional free 
text food category to add any other foods that were eaten at least 1-2 times per week. 
The frequency of consumption over the last three months of each food and drink 
were recorded using a multiple response grid. The frequency options were: never, 
once/2-3 per months, once/month, once/fortnight, 1-2 times/week, 3-6 times/week, 
once/day and more than once a day. The intake options for the consumption of milk 
were: <75ml, 75-149ml, 150-300ml and >400ml. The respondents were also asked 
about the type of milk that was predominantly drunk. Women were asked to indicate 
the frequency of each item by ticking the appropriate box.  
5.3.2. Measuring infant feeding behaviours 
The type and amount of feed the infant receives is the primary driver of early infant 
growth. There are no gold standards for choosing a dietary assessment method in 
infants and all methods have some inherent flaws.   
 
The questionnaire chosen for the second study of this PhD project was developed by 
Grimshaw (Grimshaw, 2012) as a valid and reliable instrument for collecting the 
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required weekly feeding practices of an infant. An adapted version of the 
questionnaire (4-days a week as opposed to 7-days) was developed for this study 
(appendix 5.2). This was mainly for convenience of the mothers as it has been shown 
that a 4-day timeframe is as informative as a longer 7-day diary (Livingstone & 
Robson, 2000). Mothers were asked to record the infant diet at four time points 
(morning 5am-12pm, afternoon 12-4pm, evening 4-10pm, night 10pm-5am) for each 
of the four days. Women were asked to record the volume and number of formula 
feeds and if breast-fed, the duration and times of breast-feeding at each time point. 
Questions were also included about age of introduction of formula, any drinks and 
solids. Parents were additionally asked to report infant weight as recorded in their red 
book, the infant personal child health record. 
5.4. Methods 
5.4.1. Study design and setting 
This was a cohort study of pregnant women and their children followed-up until 6 
months of age and was conducted as part of the Portsmouth Birth Cohort (PBC) 
registry. The settings for recruitment of pregnant women and follow-ups of their 
children were the antenatal NHS clinic in Queen Alexandra (QA) hospital, 
Portsmouth and within the community, respectively. 
5.4.2. Study sample and recruitment 
The target population for the PBC database registry were pregnant women attending 
antenatal NHS clinics in QA hospital, Portsmouth, at any stage in pregnancy. For this 
second study, a convenient sample of pregnant women that were due to give birth 
between February-August 2016 and their newborns were included. The study 
flowchart is presented in Figure 5.1. The inclusion criteria were defined as: being over 
16 years of age, resident in Portsmouth city area only, being able to understand, write 
and speak English. Exclusion criteria was pregnancies that were terminated due to late 
abortion or stillbirth and an extra exclusion criterion for this PhD project was defined 
for infants with a suspicion of congenital abnormality or diagnosed with congenital 
abnormality/chronic condition since these are likely to influence normal development 
(including feeding behaviour). 
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Women were approached by the study midwives at QA hospital at the time of their 
routine visit to the antenatal NHS clinic and were provided with the study information 
sheet and consent form (appendices 5.3 and 5.4). Women were either consented on 
the same day or were able to return the consent form via post at a later time. Enrolled 
women consented to be contacted for further studies.  
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Figure 5.1. The study design 
 
5.4.3. Ethical considerations 
Ethical approval for the PBC registry was granted from Berkshire NHS Research 
Ethics Committee on 23
rd
 January 2015 (appendix 5.5). The registry included two 
waves, known as wave 0 and wave 1, which collected data during pregnancy and birth 
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respectively using the recruitment and birth questionnaires (appendices 5.6 and 5.7). 
In order to ask participants to complete the additional questionnaires for this study 
(FFQ-P at second and third trimesters of pregnancy and MD at 1 and 4 months age) a 
substantial amendment form was submitted to the Berkshire NHS ethics committee. 
Further ethical approval for the revised birth cohort registry questionnaires was 
obtained on 12
th
 May 2015 (appendix 5.8). The NHS R&D approval from the QA 
hospital, as the setting for conducting the PBC birth cohort, was obtained on 11
th
 
December 2015, following the initial communications with the QA hospital in 
February 2015 (appendix 5.9). Following both the NHS R&D and ethical approval, 
recruitment of pregnant women began in December 2015. 
 
Two further amendments were requested from the NHS ethics committee and were 
granted on 28
th
 January 2016 and 9
th
 May 2016 (appendices 5.10 and 5.11). Firstly, it 
was requested that the FFQ-P be completed only at the third trimester of pregnancy, 
since the two initial planned time points were quite close and also, data on the second 
trimester could not really reflect the real dietary pattern of pregnant women due to 
morning sickness. Secondly, a change was made to the length of the MDs 
questionnaire and the time they were collected, amended to when the infants were 2-3 
months of age. This change was because a few mothers that were contacted when 
their baby was 1-month old did not respond and one withdrew from the study. It was 
hypothesised that the questionnaire was too long and that women found it difficult to 
participate in the study during this hectic transition in their life. An additional ethical 
approval was also requested for the 6-months follow-up questionnaire and obtained 
on 8
th
 July 2016 (appendix 12). 
 
Data for the PBC registry was created using Microsoft Access software version 10
9
 
and was password protected. Data was anonymised and when not in use, secured in 
locked filing cabinets. Online questionnaires were administered via Bristol Online 
Surveys (BOS) (http://www.survey.bris.ac.uk), for which there is encryption, 
ensuring the data cannot be intercepted by third parties. Women were free to 
withdraw from the study at any time.  
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5.4.4. Administration of questionnaires 
At the time of enrolment into the PBC database registry, midwives completed the 
wave 0 questionnaire (appendix 5.6) that included several sections collecting 
information such as demographic data, history of mental and physical health 
problems. Maternal and paternal occupations were captured using an open question 
and grouped based on the coding of the Office for National Statistics’ (ONS) Standard 
Occupational Classification (SOC) hierarchy. The SOC hierarchy has 9 major 
occupational groups and replies that could not be coded using the SOC coding system 
were grouped separately as “not classified”. Other codes defined were: unemployed, 
student, housewife and missing replies. The wave 1 questionnaire collected data on 
pregnancy and birth outcomes (appendix 5.7), which was filled in by the midwives 
consulting the medical records at QA hospital.  
 
The questionnaires for this PhD project, namely the FFQ-P and MD were both self-
administered and women were provided with contact details of the research team to 
clarify any queries. Women received the FFQ-P in their third trimester of pregnancy 
and based on their preference, it was completed either online or as a postal 
questionnaire. Online reminders were sent to non-respondents within 5-7 days of the 
date of first email. If no replies within a week, they received a phone call to ask if 
they were willing to take part and whether they wished to receive the questionnaire 
online or by post.  Women who received the FFQ-P via post were given three weeks 
to return the completed questionnaire. The non-respondents received a reminder 
phone call and if necessary, a second questionnaire was posted. The questionnaires 
were posted out along with prepaid addressed return envelopes.   
 
MDs and a prepaid envelope were posted to mothers when their babies were two 
months of age, and if they had not responded within three weeks they received a 
phone reminder.  
5.4.5. Questionnaire coding 
Where possible, questionnaires were coded and scored according to published 
standards. To ensure consistency in coding of questionnaires, a coding logbook was 
maintained. The data from a questionnaire were used if it was at least 75% complete. 
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5.4.5.1. Food Frequency Questionnaire in Pregnancy (FFQ-P) 
The food items in the administered FFQ-P were adjusted with the Alternative Healthy 
Eating Index (AHEI) (Rifas-Shiman, Rich-Edwards, Kleinman, Oken, & Gillman, 
2009). The AHEI measures diet quality on a 90-point scale with nine components, 
each contributing 10 possible points: vegetable, fruits, ratio of white to red meat, 
fibre, trans fat, ratio of PUFA to saturated fatty acids; folate, calcium and iron from 
foods. The AHEI components were adjusted to our FFQ-P since our questionnaire 
only measured the frequency of food items and not portion size; therefore it was not 
possible to calculate the nutrient intake and also ratio for the components from foods. 
In total, given that the FFQ-P administered in this study is a quantitative measure, 
including 99 food items and also taking into account the UK guidelines for a healthy 
diet in pregnancy, we defined seven AHEI components from the FFQ-P as follows: 
vegetable and fruit, iron-rich foods, fibre, dairy, fish, fat and Vitamin D. As per the 
UK guidelines, recommended healthy eating during pregnancy is: at least five 
portions a day of fruit and vegetables, three servings a day of iron-rich foods, daily 
consumption of fibre from sources rich in fibre such as vegetable/fruit and starchy 
foods, four servings a day of dairy products, two portions of fish a week including one 
oily fish, low consumption of fatty foods and fats particularly from saturated sources 
and daily intake of 10μgram of Vitamin D. Consumption of each food item was 
calculated per week since the recommended criteria for intake of different food 
groups varies such as daily intake of fruit and vegetables versus weekly intake of fish. 
To reflect consumption per week, a numeric value was assigned to each frequency 
category, ranging from 0 to 14 (never=0, once every 2-3 months=0.1, once a 
month=0.25, once a fortnight=0.5, 1-2 times per week=1.5, 3-6 times per week=4.5, 
once a day=7 and more than once a day=14). The frequencies of each contributing 
food item in the components were added to calculate the weekly frequency intake of 
food components (vegetable/fruit, iron-rich foods, fibre, dairy). The iron-rich food 
component included red meat items defined as pork, lamb, beef and minced meat 
dishes as well as beans/pulses and spinach. Other meats (gammon/bacon, ham, 
sausages and meat pies) were defined as processed meat and were not considered in 
this component.  
 
Missing replies to food items were replaced in the following way: if there were ≥25% 
of missing data, the missing replies were not calculated. For missing replies <25%, 
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scores of the food items included in each component were summed and divided by the 
total replies and the mean frequency was replaced for the missing reply. One 
participant did not reply to any vegetable items and for this woman we calculated the 
number of intakes of fruits only per week. The number of intakes of fruit that she had 
per week (55.5) equals 7.9 per day. This was higher than the number of portions of 
fruit/vegetables to score the maximum score of 10 for the healthy eating index. So she 
was included in the analysis with the maximum score of 10. One participant also did 
not reply to two out of five questions for the fibre component, which was greater than 
25% and therefore, the missing scores were not calculated for this woman.  
 
The total score of each component was from 0 to 10 where a score of 10 indicates that 
the participant meets the UK guidelines for healthy eating. The intermediate scores 
were calculated proportionately based on the recommended daily serving of food 
items as per the UK guideline, converted for weekly consumption. For example, for a 
participant with ≥35 frequency consumption of vegetable/fruit per week (five portions 
a day), a total score of 10 was assigned. Similarly, vegetable/fruit frequency 
consumption of 0, 7 and <14; 14 and <21; 21 and <28; and 28 and <35 per week were 
assigned a score of 0, 2, 4, 6 and 8, respectively. For scoring the fibre component, we 
looked at the distribution of raw scores in our sample since there is no specific 
guideline for daily consumption of fibre. The frequency consumption of fibre per 
week in our sample were 0 to <7, 7 to <14, 14 to <21, 21 to <28, 28 to < 35 and 35 
(five servings a day) which were assigned a total score of 0, 2, 4, 6, 8 and 10 
respectively. A logbook was kept to assure the consistency of scoring for all 
components.  
 
Calculation of total scoring for fish, fat and Vitamin D components were conducted 
differently since this involved extrapolating the scores from the responses given to 
open questions. These are described below:  
 Fish component: intake of fish was considered as the main source of omega-3 
fatty acids. The intake of white and oily fish, one intake each per week as per 
the UK guideline, was considered for scoring. At the same time, if women had 
specified that they took pregna-care and/or pregna-max that includes omega-3, 
they were also given a score of 10. The general agreement for the scoring was 
as follows: 2 intakes of oily fish got a score of 10. Taking only an omega-3 
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vitamin source got a score of 10. One intake of oily fish and one intake of 
white fish got a score of 10. One intake of oily fish only got a score of 5 and 
one or more intake of white fish with no portion of oily fish got a score of 5. 
Less than one intake of fish got a score of 0. Participants consuming omega-3 
as well as oily fish once or more per week were also assigned a score of 10.  
 Fat component: participants were asked to specify the type and frequency of 
spreading, frying fat/oil and other oil separately. There were a lot of missing 
replies to the “other oil” question and the specified replies were mayonnaise 
and different salad dressings; therefore replies to this question were not 
included in the calculation. The replies to “spreading and frying fat” greatly 
varied and included two missing replies to one or both questions. Using an 
Internet search, we identified the percentage of saturated fat for each brand. 
The agreement for scoring was as follows: for each spreading and frying 
fat/oils, saturated fat of greater than 50% got a score of 0, between 25-50% got 
a score of 5 and less than 25% got a score of 10. Combined replies of lower 
and higher saturated fat sources such as butter or margarine got a score of 5. 
For general replies for some brands such as fry light oil, they got an average 
score of 5 because there are 3 different varieties of the brand. Women that 
replied “never used” the spreading/frying oil were given a score of 10. 
Missing replies to either or both fat questions were considered as a score of 0 
assuming that those had unhealthy habits. We did not consider frequency of 
the fats consumed per week for scoring because we did not have information 
for portion size. Therefore, the scoring was only conducted for the type of fat 
and total score was calculated by adding the scores for spreading and frying 
oil together and divided by two.  
 Vitamin D: this component was considered for the intake of Vitamin D and 
participants were asked whether they took any nutritional supplements 
including vitamins and if yes, to specify the type. The replies were diverse and 
there were 19 missing replies. The agreements for scoring were as follows: 
participants who specified taking multivitamins/Vitamin D were given a score 
of 10. Participants with either a missing reply or those who did not specify the 
type were scored 0. It was also assumed that women consumed the specified 
multivitamin(s) daily. Three women replied “yes”, they took supplements but 
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did not specify the type and got a score of 0. We were not able to calculate 
intermediate scores for this component and the total scoring was either 0 or 
10.  
The scores of all components were added together to obtain the total diet quality score 
that ranged from 0 (lowest) to 70 (highest), indicating women with higher scores had 
a better quality diet and met the recommendations partially to fully. There was one 
missing score relating to one participant with two missing replies for the fibre 
component. This was replaced by the mean of her other six calculated components. 
The food items included in each food component and number of missing replies are 
presented in Table 5.1.  
 
Table 5.1.  Food items included in each food component 
Food group Food items included Missing replies  
Vegetable/fruit Questions (Qs) 14 to 41 (28 items) 5 
Rich-iron foods Qs 18, 20, 53, 58-60 (6 items) 0 
Fibre Qs 2-5 & 12 (5 items) 2 
Dairy Qs 73-78 (6 items) 0 
Fish Qs 67-69 (3 items) 0 
Fat Qs 97 & 99 (3 items) 2 
Vitamin D Q 5.4 (1 item) 19 
 
The “unhealthy eating behaviours” were also considered from the other items 
included in the FFQ-P. These were defined as sugar consumption (including 15 items 
of cola, soft and energy drinks, drinking chocolate and sweets), processed food 
(including 4 items of sausages, ham, bacon/gammon and meat pies) and junk foods 
(including 4 items of take away/fast food, ready meals, crisps/savoury snacks and 
roast potatoes/chips). The frequency of consumption of these items were calculated 
per week using the same method described for AHEI-P components; however we did 
not calculate a total score from 0 to 10 for these components and they were treated as 
continuous variables. Therefore, higher frequency intake of unhealthy items equates 
to a higher score.  
5.4.5.2. Milk Diary (MD)  
The raw data for the milk diary was coded and the mean values were calculated 
allowing the resultant variables to be analysed in a number of different ways. Method 
of feeding was categorised as exclusive breast-feeding, formula feeding and partially 
breast-fed (for any infant that has ever been introduced to formula). Mean duration 
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and number of breast-feeds were calculated. The volume of breast milk intake per day 
for each infant was calculated for the infant’s age according to the standard values for 
the daily mean intake (Haisma et al., 2003; Paul, Black, Evan, Cole, & Whitehead, 
1988). The quoted average breast milk intake by age is as follow: 
 
0-2 months: 2-5oz per feeding, 26oz per day (736gram) 
2-4 months: 4-6oz per feeding, 30oz per day (850gram) 
4-6 months: 5-7oz per feeding, 31oz per day (878gram) 
 
The volume of formula milk consumed was converted to millilitres and mean values 
for the volume and number of formula feeds per day were calculated. For partially 
breast-fed infants, the standard daily volume of breast milk for age was subtracted 
from the formula taken. If the baby had consumed water, this was not included in the 
total mean calculated for either formula or breast milk intake.  
 
Infant weight was recorded at 2-3 and 6 months follow-ups using the information 
from the baby’s red book. Data on introduction of solids into an infant diet and the 
age of introduction were collected at the 6-months follow-up questionnaire.  
5.4.6. Data analysis  
The Statistical Package for Social Sciences (SPSS) software (IBM, version 23) was 
used to analyse the data. Data sets were checked for outliers. Weight measurements at 
birth and the two follow-up time points were converted into weight/age using the 
LMS Growth software (Cole, 1990). Descriptive statistics were used to describe the 
data and all continuous variables were tested for normality using histograms. The 
mean and SD were presented for normally distributed data and otherwise, median and 
range reported. Categorical variables were expressed as frequency and percentage. 
Spearman bivariate correlations were used to assess the relations between the food 
components, since some were not normally distributed. The χ2 test was used for 
categorical variables. One-way ANOVA analysis was performed to measure the effect 
of one categorical variable such as attention to diet and infant feeding behaviour with 
the continuous outcome(s). To assess the effect of multiple factors on the main 
outcome measures, multiple regression analyses were conducted. The significance 
level for all analyses was defined at the 0.05 level.  
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Multiple demographic and behavioural factors during pregnancy such as smoking, 
maternal age, and education could contribute towards the quality of maternal diet and 
thus, the risk of developing childhood obesity. Investigating the detailed associations 
of these factors on infant weight was not within the remit of the current study. There 
were also a few smokers (5%) among mothers who responded to the milk diary 
questionnaire and additionally, no correlations were found between maternal age and 
education with AHEI-P score and unhealthy dietary habits. Therefore, the regression 
models were not adjusted for these factors. 
5.5. Results 
Pregnant women with the expected date of delivery between mid February to 30
th
 
August 2016 were approached to take part in this project. A total of 134 pregnant 
women were consented to take part in this project. Women who were recruited at very 
late stages of pregnancy (32-39 gestation weeks) were not invited to complete the 
FFQ-P and therefore, a total of 103 women were asked to complete the FFQ-P. Four 
women were not sent the MDs due to delays in obtaining NHS Health Research 
Authority (HRA) approval and also, one baby was born prematurely and was still in 
hospital at 2 months of age. Hence, a total of 129 pregnant women were invited to 
respond to the MD. 
 
 
 
Figure 5.2. Replies to study questionnaires  
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5.5.1. Description of study sample 
Detailed demographic characteristics of the whole sample and those who responded to 
each questionnaire are shown in Table 5.2. Where there were missing replies to any of 
the reported outcomes, these are specified. Continuous data (maternal age and number 
of children) were checked for normality and where not normally distributed, median 
reported.  
 
Maternal age was normally distributed, whereas data for number of children was 
skewed to the left, indicating that most participants had smaller families. Of the 
sample invited, 61.2% participants were married and 31.3% women and 22.4% of 
their husbands/partners reported having professional jobs. Also, 53% of women were 
educated with university degrees while 39.6% of the fathers had university degrees. 
82.1% were white British and 58.2% reported having no religion.  
 
There were statistically significant differences between responders and non-
responders as more of the responders had higher professional roles and educational 
level, were married and also owned a property.  
 
Table 5.2.  Demographic characteristics of the respondents 
 Whole 
sample 
(N=134) 
FFQ-P 
(N=94) 
Milk Diary 
(N=79) 
6-month  
F-U 
(N=80) 
Age (years)  
[Mean (SD)] 
30.30 (4.98) 31.09 (4.25) 31.37 (4.22) 31.22 
(4.48) 
Mother’s job (%) 
Managers, directors & senior officials 
Professional occupations 
Associate professional & technical 
occupations 
 
Administrative & secretarial occupations 
 
Skilled trade occupations 
Caring, leisure & other service 
occupations 
Sales & customer service occupations 
 
Process, plant & machine operatives 
 
Elementary occupations 
Unemployed 
Student 
Housewife 
Decision not made 
 
9 (6.7) 
42 (31.3) 
12 (9.0) 
 
 
14 (10.4) 
 
---- 
10 (7.5) 
 
6 (4.5) 
 
---- 
 
6 (4.5) 
10 (7.5) 
4 (3.0) 
12 (9.0) 
9 (6.7) 
 
5 (5.3) 
37 (39.4) 
9 (9.6) 
 
 
12 (12.8) 
 
---- 
5 (5.3) 
 
4 (4.3) 
 
---- 
 
4 (4.3) 
3 (3.2) 
1 (1.1) 
7 (7.4) 
7 (7.4) 
 
5 (6.3) 
34 (43.0) 
5 (6.3) 
 
 
10 (12.7) 
 
---- 
5 (6.3) 
 
3 (3.8) 
 
---- 
 
3 (3.8) 
3 (3.8) 
1 (1.3) 
6 (7.6) 
4 (5.1) 
 
7 (8.7) 
34 (42.5) 
7 (8.7) 
 
 
8 (10.0) 
 
--- 
4 (5.0) 
 
3 (3.7) 
 
---- 
 
2 (2.5) 
3 (3.8) 
1 (1.3) 
6 (7.5) 
5 (6.3) 
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 Whole 
sample 
(N=134) 
FFQ-P 
(N=94) 
Milk Diary 
(N=79) 
6-month  
F-U 
(N=80) 
Father’s job (%) 
Managers, directors & senior officials 
 
Professional occupations 
Associate professional & technical 
occupations 
Administrative & secretarial occupations 
 
Skilled trades occupations 
Caring, leisure & other service 
occupations 
Sales & customer service occupations 
 
Process, plant & machine operatives 
 
Elementary occupations 
Unemployed 
Student 
Not classified 
Missing  
 
12 (9.0) 
 
30 (22.4) 
19 (14.2) 
 
6 (4.5) 
 
20 (14.9) 
3 (2.2) 
 
4 (3.0) 
 
6 (4.5) 
 
7 (5.2) 
5 (3.7) 
2 (1.5) 
13 (9.7) 
7 (5.2) 
 
9 (9.6) 
 
27 (28.7) 
18 (19.1) 
 
6 (6.4) 
 
14 (14.9) 
2 (2.1) 
 
2 (2.1) 
 
2 (2.1) 
 
2 (2.1) 
3 (3.2) 
1 (1.1) 
7 (7.4) 
1 (1.1) 
 
6 (7.6) 
 
23 (29.1) 
16 (20.3) 
 
4 (5.1) 
 
14 (17.7) 
2 (2.5) 
 
---- 
 
3 (3.8) 
 
3 (3.8) 
2 (2.5) 
---- 
6 (7.6) 
---- 
 
9 (11.3) 
 
23 (28.6) 
14 (17.5) 
 
5 (6.3) 
 
14 (17.5) 
1 (1.3) 
 
1 (1.3) 
 
3 (3.7) 
 
2 (2.5) 
--- 
--- 
7 (8.7) 
1 (1.3) 
Mother’s Education (%) 
School 
Further (After GCSEs) 
Higher (University) 
Don’t know 
Missing  
 
9 (6.7) 
52 (38.8) 
71 (53.0) 
---- 
2 (1.5) 
 
3 (3.2) 
30 (31.9) 
59 (62.8) 
---- 
2 (2.1) 
 
2 (2.5) 
23 (29.1) 
53 (67.1) 
1 (1.3) 
---- 
 
2 (2.4) 
24 (30.0) 
53 (66.3) 
1 (1.3) 
---- 
Father’s education (%) 
School  
Further (After GCSEs) 
Higher (University) 
Don’t know 
Missing  
 
20 (14.9) 
54 (40.3) 
53 (39.6) 
2 (1.5) 
5 (3.7) 
 
12 (12.8) 
31 (33.0) 
48 (51.1) 
1 (1.1) 
2 (2.1) 
 
10 (12.7) 
31 (39.2) 
37 (46.8) 
1 (1.3) 
--- 
 
6 (7.5) 
32 (40.0) 
40 (50.0) 
2 (2.5) 
--- 
Marital status (%) 
Domestic partnership  
Married 
Single 
 
42 (31.3) 
82 (61.2) 
10 (7.5) 
 
28 (29.8) 
62 (66.0) 
4 (4.3) 
 
20 (25.3) 
57 (72.2) 
2 (2.5) 
 
26 (32.4) 
53 (66.3) 
1 (1.3) 
No. of children (%) 
[Median (range)] 
 
1.0 (0-4) 
 
1.0 (0-3) 
 
1.0 (0-3) 
 
1.0 (0-3) 
Type of property (%) 
Own home 
Parents home 
Housing association 
Private rent 
Other  
 
77 (57.5) 
5 (3.7) 
10 (7.5) 
32 (23.9) 
10 (7.7) 
 
61 (64.9) 
3 (3.2) 
6 (6.4) 
18 (19.1) 
6 (6.4) 
 
55 (69.6) 
2 (2.5) 
2 (2.5) 
14 (17.7) 
6 (7.6) 
 
55 (68.7) 
1 (1.3) 
3 (3.8) 
14 (17.5) 
7 (8.7) 
Ethnicity (%) 
White  
(English/Welsh/Scottish/Northern Irish) 
White (Irish/any other) 
Other ethnic groups 
Missing  
 
110 (82.1) 
 
15 (11.1) 
8 (6.10) 
1 (0.7) 
 
79 (84.0) 
 
12 (12.7) 
2 (2.2) 
1 (1.1) 
 
63 (79.7) 
 
13 (16.4) 
2 (2.6) 
1 (1.3) 
 
63 (78.6) 
 
14 (17.6) 
2 (2.5) 
1 (1.3) 
Religion (%) 
Christian  
No religion 
Hindu 
Muslim 
Other 
Not stated 
 
40 (29.8) 
78 (58.2) 
2 (1.5) 
1 (0.7) 
1 (0.7) 
12 (9.0) 
 
29 (30.9) 
53 (56.4) 
1 (1.1) 
--- 
1 (1.1) 
10 (10.5) 
 
24 (30.4) 
45 (57.0) 
1 (1.3) 
--- 
1 (1.3) 
8 (10.1) 
 
26 (32.5) 
43 (53.6) 
1 (1.3) 
--- 
1 (1.3) 
9 (11.3) 
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Details of pregnancy and birth outcomes are presented in Table 5.3. One mother 
withdrew before giving birth and therefore, data on pregnancy and birth outcomes 
were not available. There were two sets of twins and hence, data for pregnancy and 
birth outcomes were available for 133 mothers and 135 babies, respectively. Where 
there were missing replies to any of the reported outcomes, these are specified. 
Measurement of birth weight (kg) was within the normal range and mean and SD are 
reported. The majority of babies were born at term and were normally delivered. They 
were all live births and mean birth weight was 3.32kg.  
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Table 5.3. Pregnancy and birth related outcomes 
Pregnancy-related outcomes All sample N=133
*
 (%) 
Gestational age at birth (weeks) (n=127) 
Term & post-term babies 
Late preterm (34-37 weeks) 
Extreme premature (<28 weeks)  
Missing  
 
112 (83.6) 
14 (10.4) 
1 (0.7) 
7 (5.2) 
Single birth  131 (98.5) 
Type of delivery 
Normal 
Caesarean 
Instrumental  
 
75 (56.4) 
45 (33.8) 
13 (9.8) 
Perinatal trauma or episiotomy (n=130) 
1
st
 degree 
2
nd
 degree 
3
rd
 degree 
Episiotomy 
None  
Missing  
 
15 (11.3) 
34 (25.6) 
1 (0.8) 
15 (11.3) 
65 (48.9) 
3 (2.3) 
No. of days mother spent at QA hospital (N=91) 
[Mean (range)] 
 
2.15 (1-9) 
Birth-related outcomes  N=135
**
 
Birth weight [kg)  
[Mean (SD)]  
Range 
 
3.32 (0.60) 
(0.650-4.52) 
Birth weight Z-score (SD units) (n=134)  -0.087 (0.95) 
Birth weight Z-score (SD units), term babies (n=112) 0.038 (0.88) 
Gender (n=134) 
Male 
Female 
Missing  
 
68 (50.4) 
66 (48.9) 
1 (0.7)
***
 
Method of feeding on 1
st
 day of birth  
Breast  
Bottle 
Both  
Missing  
 
101 (74.8) 
27 (20.0) 
6 (4.4) 
1 (0.7) 
Apgar score  
1 minute [mean (range)] (n=135) 
5 minutes [mean (range)] (n=134) 
 
8.62 (2-10) 
9.17 (5-10) 
Admitted to Neonatal Intense Care Unit 
Yes  
No  
Missing  
 
13 (9.6) 
119 (88.2) 
3 (2.2) 
*One mother withdrew before giving birth                                                            **Includes 2 sets of twins                                                                   
***One baby was born in Birmingham and the staff did not have access to hospital system 
 
5.5.2. FFQ-P data and the Healthy Eating Index score  
Of the 103 pregnant women that were asked to complete the FFQ-P, 94 responded 
(91.26%). Fifty-five (58.5%) of the respondents reported that they excluded foods 
from their diet and of these, over 90% specified the reason was based on the 
guidelines and recommendations during pregnancy. Other reasons were: being 
allergic (two), vegetarian (two) and coeliac disease (one). The main food groups 
excluded were raw/rare meat, soft cheese, eggs, shellfish and liver/pate. In response to 
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the question ‘How much attention do you pay to your diet in terms of healthy 
eating?’, 7 (7.6%) and 70 (76.1%) replied very little and somewhat, respectively. 
Only 15 women (16.3%) specified “a great deal” and two women did not respond. 
Also 62.1% of participants reported that they have taken any medications during 
pregnancy. Table 5.4 describes the list of medications taken during pregnancy. 
Missing replies are not reported in the table. Other medications were mainly reported 
as antiemetic and digestive tablets and nutritional supplements mostly multivitamins 
and iron/folic acid tablets. 
 
Table 5.4. Medications taken during pregnancy 
 Medications during pregnancy N (%)  
Antibiotics (n=67) 
Yes  
No  
 
21 (31.3) 
46 (68.7) 
Paracetamol (n=68) 
Yes  
No 
 
47 (69.1) 
21 (30.9) 
Aspirin (n=60) 
Yes 
No 
 
3 (5.0) 
57 (95.0) 
Other medications (n=63) 
Yes 
No  
 
25 (39.7) 
38 (60.3) 
Nutritional supplements (n=75) 
Yes 
No 
 
58 (77.3) 
17 (22.7) 
 
Criteria for scoring the AHEI-P is described in section 5.4.5.1. where the minimum 
and maximum possible scores were 0-70 and a higher score indicates a higher level of 
healthy eating. Mean of the total AHEI-P score was 33.60. The frequency intake of 
food components and their total is shown in Table 5.5. Missing replies to food items 
were as follows: vegetable/fruit (5), fibre (2) and sugar (6) items.  
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Table 5.5.  Mean frequency intakes in last trimester of pregnancy and AHEI-P 
scores of 94 pregnant women who responded 
Food component Frequency 
intake
a
 
Criterion for 
min. score of 
0
b
 
Criterion for 
max. score of 
10 
Score 
Mean (SD) Mean (SD) Range 
Vegetable/Fruit 48.42 (20.49) <7 ≥35 8.87 (2.04) 2-10 
Iron rich 10.17 (5.33) 0 3 3.26 (2.80) 0-10 
Dairy 14.44 (6.50) 0 ≥28 3.90 (2.52) 0-10 
Fibre 9.80 (7.53)
d
 0 ≥35 1.99 (2.04) 0-10 
Fat
c
 --- 0 10 7.36 (2.89) 0-10 
Fish (omega-3)
c
 --- 0 10 3.29 (3.91) 0-10 
Vitamin D
c
 --- 0 10 4.89 (5.02) 0-10 
Total AHEI-P 
score 
   33.60 (8.93) 14-57 
aFrequencies were normally distributed and mean (SD) reported 
bIntermediate frequency intakes were proportionately scored between 0 and10 
cNot possible to calculate the frequency and only scoring  
dThe distribution of fibre component was partially normal and the median (range)=9.24 (0-35) 
 
Unhealthy eating habits were treated as continuous variables and scores represent 
number of times unhealthy foods consumed per week. The median frequency intake 
of unhealthy eating habits is presented in Table 5.6.  
 
Table 5.6. Median frequency intakes of unhealthy eating habits in last trimester 
of pregnancy in participating pregnant women 
Unhealthy eating components Frequency intake
a
  
Median  Range 
Sugar (n=93) 16.15  1.05-70.44 
Processed meat (n=94) 2.5  0.0-9.50 
Junk food (n=94) 6.42  0.25-27.45 
aFrequencies were not normally distributed and median (range) reported 
 
5.5.3. Infant feeding practice 
Of 129 women that received the MD questionnaire, 79 completed the questionnaire 
(61.2%). One child was extremely premature, born at 24-25 gestation weeks and the 
MD was not posted. Weight of babies at 2-3months of age was within the normal 
range, whereas age of the introduction of formula was not normally distributed. Mean 
weight of babies at 2-3months was 5.51kg. Details of introduction of drinks and solids 
into the diet of babies and their feeding characteristics are presented in Table 5.7. 
There were missing replies to weight of babies and a few other questions. Mean age 
of babies at the time of completion the MD questionnaire was 2.7months. Where the 
distributions of continuous data were within normal range, mean and SD is reported 
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and otherwise, median and range reported. Infant formulas consumed more 
commonly were Aptamil, C&G and SMA and the specialised formulas, used by three 
infants, were Nutramigen and SMA staydown. Water was the only drink reported to 
have been introduced by 11 participating women (introduced at <1 month one baby, 
1-2 months five babies, 2-3 months four babies and >3 months one baby). Seven 
mothers reported that they added items into their baby’s bottle and these were listed 
as Gaviscon (six babies) and Gripe water (one baby). Only two women stated that 
they had introduced solids into the diet of their babies and specified these as baby 
rice, pureed vegetable and bean sauce for the two babies. Expressed breast milk was 
introduced by nine mothers [with median (range) 300.00 (90.00-738.74ml)].  
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Table 5.7. Baby weight measurements at 2-3 and 6 months follow-ups and 
feeding characteristics of babies at 2-3 months 
 MD responses 
Baby weight at 2months (n=75)
*
 
Mean kg (SD) 
 
5.51 (0.96) 
Weight/age at 2 months (SD units), whole sample (n=73)
**
  
-0.17 (1.11) 
Weight/age at 2 months (SD units), term babies (n=64)  
-0.02 (1.01) 
Baby weight at 6months (n=73)
***
 
Mean kg (SD) 
 
7.63 (1.35) 
Weight/age at 6 months, whole sample (n=71)
****
 (SD units)  
0.102 (1.67) 
Weight/age at 6 months (SD units), term babies (n=66)  
0.19 (1.67) 
Introduction of formula (%) 
Yes 
No 
 
45 (57.0) 
34 (43.0) 
Age at 1
st
 introduction of formula (days) (n=44)  
Median (range) 
 
3 (1-91) 
Type of formula  
Regular  
Specialised  
 
42 (93.3) 
3 (6.7) 
Introduction of drinks (n=79) 
Yes 
No 
 
11 (13.9) 
68 (86.1) 
Adding anything to baby bottle (n=78) 
Yes 
No 
 
7 (9.0) 
71 (91.0) 
Introduction of solids (n=78) 
Yes 
No  
 
2 (2.6) 
76 (97.4) 
Current feeding practice of infant 
Exclusive breast-feeding 
Exclusive formula-feed 
Partially breast-feed 
 
35 (44.3) 
32 (40.5) 
12 (15.2) 
Median volume of formula (ml/day) 
Median (range) 
 
781.36 (0.50-1086.79) 
Median number of formula feed (day) 
Median (range) 
 
5.25 (0.25-9) 
Median duration of breast-feeding (minute) per day  
Median (range) 
 
116.25 (45-324) 
Median number of breast-feeding per day  
Median (range) 
 
8.75 (4.00-15.25) 
Median volume of breast milk intake (ml) (based on infant’s 
age) Median (range) 
 
850 (345.26-875.00) 
Median volume of milk intake (ml) (breast/formula/both)  
Median (range) 
 
850 (564.46-1086.79) 
*Data for 4 babies were missing                                          **Relevant data for calculation of weight/age were not available for 2 infants                                     
***Collected at 2nd follow-up                                ****Relevant data for calculation of weight/age were not available for 9 infants 
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5.5.4. Main outcome measures 
5.5.4.1. Correlation between FFQ-P food components and their predictive effect 
on infant birth weight Z-score 
The correlation between AHEI-P food components is shown in Table 5.8. The 
vegetable/fruit component was found to be significantly correlated with the iron-rich, 
fibre and dairy components. Iron-rich foods, dairy and fibre components were also 
positively correlated to each other, whereas all were weakly inversely correlated with 
the fat component. The fish component was not correlated to any of the other food 
components and Vitamin D intake had a negative weak correlation with all the food 
components, except for the vegetable/fruit and fibre components.  
 
Sugar intake and unhealthy junk food consumption were significantly correlated, and 
processed meat was also significantly correlated with sugar. All the unhealthy eating 
habits were negatively correlated with the total AHEI-P score and a significant 
correlation was found for the junk food component. Correlation of unhealthy eating 
habits and total AHEI-P score is shown in Table 5.9. 
 
Using the one-way ANOVA analysis, the association between unhealthy eating habits 
as well as AHEI-P score and question of “how much attention do you pay to your diet 
in term of healthy eating?” was also investigated. The replies to this question were: 
“very little”, “somewhat” and “a great deal”. Women who responded that attention to 
their diet was “a great deal” scored lower for the sugar consumption compared to the 
“very little” response only (p=0.04). There were no significant differences between 
the responses to this question with “processed meat” and “junk food” unhealthy 
eating habits. In addition, mean score of AHEI-P for women that responded “a great 
deal” were significantly higher than the replies specified as “very little” (p=0.04) and 
“somewhat” (p=0.005).  
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Table 5.8. Correlation of AHEI-P food components to each other 
 Vegetable/fruit Iron-rich foods Dairy Fibre Fat Fish  Vitamin D 
Vegetable/fruit 1 .33** .21* .32** .05 .15 .002 
 .001 .03 .001 .62 .14 .98 
Iron-rich foods .33** 1 .34** .37** -.20* .01 -.01 
.001  .001 .000 .04 .87 .86 
Dairy .21* .34** 1 .15 -.01 .04 -.04 
.03 .001  .13 .86 .67 .69 
Fibre .32** .37** .15 1 -.25* .09 .09 
.001 .000 .13  .01 .37 .37 
Fat  .05 -.20* -.01 -.25* 1 .001 -.05 
.62 .04 .86 .01  0.98 .62 
Fish .15 .01 .04 .09 .001 1 -.06 
 .14 .87 .67 .37 .98  .52 
Vitamin D .002 -.01 -.04 .09 -.05 -.06 1 
.98 .86 .69 .37 .62 .52  
^1st and 2nd rows in each cell represent Spearman Rank Order correlation coefficient and p value   *Correlation is significant at the 0.05 level (2-tailed) 
**Correlation is significant at the 0.01 level (2-tailed) 
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Table 5.9. Correlation of unhealthy eating habits and total AHEI-P scores 
 Sugar Processed meat Junk food Total AHEI-P score  
Sugar 1 .20* .37** -.07 
 .04 .000 .45 
Processed meat .20* 1 .04 -.009 
.04  .69 .93 
Junk food .37** .04 1 -.21* 
.000 .69  .03 
Total AHEI-P score -.07 -.009 -.21* 1 
.45 .93 .03  
*Correlation is significant at the 0.05 level (2-tailed)   **Correlation is significant at the 0.01 level (2-tailed) 
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Multiple linear regression analyses, using a standard regression process, were undertaken to investigate 
whether maternal dietary habits during pregnancy predict the infant birth weight Z-score. The model was 
checked for the required assumptions and no violation for normality, linearity, multicollinearity and 
homoscedasticity were found. In the final model, 6% of the variance in infant birth weight Z-score could 
be explained (R=0.06, SE=0.85).  
 
The results indicated that maternal sugar consumption contributed the most to infant birth weight Z-score 
(β=-0.01, p=0.007). Table 5.10 shows the details of the associations. These results did not change when 
the analysis was restricted to term babies (n=82).  
 
Table 5.10. Linear regression model for the association between AHEI-P and birth weight Z-score 
 β (SE) 95% CI P value 
The model (n=91)  Lower bound Upper bound  
AHEI-P score 0.01 (0.01) -0.007 0.03 0.18 
Sugar consumption -0.01 (0.007) -0.03 -0.005 0.007 
Processed meat 0.03 (0.04) -0.04 0.11 0.41 
Junk food 0.01 (0.01) -0.02 0.04 0.62 
 
There was one outlier in baby’s birth weight Z-score (>-3) and excluding that baby from the analysis the 
effect of maternal sugar consumption during pregnancy on baby’s birth weight Z-score became non-
significant (p=0.10).  
5.5.4.2. Predictors of baby weight Z-score at 2-3 months of age 
To determine whether the type of milk infants consumed (breast, formula and partial) at 2-3 months of 
age is associated with weight/age Z-scores of babies’ at the two follow-up time points, a one-way 
ANOVA was conducted (Table 5.11). There was no significant difference between the infant weight/age 
at 2-3 months age and the type of milk fed between groups or within groups (p=0.24) and the results 
remained non-significant when only the term babies at birth were included in the analysis (n=64). There 
was one outlier in baby weight at 2 months (Z-score >-3) and when excluding that baby from the analysis 
the results remained non-significant. 
 
As shown in Table 5.11, a significant difference was found for the weight/age Z-score at 6 months 
(p=0.01) and the effect remained significant when only term-babies at birth were included in the analysis 
(p=0.002). The detailed descriptive data (LSD test) indicated partially breast-fed infants had lower 
weight/6months Z-score than both breastfed and formula-fed infants. When the outliers were excluded 
from the analysis (Z-score <-3 and >3, two and one cases respectively), the results remained significant 
(n=59, p=0.01).  
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Table 5.11. Associations between infant feeding behaviours at 2-3 months and weight/age Z-scores 
at 2-3 and 6 months 
 Weight/2 months  
Z-score (n=73) 
P 
value 
Weight/6 months  
Z-score (n=62) 
P 
value 
Mean (SD units) Mean (SD units) 
Exclusively BF  0.006 (1.09) 
n=33 
0.24 -0.09 (1.26) 
n=28 
0.01 
Exclusively formula feeding  -0.206 (1.02) 
n=29 
0.20 (1.37) 
n=25 
Partially BF  -0.64 (1.33) 
n=11 
-1.24 (0.92) 
n=9 
 
Multiple linear regression analysis, using a standard regression process, was undertaken to investigate 
whether maternal dietary habits during pregnancy as well as infant milk feed type predict the baby weight 
Z-score at 2-3 months of age. There was no violation of the assumptions of normality, linearity, 
multicollinearity and homoscedasticity. In the final model, 3.6% of the variance in infant weight at 2 
months Z-score could be explained (R=0.036, SE=1.00). None of the factors included were significant 
predictors of the weight Z-score at 2-3 months of age (Table 5.12).  
 
Table 5.12. Linear regression model for predictors of baby weight at 2 months Z-score 
 β (SE) 95% CI P value 
The model (n=65)  Lower bound Upper bound  
Infant feeding  
Breast-fed 
Formula fed 
Partially breast-fed 
 
1 (ref) 
-0.12 (0.28) 
-0.74 (0.40) 
 
 
-0.68 
-1.55 
 
 
0.44 
0.06 
 
 
0.66 
0.07 
AHEI-P score -0.01 (0.01) -0.04  0.01 0.23 
Sugar consumption 0.006 (0.009) -0.01 0.02 0.53 
Processed meat 0.05 (0.05) -0.06 0.16 0.36 
Junk food -0.04 (0.02) -0.09 0.009 0.10 
 
When excluding the one outlier from the regression analysis (Z-score >-3), a significant association was 
found for partially breast-fed infants indicating that these babies had lower weight at 2 months Z-score 
(p=0.04). 
Looking at breast-feeding infants only, the model was also adjusted for the mean duration and number of 
breast-feeding per day (n=32). None of the covariates contributed to the models.  
 
When the model only included formula-fed infants, excluding the outlier on baby’s weight at 2 months Z-
score, the mean volume and number of formula feedings per day were added into the model (n=25). The 
model explained 54% of the variances (R=0.54, SE=0.70). Mean number of formula feedings per day in 
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addition to AHEI-P score and junk food made a significant contribution to the models. Details are shown 
in Table 5.13.  
 
Table 5.13. Linear regression model for predictors of baby weight at 2 months Z-score in formula-
fed babies 
 β (SE) 95% CI P value 
The model (n=25)  Lower bound Upper bound  
Mean volume of formula-
feeds per day (ml) 
0.002 (0.001) 0.000 
 
0.005 0.09 
Mean number of formula-
feeds per day 
-0.28 (0.12) -0.54 -0.02 0.03 
AHEI-P score -0.04 (0.01) -0.08  -0.01 0.01 
Sugar consumption 0.007 (0.01) -0.01 0.02 0.49  
Processed meat -0.08 (0.06) -0.22 0.05 0.22 
Junk food -0.08 (0.03) -0.15 -0.003 0.04 
 
When age of introduction of formula was added into the above model (n=24), no significant association 
was observed for this variable and the effect of maternal AHEI-P score also became non-significant 
(p=0.06).  
5.5.4.3. Predictors of baby weight Z-score at 6 months of age 
Multiple linear regression analyses, using a standard regression process were undertaken to investigate 
whether maternal dietary habits during pregnancy as well as infant’s milk-fed type at 2 months and 
introduction of solids predict the baby’s weight Z-score at 6 months of age. No violations of the 
assumptions of normality, linearity, multicollinearity and homoscedasticity were found. In the final 
model, 16% of the variance in infant’s birth weight Z-score could be explained (R=0.16, SE=1.21). 
Frequency of sugar consumption per week was the only factor that significantly contributed to the model 
(Table 5.14).  
Table 5.14. Linear regression model for predictors of baby weight at 6 months Z-score 
 β (SE) 95% CI P value 
The model (n=43)  Lower bound Upper bound  
Infant feeding  
Breast-fed 
Formula fed 
Partially breast-fed 
 
1 (ref) 
0.58 (0.41) 
-0.77 (0.61) 
 
 
-0.25 
-2.01 
 
 
1.42 
0.46 
 
 
0.16 
0.21 
AHEI-P score -0.02 (0.02) -0.06 0.01 0.20 
Sugar consumption -0.03 (0.01) -0.07 -0.002 0.04 
Processed meat -0.07 (0.09) -0.27 0.11 0.42 
Junk food  -0.04 (0.03) -0.11 0.03 0.25 
Introduction of solids 
(weeks) 
 
-0.02 (0.04) 
 
-0.12 
 
0.07 
 
0.64 
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When excluding the outliers from the regression analysis (Z-score <-3 and >3), the significant effect for 
maternal sugar consumption on weight at 6 months Z-score was weakened (n=42, p=0.07).   
 
Subgroup analyses on breast and formula feeding babies were not conducted since the number of infants 
within each group were small (n=21 and 17 respectively).  
 
The association between types of milk consumed at 6 months (breast, formula and partial-fed) and weight 
at 6 months Z-score was also investigated in ANOVA analysis and no significant differences were found 
(p=0.13).  
5.6. Discussion 
The primary objective of this cohort study was to investigate the associations between maternal dietary 
intake during pregnancy and infant feeding practices in early life with infant weight Z-scores at birth, 2-3 
and 6 months of age. Overall, the quality of maternal diet in this sample of pregnant women was 
suboptimal. Partially breast-fed infants had lower weight at 6 months Z-score (ANOVA analysis, Table 
5.11) and also, a lower weight Z-score at 2 months in an adjusted model when an outlier was excluded. In 
sub-group regression analysis, the number of formula feeds together with AHEI-P score and consumption 
of junk foods in pregnancy predicted the baby weight Z-score at 2 months. Furthermore, inverse 
associations were found between maternal sugar consumption during pregnancy with weight/age at birth 
and 6 months of age, although these effects became non-significant when excluding the outliers on baby 
weight from the models. The following sections will discuss these results.  
5.6.1. Maternal diet during pregnancy 
Mean total score of the AHEI-P in pregnant women was low (mean=33.60/70, SD=8.93), meaning that 
the quality of diet in women enrolled in this study was poor. The vegetable/fruit component was the most 
highly scored food group (mean score=8.87/10) followed by fat (from unsaturated sources) (mean 
score=7.36/10). The most poorly scored food component was fibre (mean score=1.99/10) and overall, 
scores for the other food components were low (Table 5.5). The frequency of intakes of unhealthy items 
(sugar, processed meat and junk food) were also relatively high (Table 5.6) and these were negatively 
correlated with the AHEI-P score, which was only significant for the junk food component. Significant 
correlations were identified between vegetable/fruit, iron-rich foods, dairy and fibre components; 
however the dairy and fibre components were not correlated. Also negative or no correlations were found 
between these components and fat, fish and Vitamin D components. One reason could be that the scores 
for the latter components were calculated differently since these were extracted from open questions and 
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data on frequency consumption were not included. The fat component also showed negative significant 
correlations with iron-rich foods and fibre components. The fact that there are no clear guidelines for the 
consumption of fat but only for the type (unsaturated vs. saturated fats) pinpoints the difficulties 
regarding measurement of fat intake. Also, there are a lot of confusing messages from the media about the 
healthiest types of oil/fat to consume. For example, while coconut oil is a rich source of saturated fat, it is 
usually promoted as a healthy oil/fat. Inadequate consumption of Vitamin D from supplements and 
omega-3 from foods i.e. oily fish was also a concern in this study sample, particularly because women 
might limit consumption of fish during pregnancy due to pregnancy sickness and safety reasons. 
 
Several lines of research have investigated the adequacy of maternal diet during pregnancy, using either 
diverse healthy eating index scores and dietary patterns or quantifying the intake of foods/nutrients by 
serving sizes. The results from this study are in line with previous research indicating that pregnant 
women do not meet the national recommendations outlined in the dietary guidelines and generally have a 
suboptimal quality of diet for many nutrients (Blumfield, Hure, MacDonald-Wicks, Smith, & Collins, 
2012; Malek, Umberger, Makrides, & Zhou, 2015; Morton et al., 2014). Also consistent with this study, it 
has been shown that usually adherence of women to consumption of fruit and vegetable in pregnancy is 
favourable (Skreden, Bere, Sagedal, 2017), whilst intake of fibre, carbohydrates and PUFAs are 
commonly lower than the recommendations (Blumfield, et al., 2012).  
 
It can be hypothesised that many women do not sustain a healthy diet prior to pregnancy and 
subsequently maintain the same nutritional behaviour during pregnancy. It might be that women do not 
have accurate knowledge of relevant dietary guidelines and hold misbeliefs and incomplete knowledge 
leading them to make inappropriate food choices at reproductive age. In support of this hypothesis, 
previous research from longitudinal studies reported that overall women maintain their dietary patterns 
from pre-pregnancy throughout pregnancy, with little changes except for the consumption of some 
nutrients (Crozier, Robinson, Godfrey, Cooper, & Inskip, 2009). For example, it has been found that 
intake of fruit is increased during pregnancy although there are mixed reports for the consumption of 
vegetables (Chen et al., 2013; Crozier, et al., 2009; Pinto, Barros, Dos, & Silva, 2009).  
 
Diet in pregnancy has a crucial role for the health of both mother and foetus. Evidence indicates that the 
nutritional state of women prior to pregnancy together with nutrition during pregnancy may influence 
both pregnancy and foetal outcomes (Gluckman, 2008; Inskip et al., 2014; Martin et al., 2016). Generally 
speaking, diet is a complex behaviour that is affected by a number of factors. Systematic reviews from 
observational and qualitative studies have specified a number of factors including pregnancy-related 
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(parity, sickness), socio-demographic (age, educational level, income and co-habiting), psychological 
(stress, anxiety, depression), environmental (social, food environment) in addition to self-efficacy beliefs 
and nutrition knowledge that could influence dietary behaviours of women prior and during pregnancy 
(Doyle, Borrmann, Grosser, Razum, & Spallek, 2016; Malek, Umberger, Zhou, & Makrides, 2015). In the 
current study, the statistical analyses regarding the influential factors on quality of maternal diet e.g. 
demographic characteristics were not conducted since it was beyond the scope of this thesis.  
 
To conclude, the fact that the findings of this study and others indicate that in general pregnant women 
fail to meet the key food and nutrient targets highlights the importance of community interventions in 
order to improve knowledge of nutritional choices and healthy eating during pregnancy. It is also 
important to study the underlying factors of how the acquired knowledge could be translated into 
behaviour at the population level.  
5.6.2. Infant weight and feeding characteristics  
Overall, most babies were born at full term (83.6%) and the mean birth weight was 3.32kg which is in 
line with national data of mean birth weight 3kg (McAndrew et al., 2010). The birth weight Z-score for 
term babies was also broadly average (SD units=0.03). Most babies were breast-fed (74.8%) on their first 
day of birth, and the rest were either bottle-fed (20%) or fed with both methods (4.4%). The median age 
of introduction of formula was 3 days  (range=1-91). At two months of age, 44.3% of babies were 
exclusively breast-fed with 40.5 and 15.2% being exclusively formula-fed and partially breast-fed, 
respectively. McAndrew and colleagues (2010) reported that the current initiation rate of breast-feeding 
in the UK is 81%, and the prevalence rate declines to 55 and 34% at six weeks and six months 
respectively. Nationally, 67% of infants are being introduced to formula between 4-10 weeks at least 
once, and approximately half of the infants are exclusively formula-fed (46%). Overall, data on infant 
feeding practices in the current study compares well to national data. 
 
In the current study, ANOVA analysis for type of milk consumed at 2 months of age showed that partially 
breast-fed babies weighed significantly less than exclusive breast and formula-fed infants at 6 months 
(Table 5.11). However, the analysis for milk consumed (breast, formula, partial-fed) at 6 months of age 
did not show an association with weight at 6 months Z-score. The adjusted regression model, excluding 
the outlier on baby weight at 2 months of age, showed partial breast-fed babies had a lower mean weight 
at 2 months Z-score (p=0.04).  
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As described in Chapter 2 section 2.9.3. the association between breast-feeding and childhood obesity has 
been assessed in numerous studies. Large discrepancies exist between the conducted studies in terms of 
measurement of breast-feeding as well as obesity, and systematic reviews have been conducted to infer a 
conclusive result. An overview of systematic reviews by Patro-Gołąb and colleagues (2016) concluded 
that any duration of breast-feeding could reduce the risk of overweight and obesity in children by 13%, 
while exclusive breast-feeding does not protect against childhood obesity. The results from this study are 
consistent with this overview of systematic reviews, although the current study only examined “weight 
for age” in very early life as a growth measure and further follow-ups of these babies could provide data 
on later risk of obesity. The non-significant findings between the type of milk consumed at 6 months and 
weight at 6 months Z-score could be because the totality of diet at 6 months of age is affected by other 
factors such as starting weaning and volume of milk consumed. The study might have also been 
underpowered to detect any associations.  
 
Moreover, subgroup analysis for the type of milk feeding in this PhD study showed there was an inverse 
significant association between number of formula feedings with weight at 2 months Z-score (Table 
5.13), indicating that perhaps babies were fed with a higher volume of formula per feed. Similarly, 
combined pooled data from a large study on the West Australian Pregnancy Cohort (Raine) and 3 
European cohort studies showed that introducing formula earlier than 3 months of age was significantly 
associated with rapid growth patterns in infants by 6 years and BMI trajectories by 20 years (Rzehak et 
al., 2017). Altered body composition of formula-fed babies compared to breast-feeding babies is also 
established in a systematic review and meta-analysis (Gale et al., 2012) that is characterised with a 
transient lower fat mass and a higher fat-free mass from 3-6 months of age. Overall, human breast milk 
contains growth hormones and bioactive factors, and infants receive less energy per volume. The main 
differentiating factor between formula and breast milk appears to be the protein content and thus, formula 
feeding could surge the number and size of adipocytes in infants (Brands, Demmelmair, & Koletzko, 
2014; Ziegler, 2006). Furthermore, a systematic review of RCTs reported that consumption of formula 
milk with lower protein concentration could have transient effects on baby growth from 3-12 months age 
and concluded the available evidence is limited for assessing the effects of protein concentration in infant 
formulas on later risk of obesity in children (Patro-Goł ąb et al., 2016). Subsequently, formula feeding 
remains a primary risk factor for early childhood obesity. 
 
Ideally, the infant feeding type in the current study could be grouped: exclusively breast-fed (BF), 
dominantly BF, partially BF and exclusively formula-fed that would provide more reliable data for 
statistical purposes. However, the sample in this study was not sufficiently powered to distinguish the 
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differences using this grouping with the small number of infants within each group. In addition, in this 
PhD study, “weight Z-scores” was the only parameter for quantifying growth in babies, since measures on 
baby height was recorded for only a small percentage of babies in the follow-up questionnaires, and 
therefore it was not possible to calculate BMI.  
5.6.3. Associations between maternal diet during pregnancy and infant weight/age Z-scores  
The quality of maternal diet during pregnancy measured by AHEI score in this study was not associated 
in the adjusted models with weight Z-score either at birth or baby follow-ups at 2 and 6 months. Subgroup 
analysis on formula-fed babies however showed inverse associations between maternal AHEI-P score and 
junk food consumption during pregnancy with weight at 2 months Z-score, so that babies of mothers who 
ate more junk food and better met the UK food guidelines during pregnancy weighed less at 2 months. In 
addition, babies of mothers who consumed more sugar in pregnancy had a lower birth weight Z-score and 
the effect persisted by 6 months of age, although the effect at both time points became non-significant by 
excluding the outliers on baby weight from the models. The inverse association observed between AHEI 
score and weight at 2 months Z-score could be because of the small sample included in the current study. 
Further research with a larger sample could replicate these findings. 
 
Studies assessing the impact of maternal diet during pregnancy on birth weight and/or SGA or the risk of 
obesity later in life have either used a priori or a posteriori approach. A priori approach measures the 
quality of diet using national or international recommendations, as used in the current study and is shown 
to have a good generalisability across different cohorts (Liese et al., 2015). A posteriori approach is data-
driven using different statistical methods for extracting dietary patterns and is highly dependent on the 
population under study. A few studies that measured a diet quality index in pregnant women have shown 
positive associations between higher diet quality scores and growth parameters at birth i.e. weight and 
length (Ferland & Turgeon O’Brien, 2003; Rodríguez-Bernal et al., 2010). A recent cohort of 1,079 
pregnant women assessed the effect of quality of diet, via repeated 24-hour recall on neonatal adiposity 
and showed HEI score ≤57 increased percentage fat mass and fat mass at birth (Shapiro et al., 2016). 
Moreover, the Norwegian Mother and Child Cohort Study of 62,494 term singleton pregnancies has 
established evidence that consumption of rapidly absorbed sugar from sugar-sweetened carbonated soft 
drinks had inverse associations with birth weight in normal pregnancies (Grundt, Eide, Brantsæter, 
Haugen, & Markestad, 2016). Other research assessing the effect of maternal diet during pregnancy on 
later risk of obesity has shown contradictory results. One study from China established a link between a 
dietary pattern higher in intake of vegetables/fruit and lower in fast foods, with reduced risk of child 
adiposity at 4.5 years (Chen et al., 2017), a cohort from Spain with maternal adherence to a 
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Mediterranean diet was not associated with childhood overweight at 4 years but lower waist 
circumference (Fernandez-Barres et al., 2016). In the current study, the lack of an association between 
AHEI score and weight Z-scores at birth and follow-ups could be because the study was not sufficiently 
powered to detect the associations. Also, it was not possible to consider the role of other underlying 
confounders such as maternal pre-pregnancy BMI, GDM or weight gain during pregnancy in the 
regression models due to limitations in the collected data; however, the models were adjusted for 
unhealthy eating habits during pregnancy, and weight for age Z-scores were also calculated. The 
significant associations observed for maternal consumption of sugar at birth and 6 months and also for the 
AHEI-P score and junk food (for formula-fed babies) in the current study, still provide some evidence for 
the importance of quality of maternal diet during pregnancy and warrants further research within this 
under investigated population. It is documented that environmental factors e.g. poor quality of maternal 
diet in pregnancy has damaging effects on placental vascular network and possibly the state of oxidative 
stress leading to placental dysfunction that consequently contributes to abnormal foetal development 
(Pereira et al., 2015).   
 
A number of studies have assessed the impact of dietary patterns during pregnancy on birth weight or 
SGA and their findings are comparable with the current study. A large study from the UK on the Avon 
longitudinal data found five dietary patterns in pregnant women: health conscious, traditional, processed, 
confectionary and vegetarian (Northstone, Emmett, & Rogers, 2008), and reported a health conscious diet 
pattern was associated with better birth weight. A review of seven studies from high-income countries 
(the UK, US, Denmark, New Zealand, Netherlands and Japan) on dietary patterns in pregnancy and birth 
weight indicated data were collected at different time points from throughout pregnancy to years after 
birth (Kjøllesdal & Ottesen, 2014). Dietary patterns were explored using principal component analysis (5 
studies), and also cluster analysis and logistic regression (each in one study) and between one and seven 
dietary patterns were reported in the studies. Across studies, the diet patterns positively associated with 
birth weight were: “nutrient dense, protein rich, health conscious and Mediterranean” whereas “western, 
processed, vegetarian, transitional and wheat products” were negatively associated with birth weight. 
Further studies have provided evidence that a “varied diet” in China (Lu et al., 2016), a “vegetable, fruit 
and white rice” pattern in Singapore (Chia et al., 2016), a “health conscious diet” in Ghana (Abubakari & 
Jahn, 2016) and a pattern characterised by intake of “eggs, starchy vegetables and non-whole grains” in 
the US (Starling et al., 2017) were associated with either birth weight size or newborn adiposity. 
Collectively, it should be stressed that although the dietary patterns across various studies were termed 
differently, common features can be found between the patterns. For example, high consumption of 
vegetables, fruit and dairy products are common characteristics of dietary patterns associated with higher 
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birth weight and comparably, patterns linked with low birth weight are typically characterised by elevated 
loadings of processed, high-fat meat, fats and oils and sugar rich products. In summary, data from both 
diet quality and dietary patterns research in pregnancy signifies the importance of maternal diet on infant 
growth parameters and risk of overweight/obesity later in life. 
5.6.4. Strengths  
The sample of pregnant women enrolled in this cohort study is representative of the Portsmouth 
population in terms of ethnic group profile (82.1% white British), although the proportion of married 
women and who owned a property was higher than the Portsmouth figures (Research and Intelligence, 
2013). A particular strength of this study is that the data was collected prospectively which would 
minimise the recall bias and there was a good response rate (91.4 and 61.2% to FFQ-P and MD, 
respectively). Diet in pregnant women was assessed as a whole where quality of diet was measured by 
AHEI score, reflecting consumption of actual foods and food groups similar to other studies. It can be 
argued that whilst measuring grams of foods or food groups could facilitate national and/or international 
comparisons of dietary intakes, this approach fails to evaluate the appropriateness of dietary guidelines in 
relation to population group intake. Moreover this is the first report of its kind from the city of 
Portsmouth, although one might argue that the sample is small and might not be nationally representative. 
All questionnaires were also specific to the study groups and validated, and the coding, analysis and 
interpretation of results conducted by the same researcher to minimise the effect of researcher error.  
5.6.5. Limitations 
The present study did have a number of limitations. The key one is the small sample included in this 
cohort of pregnant women, thus limiting the generalisability of the results. There are some limitations for 
the FFQ-P used since the replies rely on respondent’s memory, and therefore it is subject to recall bias. 
The frequency of food consumption could have also been overestimated and specifically for the healthy 
food items. Also, the nature of data collected did not allow us to calculate the frequency of consumption 
of fat, Vitamin D and omega-3 from vitamins with the same method used for the other food components. 
Moreover, consumption of sugar in pregnancy was calculated for the sugary items in the questionnaire, a 
mix of drinks and chocolate and as an example, not particularly for artificially sugar-sweetened 
beverages, so this might limit the comparability of these data with other research.  
 
With regards to the MD questionnaire, the nutritional intakes were estimated and not validated against 
any biomarkers. In addition, it takes a number of days to complete and therefore this demands a level of 
responsibility for mothers which could have had the potential to minimise the response rate. The 
unavailability of other growth parameters and adiposity measures in infants along with the short-term 
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follow-up might also be a limitation of this study. In addition, the regression models were relatively weak 
and data on other maternal-related risk factors were not available i.e. pre-conception overweight/obesity, 
gestational weight gain and diabetes. However there were not sufficient resources to address these for this 
PhD study.  
5.6.6. Conclusion 
Both maternal diet during pregnancy and early feeding practices in infants could have life-long lasting 
effects on weight outcomes in infants. Further larger studies could clarify whether these should be 
targeted in public health policies for early prevention of childhood obesity.  
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Chapter 6: Relationship between family history of allergy, quality of 
maternal diet during pregnancy, infant diet and the development of 
allergic outcomes in children by 6 months of age 
6.1. Overview of the chapter  
This chapter examines the relationship between family history of allergy, quality of maternal diet during 
pregnancy, infant diet and the development of allergic outcomes in children by 6 months of age. 
Parents/guardians were asked to complete a validated questionnaire of Food Frequency Questionnaire 
(FFQ) when their child was 6 months of age. The questionnaire used will be described and its choice 
justified. Symptoms of allergy in children were also captured at 6 months and they are considered in 
relation to infant dietary intake as well as family history of allergy and quality of maternal diet during 
pregnancy. The findings are discussed in terms of their contribution to the existing evidence base on early 
risk factors of allergy. 
6.2. Objectives 
a. To describe family history of allergies in children and its association with development of allergic 
symptoms at 6 months of age 
b. To determine the effect of maternal dietary intake during pregnancy, measured by AHEI score 
and the development of allergic symptoms in children at 6 months of age  
c. To determine infant feeding practices (breast vs. formula fed) at 6 months and its association with 
allergic symptoms  
d. To investigate the association between introduction of key allergenic foods in infant diet and 
allergic symptoms at 6 months of age 
e. To investigate the association between other dietary intakes and allergic symptoms at 6 months of 
age  
f. To determine if any of the factors listed in a-e are predictors of allergic outcomes at 6 months of 
age  
6.3. Rationale for choice of questionnaire 
Questionnaires were selected if they had been validated in the target group and they were relevant for the 
study age group. In addition, the time needed to complete the questionnaires was considered. 
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6.3.1. Measuring infant dietary intake  
As already outlined in Chapter 5 (section 5.3.1), measuring dietary intake or dietary variety is defined by 
a simple count of foods or food groups consumed over a given reference period (Ruel, 2003). In this 
study, dietary intake of infants at 6 months was quantified by the number of foods using a validated FFQ. 
A number of specifically designed infant FFQs have been developed, as summarised in a systematic 
review (Ortiz-Andrellucchi et al., 2009). The questionnaire administered in this study (appendix 6.1, 
section 3.16) was an amended version of the Southampton Women’s Survey FFQ at 6 months (Marriott 
et al., 2008). This particular FFQ was chosen since it was validated in a group of 6-month-old infants 
against a four-day weighed food diary in a geographical population similar to this target study 
population. The original questionnaire was semi-quantitative, asking portion sizes and frequency intake 
of foods.  For this study, the portion sizes were removed since the nutritional information was not being 
assessed and therefore, the FFQ in this study only asked for the frequency of intake. The questionnaire 
consisted of a list of 38 foods and drinks, divided into subcategories. The subcategories of food and 
drinks were: ready-made baby foods (12 foods), starchy foods (eight foods), vegetables (two items), fruit 
(three items), yogurt and fromage frais (one item), meat and fish (two foods) and non-water drinks (nine 
items) and water. The frequency of consumption over the previous month of each food and drink was 
recorded using a multiple response grid. The frequency options were: never, 1-3 times/month, 
once/week, 2 times/week, 3 times/week, 4 times/week, 5 times/week, 6 times/week, 7 times/week and 
more than once a day. Parents were asked to indicate the frequency of each item by ticking the 
appropriate box. Parents were also asked about the type of milk the infant was consuming and if formula-
fed, to specify timing of introduction and its type in addition to the age of introduction of solids.  
6.3.2. Identification of allergic symptoms and consumption of other allergenic foods  
Allergic symptoms at 6 months were established using the most widely utilised self-reported validated 
tool- the International Study of Asthma and Allergies in Childhood questionnaire (ISAAC) (Asher et al., 
1995). Since there is no gold standard for the classification of allergic diseases at a very young age, a 
combination of symptoms were used for identification of allergic symptoms. For the purpose of this 
study, the ISAAC questionnaire was supplemented with additional questions on vomiting, diarrhoea, 
constipation, colic and food allergies. With the exception of two allergic symptoms (wheeze and dry 
cough), mothers were asked to specify the cause of other allergic symptoms if known (appendix 6.1, 
section 2). Mothers were also asked whether they had consulted with their GP about any of these 
symptoms and where relevant, to specify the recommendation(s). 
 
In addition, a list of allergenic foods as a possible cause of allergic symptoms (including wheat, egg, 
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milk, fish, nuts and sesame) was added to the questionnaire. This list was developed by the Enquiring 
About Tolerance (EAT) study team, to assess the feasibility of early introduction of allergenic foods in 
breast-fed infants on prevalence of food allergy (Perkin et al., 2015).  
6.4. Methods 
6.4.1. Study design and setting 
Please see Chapter 5, section 5.4.1.  
6.4.2. Study sample and recruitment 
Please see Chapter 5, section 5.4.2.  
6.4.3. Ethical considerations 
Please see Chapter 5, section 5.4.3. An independent permission was also sought from the Allergy team in 
King’s College London, St Thomas’ hospital, in order to include the list of highly allergenic foods in the 
6 months follow-up questionnaire. 
6.4.4. Administration of questionnaire 
As outlined in Chapter 5, section 5.4.4 midwives completed the wave 0 questionnaire (appendix 5.6) that 
also included family history of allergy asking whether either a parent of the infant or any sibling had ever 
had symptoms of asthma, hay fever, rash, wheeze, runny nose and food allergies.   
 
The 6 month follow-up questionnaire for this PhD project was self-administered and women were 
provided with contact details of the research team to clarify any queries. The questionnaire and a prepaid 
envelope was posted to mothers when their babies were six months of age, and if they had not responded 
within three weeks, they received a phone reminder.  
6.4.5. Questionnaire coding 
Where possible, the questionnaire was coded and scored according to published standards. To ensure 
consistency in the coding of the questionnaire, a coding logbook was maintained. Data from individual 
questionnaires was used if at least 75% of the questionnaire had been completed. 
6.4.5.1. Food Frequency Questionnaire (FFQ) 
Consumption of the food items in the FFQ questionnaire was calculated per week, being consistent with 
the frequency options in the original questionnaire. To reflect consumption per week, a numeric value 
was assigned to each frequency category, ranging from 0 to 14 (never=0, 1-3 times per month=0.5, once 
 295 
per week=1, twice per week=2, 3 times per week=3, 4 times per week=4, 5 times per week=5, 6 times per 
week=6, 7 times per week=7 and more than once a day=14). The frequencies of each contributing food 
item in the food groups were added to calculate the weekly frequency consumption of each food group 
(ready-made baby foods, starchy foods, vegetables, fruit, yogurt and fromage frais and meat/fish). The 
weekly consumption of drinks and water were also calculated as explained above. The weekly 
consumption of food groups and drinks were treated as continuous variables; therefore, higher frequency 
intakes of these equals a higher score. In addition, the scores of all food groups, excluding drinks, were 
added together to obtain a total score for all foods consumed where the higher score indicates higher 
consumption. 
 
Missing replies to food items were replaced in the following way: if the baby had not been weaned (reply 
to “when did you first introduce solids into baby’s diet?” was answered “no, n/a”) and the replies to food 
items (allergenic and other food items) and drinks were left blank, it was decided to give a score of 0 to 
all the food items and drinks. If babies were weaned and there were missing replies to single food items, 
these were replaced by 0. Three mothers had started weaning and missed the replies to the list of 
allergenic foods and these were not replaced. The food items included in each food component and 
number of missing values are presented in appendix 6.2.  
6.4.6. Data analysis  
The Statistical Package for Social Sciences (SPSS) software (IBM, version 23) was used to analyse the 
data. Data sets were checked for outliers. Descriptive statistics were used to describe the data and all 
continuous variables were tested for normality using histograms. The mean and standard deviation (SD) 
were presented for normally distributed data, and otherwise median and range reported. Categorical 
variables were expressed as frequency and percentage. The χ2 test was used for categorical variables. To 
assess the effect of multiple factors on the main outcome measures, multiple logistics regression analyses 
were conducted. The significance level for all analyses was defined at 0.05 level.  
6.5. Results 
Of 134 pregnant women who received the 6 months follow-up questionnaire, 80 responded (59.70%). 
Mean age of babies was 6.82 months (SD=0.89) and mothers had completed the questionnaires by 
themselves (100%).  
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6.5.1. Description of sample and by developing allergies in children 
Detailed demographic characteristics of participants who responded to the 6 month follow-up 
questionnaire are shown in Table 5.2 (Chapter 5, section 5.5.1). Specific allergic symptoms and any 
allergies in children at 6 months of age is shown in Table 6.1. Wheezing was the most frequent allergic 
symptom reported (25%) and vomiting, constipation and colic were the most common food-related 
symptoms reported. Any allergies in children were defined, as whether they had experienced symptoms 
of “wheezing and dry cough” or when food was the cause for another allergic symptom (rash, vomiting, 
diarrhoea, constipation, colic and other food-related problems). In total, 42 children (52.7%) reported any 
symptoms of allergies. Also, ten babies (12.5%) had developed itchy rash and 4 were reported to be 
caused by food.  
 
Twenty four mothers (30%) had consulted their GP or paediatrician about the allergic symptoms reported 
and recommendations were: referral to paediatrician (n=3), dairy intolerance/avoiding cow’s 
milk/lactulose (n=4), and the rest were either prescribed medications such as Gaviscon, infacol, ranitidine 
or did not require any further treatment. 
 
Table 6.1. Allergic symptoms in children 
 Yes  
N (%) 
No  
N (%) 
Don’t know 
N (%) 
Wheezing/whistling (n=80) 20 (25.0) 59 (73.7) 1 (1.3) 
Dry cough at night (n=80) 8 (10.0) 71 (88.8) 1 (1.3) 
Itchy rash (n=80) 
Identified cause of rash 
Rash caused by food 
Foods caused the rash 
Cow’s milk allergy 
 
10 (12.5) 
8 (80) 
4 (50.0) 
4 (2.8) 
70 (87.5) 
2 (20) 
4 (50.0) 
 
- 
- 
 
- 
 
- 
Vomiting (>1tbsp) (n=80) 
Identified cause of vomiting 
Vomiting caused by food 
Foods caused vomiting 
Cow’s milk allergy (formula) 
Orange 
Dairy +soya 
Reflux 
Too much milk 
Weaning  
Not specified  
35 (43.7) 
29 (82.9) 
12 (41.4) 
 
6 (4.2) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
45 (56.3) 
6 (17.1) 
17 (58.6) 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
Diarrhoea (n=80) 
Identified cause of diarrhoea 
Diarrhoea caused by food 
Foods caused diarrhoea 
Baby rice 
Cow’s milk allergy 
Milk, yoghurt, cheese 
Mum had pickled onion 
Not sure what food 
24 (30.0) 
17 (68.0) 
7 (41.2) 
 
1 (0.7) 
3 (2.2) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
55 (68.8) 
7 (28.0) 
10 (58.8) 
 
- 
- 
- 
- 
- 
1 (1.2) 
1 (4.0) 
- 
 
- 
- 
- 
- 
- 
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 Yes  
N (%) 
No  
N (%) 
Don’t know 
N (%) 
Constipation (n=80) 
Identified cause of constipation 
Constipation caused by food 
Foods caused constipation 
Carrots 
Egg 
Gaviscon 
Introduction of solids/weaning 
Formula 
Stay down milk/Gaviscon 
Not specified 
26 (32.5) 
18 (69.2) 
10 (55.6) 
 
1 (0.7) 
1 (0.7) 
1 (0.7) 
2 (1.5) 
2 (1.5) 
1 (0.7) 
2 (1.5) 
52 (65.0) 
6 (23.1) 
8 (44.4) 
 
- 
- 
- 
- 
- 
- 
- 
2 (2.5) 
2 (7.7) 
- 
 
- 
- 
- 
- 
- 
- 
- 
Colic/tummy ache 
Identified cause of colic 
Colic caused by food 
Foods caused colic  
Cow’s milk allergy 
Curry (spicy) 
Dairy + soya 
Pickled onions (eaten by mum) 
Did not specify 
 
38 (47.5) 
23 (60.5) 
10 (43.5) 
 
4 (3.0) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
3 (2.1) 
35 (43.8) 
10 (26.3) 
13 (56.5) 
 
- 
- 
- 
- 
- 
7 (8.7) 
5 (13.2) 
- 
 
- 
- 
- 
- 
- 
Other food related problems 
Food-related problem  
Facial-rash 
Possible acid reflux + stridor 
Rash/vomit/poo/wind/sleep apnea/blistered lip 
Reactions to dairy, soya, egg, nut, gluten 
Reflux 
Rash, but not itchy 
Sickness, diarrhoea, acid reflux 
Tummy ache + wind 
Cause of food-related problem 
Cow’s milk allergy 
Garlic + onions 
Soya milk in food 
Not known/unidentified 
8 (10.0) 
 
1 (0.7) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
 
1 (0.7) 
1 (0.7) 
1 (0.7) 
1 (0.7) 
4 (3.0) 
1 (0.7) 
1 (0.7) 
2 (1.5) 
71 (88.7) 
 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
1 (1.3) 
 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Developing any allergic symptoms  42 (52.5) 38 (47.5) - 
 
 
6.5.2. Family history of allergies in the sample studied 
The prevalence of family history of allergies in the overall sample, broken down by child allergy status at 
6 months, is shown in Table 6.2. There were no associations between those with a maternal family history 
of asthma (p=0.48) or other allergies (p=0.73) with developing allergic symptoms at 6 months.  
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Table 6.2. Family history of allergies 
Family history Responded to 6months 
questionnaire (n=80) 
N (%) 
Allergic children 
(n=42) 
N (%) 
Non-allergic 
children (n=38)  
N (%) 
Asthma 
Mother (n=79)
*
 
Any
**
 (n=79) 
 
15 (19.0) 
24 (30.4) 
 
9 (22.0) 
14 (34.1) 
 
6 (15.8) 
10 (26.3) 
Hay fever 
Mother (n=80) 
Any (n=79) 
 
23 (28.7) 
41 (51.9) 
 
12 (28.6) 
21 (51.2) 
 
11 (28.9) 
20 (52.6) 
Rash 
Mother (n=80) 
Any (n=79) 
 
12 (15.0) 
23 (29.1) 
 
7 (16.7) 
12 (29.3) 
 
5 (13.2) 
11 (28.9) 
Wheeze 
Mother (n=80) 
Any (n=80) 
 
18 (22.5) 
30 (37.5) 
 
12 (28.6) 
19 (45.2) 
 
6 (15.8) 
11 (28.9) 
Runny nose 
Mother (n=80) 
Any (n=80) 
 
19 (23.8) 
39 (48.8) 
 
10 (23.8) 
20 (47.6) 
 
9 (23.7) 
19 (50) 
Food allergy 
Mother (n=80) 
Any (n=80) 
 
10 (12.5) 
19 (23.8) 
 
5 (11.9) 
12 (28.6) 
 
5 (13.2) 
7 (18.4) 
Any allergies
**
 (n=80) 64 (80.0) 33 (78.6) 31 (81.6) 
*Difference between allergic and non-allergic children not significant using χ2 test 
**Family history of asthma/hay fever/rash/wheeze/runny nose/food allergy either in mother, father or sibling(s)  
 
 
6.5.3. Maternal diet during pregnancy (AHEI score) and allergies in children 
The measurement and calculation of AHEI score in pregnancy is outlined in Chapter 5, section 5.4.5.1. 
The association between maternal AHEI score and the development of allergies in children was assessed 
using an independent student t-test, where the mean of maternal AHEI score in pregnancy was not 
significantly different between allergic and non-allergic children (33.35 vs. 34.39, p=0.72). 
 
6.5.4. Infant milk feeding type(s)   
Details of type of milk infants consumed and age of weaning is shown in Table 6.3. At the time of data 
collection, 37.5% of infants were exclusively breast-fed whilst 52.5% were formula-fed. Mean age of 
solid food introduction was 22.3 weeks and some foods were avoided by ten infants (15.2%) due to 
reported allergies. Foods avoided were: any dairy and soya (N=1), cow’s milk (N=1), cow’s 
milk/yoghurt/butter (N=1), dairy/soya/nut/egg/gluten/wheat (N=1), egg and nuts until 12 months (N=1), 
nuts (N=2), orange (N=1), soy and milk (N=1) and one did not specify. No significant differences were 
found between the types of milk that infants consumed (breast vs. formula vs. mix of both), timing of 
introduction of solids and other variables included in Table 6.1.  
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Table 6.3. Infant feeding characteristics of children 
 All (n=80) 
No. (%) 
Allergic children 
(n=42) No (%) 
Non-allergic 
children (n=38) 
No. (%) 
P
*
 
Baby feeding type  
Exclusively breast milk 
Exclusively formula 
Mix of breast and formula  
 
30 (37.5) 
42 (52.5) 
8 (10.0) 
 
16 (38.1) 
22 (52.4) 
4 (9.5) 
 
14 (36.8) 
20 (52.6) 
4 (10.5) 
 
0.98 
 
Solid food introduction (weeks) 
<4months 
4-6months 
>6months 
Not specified 
Not started 
Mean (SD) 
Median (range) 
 
2 (2.5) 
43 (53.8) 
20 (25.0) 
4 (5.0) 
11 (13.8) 
22.30 (3.53)  
23.0 (11-30) 
 
1 (2.4) 
24 (57.1) 
9 (21.4) 
2 (4.8) 
6 (14.3) 
21 .47 (3.55) 
21 (12-28) 
 
1 (2.6) 
19 (50.0) 
11 (28.9) 
2 (5.3) 
5 (13.2) 
23.20 (3.33) 
24 (11-30) 
0.95 
 
 
 
 
 
 
 
Avoiding foods due to allergy 
Yes 
No 
Missing  
 
10 (12.5) 
56 (70.0) 
14 (17.5) 
 
8 (19.0) 
27 (64.3) 
7 (16.7) 
 
2 (5.3) 
29 (76.3) 
7 (18.4) 
0.08 
 
 
Type of weaning food  
Home made 
Shop bought 
Mixture of both 
Missing  
 
38 (47.5) 
5 (6.3) 
23 (28.7) 
14 (17.5) 
 
20 (47.6) 
3 (7.1) 
12 (28.6) 
7 (16.7) 
 
18 (47.4) 
2 (5.3) 
11 (28.9) 
7 (18.4) 
1.00 
 
 
Dietary supplements 
Yes 
No 
Missing  
 
9 (11.20) 
56 (70.0) 
15 (18.8) 
 
6 (14.3) 
28 (66.7) 
8 (19.0) 
 
3 (7.9) 
28 (73.7) 
7 (18.4) 
0.48 
 
 
Attention paid to healthy-eating 
of baby 
Very little 
Somewhat 
A great deal 
Missing  
 
 
-- 
10 (12.5) 
56 (70.0) 
14 (17.5) 
 
 
-- 
4 (9.5) 
31 (73.8) 
7 (16.7) 
 
 
-- 
6 (15.8) 
25 (65.8) 
7 (18.4) 
0.49 
 
 
 
 
*Fishers’ exact test 
 
 
6.5.5. Introduction of allergenic foods 
The allergenic foods introduced to the diet of infants are shown in Table 6.4. With the exception of one 
infant who was exposed to cow’s milk earlier than 3 months of age, none of the other allergenic foods 
were introduced at this age. Overall, the most commonly allergenic foods introduced between 3 and 6 
months and after 6 months were wheat (37.6% and 27.3%) and milk (22.1% and 31.2%). The least 
commonly allergenic foods introduced between 3 and 6 months and after 6 months were nuts (1.3% and 
9.1%) and sesame (3.9% and 5.2%). Differences between allergic and non-allergic children for the intake 
of each allergenic food were not significant (Table 6.4).  
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Table 6.4. Introduction of allergenic foods to baby diet (n=77)
*
 
 All (n=77) 
No. (%) 
Allergic children (n=41) 
No. (%) 
Non-allergic children 
(n=36) No. (%) 
P 
Wheat 
Never 
<3 months 
3-6 months 
>6 months  
 
27 (35.1) 
- 
29 (37.6) 
21 (27.3) 
 
18 (43.9) 
- 
16 (39.0) 
7 (17.1) 
 
9 (25.0) 
- 
13 (36.1) 
14 (38.9) 
0.06
**
 
Egg 
Never 
<3 months 
3-6 months 
>6 months 
 
57 (74.0) 
- 
4 (5.2) 
16 (20.8) 
 
33 (80.5) 
- 
2 (4.9) 
6 (14.6) 
 
24 (66.7) 
- 
2 (5.6) 
10 (27.7) 
0.34
***
 
Milk 
Never 
<3 months 
3-6 months 
>6 months 
 
35 (45.5) 
1 (1.3) 
17 (22.1) 
24 (31.2) 
 
21 (51.2) 
1 (2.4) 
9 (22.0) 
10 (24.4) 
 
14 (38.9) 
- 
8 (22.2) 
14 (38.9) 
0.36
***
 
Fish 
Never 
<3 months 
3-6 months 
>6 months 
 
56 (72.7) 
- 
6 (7.8) 
15 (19.5) 
 
31 (75.6) 
- 
5 (12.2) 
5 (12.2) 
 
25 (69.4) 
- 
1 (2.8) 
10 (27.8) 
0.08
***
 
Nuts 
Never 
<3 months 
3-6 months 
>6 months 
 
69 (89.6) 
- 
1 (1.3) 
7 (9.1) 
 
38 (92.7) 
- 
- 
3 (7.3) 
 
31 (86.1) 
- 
1 (2.8) 
4 (11.1) 
0.38
***
 
Sesame  
Never 
<3 months 
3-6 months 
>6 months 
 
70 (90.9) 
- 
3 (3.9) 
4 (5.2) 
 
38 (92.7) 
- 
2 (4.9) 
1 (2.4) 
 
32 (88.9) 
- 
1 (2.8) 
3 (8.3) 
0.45
***
 
*There were three missing replies to these questions  ** χ2 test   ***Fisher’s exact test   
 
6.5.6. Infant food frequency questionnaire   
Median frequency consumption of different food groups is shown in Table 6.5. Criteria for grouping and 
scoring the food groups are described in section 6.4.5.1. The median consumption of ready-made baby 
foods, starchy carbohydrates and yogurt/fromage frais were lower in allergic children, while the 
consumption of vegetables and fruit were very similar. Introduction of meat/fish and non-water drinks 
were very low in either group and water had a similar pattern. In total, there were no significant 
differences in consumption of the food groups between allergic and non-allergic children (Table 6.6). 
When considering all foods, the allergic children scored lower than non-allergic children (19.75 vs. 
22.75) meaning the intake of foods was less varied in allergic children; however the difference was not 
significant (p=0.81). 
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Table 6.5. Median frequency consumption of food groups and drinks per week 
 All (n=80) 
Median (range) 
Allergic children 
(n=42) 
Median (range) 
Non-allergic 
children (n=38) 
Median (range) 
P
*
 
Ready-made baby 
foods 
4.75 (0-33) 3.25 (0-29.5) 5.5 (0-33) 0.81 
Starchy carbohydrates 2.0 (0-23.5) 1.75 (0-23) 2.25 (0-23) 0.80 
Meat and fish 0.0 (0-28) 0.0 (0-8) 0.0 (0-28) 0.46 
Vegetables 5.0 (0-18) 5.0 (0-16) 5 (0-18) 0.69 
Fruit 4.0 (0-19) 3.75 (0-19) 4.0 (0-18) 0.72 
Yogurt, fromage frais 0.0 (0-7) 0.0 (0-7) 0.5 (0-7) 0.93 
Non water drinks 0.0 (0-14) 0.0 (0-14) 0.0 (0-14) 0.33 
Water 7.0 (0-14) 7.0 (0-14) 7.0 (0-14) 0.73 
All foods
**
 21.25 (0-95) 19.75 (0-75) 22.75 (0-95) 0.81 
* χ2 test    **Not including non-water drinks and water  
 
 
6.5.7. Predictive effects of defined risk factors on developing allergies in children 
Logistic regression analysis was undertaken to investigate the impact of all defined risk factors on 
developing allergies at 6 months of age (Table 6.6). The introduction of solids was introduced as a binary 
factor into the model where the “less than 4 months” (2 babies) and “between 4-6 months” categories 
were grouped together and also, the “not started weaning” (11 babies) was combined with “more than 6 
months” category. This was done to yield plausible numbers within groups for statistical purposes. Of the 
factors included in the model, only introduction of wheat at 3-6 months was found to be associated with 
allergies in children with a protective effect (β=-2.07, p=0.04), although its introduction after 6 months 
showed a borderline association (β=-2.47, p=0.06).  
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Table 6.6. Logistic regression model for predictors of allergies in babies 
 β (SE) 95% CI P 
Main model   Lower bound Upper bound  
Family history of allergies 
Yes 
No 
 
1 (ref) 
-0.33 (0.81) 
 
 
0.14 
 
 
3.52 
 
 
0.68 
AHEI-P score 0.005 (0.03) 0.94  1.07 0.87 
Infant milk-fed type 
Exclusively breast-fed 
Exclusively formula-fed 
Partially breast-fed 
 
Ref (1) 
-0.42  (0.76) 
-0.03 (1.15) 
 
 
0.14 
0.10 
 
 
2.90 
9.35 
 
 
0.57 
0.97 
Wheat 
Never  
3-6 months 
>6months 
 
Ref (1) 
-2.07 (1.00) 
-2.47 (1.33) 
 
 
0.01 
0.006 
 
 
0.90 
1.16 
 
 
0.04 
0.06 
Egg  
Never  
3-6 months 
>6months 
 
Ref (1) 
-0.56 (1.79) 
-1.58 (1.39) 
 
 
0.01 
0.01 
 
 
19.10 
3.17 
 
 
0.75 
0.25 
Milk  
Never  
3-6 months 
>6months 
 
Ref (1) 
0.43 (0.99) 
0.26 (1.19) 
 
 
0.21 
0.12 
 
 
10.90 
13.38 
 
 
0.66 
0.82 
Fish  
Never  
3-6 months 
>6months 
 
Ref (1) 
0.04 (1.78) 
0.71 (1.30) 
 
 
0.03 
0.15 
 
 
34.31 
26.21 
 
 
0.97 
0.58 
Nuts  
Never  
3-6 months
*
 
>6months 
 
Ref (1) 
- 
1.34 (1.53) 
 
 
- 
0.19 
 
 
- 
77.12 
 
 
- 
0.37 
Sesame  
Never  
3-6 months 
>6months 
 
Ref (1) 
0.16 (1.63) 
-2.01 (1.92) 
 
 
0.04 
0.003 
 
 
29.18 
5.81 
 
 
0.92 
0.29 
Other foods
**
 (total score) 0.02 (0.02) 0.98 1.08 0.24 
Solids  
>6months  
4-6months  
 
Ref (1) 
1.01 (0.89) 
 
 
0.06 
 
 
2.10 
 
 
0.26 
*Only one baby was introduced and the analysis not reported
  
**Including ready-made baby foods, starchy carbohydrates, meat & fish, vegetable, fruits, yogurt
 
 
The family history of maternal asthma (n=67), on its own and also together with the family history of all 
allergies, was included in the model and the results did not change.  
 
6.6. Discussion  
This cohort study set out to assess the effects of family history of allergies, quality of maternal diet during 
pregnancy and feeding practices in infants on the development of allergies at 6 months of age. There were 
no significant associations between the defined individual primary risk factors and allergies in children at 
6 months. Assessing the influence of all the risk factors in a logistic regression model showed that 
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consumption of wheat between 3-6 months had a protective effect on the development of allergies at 6 
months of age.   
6.6.1. Allergic symptoms reported in children 
In total, 52.7% of infants in this study reported any symptoms of allergies, and wheezing was the most 
reported allergic symptom followed by the frequently food-related symptoms of vomiting, constipation 
and colic. It is important to add that the allergic symptoms were reported symptoms by parents and no 
clinical tests such as SPT were used to assess sensitisation. As outlined in Chapter 2, allergies frequently 
begin early on in infancy and infants are prone to developing atopic dermatitis, food allergies and 
recurrent wheezing whereas asthma and allergic rhinitis usually occur later in childhood (Bieber, et al., 
2013). In this sample of infants, cow’s milk allergy appeared to be the most common allergy, as reported 
by mothers and their GP consultation (Table 6.1). Studies indicate that manifestation of allergies to cow’s 
milk protein (CMP) is most common in the first few months when the infant is exposed to cow’s milk via 
breast milk, infant formula or solid foods; however most infants develop tolerance by late childhood 
(Allen & Koplin, 2012). The symptoms of allergy in this study were taken from a standardised 
questionnaire (Asher, et al., 1995) and it was supplemented with additional allergic symptoms. There is a 
possibility that reporting of allergic symptoms has been influenced by a different understanding of the 
questions among individuals, for example, the interpretation for the definition of wheeze or colic may 
vary between people.   
 
There were no links between either maternal family history of asthma or any other allergies with allergic 
symptoms in the studied sample, and it is possible that the study was underpowered to detect any 
associations. As described in Chapter 2 (section 2.5.1) family history of allergy plays an important role in 
developing allergies in child particularly for maternal asthma ((Böhme, et al., 2003; Kjellman & 
Johansson, 1976; Koppelman, et al., 1999). 
6.6.2. Maternal diet during pregnancy 
The present study did not find an association between mean score of AHEI-P, as a proxy measure for 
quality of maternal diet during pregnancy, and likelihood of developing allergies in children at 6 months 
of age. This could be because the study was not sufficiently powered; however this result is consistent 
with two studies conducted in the US (Lange et al., 2010) and the UK (Moonesinghe et al., 2016), that 
found no association between maternal HEI and childhood asthma and other allergies. These studies had a 
follow-up duration of 3 and 10 years respectively, and the UK study used an allergy-focused HEI diet.  
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As described in Chapter 5, diet could be assessed using either an a priori (based on previous knowledge) 
or posteriori approach (dietary patterns) and the current evidence in pregnant women heavily relies on 
knowledge from eating style patterns among different populations. Literature around maternal diet during 
pregnancy and childhood allergies is already outlined in Chapter 2 (section 2.5.2) and in summary, 
evidence from a systematic review and meta-analysis of cohort studies (Beckhaus et al., 2015) only 
showed protective effects for maternal consumption of certain nutrients (Vitamins D, E and zinc) in 
pregnancy on childhood wheeze and a few studies contributed to their meta-analysis. A recent narrative 
review assessing the evidence on adherence to Mediterranean style diet during pregnancy showed the 
eating pattern is beneficial for childhood asthma/wheeze during the first year of life but no promising 
effects for other allergic outcomes were reported (Castro-Rodriguez & Garcia-Marcos, 2017). A further 
study from Singapore (Loo et al., 2017) also showed that, of the emergent dietary patterns, only the 
seafood and noodles style showed a beneficial effect on allergen sensitisation at 18 and 36 months of age 
in an adjusted analysis. To conclude, there is a paucity of evidence from studies assessing HEI in 
pregnancy and childhood allergies and nevertheless, current results from both these studies and dietary 
patterns in pregnant women seem to be inconclusive due to large heterogeneities between studies in terms 
of the definition and measurement of diet. This would suggest there is a need for well-defined studies to 
address maternal diet as a risk factor for childhood allergies.   
6.6.3. Infant milk feeding practices  
At 6 months of age, the rate of exclusive breast and formula feeding were 37.5% and 52.5% respectively, 
indicating that breast-feeding in this sample was slightly above the average national figure where 34% of 
infants are being breast-fed at 6 months old (McAndrew et al., 2010). The type of milk that infants 
consumed was not associated with allergies in children at 6 months. The role of breast-feeding on 
childhood allergies has been the subject of a number of studies and the relevant literature is discussed in 
Chapter 2 (section 2.5.3). In brief, a systematic review of studies with varied designs showed that 
duration of breast-feeding (more vs. less) decreased the risk of asthma at 5-18 years and also allergic 
rhinitis by ≤5 years and eczema by ≤2 years of age; however, high levels of heterogeneity were found in 
the conducted meta-analyses (Lodge et al., 2015). These results however, do not directly compare to the 
current study since this study only followed-up children at 6 months old. Also because the diagnosis of 
allergies in very early childhood is difficult, occurrence of allergies was defined by symptoms for 
common allergies caused by food; additionally, the study might be underpowered to identify these 
associations.  
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6.6.4. Timing of introduction of solids and allergenic foods 
Nationally, 75% of babies are introduced to solids by five months old (McAndrew et al., 2010). In this 
study, most babies were weaned between 4-6 months age (53.8%) and statistically, there were no 
significant differences between the age of introduction of solids and developing allergies in children. 
Also, introduction of allergenic foods at different ages was not associated with subsequent development 
of allergies in children, although, in the logistic regression model, babies who were exposed to wheat 
between 3-6 months of age had lower prevalence of allergies (p=0.04). Prevention of food allergies by 
early introduction of common food allergens (peanut, cooked hen’s egg, cow’s milk, sesame, white fish 
and wheat) from 3 months of age in the EAT trial conducted in the UK failed to show a beneficial effect 
in the ITT analysis and further analysis of their data suggested that adherence and dose of these foods 
might play a role (Perkin et al., 2016). However, this RCT included exclusive breast-feeding babies and 
assessed the occurrence of food allergy by means of SPT and therefore, the results are not directly 
comparable with this observational study where interaction between the defined risk factors was assessed 
in a regression model. 
 
The history and evidence around the introduction of allergenic foods into the infant diet and prevention of 
allergies from observational studies and RCTs is detailed in Chapter 2 (section 2.5.4). As shown in the 
review by Ierodiakonou and colleagues (2016) the current knowledge from observational studies on the 
topic is inconclusive, although the results from RCTs have incited some revisions only for introduction of 
peanuts in practice for early prevention of childhood allergies among professional bodies and allergists. A 
recent study from Singapore (Tham et al., 2017) reported that the prevalence of food allergy in a cohort of 
1,152 children was low (between 0.1% to 1.8%) at 18 and 36 months of age in adjusted analysis, despite 
the late introduction (after 10 months of age) of allergenic foods into the infant diet. The findings from 
this large observational study highlight the fact that early introduction of allergenic foods might not be a 
practical approach in all populations and suggests that international/national guidelines for prevention of 
allergies need to be revised and adapted based on the ethnic/geographical differences and epidemiology 
of food allergies in countries.  
6.6.5. Consumption of food groups in infants  
Consumption of food groups between the allergic and non-allergic children did not significantly differ, 
although with the exception of vegetable and fruit groups, allergic children scored lower for the median 
consumption of most food groups. In addition, allergic children scored lower for overall food indicating 
that they had a less varied diet compared to the non-allergic group; however this was not statistically 
significant. Also, type of food in terms of home-made vs. shop bought or both was not significantly 
 306 
different between allergic and non-allergic children, although 17.5% did not specify because they had not 
started on weaning and there were also missing data for this item. Of note, the current study provides data 
on the initial stages of weaning in infants where only 56.3% of mothers had started weaning by 6 months 
of age. In addition, diet at this very young age is not very diverse but is expected to be within a few 
months. Hence, the associations between variety of foods consumed and allergy status at this early age 
may not be representative of later ages. A study from the UK with a nested case-control design reported 
that the early infant diet pattern (in the first year of life) was not different between children with and 
without food allergies, whereas the ongoing diet pattern by 2 years of age was significantly different 
between the groups (Grimshaw et al., 2014), where non-allergic children ate a diet richer in fruit, 
vegetables and home-prepared foods (healthy diet). A large birth cohort from the UK also showed that a 
healthy dietary pattern was linked to lower risk of food hypersensitivity by 2 years of age in both IgE and 
non-IgE mediated phenotypes (Grimshaw et al., 2015). In this PhD study, patterns of intake for 
vegetables and fruit in allergic children were similar to that of non-allergic children, which could be 
because mothers perceive these foods as safe. However the results from this PhD study can not be directly 
compared to the aforementioned studies where the diagnosis of food allergy was conducted by means of 
DBPCFC and children were followed-up by 2 years age. A larger study on this population with a longer 
follow-up duration could replicate the results. 
An observational study from five European countries has furthermore reported that diversity of food in 
the first year of life, measured for 12 food/food categories, can have a protective effect on the 
development of asthma, food allergies and food sensitisation by 6 years of age (Roduit et al., 2014). The 
observed association persisted when children with food allergies were excluded from their analysis thus 
eliminating the reverse causality.  Generally speaking, it can be hypothesised that it is the diet pattern that 
contributes towards the development of food allergies in children, or having a food allergy in infancy is 
the resulting factor for the diet pattern. Altogether, a causation effect cannot be inferred from either the 
discussed papers or current PhD study because of their prospective nature and yet, it appears that quality 
of diet early in life is an underlying factor for allergies in older age. 
6.6.6. Strengths 
Validated questionnaires designed for the target age group were used to collect data on symptoms of 
allergies and infant diet. The ISAAC questionnaire was supplemented with additional questions on 
gastrointestinal symptoms e.g. colic or diarrhea, to assist with identification of allergic symptoms at this 
very young age and whether they were caused by food(s), were deemed as allergic symptoms. Other 
strengths of the study are as previously outlined in Chapter 5 (section 5.6.5). 
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6.6.7. Limitations 
Lack of use of clinical test(s) for the diagnosis of allergies in children is a key limitation for this cohort 
study. In addition, the short-term follow-up by 6 months age meant that direct comparison with other 
studies could not be made. Other limitations related to sample size and measurement of maternal diet 
during pregnancy are as previously explained in Chapter 5 (section 5.6.4).  
6.6.8. Conclusion 
The effect of maternal diet during pregnancy and feeding practices of babies early in life on the 
development of allergies at 6 months of age remains inconclusive and demands further investigation. 
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Chapter 7: General discussion and conclusion 
7.1. Overview  
The overall findings of this PhD study are brought together in this chapter. A recap of the rationale and 
principal aims for the research are presented followed by the main findings of the two studies conducted 
in this PhD and their implications. The methodological strengths and limitations are addressed and future 
research needs are discussed.  
7.2. Rationale, hypothesis and aims of this programme of research 
The main aim of this research was to examine the role of nutrition in pregnancy and early in life on the 
development of allergies and obesity in children and was conducted as two separate complementary 
studies. The first study aimed to synthesise the evidence of effectiveness of prenatal nutritional/dietary 
interventions on prevention of childhood allergies and obesity. The rationale for this was in response to an 
increasing trend of childhood allergies and obesity, avenues of research for prenatal nutritional 
interventions have been proposed as the first line for primary prevention of these conditions. Previous 
reviews have assessed the effect of some of the nutritional interventions during pregnancy, and mostly 
also included postnatal interventions and reported single allergic outcomes e.g. asthma (please see 
respective section 3.3.2.2) and obesity e.g. BMI (please see respective section 4.3.2.2). The evidence base 
for nutritional interventions that were conducted solely during pregnancy and which assessed the 
occurrence of overall allergic and obesity outcomes was extremely limited and not synthesised. 
Consequently, the first study of this PhD research programme intended to synthesise the most up to date 
evidence on the nutritional interventions administered only throughout pregnancy with a minimum 
follow-up of one month after birth, and incorporates a comprehensive range of allergic and obesity 
outcomes in children.  
 
The second study of this research programme collected data prospectively in the Portsmouth birth cohort 
registry to investigate the associations between quality of maternal diet during pregnancy and early life 
feeding practices on weight/Z-score outcomes and allergies in children by 6 months of age. As discussed 
in detail in Chapter 2, because of large heterogeneities that exist between studies, there are a number of 
unanswered questions relating to the associations between maternal diet in pregnant women and feeding 
practices in early life, with the development of childhood allergies and obesity. In addition, quality of 
maternal diet using national/international guidelines is assessed in a few studies and most studies have 
reported dietary patterns which is data-driven using statistical methods; hence the subject is yet to be 
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assessed in further studies. Furthermore, the health status of the population in Portsmouth is below the 
national average and the results of this study, as the first survey conducted in this understudied 
population, could provide robust and reliable data for appropriate public health policies to promote the 
health and well-being of the residents, and also other regions with comparable population.  
7.3. Main findings of the research 
7.3.1. Nutritional interventions during pregnancy for prevention of childhood allergies 
Findings of meta-analyses provided evidence that consumption of probiotics during pregnancy only had a 
protective effect on childhood eczema. A protective effect was also found for prenatal supplementation 
with fatty acids and the development of sensitisation in children. It should be noted that the high 
heterogeneity between the studies such as variability of the supplementation (probiotics, fatty acids), 
dosage and timing of interventions limits the confidence we have in the conclusiveness of these results. 
Therefore, the current evidence cannot be definitely translated into practice and further research via multi-
centre, well-executed, harmonised RCTs are necessary. Also, given the immunomodulatory effects of 
both probiotics and fatty acids, their efficacy on reducing the development of other childhood allergies 
should be the subject for further research.  
 
There was no evidence that food avoidance during pregnancy could protect against childhood allergies, 
indicating that the food avoidance theory favoured in the 1980s does not appear to hold true. Infancy is a 
plasticity period during which the development of the immune system occurs and in fact, early exposure 
to allergenic foods via maternal diet, particularly in the first trimester, could develop tolerance in the 
foetus but sensitising to allergens (Devereux et al., 2006; Julia, Macia, & Dombrowicz, 2015). These 
findings in line with the current guidelines highlight the fact that women need to follow a normal and 
balanced diet with no restrictions during pregnancy (Australasian Society of Clinical Immunology and 
Allergy, 2016; Boyce et al., 2011; Muraro et al., 2014).  
 
The meta-analysis of studies that supplemented pregnant women with vitamins showed that prenatal 
consumption of Vitamin D could be associated with the development of childhood wheeze. The certainty 
of evidence is, however, low due to a paucity of studies and heterogeneities between these studies; 
nonetheless this novel finding could have valuable implications in practice for early prevention of 
childhood wheezing, which could have implications for the subsequent development of asthma given that 
this is one of the main risk factors for its development later in life. Further follow-ups of these studies are 
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also warranted to determine the longer-term effects of prenatal Vitamin D intervention. The anti-oxidative 
effects of vitamins on human immune function makes a strong theoretical case for their ability to prevent 
childhood allergies, but given the current paucity of evidence, it should be an important priority to assess 
the effectiveness of vitamins for prevention of allergies in larger well-designed trials. 
7.3.2. Nutritional interventions during pregnancy for prevention of childhood obesity 
No evidence was found that prenatal nutritional interventions of fatty acids and probiotics could have a 
protective effect on obesity outcomes in children. However this statement stems from a limited number of 
studies with substantial heterogeneity e.g. dosage/type of supplement and timing of intervention and 
furthermore, most of the studies were primarily conducted to measure outcomes other than obesity. 
Therefore, the evidence for the influential role of these supplements on childhood obesity is not yet 
definitive and demands further research. Combined use of these nutritional supplements with a balanced 
diet during pregnancy could also be considered in future studies.  
 
A few studies investigated the effect of LG index diet and life-style change as dietary interventions in 
pregnancy on childhood obesity, and because the studies reported different outcomes it was not possible 
to conduct meta-analyses. These studies had a large loss to follow-up and their individual results within 
each dietary group were not promising for the reported obesity outcomes in infants. It is worth noting that 
women in the intervention groups, within both dietary classes, achieved modest improvements in the 
quality of their diet and/or level of physical activity. However, it appears that there is a low quality of 
evidence for the efficacy of these prenatal dietary interventions on infant outcomes, which calls for 
further large-scale trials. Effective approaches also need to be defined in order to maintain compliance 
with the intervention and minimise the rate of attrition. As previously discussed in Chapter 2, the in utero 
environment programmes the foetus from the very early days; hence, theoretically at least, timely 
maternal dietary interventions could be the potential solution for a favourable prenatal environment and 
childhood outcomes. 
7.3.3. Findings of the cohort studies in relation to maternal diet during pregnancy  
The quality of maternal diet in this sample of pregnant women was low, on average women scored 33.6 
out of the maximum possible 70 for the AHEI-P score. A main distinction of the current study is that it 
measured the quality of maternal diet using a HEI score, which is based on the UK national guidelines for 
healthy eating in pregnancy. Relatively high frequency consumptions were also found for unhealthy items 
(sugar, processed meat and junk foods). These findings, as the first study in the city of Portsmouth, are 
concerning and highlight the need for public health policies to address the underlying factors for the 
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nutritional behaviours/choices within this understudied population. Other research worldwide has also 
shown that generally pregnant women do not meet the national nutrition recommendations and reported 
unfavourable intake for many nutrients (Blumfield, et al., 2012; Fowler & Evers, 2012; Malek, et al., 
2015; Morton et al., 2014). Indeed, a number of factors such as pregnancy-related, demographic and 
environmental elements could affect the quality and quantity of diet in women at reproductive age 
(Doyle, et al., 2016; Malek, et al., 2015) and this needs to be addressed in further research within this 
population.  
7.3.4. Findings of the cohort study in relation to the associations between the quality of 
maternal diet and weight/age outcomes in children  
The weight/age Z-scores at birth and follow-ups were not associated with maternal AHEI-P score. 
However higher maternal sugar consumption was linked to lower weight/age Z-scores at birth and 6 
months, although these effects disappeared when excluding the outliers on baby weight from the models. 
Negative associations were also found for formula-fed babies where higher maternal consumption of junk 
food and lower AHEI-P score were related with lower weight/age at 2 months. Overall, these findings 
support the importance of maternal diet during pregnancy since it could have implications for the risk of 
developing obesity later in life. As detailed earlier, different dietary patterns during pregnancy and also 
HEI scores could affect the risk of childhood obesity.  
 
In this study, a small sample of pregnant women was included, and therefore further research with a 
larger sample is needed to replicate these findings. It must be highlighted that, in the current study, it was 
not possible to measure other indicators of obesity in infants e.g. BMI or body composition such as SFT, 
which limits the study findings to an extent. Moreover, the high prevalence of obesity globally has led to 
many women entering their pregnancy while obese. Obesity on one side could relate to the quality of 
maternal diet during pregnancy, while on the other side it could also affect infant growth and the later risk 
of obesity in the child. In this study, data on other maternal-related factors such as pre-pregnancy 
overweight/obesity and gestational weight gain were not available; this could have limited the regression 
models and thus the explanatory power of the model predicting weight/age outcomes in babies. 
7.3.5. Findings of the cohort study in relation to the associations between quality of 
maternal diet and allergic outcomes in children  
The likelihood of developing allergies in this sample of children was not linked to the quality of maternal 
diet during pregnancy. This supports the current evidence from the existing studies on the quality of 
maternal diet (assessed by HEI scores) and subsequent development of childhood allergies in offspring. 
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As previously discussed in Chapter 2, generally speaking, observational studies have reported mixed 
messages for the associations between the intakes of different nutrients or dietary patterns in pregnancy 
and the development of various phenotypes of allergy in children.  
7.3.6. Findings of the cohort study in relation to infant feeding practices and weight/age 
outcomes  
Partially breast-fed babies at 2 months of age weighed less for age at 2 and 6 months than exclusively 
breast and formula-fed babies and additionally, number of formula feeds was associated with higher 
weight at 2 months Z-score in exclusively formula-fed babies. The window of opportunity for 
programming the risk of life-long obesity extends into postnatal life. Breast-feeding in comparison to 
formula-feeding could influence a healthier growth trajectory characterised by lower weight gain and 
percentage body fat. Indeed, an overview of systematic reviews indicated that breast-feeding for any 
duration could reduce the risk of childhood overweight and obesity by 13% (Patro-Gołąb et al., 2016).  
 
Rapid weight gain during the first year of life is also a strong predictor of childhood obesity (Druet et al., 
2012) and in this context, the advantages of breast-feeding as a primary prevention for obesity need to be 
more significantly publicised. Timing of introduction of formula additionally has a significant role since 
weight gain during the first week of life in formula-fed infants poses a great risk of obesity later in life 
(Stettler et al., 2005). In this study sample, 20% of babies were bottle-fed on first day of birth and 
community interventions informing mothers of the very early risk factors for obesity in children could 
encourage healthier feeding practices in infancy.  
7.3.7. Findings of the cohort study in relation to infant feeding practices and developing 
allergies at 6 months  
Gastrointestinal conditions such as colic, diarrhoea and constipation are commonplace in infancy and are 
usually transient. In this study these were considered as symptoms of allergy when there appeared to be a 
link in their occurrence and the digestion of a certain food. In addition, occurrence of any allergies in 
children was based on parental-report of eight symptoms defined in the questionnaire, since diagnosis of 
allergy at this very young age is not definitive.  
 
In this study, individual analyses for infant feeding practices (type of milk, timing of introduction of 
solids, introduction of allergenic foods and also other foods) did not find an association between these and 
the development of allergies. In the regression analysis, however, the protective effect for the early 
exposure to wheat between 3-6 months of age is very thought-provoking and adds weight to the argument 
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that early intake of allergenic food in infants could be safe, and may even be protective. This is certainly 
an area of current research focus, for example, the feasibility of early introduction of allergenic foods e.g. 
wheat and peanut has been investigated in a recent trial (Perkin et al., 2015).  
 
The ideal time for introduction of solids into an infant’s diet is currently suggested after 6 months (World 
Health Orgnisation, 2003) and there is a controversy surrounding the risk of allergy if solids are offered 
after 6 months. Most infants are developmentally ready by 6 months of age in terms of being able to 
safely manage complementary feeding, and there is an argument that delayed weaning could increase the 
risk of allergies (Scientific Advisory Committee on Nutrition, 2017; Togias et al., 2017). In this study, 
25% and 13.8% of babies were weaned after 6 months or not weaned yet respectively, suggesting the 
educational needs of parents in the city of Portsmouth with an emphasis that babies need to be exposed to 
a wide variety of age-appropriate nutritious foods in early life (Palmer & Prescott, 2017).    
 
In addition, although babies in the current study were in the early stages of weaning, allergic children had 
a less varied diet than non-allergic children, scoring lower for the total intake of other foods although this 
was not significant. This has relevance for health professional practices in order to avoid unnecessary 
exclusion(s) from an infant’s diet since manipulation of dietary intake during infancy can have a profound 
effect on the later risk of allergies (Scientific Advisory Committee on Nutrition, 2017; Togias et al., 
2017).  
 
Generally speaking, the findings from the first study in this PhD provided some evidence for the 
importance of consumption of nutritional supplements in pregnant women and more specifically Vitamin 
D. In the second study, a small percentage of pregnant women reported that they consumed either any 
nutritional supplements (42.6%) or Vitamin D (33.8%) and detailed information for the consumption of 
probiotics, fatty acids was not assessed. The low consumption of Vitamin D suggests that the guidelines 
are not being well communicated to pregnant women and calls for health promotion initiatives. 
7.4. Implications for future research 
The first study of this research programme provided an up-to-date review of the evidence from studies of 
prenatal interventions for the prevention of allergic and obesity outcomes in the offspring and established 
some novel findings in relation to certain interventions i.e. probiotics, fatty acids and vitamins and the 
prevention of specific allergic outcomes. However, the heterogeneities observed between the conducted 
studies limit their findings in practice and calls for these to be addressed in further research. The key 
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potential for the maternal interventions during pregnancy is that they could modulate the gut microbiota 
and thus the immune system from very early in life, and, therefore, are a good primary prevention 
approach. The life-style interventions particularly need to target women in the preconception stage to 
regulate the maternal-related factors e.g. high BMI or diabetes that could directly affect the maturation of 
the foetal immune system during pregnancy. Given the multifactorial nature of allergies and obesity, 
future trials would ideally employ multifaceted schemes enabling them to control for other environmental 
factors such as quality of maternal diet to maximise their ability to assess the effectiveness of the 
interventions.  
 
The second study of this research programme, as the first cohort study in the city of Portsmouth, 
investigated the relationship between quality of diet in pregnant women and weight outcomes and the 
development of allergies by 6 months of age. The results provided some evidence for the influential role 
of maternal diet on weight outcomes but not for allergies. However, longer-term follow-up of these babies 
would provide more reliable data on whether these effects will persist in later life.  
 
The feeding practices of babies at 2 and 6 months of age also showed some associations with weight 
outcomes and allergies, which are not only novel findings as its first kind in the city of Portsmouth, but 
also could have implications in the other regions with a similar population. It is not possible, nonetheless, 
to predict whether these results will persist into later ages and further follow-up of these studies could 
assess to what extent the totality of diet at older age could affect the obesity and allergic outcomes in 
these children. It is worth noting that the longer-term follow-up is of more importance for assessing the 
allergic outcomes in these babies since there is no definitive diagnosis for allergies at a very early age, 
and their prevalence could also be affected by the diversity of foods digested as babies grow.  
  
Furthermore, future research involving a larger sample of pregnant women and their babies would allow 
more detailed statistical analysis to be undertaken. For example it was not possible with the number of 
participants recruited in the current study, to differentiate the weight outcomes between exclusive and 
dominant breast-feeding practices, and, therefore, these were combined.  
7.5. Strengths of the research 
The first study of the research used an a priori published protocol that allowed complete coverage of the 
relevant literature. In addition, the systematic reviews only included trials that started the specific 
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nutritional/dietary intervention throughout pregnancy and a comprehensive range of childhood allergic 
and obesity outcomes were defined as the outcomes of interest in the reviews.  
 
The main strength for the second study of research is that the cohort design allowed data to be collected 
prospectively and thus, minimising the recall bias. Dietary intake of pregnant women was also 
investigated for the total quality and a HEI score was calculated reflecting consumption of actual foods 
and food groups. The questionnaires used were all validated and age-appropriate for the follow-up 
assessments.  
7.6. Limitations of the research 
The limitations for the first study of research, synthesising the evidence from RCTs for the effectiveness 
of prenatal interventions for prevention of allergies and obesity outcomes in children, stems from the 
shortages in the studies conducted. These were mainly listed as differences in dosage/type/timing of 
intervention and issues in terms of sampling and duration of follow-up. There was also a deviation from 
the a priori protocol for this research in that the sub-group analyses (e.g. different strains of certain 
interventions, high vs. low risk participants) were not conducted in order to avoid a type two error or 
where these were already addressed in previous reviews. In addition, the standard for the conduct of 
systematic reviews is they are conducted within a team of researchers and for this PhD the student mainly 
conducted the reviews as a sole researcher. All the measures however, were carried out to assure the 
quality of the systematic reviews. For example, the main reviewer conducted cross-referencing and 
sought expert opinion to ensure that all the relevant studies were included in the reviews. Similarly, every 
effort was made to do the screening with great care and attention to detail, and any disagreement was 
discussed within the supervisory team. Also, any bias for the appraisal of studies and data extraction were 
minimised by crosschecking within the supervisory team. Furthermore, including the longest follow-up 
data from the included trials in the systematic reviews might have introduced heterogeneities into the 
meta-analyses since the length of follow-up between trials were varied however, this approach has 
provided insight for the longer term benefits of the interventions as opposed to the short-term effects. The 
findings of the systematic reviews, additionally, could have informed the observational study in this PhD. 
However, the time scale for completing this PhD research (particularly in light of the need to allow time 
for follow-up in the cohort study, and that the cohort study was part of a larger study with its own 
timescales) necessitated that these studies were undertaken concurrently. 
 
 316 
For the second study of research, the key limitation was the small sample size, and also the short duration 
of follow-up. It was however an important opportunity to assess the short-term impact of the quality of 
maternal diet and infant feeding practices on growth and allergic outcomes and of course, further follow-
up is an important tool to assess the impact as children grow. In addition, data on other growth parameters 
and obesity measures were not available and it was not feasible to collect data on maternal-related risk 
factors e.g. gestational weight gain. 
  
The methodological issues concerning the collection of dietary data in pregnant women, using FFQ-P and 
also milk diary in infants, have previously been explained. However, these are inherent to nutritional 
assessment studies and this study attempted to choose appropriate dietary assessment methods for each 
target group. Using a logbook, possibility of any biases in the collected data and analysis were minimised. 
It is also acknowledged that nutritional intake of infants at 2 months of age were not validated against 
biomarkers and additionally, no clinical tests were used for the diagnosis of allergies at 6 months of age. 
7.7. Concluding remarks  
The original contribution of the first study of this research is that prenatal consumption of Vitamin D 
could protect against the development of wheeze in the offspring. The further follow-up of the included 
studies, however, could provide more robust data on whether the intervention could also prevent the 
development of childhood asthma.  
 
The second studies conducted as cohort also provided evidence that unhealthy eating behaviours during 
pregnancy i.e. consumption of sugar and junk food, could have direct impact on weight outcomes in 
infants. Moreover, feeding practices early in life had an influence on the weight/Z-scores at 2 and 6 
months of age where the partially breast-fed infants weighed lower. This has implications for public 
health policies to emphasise how any duration of breast-feeding could contribute to lower risk of obesity 
in life-long. Furthermore, the protective effect of early introduction of wheat between 3-6 months of age 
on the development of allergies at 6 months of age suggests that early introduction of allergenic foods 
could be considered beneficial.  
 
The importance of the first 1,000 days in a baby’s life is highlighted in the introductory Chapter of this 
thesis where nutrition status in mother and infant could have an influential role on the proper maturation 
of an infant’s immune system. The findings from this PhD research have enhanced our understanding in 
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this field as to how early-life nutrition, as epigenetic environmental factor, can modify the risk of obesity 
and allergies in children.  
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Appendix 3.2: Search strategy (allergic outcomes) 
 
The following four important concepts were identified based on the research question:  
 Pregnancy 
 Diet  
 Allergy (Non-communicable diseases)  
 Randomised controlled trial 
A variety of keywords and synonyms were identified using the Patient Intervention Comparison Outcome 
Study (PICOS) approach. A full list of the used keywords for each concept in the databases is presented 
in the following table.  
Within groups of terms, the terms were combined using OR and the groups of terms themselves were 
then combined in the following manner: #1 AND #2 AND #3 AND #4. 
Relevant citations and key authors were identified. To prevent bias, no restriction was placed on the 
year of publication or language.  
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Search Log-MEDLINE (From inception-January 2015) (appendix 3.2) 
Search No. Date of search Concepts Terms used Hits Comments 
1 9/12/2014 1
st
 filter pregnan* OR ( (antenatal or ante-natal or ante natal) ) OR ( (prenatal or pre-
natal or pre natal) ) OR ( (mother or maternal) )  
942,914  
2 9/12/2014  (MH " Pregnancy+")  714,997  
3 9/12/2014  S1 OR S2 (#1 & #2) 956,346  
4 9/12/2014 2
nd
 filter Diet* or (food or consumption or intake) OR (mineral or nutrition or nutrient) 
OR (milk or egg or peanut or fruit or vegetable) OR (vitamin* or fatty acid* or 
supplement*) OR (probiotic* or prebiotic*) OR folic acid  
1,857,545  
5 9/12/2014  (MH "Nutritional Physiological Phenomena+")  396,003  
6 9/12/2014  S4 OR S5  (#4 & #5) 1,957,574  
7 9/12/2014 3
rd 
filter non-communicable disease* OR noncommunicable disease* OR non 
communicable disease*  
4,315 No MESH terms for non 
communicable diseases 
8 9/12/2014  allerg* or atopy or dermatitis or eczema) OR (asthma or wheez*) OR (food 
hypersensitivity or food allergy or food intolerance) OR (non IgE or non-IgE or 
mediated allerg*) OR hypersensitivity OR rhinitis  
433,069  
9 9/12/2014  (MH "Hypersensitivity+")  280,496  
10 9/12/2014  S8 OR S9 (#8 or #9) 470,051  
11 9/12/2014  S7 OR S10 (#7 or #10) 474,253  
12 9/12/2014 4
th
 filter randomised controlled trial or randomised control trial or randomised controlled 
study or randomised clinical trial or controlled clinical trial or controlled trial or 
random allocation ) OR ( single blind or single blind method or single blind trial 
or double blind method OR double-blind method ) OR ( clinical trial* or quasi-
experimental study or placebo-controlled trial or placebo control or intervention 
study or follow-up stud* 
1,134,412  
13 9/12/2014  (MH "Clinical Trials as Topic+") OR (MH "Controlled Clinical Trials as 
Topic+")  
279,911  
14 9/12/2014  S12 OR S13 (#12 or #13) 1,195,071  
15 9/12/2014 combined S3 AND S6 AND S11 AND S14  423 423 
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Search Log-COCHRANE (From inception-January 2015) (appendix 3.2) 
Search No. Date of search Concepts Terms used Hits Comments 
1 10/12/2014 1
st
 filter pregnan* or antenatal or ante-natal or ante natal or prenatal or pre-natal or pre natal or mother 
or maternal 
33049  
2 10/12/2014  MeSH descriptor: [Pregnancy] explode all trees 5824  
3 10/12/2014  #1 or #2 33172  
4 10/12/2014 2
nd
 filter diet or food or consumption or intake or mineral or nutrition or nutrient or milk or egg or 
peanut or fruit or vegetable or vitamin* or fatty acid* or supplement* or probiotic* or 
prebiotic* or folic acid 
115882  
5 10/12/2014  MeSH descriptor: [Nutritional Physiological Phenomena] explode all trees 20196  
6 10/12/2014  #4 or #5 119305  
7 10/12/2014 3
rd
 filter non-communicable disease* or non communicable disease* or noncommunicable disease* 322  
8 10/12/2014  allerg* or atopy or dermatitis or eczema or asthma or wheez* or food hypersensitivity or food 
allergy or food intolerance or non IgE or non-IgE or mediated allerg* or hypersensitivity or 
rhinitis 
42512  
9 10/12/2014  MeSH descriptor: [Hypersensitivity] explode all trees 15654  
10 10/12/2014  #8 or #9 43167  
11 10/12/2014  #7 or #10 43452  
12 10/12/2014 4
th 
filter randomised controlled trial or randomised control trial or randomised controlled study or 
randomised clinical trial or controlled clinical trial or controlled trial or random allocation or 
single blind or single blind method or single blind trial or double blind method or double-
blind method or clinical trial* or quasi-experimental study or placebo-controlled trial or 
placebo control or intervention study or follow-up stud* 
652339  
13 10/12/2014  MeSH descriptor: [Randomized Controlled Trial] explode all trees 139  
14 10/12/2014  #12 or #13 652339  
15 10/12/2014 combined #3 and #6 and #11 and #14 1465 In Cochrane 
Reviews 
(reviews and 
protocols, other 
reviews and 
trials), limited to 
trials only yields 
255 hits 
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Search Log-SCOPUS (From inception-January 2015) (appendix 3.2) 
Search No. Date of search Concepts Terms used Hits Comments 
1 15/12/2014 1
st
 filter (TITLE-ABS-KEY(pregnan*) OR TITLE-ABS-KEY(antenatal or ante-natal or ante 
natal) OR TITLE-ABS-KEY(prenatal or pre-natal or pre natal) OR TITLE-ABS-
KEY(mother or maternal)) 
1,151,775 Scopus does not 
use a controlled 
vocabulary, like 
MeSH to search 
2 15/12/2014 2
nd
 filter (TITLE-ABS-KEY(diet*) OR TITLE-ABS-KEY(food or consumption or intake or 
mineral) OR TITLE-ABS-KEY(nutrition or nutrient) OR TITLE-ABS-KEY(milk or egg 
or peanut or fruit or vegetable) OR TITLE-ABS-KEY(vitamin* or fatty acid* or 
supplement*) OR TITLE-ABS-KEY(probiotic* or prebiotic*) OR TITLE-ABS-
KEY(folic acid)) 
3,718,859  
3 15/12/2014 3
rd
 filter ( TITLE-ABS-KEY ( non-communicable  disease* )  OR  TITLE-ABS-
KEY ( non  communicable  disease* ) OR  TITLE-ABS-
KEY ( noncommunicable  disease* ) )  
7,196  
4 15/12/2014  ( TITLE-ABS-KEY ( allerg* )  OR  TITLE-ABS-KEY ( atopy )  OR  TITLE-ABS-
KEY ( dermatitis )  OR  TITLE-ABS-KEY ( eczema )  OR  TITLE-ABS-
KEY ( asthma )  OR  TITLE-ABS-KEY ( wheez* )  OR  TITLE-ABS-
KEY ( food  hypersensitivity )  OR  TITLE-ABS-KEY ( food  allergy )  OR  TITLE-ABS-
KEY ( food intolerance )  OR  TITLE-ABS-KEY ( non  ige )  OR  TITLE-ABS-KEY ( non-
ige  OR  mediated  allerg* )  OR TITLE-ABS-KEY ( hypersensitivity )  OR  TITLE-ABS-
KEY ( rhinitis ) )  
593,466  
5 15/12/2014  #3 or #4 600,386  
6 15/12/2014 4
th
 filter ( TITLE-ABS-KEY ( randomised  controlled  trial )  OR  TITLE-ABS-
KEY ( randomised  control  trial )  OR TITLE-ABS-
KEY ( randomised  controlled  study )  OR  TITLE-ABS-
KEY ( randomised  clinical  trial )  OR TITLE-ABS-KEY ( controlled  clinical  trial )  OR  TITLE-
ABS-KEY ( controlled  trial )  OR  TITLE-ABS-KEY ( random  allocation )  OR  TITLE-ABS-
KEY ( single  blind )  OR  TITLE-ABS-KEY ( single  blind method )  OR  TITLE-ABS-
KEY ( single  blind  trial )  OR  TITLE-ABS-KEY ( double  blind  method )  OR TITLE-ABS-
KEY ( double-blind  method )  OR  TITLE-ABS-KEY ( clinical  trial* )  OR  TITLE-ABS-
KEY ( quasi-experimental  study )  OR  TITLE-ABS-KEY ( placebo-
controlled  trial )  OR  TITLE-ABS-KEY ( placebo  control )  OR  TITLE-ABS-
KEY ( intervention  study )  OR  TITLE-ABS-KEY ( follow-up  
2,636,519  
7 15/12/2014 combined #1 and #2 and #5 and #6 1,364 Limited to 
original studies 
(n=796) 
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Search Log-Other databases (appendix 3.2) 
Search No. Date of search Concepts Terms used Hits Comments 
1 10/01/2015 Web of Science Primary prevention of atopic disease by perinatal dietary interventions 3 One is a published 
book, might need 
further attention 
2 10/01/2015  Prevention of atopic disease by maternal dietary interventions in pregnancy 16 all results are also 
identified in main 
databases’ search  
3 10/01/2015 ETHoS Prevention of allergic disease by maternal dietary interventions 1  
4 10/01/2015 Clinicaltrials.gov Prevention of allergic disease by maternal interventions in pregnancy 12  
5 10/01/2015  Primary prevention of atopic disease by perinatal interventions 1 Identified in other 
as well as main 
data bases 
 10/01/2015  Prevention of atopic diseases by maternal nutritional interventions in pregnancy 3 Identified in other 
as well as main 
data bases 
6 11/01/2015 
 & 
12/01/2015 
ICTRP** Prevention of allergic disease (in the title) or pregnancy (in the condition) or nutrition 
interventions (in the intervention)*** 2182 
2 relevant study, 
also found in main 
data bases 
*Short phrases were used using different synonyms and for each database, the phrases that have yielded any results are shown. 
**WHO International Clinical Trials Registry Platform 
***Also, the list of trials by health topic, from the WHO above-mentioned platform, was looked into and trials’ titles in some health topics were checked as follows: 
a. Child Health (99) 
b. Food Safety (3) 
c. Food Insecurity (5) 
d. Maternal Health (9) 
e. Women’s Health (49) 
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Study eligibility form-Allergic outcomes  
 
PICOS Yes Unclear No 
Participants 
 
   
Are the participants classed as pregnant women, from general population, and 
their offspring? 
   
    
Type of study  
Is the study one of the following designs during pregnancy or continued after 
pregnancy, either in mother or infant or both? 
   
 
Randomised controlled trial 
   
 
Cluster randomised controlled trial 
   
 
Quasi-randomised controlled trial 
   
    
Types of interventions (the intervention could be a combination of the 
followings) 
 
 
Food-based dietary advice (promoting a healthy diet) or nutrient intervention 
 
Multivitamins, supplementation and minerals 
 
Fatty acid supplement(s) 
 
Pre/Probiotic supplement(s)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcomes   
 
 
 
Do the outcome measure allergy, on its own as a general term, or any allergy 
related outcome(s) i.e. dermatitis, wheeze, asthma, rhinitis? 
 
Are the outcome measures validated? 
 
 
 
  
 
 
 
Study ID ___________ Reviewer ___________ Appendix 3.3 
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Appendix 3.4-Characteristics of the excluded studies-Allergic outcomes
* 
 
Intervention  Reason for exclusion 
Probiotics  
Aa 2010 Synbiotics as intervention in infants with AD 
Berni 2011 Post-natal intervention (in infants) 
Brouwer 2006 Post-natal intervention (in infants) 
Cabana 2007 Post-natal intervention (in infants) 
Chen 2010 Intervention in young children 
Chernyshove 2009 Post-natal intervention (in infants with AD) 
Ciprandi 2005 Post-natal intervention (in infants with allergic rhinitis) 
Cukrowska 2010 Intervention in children with food allergy 
Drago 2011 Intervention in adults with AD 
Farid 2011 Synbiotics as intervention in children with AD 
Folster-Holst 2006 Post-natal intervention (in infants with AD) 
Giovannini 2007 Intervention in pre-school children 
Gobel 2010 Intervention in children with AD 
Gore 2012 Post-natal intervention 
Grasimov 2010 Intervention in school children 
Gruber 2007 Post-natal intervention (in infants) 
Gutkowski 2010 Intervention in children with asthma 
Han 2012 Post-natal intervention (in infants) 
Helin 2002 Intervention in children 
Isolauri 2000 Post-natal intervention (in infants) 
Kankaanpää 2002 Post-natal intervention (in infants with AD) 
Kobuta 2014 Post-natal intervention (in mothers) 
Moro 2006 Post-natal intervention (in infants) 
Muraro 2012 Post-natal intervention (in infants) 
Prescott 2005 Pre-clinical outcomes reported 
Rautava 2006 Post-natal intervention (in mothers) 
Rose 2010 Post-natal intervention (in infants) 
Taylor 2006 Post-natal intervention 
Torii 2011 Post-natal intervention (in children with AD)  
Viljanen 2005 Post-natal intervention (in infants with AD) 
West 2009 Post-natal intervention (in infants) 
West 2012 Pre-clinical outcomes reported 
Weston 2005 Post-natal intervention (in infants) 
Woo 2010 Intervention in children with AD syndrome 
Yesilove 2012 Post-natal intervention (in infants with AD) 
Fatty acids  
Bergmann 2008 Reported Growth outcomes in infants 
Carlson 2013 Reported growth outcomes in infants 
Colombo 2004 Reported growth outcomes in infants 
Courville 2011 Reported growth outcomes at birth 
Dotterud 2013 Non-randomised multifaceted intervention  
Garnot 2011 Reported growth outcomes in infants 
Hauner 2009 Reported growth outcomes in infants 
Helland 2001 Reported growth outcomes in infants 
Innin 2007 Reported growth outcomes in infants 
Judge 2007 Reported growth outcomes in infants 
Karlsson 2010 Reported growth outcomes in infants 
Knudsen 2006 Reported maternal outcome at pregnancy 
Martin-Alvarez 2012 Published as an abstract and reported oxidative stress status in infants 
Mihrshahi 2001 Postnatal diet intervention in infants 
Pena-Quintana 2011 Published as an abstract and reported blood DHA concentration  
Romero 2013 Pre-clinical outcomes (genetic programming for allergy in infants) 
Van Gool 2003 Post-natal intervention 
Food avoidance   
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Appelt 2004 Only abstract available 
Arroyave-Hernandez 
1993 
Non-randomised trial (in Spanish) 
Arshad 1992 Post-natal multifaceted intervention in infancy  
Cant 1986 Post-natal intervention (in lactating mothers, crossover trial) 
Chandra 1986 Investigations by his University, the Memorial University of Newfoundland 
and the Canadian Broadcasting Corporation strongly suggest that the 
published data may have been fabricated. BMJ has also retracted another 
paper published by him after receiving a copy of an inquiry into the research 
of R K Chandra, which was conducted by the Memorial University of 
Newfoundland and completed in August 1995 (BMJ 2015; 351:h5682).  
Chatzi 2008 Non-randomised trial  
Hattevig 1989 Non-randomised trial 
Hermann 1996 Non-randomised trial  
Kuiper 2005 Post-natal food intervention arm  
Scho¨nberger 2005 Post-natal food intervention arm 
Swell 2013 Protocol on assessing pre-natal Mediterranean diet (MD) for prevention of 
allergies in infants (further to personal email communication on Oct 2015, the 
author confirmed that their paper in rejected). The pilot results on only 
retention and acceptability of a MD is recently published. 
Vance 2005 Post-natal intervention in infants 
Vitamins  
Baz 2014 Prospective cohort study  
Camargo 2011 Prospective cohort study  
Chawes 2014 Prospective cohort study  
Chiu 2015 Prospective cohort study  
de Jongh 2014 Prospective cohort study  
Gale 2008 Prospective cohort study  
Grant 2014 Not reported the outcomes of interest for this systematic review 
Jones 2015 Prospective cohort study  
Luczynska 2014 Prospective cohort study  
Magnus 2013 Prospective cohort  
Mohamed 2013 Prospective cohort study  
Morales 2012 Prospective cohort study  
Norizoe 2014 Post-natal intervention (in lactating mothers) 
Pike 2012 Prospective cohort study  
Rothers 2011 Prospective cohort study  
Shin 2013 Prospective cohort study  
Stelmach 2015 Prospective cohort study  
Vähämiko   2013 Non-randomised trial 
Wills 2013 Prospective cohort study  
Zosky 2014 Prospective cohort study 
* Studies that were excluded at the final stage of screening are presented and also one publication, mainly a recent work for each original study is cited  
Probiotic studies  
 Berni Canani R, Nocerino R, Terrin G, Leone L, Cosenza L, Coruzzo A, et al. 
Effect of extensively hydrolyzed casein formula supplemented with lactobacillus 
GG on tolerance acquisition in infants with cow's milk allergy: A randomized 
trial. Allergy: European Journal of Allergy and Clinical Immunology 2011; 
66:708-9. 
 Brouwer ML, Wolt-Plompen SA, Dubois AE, van der Heide S, Jensen DF, Hojjer 
MA, Kauffman HF, Duiverman EJ. No effect of probiotics on atopic dermatitis in 
infancy: a randomised placebo-controlled trial. Clin Exp Allergy 2006; 36: 988-
906. 
 Cabana MD, McKean M., Wong CC, Caughex AB. Examining the hygiene 
hypothesis: the Trial of Infant Probiotic Supplementation. Paediatric & Perinatal 
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Epidemiology 2007; 21 (Suppl. 3), 23–28. 
 Chen YS, Jan RL, Lin YL, Chen HH, Wang JY. Randomised placebo-controlled 
trial of lactobacillus on asthmatic children with allergic rhinitis. Pediatric 
Pulmonology 2010; 45:1111-20. 
 Chernyshov PV. Randomised, placebo-controlled trial on clinical and 
immunologic effects of probiotic containing Lactobacillus rhamnosus R0011 and 
L. helveticus R0052 in infants with atopic dermatitis. Microbial Ecology in 
Health and Disease 2009; 21:228-32. 
 Ciprandi G, Vizzaccaro A, Cirillo I, Tosca M A. Bacillus clausii effects in 
children with allergic rhinitis. Allergy 2005; 60:702-3. 
 Cukrowska B, Ceregra A, Klewicka E, Slizewska K, Motyl I, Libudzisz Z. 
Probiotic lactobacillus casei and lactobacillus paracasei strains in treatment of 
food allergy in children. [Polish]. Przeglad Pediatryczny 2010; 40:21-5. 
 Drago L, Iemoli E, Rodighiero V, Nicola L, De Vecchi E, Piconi S. Effects of 
Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: 
A randomized placebo-controlled study. International Journal of 
Immunopathology and Pharmacology 2011; 24:1037-48. 
 Farid R, Ahanchian H, Jabbari F, Moghiman T. Effect of a new synbiotic mixture 
on atopic dermatitis in children: A randomized-controlled trial. Iranian Journal of 
Pediatrics 2011; 21:225-30. 
 Folster-Holst R, Muller F, Schnopp N, Abeck D, Kreiselmaier I, Lenz T, et al. 
Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants 
with moderate to severe atopic dermatitis. British Journal of Dermatology 2006; 
155:1256-61. 
 Gerasimov SV, Vasjuta VV, Myhovych OO, Bondarchuk LI. Probiotic 
supplement reduces Atopic Dermatitis in preschool children: A randomized, 
double-blind, placebo-controlled, clinical trial. American Journal of Clinical 
Dermatology 2010; 11:351-61. 
 Giovannini M, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti G V, et al. A 
randomized prospective double blind controlled trial on effects of long-term 
consumption of fermented milk containing Lactobacillus casei in pre-school 
children with allergic asthma and/or rhinitis. Pediatric Research 2007; 62:215-20. 
 Gobel R, Larsen N, Molgaard C, Jakobsen M, Michaelsen K F. Probiotics to 
young children with atopic dermatitis: A randomized placebo-controlled trial. 
International Journal of Probiotics and Prebiotics 2010; 5:53-9. 
 Gore C, Custovic A, Tannock G W, Munro K, Kerry G, Johnson K, et al. 
Treatment and secondary prevention effects of the probiotics Lactobacillus 
paracasei or Bifidobacterium lactis on early infant eczema: Randomized 
controlled trial with follow-up until age 3 years. Clinical and Experimental 
Allergy 2012; 42:112-22 
 Gruber C, Wendt M, Sulser C, Lau S, Kulig M, Wahn U, et al. Randomized, 
placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic 
dermatitis in infancy. Allergy: European Journal of Allergy and Clinical 
Immunology 2007; 62:1270-6. 
 Gutkowski P, Madalinski K, Grek M, Dmenska H, Syczewska M, Michalkiewicz 
J. Effect of orally administered probiotic strains Lactobacillus and 
Bifidobacterium in children with atopic asthma. Central-European Journal of 
Immunology 2010; 35:233-8. 
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 Han Y, Kim B, Ban J, Lee J, Kim B, Choi BS, Hwang S, Ahn K, Kim J. A 
randomised trial of Lactobacillus plantarum CJLP133 for the treatment of atopic 
dermatitis. Paediatr All Immunol 2012; 23: 667-673. 
 Helin T, Haahtela S, Haahtela T. No effect of oral treatment with an intestinal 
bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: 
A placebo-controlled double-blind study. Allergy: European Journal of Allergy 
and Clinical Immunology 2002; 57:243-6. 
 Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the 
management of atopic eczema. Clinical and Experimental Allergy 2000; 30:1604-
10 
 Kankaanpää PE, Yang B, Kallio HP, Isolauri E, Salminen SJ. Influence of 
probiotic supplemented infant formula on composition of plasma lipids in atopic 
infants. J Nut Biochem 2002;13(6):364-369. 
 Kubota T, Shimojo N, Nonaka K, Yamashita M, Ohara O. Prebiotic consumption 
in pregnant and lactating women increases IL-27. BR J Nutr 2014; 111:625-32. 
 Moro G, Arslanoglu S, Stahl B, Jelinek J, Wahn U, Boehm G. A mixture of 
prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the 
first six months of age. Arch Dis Child 2006; 91: 814-9. 
 Muraro A, Hoekstra MO, Meijer Y, Lifschitz C, Wampler J L, Harris C. 
Extensively hydrolysed casein formula supplemented with Lactobacillus 
rhamnosus GG maintains hypoallergenic status: randomised double-blind, 
placebo-controlled crossover trial. BMJ 2012; 2:e000637 
 Prescott S L, Dunstan J A, Hale J, Breckler L, Lehmann H, Weston S, et al. 
Clinical effects of probiotics are associated with increased interferon-gamma 
responses in very young children with atopic dermatitis. Clinical & Experimental 
Allergy 2005; 35:1557-64 
 Rautava S, Kalliomaki M, Isolauri E. probiotics during pregnancy and 
breastfeeding might confer immunomodulatory protection against atopic disease 
in the infant. J Allergy Clin Immunol 2002; 109:119-21. 
 Rose MA, Stieglitz F, Koksal A, Schubert R, Schulze J, Zielen S. Efficacy of 
probiotic Lactobcillius GG on allergic sensitisation and asthma in infants at risk. 
Clin Exp Allergy 2010; 40: 1398-405. 
 Taylor A, Hale J, Wiltschut H, Lehman JA, Dunstan A, Prescott S. Effects of 
probiotic supplementation for the first 6 months of life on allergen- and vaccine-
specific immune responses. Clinical and Experimental Allergy 2006; 36: 1227–
1235. 
 Torii S, Torii A, Itoh K, Urisu A, Terada A, Fujisawa T, et al. Effects of oral 
administration of Lactobacillus acidophilus L-92 on the symptoms and serum 
markers of atopic dermatitis in children. International Archives of Allergy & 
Immunology 2011; 154:236-45. 
 van der Aa LB, Heymans HS, Aalderen WM, Sillevis Smitt JH, Knol J, Ben 
Amor K. Effect of a new synbiotic mixture on atopic dermatitis in infants: a 
randomized-controlled trial. 2010; 40:795-804. 
 Viljanen M, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, 
et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: 
a double-blind placebo-controlled trial. Allergy 2005; 60:494-500. 
 West CE, Hammarström ML, Hernell O. Probiotics during weaning reduce the 
incidence of eczema. Pediatr Allergy Immunol 2009; 20: 430-437.  
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 West CE, Hernell O, Andersson Y, Sjöstedt M, Hammarström ML. Probiotic 
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42: 540-9. 
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90:892-7. 
 Woo S I, Kim J Y, Lee Y J, Kim N S, Hahn Y S. Effect of Lactobacillus sakei 
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 Zosky GR, Hart PH, Whitehouse AJ, Kusel MM, Ang W, Foong RE, et al. 
Vitamin D deficiency at 16 to 20 weeks’ gestation is associated with impaired 
lung function and asthma at 6 years of age. Ann Am Thorac Soc 2014; 11:571-7. 
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Papers published after the search strategy for these systematic reviews were 
updated on January 2016 (not included in the current review) 
Study  Intervention and Outcome reported 
Hansen 2016* Fatty acid, Asthma and allergic respiratory disease at 18-19 years 
Bisgaard 2017 Fatti acid, Asthma/persistent wheeze at 3 years 
*updated follow-up (18 years old) of the study by Olsen  2008 
 
 Hansen S, Strøm M, Maslova E, Dahl R, Hoffmann HJ, et al. Fish oil 
supplementation during pregnancy and allergic respiratory disease in the adult 
offspring. J Allergy Clin Immunol 2017; 139: 104-111.  
 Bisgaard H, Stokholm J, Chawes BoL, Vissing NH, Bjarnad E, et al. Fish oil-
derived fatty acids in pregnancy and wheeze and asthma in offspring. NGJM 
2016; 375: 2530-9. 
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Appendix 3.5. Data extraction tool for allergic outcomes 
 Screening outcome 
     Exclude (Non-Randomised) 
     Study Protocol 
     Linked Record-Do not obtain data 
    Includes abstracts and later follow-up studies, provided that the later follow-up                     
has reported the same outcome(s) for the same sample at the earlier report 
 Study Details 
 Country 
 Recruitment Period 
Please record the months/years that the recruitment is done 
 Setting 
Where the sample are taken e.g. clinics, hospital, multicentre. Please record 
all reported information (provide page numbers for quotes) 
 Informed consent 
If not stated/unclear, please state as "NOT REPORTED/UNCLEAR" 
 Ethical Approval  
If stated, please record the relevant information and tick the box.  
If not stated/unclear, please state as "NOT REPORTED/UNCLEAR" 
 Source of Funding 
Please record, if stated. If not, please state "not reported". 
 Trial Type 
 PC-RCT 
Randomised Controlled Trial-Placebo Controlled 
Please provide brief description of study design. 
 RCT 
Randomised Controlled Trial 
Please provide brief description of study design. 
 CR 
Cluster Randomised, please provide brief description of study design. 
 Quasi Experimental 
Please provide brief description of study design. 
 No. & name of Study Groups/Arms 
Please state the number and name of allocated treatment arms i.e. one 
treatment group vs. one placebo group, more than one treatment with/without 
placebo 
Please record all the relevant information briefly 
 ITT 
Intention-to-treat analysis  
 Yes 
 No 
 Not mentioned 
 Study Sample  
 Matched baseline characteristics 
 Yes 
 No 
 Women's age 
If there is any information about women's age, either stated as an inclusion 
criteria or other presented information, please record the age limits 
If possible, split the age data into target group, at the study start, and actual 
reported age in results 
 Exclusion criteria 
 Yes 
 No 
 FH of Atopy 
Subjects with a family history of Atopy are selected for the study 
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 Unselected sample 
Subjects are taken from an unselected population. 
 No. of participants at randomisation 
Please record the number of PREGNANT WOMEN at the time of 
randomisation, where recruitment occurred prenatally. 
 No. at F-U 
No. of subjects at the end of follow-up in both intervention and control 
groups.  
 Missing Participants 
Please record the reasons missing numbers at birth e.g. number of infants 
eligible at birth. 
 Reasons Missing 
 Time Points Measured 
Earlier follow-up(s) reported time points  
 Infant's age at last F-U 
Please record the reported age of infants at their last follow-up 
 Intervention 
 Probiotic Type (Organism) 
Please tick all relevant boxes 
Any Pro 
 LGG 
Lactobacillus GG 
 LPR+BL999 
 ST11 and BL999 
 Bifido animalis 
 L rhamnosus 
 L reuteri 
 Mixed Pro 
 Added Prebiotic 
If applicable, please record all the relevant information i.e. type, dosage, 
in mother, infant or both 
 Daily Dosage 
Please record the total daily dosage taken in mother, infant or both, 
whichever is applicable with units 
 
If more than one type is taken, please record the total daily dosage for all 
with units 
 Mode of Int. Delivery in Infancy 
Who has delivered the intervention and how e.g. mothers and oral 
 Mode of Int. delivery during Pregnancy 
e.g. oral use 
 FA Type 
Fatty Acid type, please tick all relevant boxes 
 Any FA 
 N-3 PUFA 
 DHA 
Docosahexaenoic Acid  
 Fish oil 
 Omega-3 PUFA 
 Salmon Portions 
SIPS (Salmon In Pregnancy Study) 
 Blackcurrant Seed Oil 
 Daily Dosage 
Please record the total daily dosage taken in mother, infant or both, 
whichever is applicable with units. 
If more than one type is taken, please record the total daily dosage for all 
with units 
 Mode of Int. delivery during Pregnancy 
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 Mode of Int. delivery during Infancy 
 FI Type 
Food intervention type, please tick all the relevant boxes 
 Any FI 
 All cow's milk, egg, and peanut products 
 Dairy Product & Egg 
 All milk and dairy products 
 Maternal antigen avoidance 
 Continued avoidance in lactation period 
Please record if the avoidance is continued after pregnancy, in breast 
feeding mothers and for how long 
 Yes 
 No 
 Mode of intervention delivery in pregnancy 
 Vitamin/Suppl. Type 
 Any Vit 
 Vit C 
 Vit C & E 
 Vit D (cholecalciferol) 
 Vit D (ergocalciferol) 
 Combined Vit D 
 Daily Dosage 
Please record the total daily taken dosage, in mother, infant or both, 
whichever is applicable with units. 
If more than on type is taken, please record the total daily dosage for all 
with units 
 Mode of Int. delivery during Pregnancy 
 Mode of Int. delivery in Infancy 
 Comparisons 
 Placebo 
 No treatment 
 High diet 
 Standard diet 
 When Int. has been applied? 
 Pregnancy alone 
 Pregnancy & after delivery-In mothers 
 In Pregnancy & after delivery in Mothers & Infants 
 Pregnant women & after birth in Infants  
 Timing in Pregnancy 
Please record intake of intervention FROM/UNTIL in pregnant women 
e.g.12-40 gestation week. 
 Duration of Int. in Pregnancy 
Please record the total duration of intake, within pregnancy e.g. 6 months 
 Intake IN MOTHERS after Birth 
If the intervention is continued after birth in mothers, please record the intake 
FROM/UNTIL for that period of time e.g. 6months after birth 
 Total Duration in Women 
Please record the TOTAL duration of intake in MONTHS, including after 
birth, if continued e.g. 7 months (36 gestation wks. + 6 months after birth) 
 Timing in Infancy 
If applicable, please record the intake of intervention FROM/UNTIL in infants 
e.g. 6 months 
 Duration in Infancy 
If applicable, please record the total duration of intake in infants after birth, 
in MONTHS 
 Total duration of Int. 
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 Feeding Restrictions 
If any feeding restrictions are stated in the study i.e. Breast feeding after birth, 
Formula feeding (quote the page number) 
 Type of delivery 
Please state if not reported 
 Caesarean 
 Vaginal 
 Instrumental 
 Side Effects 
 Yes 
 No 
 N/A-NM 
Not Applicable OR Not Mentioned 
 Outcomes 
The defined and measured endpoint(s) in the study 
 Allergic disease(s) 
If the outcome reported as a general term, as allergic diseases please record 
that and quote the page number/table number.  
 Wheeze 
 Eczema 
 Asthma 
 SPT (any positive) 
 SPT (egg) 
 SPT (peanut) 
 SPT (HDM) 
 SPT (cows milk) 
 SPT (CAT) 
 SPT (Cod) 
 SPT (grass) 
 SPT (milk) 
 SPT (food) 
 SPT (wheat) 
 SPT (Dog) 
 Cashew nut sensitization 
 Sesame seed sensitization 
 Specific IgE 
 Food Allergy 
 Anaphylaxis 
 Angioedema 
 Olive tree sensitization 
 Dermatophagoides pteronyssinus sensitization 
 Dermatophagoides farinae sensitization 
 Sensitisation 
 AD 
Atopic Dermatitis 
 Rhinitis 
 Allergic rhinoconjunctivitis 
 Respiratory allergy 
 Urticaria 
 Allergy Atopy 
If the outcome is reported as Allergy atopy, please specify i.e. asthma, allergic 
rhinoconjunctivitis (ARC), allergic urticaria and eczema 
 Bronchial Obstruction 
 Cough 
 Chronic cough 
 Chest infection 
 Breathing Difficulty 
 Pneumonia/bronchiolitis 
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 Phlegm & Nasal Discharge 
 Fever 
 Atopic Eczema Dermatitis Syndrome 
 Sneezing and/or snuffling 
 Atopy 
 URTI 
upper respiratory tract infection 
 LRTI 
lower respiratory tract infection 
 SCORAD 
 SCORAD >= 25 
 SCORAD 0 
 SCORAD 1-25 
 SCORAD 25-50 
 SCORAD > 50 
 SPT (aeroallergen) 
 SPT (Inhalation allergens) 
 SPT(Birch) 
 SPT(Alder) 
 SPT (Derp 1) 
 Any IgE 
 Atopic sensitized 
 Received topical steroid preparation 
 Inhaled bronchodilator or steroid 
 Itchy skin 
 Dry skin 
 Alternaria tenuis sensitization 
 Diagnosis Method 
Please tick all that apply 
 ISAAC 
Provide a brief description how the questionnaires have been completed e.g. 
clinicians, nurse, parents 
 Clinician diagnosed 
Please provide a brief description 
 SPT 
Skin Prick Test 
If the test is conducted vs. any specific allergen, e.g. egg-peanut-milk, please 
record the details including the mean diameter of the wheal e.g. >= 3 mm  
 Self report 
Please record the mode of report e.g. parents 
 SCORAD 
 BCSS 
basic clinical scoring system 
 Research nurses/staff 
 FEno 
Fractional Exhaled nitric oxide 
 FEV 
forced expiratory volume 
 Spirometry tests 
e.g. Forced Expiratory Volume (FEV), Functional Vital Capacity (FVC), 
positive reversibility tests 
 Clinical history 
 Physical examination 
 IgE 
Measurement of IgE in cord blood e.g. cut off points >0.35 KU/L 
 F-U Questionnaires 
 Nottingham Eczema Severity Score (NESS) 
 UK Eczema Working Party criteria 
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 Asthma predictive index 
 U.K. Working Party’s diagnostic criteria for AD 
 Primary health care records 
 Cow's milk challenges 
 eNO 
Exhaled nitric oxide 
 IOS 
Impulse oscillometry  
 ARIA guidelines 
 Williams UK Working Party’s criteria 
 the British Medical Research Council questionnaire 
 the European Community Respiratory Health Survey 
 Molecular analysis of faecal microbiota 
 Hanifin 
 SASSAD 
the Six Area Six Sign in Atopic dermatitis (SASSAD) score 
 Open food challenge 
 Blood sample 
 Saliva 
 NPR 
National Patient Registry 
 Outcome Classifications 
 FH of Atopy 
 Unselected Sample 
 At risk for pre-eclampcia 
 Probiotics 
 Fatty Acids 
 Food Intervention 
 Vitamins 
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Appendix 3.6. Risk of bias judgement (pro/prebiotic trials for prevention of allergic outcomes)
*
 
Study 
author 
Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources of 
Bias 
Kalliomäki 
(2003) 
• Low  
Mothers were 
randomly assigned 
to the study arms 
using computer 
generated random 
sequence 
• Low 
Treatment codes 
were kept by the 
supplier until data 
had been collected 
and analysed 
• Low 
LGG and placebo 
capsules and contents 
looked, smelled, and 
tasted identical. Also, 
treatment codes were kept 
by the supplier until data 
had been collected and 
analysed 
• Low 
The diagnosis of 
atopic disease, 
made by a 
researcher (TP) 
who was unaware 
of the treatment 
allocation.  
• Low 
Low lost to follow-
up and the clinical 
outcomes are 
reported for all 
that followed-up 
• Low 
all pre-defined 
(as reported in 
the methods) 
outcomes are 
reported 
 
• Unclear 
No report as to 
whether the any 
commercial 
probiotics have 
been consumed 
after the 2yrs F-U. 
Kalliomäki 
(2007) 
• Low  
Same as Kalliomäki 
2003 
• Low 
Same as 
Kalliomäki 2003 
• Unclear 
No clear information 
whether the staff were un-
blinded after the 2yrs 
follow-up  
• Low 
Diagnosis of 
eczema was made 
blindly on the basis 
of both a 
questionnaire and 
clinical 
examination  
• High 
The reasons for 
attrition at 7yrs 
follow-up not 
specified and also 
SPT conducted in 
a sub-sample of 
109 children at 
7yrs.  
• Low 
Fewer outcomes 
reported 
compared to 
earlier report i.e. 
food allergy, 
specific SPTs  
• Unclear 
No report as to 
whether any 
commercial 
probiotics have 
been consumed 
later on. 
Huurre 
(2008) 
• Unclear 
Method of 
randomisation not 
mentioned 
 
• Unclear - Does 
not state anything 
about allocation 
concealment in 
either paper 
 
• Unclear 
No clear information 
(either in 2006 or 2008 
papers), just says women 
were randomised in a 
double-blind manner 
• Low 
All infants were 
clinically examined 
in blindly 
 
• High 
the SPT and pre-
clinical results 
reported for 
different  
sub-samples  
• Low 
The pre-defined 
data including 
infant 
sensitisation is 
reported 
 
• High 
No information on 
the consumption 
of probiotics after 
delivery  
 
Kopp (2008) • Low  
Randomization was 
performed in blocks 
of 4 according to a 
computerized 
randomisation list  
• Unclear 
No information 
about how 
allocation 
happened  
• Unclear 
No information about 
blinding of research team. 
LGG and placebo were 
matched for appearance, 
taste, smell and packing  
• Low 
Physicians were 
unaware of the 
contents of the 
capsules until the 
end of the study 
• Low 
Reasons of missing 
are similar 
between the 
groups  
• Low 
All the pre-
defined primary 
& secondary 
outcomes are 
reported. 
• Low 
None identified 
Study Random Sequence Allocation Double Blinding Blinding of Incomplete Selective Other Sources of 
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author Generation Concealment Outcome 
Assessment 
Outcome Data Outcome 
Reporting 
Bias 
Niers (2009) • Unclear - Does not 
state how 
randomisation was 
conducted (apart 
from stating that it 
was block 
randomisation) 
 
• Unclear 
No information 
provided about 
allocation 
concealment 
 
• Unclear 
No information on 
allocation concealment, 
however both supplements 
were identical. 
• Low 
Physicians were 
blinded with respect 
to group allocation 
until all children 
were seen at the 
age of 2yrs  
• Low 
there have been 
missing 
participants in 
both study arms 
with similar 
reasons 
• Low 
The pre-defined 
outcomes (as 
reported in the 
methods) are 
reported in detail 
• Low 
None identified 
Kuitunen 
(2009) 
• Low  
Computer-generated 
block randomization  
 
• Low 
Throughout the 
study, the 
randomisation 
code was kept by 
the database 
consultant and 
revealed to the 
statistician only  
• Low 
The randomisation code 
was kept by the database 
consultant and revealed to 
the statistician only. The 
capsules and syrups, 
looked, smelled, and 
tasted identical. 
• Unclear 
No statement as to 
whether the 
paediatrician was 
blinded to the 
treatment allocation 
at 5yrs F-U  
• Unclear 
A high number of 
mothers in both 
groups refused to 
participate and 
also, reasons for 
lost to follow-up 
not specified. 
• Low 
All pre-defined 
primary & 
secondary 
outcomes are 
reported  
 
• Low 
None identified 
Kim (2010) • Low  
Allocation to either 
probiotics or 
placebo was carried 
out using a 
computerised 
generated 
randomisation  
• Low 
Treatment of 
either probiotics 
or placebo was 
allocated by trials 
coordinator 
without detailed 
knowledge of the 
clinical history  
• Low 
Probiotic and placebo 
sachets contents looked, 
smelled, and tasted 
identical, plus blinding of 
trial coordinators 
• Low 
The paediatric 
allergist remained 
unaware of the 
actual treatment  
• High 
The 
discontinuation 
rate has been high 
in both groups, 
both after 
randomisation and 
follow-ups, mainly 
because of 
declined 
participation and 
poor compliance 
• Low 
The pre-defined 
outcomes(as 
reported in the 
methods) are 
reported 
 
• Low 
None identified 
Study 
author 
Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources of 
Bias 
Dotterud 
(2010) 
• Low  
 Through a 
computer-generated 
• Low 
Participants & 
investigators were 
• Low 
The computer-generated 
randomisation list was 
• Low 
The computer-
generated 
• Unclear  
Reasons for 
discontinued 
• Low  
The pre-defined 
outcomes (as 
• Low  
None was 
identified  
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randomisation list 
without restrictions, 
the Department of 
Applied Clinical 
Research at the 
Norwegian 
University of 
Science and 
Technology 
randomly assigned 
the participants. 
blinded to the 
groups. The 
probiotic & 
placebo products, 
in equal tastes and 
neutral packaging, 
distributed 
according to the 
randomisation list 
by a Norwegian 
company (Tine 
BA). 
revealed to the 
researchers once all of the 
participants had 
completed the end- point 
examinations, including 
the SPTs and specific IgE 
analyses at 2yrs of age. 
 
randomisation list 
was revealed to the 
researchers once 
all of the 
participants had 
completed the end- 
point examinations, 
at 2yrs of age. 
intervention in the 
study arms not 
specified. 
reported in the 
methods) in both 
samples, 
including with & 
without family 
history of atopy 
are also reported  
Boyle (2011) • Low  
Using a computer 
generated 
randomisation list 
stratified by number 
of parents affected 
by allergic disease 
(‘2’ versus ‘1 or 0’). 
• Low 
Treatment was 
allocated by a 
hospital 
pharmacist at 
enrolment 
according to the 
order in which 
subjects were 
recruited 
• Low 
Participants, clinical trial 
and laboratory staff were 
blinded to treatment 
allocations throughout the 
study  
• Low 
Participants, 
clinical trial and 
laboratory staff 
were blinded to 
treatment 
allocations 
throughout the 
study  
• Low 
Reasons of missing 
are explained at 
each stage of F-U.  
• Low 
All pre-defined 
outcomes (as 
reported in the 
methods) are 
reported 
• Low 
None identified 
Rautava 
(2012) 
• Low  
The allocation was 
carried out using a 
computer-generated 
list independently 
from the 
investigators  
• Low 
All investigations 
were performed in 
a double-blind 
fashion, and the 
allocation code 
was revealed after 
all the infants had 
completed the F-U 
and the data had 
been finalised. 
• Low 
 All investigations were 
performed in a double-
blind fashion, and the 
allocation code was 
revealed after all the 
infants had completed the 
F-U and the data had 
been finalised. 
The study preparations 
were similar in 
appearance.  
• Low 
 All investigations 
were performed in a 
double-blind 
fashion, and the 
allocation code was 
revealed after all 
the infants had 
completed the F-U 
and the data had 
been finalised. 
• Low 
The rate of 
discontinuing the 
study or lost to 
follow-up was 
similar in the 3 
study groups. 
 
• Low 
The pre-defined 
primary outcome 
measures (as 
reported in the 
methods) 
reported  
 
• Low 
None identified  
 
Study 
author 
Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources of 
Bias 
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Ou (2012) • Unclear 
These cases were 
randomly assigned 
to receive the study 
products, with no 
further details 
provided   
• Low 
Treatment codes 
were kept by the 
supplier until all 
data had been 
collected and 
analysed  
• Low 
The treatment codes were 
kept by the supplier until 
all data was collected and 
analysed.  
LGG and placebo 
capsules were matched for 
appearance, taste, smell, 
and packing.  
• Low 
The group 
allocation 
concealed until 
completion of data 
analysis. 
 
• Unclear 
Reasons for lost to 
follow-up in study 
arms not specified 
(Figure 1) 
• Low 
All pre-defined 
outcomes (as 
reported in the 
methods) 
reported 
including 
Cumulative 
prevalence 
• Unclear 
No information 
whether women 
have continued 
consumption of 
probiotics after 
the termination of 
intervention  
Abrahamsson 
(2013) 
• Unclear 
Randomisation was 
stratified for each 
study centre. No 
more information is 
given 
• Low 
Each centre was 
provided an 
allocation list with 
unique ID No. for 
each subject. Prior 
to randomisation, 
each study product 
bottle was labelled 
with the unique ID 
No. and randomly 
mixed by an 
independent 
contract 
manufacturer. 
• High 
'The study was conducted 
in a double blind fashion 
until all infants had 
completed the 2ysr follow-
up. 
• High 
The study was 
conducted in a 
double blind 
fashion until all 
infants had 
completed the 2y F-
U.  
• High 
There was high 
loss to follow-up, 
but equally spread 
across both 
groups. However, 
reasons for being 
lost to follow-up 
are not reported. 
• Low 
All pre-defined 
outcomes (as 
reported in the 
methods)  are 
reported 
 
• High 
Infants in the 
placebo group did 
not receive the 
supplement after 
birth. Also, At 7y 
of age, 19% in the 
L. reuteri and 26% 
in placebo group 
reported to have 
taken any 
probiotic strain 
during the last 
month (p=0.30).  
Wickens 
(2013) 
• Low  
Randomisation was 
stratified by study 
centre and 
performed in blocks 
of 15 according to a 
computer-generated 
randomisation list. 
• Low 
Randomisation 
and allocation of 
supplements were 
performed by a 
clinical trials 
pharmacist with 
no contact with the 
participants.  
• High 
After the 2-year follow-up 
parents were not blind to 
study group, and were 
subsequently asked to 
report subjectively on 
eczematous symptoms. 
• Low 
Study nurses 
remained blinded to 
participant study 
group through-out  
• High 
Imputed analysis 
is used for some of 
the reported 
outcomes; also the 
reasons for lost to 
F-U are not 
specified.  
• Low 
All pre-defined 
outcomes (as 
reported in the 
methods) are 
reported in 
details. 
 
• Low 
Infants excluded if 
exposed to 
commercially 
available non-
study probiotics, 
either directly or 
through breast 
milk during the 
course of the study  
Study 
author 
Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources of 
Bias 
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Allen (2014) • Low  
A computer-
generated, random 
allocation sequence, 
produced by the 
independent 
statistician, without 
blocks allocated the 
mother-infant dyad 
at 36wks of 
gestation to either 
the treatment or 
placebo arm of the 
study on a 1:1 basis. 
• Low 
The allocation 
sequence was held 
in sealed, opaque 
envelops at the 
trial site for 
emergency access 
but was not 
available to any 
member of the 
research team. 
Research staff 
allocated dyads 
sequentially to the 
next number in the 
sequence. 
• Low  
Allocation concealment 
was at low risk of bias 
therefore study 
investigators did not know 
the group to which 
participants were 
allocated. They report 
efforts to ensure the 
placebo looked the same 
as the intervention so fair 
to assume that the 
participants were not 
aware of their group.  
• Low 
Assessed by self-
report (mothers 
blinded) or by 
physicians external 
to the research 
team. 
 
• Low 
There is missing 
data at all follow-
ups but in the 
discussion, the 
authors state that 
this was due to 
missed 
appointments by 
mothers who work, 
and both groups 
appear to have 
been similarly 
affected.  
• Low 
All pre-defined 
primary and 
secondary 
outcomes (as 
reported in the 
methods) are 
reported 
 
• Low  
Non identified 
 
Gorissen 
(2014) 
• Unclear 
It does not say how 
randomisation was 
conducted apart 
from block 
randomization with 
a block size of 10 
was used 
• Unclear 
In neither this nor 
the Niers 2009 
report of the same 
study is allocation 
concealment 
mentioned 
 
 
 
• High 
The study was conducted 
in a single blind fashion 
with the investigator being 
blinded 
 
 
 
• High 
Although the 
investigator was 
blinded, the parents 
had not blinded 
been at 2yrsF-U 
and might have 
given reports at F-
U assessments  
• Low 
Although high 
numbers did not 
participate in the 
follow-up, this was 
equally spread 
across groups with 
no differences in 
baseline 
characteristic 
• Low 
All pre-defined 
outcomes(as 
reported in the 
methods)  are 
reported 
• Unclear 
No information 
whether the study 
participants 
consumed 
probiotic 
products, from the 
last F-U at 2yrs 
age 
Simpson 
(2015) 
• Low  
Through a computer-
generated 
randomisation list 
without restrictions, 
the Department of 
Applied Clinical 
Research at the 
• Low 
 Participants & 
investigators were 
blinded to the 
groups. The 
probiotic & 
placebo products, 
in equal tastes and 
• High 
Participants were un-
blinded after the 
publication of the 2 year 
follow-up results  
• High 
Prior to this, the 
participants and 
investigators were 
blinded to treatment 
allocation 
• High 
The non-response 
rate to both 
questionnaire and 
examination 
follow-up has been 
high, with higher 
rates in probiotic 
• Low 
The pre-defined 
outcomes (as 
reported in the 
methods), in both 
samples with & 
without family 
history of atopy 
• Low 
None identified 
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*Data extracted from original and companion papers, where applicable 
Norwegian University 
of Science and 
Technology randomly 
assigned the 
participants. 
neutral packaging, 
distributed 
according to the 
randomisation list 
by Tine BA, a 
Norwegian 
company. 
group  are also reported 
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Appendix 3.7. Risk of bias judgement (fatty acid trials for prevention of allergic outcomes)
* 
Study 
author 
Random 
Sequence 
Generation 
Allocation Concealment Double Blinding Blinding of Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources of 
Bias 
Dunstan 
(2003a) 
 
 
• Unclear 
The groups were 
block-
randomized 
according to 
parity, but not 
mentioned how 
 
• Low 
Randomisation and 
allocation of capsules 
occurred at a different 
centre separate from the 
recruitment of participants.  
 
 
 
 
 
 
 
Low 
The participants, 
research scientists, and 
pediatrician remained 
blinded to the groups 
for the duration of the 
study. The capsules in 
the 2 groups were 
image-matched  
• Low 
A detailed history and 
examination by the same 
pediatrician (SLP) who 
remained blinded to the 
intervention  
 
• High 
A high lost to F-U 
rate was observed in 
the Int. arm (12 vs. 
3) and the 
discontinuation rate 
due to nausea in the 
Int. group was 
higher than the 
control (7 vs. 1) 
 
 
• Low 
All the pre-
defined 
outcomes 
are 
reported 
• Low 
None identified, 
however it is worth 
note that only 
healthy infants 
were included in 
the data analysis, 
to avoid the 
confounding effects 
of prematurity  
Olsen (2008) • Unclear 
Although the 
authors report 
that they 
conducted 
stratified 
randomisation, 
they do not 
report how 
randomisation 
itself was 
conducted 
• Low 
Women who agreed to 
participate, were allocated 
by randomisation numbers 
concealed in sealed 
envelopes  
• High 
Women would know if 
they were in the 
control group, as they 
would not receive any 
tablets.  This would 
very much depend on 
what information was 
provided to 
participants. If they are 
fully informed (i.e. in 
order to give proper 
consent) then they 
should have been told 
what being part of the 
control group would 
involve. Does not 
report blinding of 
investigators. 
• Low 
Diagnoses were 
external to study team 
by using a unique 10-
digit personal 
identification number 
with a link from mother 
to child and vice versa 
• Low 
A few numbers are 
missing from two 
study groups which 
are reported with 
the reasons missing. 
 
• Low 
All pre-
defined 
outcomes 
(as 
reported in 
the 
methods) 
are 
reported 
• Low 
None identified 
 
 399 
Study 
author 
Random 
Sequence 
Generation 
Allocation Concealment Double Blinding Blinding of Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources of 
Bias 
Linnamaa 
(2010) 
• Low  
Randomisation 
was assigned by 
a random 
number list  
• Low  
The random allocation 
sequence was concealed until 
interventions were assigned. 
Different personnel than 
randomization carried out 
recruitment and subsequent 
contacts with the study 
subjects.  
 
• Low 
Both oils were similar, 
applied to mothers & 
infants. Recruitment & 
subsequent contacts 
with the study subjects 
were carried out by 
different personnel 
than randomization 
• Low 
The treatment codes 
were not opened until 
the study material had 
been analysed in March 
2008.  
• High 
Lost to F-U were 
similar across the 
study arms; however 
a high rate (>50%) 
was observed mostly 
due to pregnancy 
related nausea and 
poor compliance  
• Low 
The pre-
defined 
study 
endpoints 
(as 
reported in 
the 
methods) 
are 
reported 
• Low 
None identified 
Furuhjelm 
(2011) 
• Unclear 
 Says block 
randomisation 
was performed, 
but now how 
• Unclear 
No information about how 
women were allocated 
• Low 
The mothers, as well as 
the staff handling 
clinical and laboratory 
F-U, were blinded to 
group allocation. 
Active and placebo 
capsules could not be 
distinguished from 
each other. 
• Low 
The research nurses, 
the paediatricians & the 
person performing the 
laboratory analyses 
were blinded during the 
intervention and F-U. 
Further, all staff 
members working with 
the intervention and F-
U were blinded 
throughout the whole 
study 
• High 
Sixteen (23%) of the 
mothers in the Int. 
arm and 9 (12%) in 
the placebo group 
did not complete the 
minimum 15wk of 
supplementation 
required, i.e. 
throughout 
pregnancy. Also 54 
(77%) and 65 (87%) 
of women in the int. 
and placebo arms 
were approached 
respectively at 2yrs 
F-U. 
• Low 
All pre-
defined 
outcomes 
(as 
reported in 
the 
methods) 
are 
reported  
 
 
• Low 
None identified 
Noakes 
(2012) 
• Low  
The women were 
allocated to 1 of 
2 groups 
according to a 
previously 
• Unclear 
No reference made to 
allocation concealment 
 
• High 
Single blind study, 
researchers responsible 
for assessing outcome 
measures (both 
laboratory and clinical) 
• Low 
Researchers 
responsible for 
assessing outcome 
measures (both 
laboratory and clinical) 
• High 
Reasons for lost to 
F-U not mentioned 
• Low 
All pre-
defined 
outcomes 
(as 
reported in 
• Low 
None identified 
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generated 
random number 
table  
remained blinded to the 
groups.  
 
remained blinded to the 
groups. 
the 
methods) 
are 
reported 
Study author Random 
Sequence 
Generation 
Allocation Concealment Double Blinding Blinding of Outcome 
Assessment 
Incomplete Outcome 
Data 
Selective 
Outcome 
Reporting 
Other Sources of 
Bias 
Palmer 
(2013) 
• Low  
A computer 
driven telephone 
randomisation 
service 
according to an 
independently 
generated 
randomisation 
schedule, with 
balanced 
variable sized 
blocks.  
• Low 
Palmer 2012: the allocation 
sequence was held off site 
and managed by random 
number allocation  
• Low 
Neither the women nor 
the research staff were 
aware of the treatment 
allocated.  All capsules 
were similar in size, 
shape and colour. 
 
• Low 
All staff were blinded to 
treatment group 
allocation and had 
quality assurance 
reviews every 6 months 
with one of the 
investigators. 
 
• Low 
Reasons for missing 
in both group are 
similar and fully 
reported, imputed 
analysis with 50 
complete data sets 
were used which 
appeared 
reasonable for their 
data 
 
• Low 
All pre-
defined 
outcomes 
(as 
reported in 
the 
methods) 
are 
reported. 
• Low 
None identified 
 
Escamilla-
Nuñez 
(2014) 
• Unclear  
Says block 
randomisation 
to randomly 
create balanced 
replication of 
four treatments, 
but does not say 
how  
• Low 
The assignment codes were 
placed in sealed envelopes 
at the beginning of the 
study. 
 
 
• Low 
All study participants 
and members of the 
study team remained 
blinded to the 
treatment scheme 
throughout the 
intervention period of 
the study.  
The placebo capsules 
were similar in 
appearance & taste to 
DHA capsules. 
• Low 
Data were unblended 
for the analytical study 
team after the last baby 
in the study was born 
and had reached 6 
months of age, at which 
time participants were 
no longer taking 
supplements. Since the 
study is on going for F-
U of children, the 
participants and 
fieldworkers remain 
blinded to the treatment 
allocation. 
• Low 
Reasons missing are 
explained in Figure 
1 and the statistical 
analysis is 
performed on 869 as 
the total available 
sample of mother-
child pairs 
 
• Low 
All the pre-
defined 
outcomes 
(as 
reported in 
the 
methods) 
are 
reported 
 
• Low 
None identified 
*Data extracted from original and companion papers, where applicable 
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Appendix 3.8. Risk of bias judgement (food avoidance trials for prevention of allergic outcomes)
* 
Study 
author 
Random 
Sequence 
Generation 
Allocation 
Concealment 
Double Blinding  Blinding of 
Outcome 
Assessment 
Incomplete Outcome 
Data 
Selective 
Outcome 
Reporting 
Other Sources of Bias 
Lilja 
(1989) 
• Unclear 
Says randomly 
allocated but not 
how  
 
• Unclear 
No clear 
information 
about how 
allocation was 
conducted  
• High 
It would not be 
possible to blind 
participants to 
this intervention, 
they would have 
known which 
group they were 
in.  
• Low 
The physicians 
who performed 
the physical 
examination at 
18 months of age 
were unaware of 
the mothers' diet 
during the trial 
 
• Low 
There was attrition but 
reasons for withdrawal 
are presented and do 
not appear to be linked 
to the intervention  
• Low 
The risk of atopic 
disease has been 
defined as the 
main outcome and, 
based on that the 
results(as reported 
in the methods)  
are presented in 
detail in tables. 
 
• High 
Women were initially selected 
from 3 cities with four different 
allocated interventions and 
these are pooled together in 
their further reports introduced 
as high and reduced diets. Also 
some women in the reduced 
group have decided, on their 
own, to continue their diet 
during breast-feeding. The 
actual number of participants 
presented for the outcomes do 
not also match with the 
numbers allocated to each 
group after exclusion (Table 1).  
Fälth-
Magnusso
n (1992) 
• Unclear 
Says mothers 
randomised, but 
not how  
• Unclear 
there is no 
information 
about allocation 
concealment.  
• High 
it is not possible 
to blind due to 
the nature of the 
intervention. 
• Unclear 
No information 
as to whether the 
specialised nurse 
or the author 
who did the 
physical 
examinations 
were blind to 
allocation 
groups  
• High 
22 women switched 
from D to ND, and 7 
from ND to D, without 
allocating to it. 
Although both groups 
were similar at baseline 
for allergy-related 
characteristics and it 
could be assumed that 
the reasons for 
switching groups were 
unrelated to this and/or 
would have no bearing 
on the allergy outcomes. 
• Low 
All the symptoms 
of allergy 
according to the 
questionnaires are 
reported and 
explained as well 
as signs at 
examination, 
however 
assessment of 
allergic disease by 
authors is 
presented as a 
percentage only  
 
• High 
Some mothers by their own 
choice continued to restrict 
their intake of cow's milk and 
egg during the first 6 weeks of 
lactation. Also, 10 mothers 
receiving the diet continued a 
strictly egg and milk-free diet, 
whereas 57 D and 24 ND 
mothers took reduced amounts 
of cow's milk and egg (at most 
2 dl of milk per day and two 
eggs per week). There was also 
a significant difference between 
D and ND group children for 
smoking behaviour of their 
parents. 
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Study author Random 
Sequence 
Generation 
Allocation 
Concealment 
Double 
Blinding 
Blinding of Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources of Bias 
Zeiger (1992) • Low  
A computer 
generated 
random numbers 
list was used 
• Unclear 
No 
information 
about method 
of allocation is 
presented 
 
• High 
Although this 
was attempted at 
all times did not 
remain absolute, 
since 
occasionally the 
infant's group or 
formula was 
designated by 
the mother or 
noted in the 
medical chart by 
a pediatrician.  
 
• Unclear 
Evaluation of 
outcomes was based 
on medical record 
review and physical 
examination were 
performed without 
physician knowledge 
of the subject's group, 
although unmasking 
occurred due to 
parental assertion to 
the primary 
pediatrician who 
recorded on rare 
occasion.  
• High 
The trial has a 
gross loss to F-U, 
although says 
similar rates of 
attrition were 
observed in both 
study groups (page 
5, results), the 
number loss-to 
follow are high. 
 
• Low 
Pre-defined 
outcomes (as 
reported in the 
methods) are 
reported in detail 
 
• Low 
Interventions common to both 
groups: Breastfeeding was 
recommended for at least 4 to 6 
months. Infant vitamin 
supplementation was left to the 
discretion of the personal 
pediatrician. Parents were 
encouraged, through 
information exchange (lecture, 
slide presentation, and 
brochures), to reduce 
household aeroallergens and to 
discontinue smoking. Mean 
heights and weights at 3 & 4 
years were similar in the study 
groups (data not shown. 
Lovegrove 
(1994) 
• High 
The atopic 
group was 
randomly 
allocated into 
the prophylaxis 
group or the 
control group, 
but is not 
reported how. 
• Unclear 
whether 
allocation 
concealment 
has occurred is 
not reported. 
 
• High 
On admittance to 
hospital the 
nurses were 
informed about 
the maternal 
dietary 
restriction and 
the necessity not 
to give the 
babies 'top-up’ 
bottle-feeds. 
 
• Low 
A ‘blind’ physical 
examination, was 
performed by a 
paediatrician who was 
unaware to which 
group the infants’ 
mothers were 
assigned. 
 
• Low 
There is no missing 
data and a sub-
group analysis also 
conducted 
excluding the 3 
infants in the 
atopic-diet group 
who inadvertently 
received at least 1 
feed of commercial 
infant formula 
derived from cow’s 
milk shortly after 
delivery.   
• Low 
All the pre-
defined outcomes, 
pre-clinical and 
clinical (as 
reported in the 
methods) are 
reported  
• Unclear 
The study is generously 
supported by Cow & Gate, 
Trowbridge, Wilts and also 
provided Peptijunior, a 
hypoallergenic formula that 
was used as a milk alternative 
for the mother and infant in 
their study. 
 
 
*Data extracted from original and companion papers, where applicable 
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3.9. Risk of bias judgement (vitamin trials for prevention of allergic outcomes)
*
 
Study author 
(year) 
Random 
Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective 
Outcome 
Reporting 
Other Sources of Bias 
Greenough 
(2010) 
• Unclear 
The randomisation 
sequence was 
blocked—i.e., 
balanced—but not 
how randomisation 
sequence was 
generated  
• Low 
 DHP 
Investigational 
Medicinal Products 
Clinical Trial 
Supplies 
(Crickhowell, 
Powys, Wales, UK) 
packaged the 
tablets and 
capsules sealed in 
blister strips each 
with 1 week’s 
supply, according 
to the 
randomisation 
sequence provided 
• High 
The trial staff or 
other person 
involved in the 
trial were blind to 
the allocated 
treatment until 
after completion 
of the VIP trial 
(the1
st
 phase of 
the study). There 
is no information 
whether mothers 
were still blind to 
their allocated 
treatment as says 
they were sent the 
information about 
the respiratory  
F-U study  
• Low 
Researchers 
assessing the 
respiratory outcome 
of the infants were 
blind to the maternal 
allocation of 
treatment  
• High 
A high rate of lost to 
follow-up was 
observed due to no 
response/mother 
declined 
 
• Low 
Detailed report of 
all pre-defined 
outcomes (as 
reported in the 
methods) 
 
• High 
No information whether 
women have consumed 
vitamin C & E after 
birth. Also this study is 
an unplanned F-U of 
an RCT especially as 
the authors are not 
clear whether mothers 
were made aware of 
their allocation at the 
planned end of the trial. 
If they were made 
aware this could have 
disproportionately 
influenced which 
mothers decided to 
participate in the F-U. 
Having said that, 
roughly equal numbers 
from each group 
participated in this 
follow-up. 
Goldring 
(2013) 
• Low  
A computer 
generated random 
number list in 
blocks of 15, 
• Low 
The researcher 
gave participants a 
study number on 
entry to the trial, 
• High 
Not possible to 
blind participants 
or investigators 
as would know if 
• Low 
Investigators kept 
blind to original 
treatment allocation 
assessed offspring at 
• Low 
Reasons for missing 
data are reported 
and well balanced 
between the groups. 
• Low 
All defined 
outcomes (as 
reported in the 
methods) are 
• Low 
This trial was 
conducted before 
national guidance on 
routinely providing 
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stratified by 4 
ethnic groups in a 
1:1:1 ratio  
and treatment was 
allocated from the 
hospital pharmacy  
they had no 
treatment, daily 
tablets or a single 
bolus. 
three years of age 
using a validated 
health questionnaire 
and clinical 
assessment  
Sensitivity analysis 
was also performed, 
as 22 offspring were 
not followed up. 
There was no 
significant difference 
between groups. 
reported 
 
advice on vitamin D 
intake during 
pregnancy was 
introduced in March 
2008  
McEvoy 
(2014) 
• Unclear 
Randomization 
was stratified 
according to 
gestational age at 
randomization but 
the method of 
randomisation was 
not reported.  
• Unclear 
No information on 
how allocation has 
happened 
• Low 
The investigators, 
clinicians and 
patients were 
unaware of 
treatment 
allocation 
through age 1yr 
and analyses of 
all primary and 
secondary 
outcomes. The 
OHSU research 
pharmacy 
dispensed study 
capsules. 
• Low 
Clinical research 
personnel unaware 
of treatment 
assignment 
administered the 
respiratory 
questionnaire17 
(pediatric version) 
to the infant’s 
primary caretaker 
when the infant was 
approximately 
12mon old. 
• Low 
Number of missing 
are equal in both 
study groups (for 
pre-clinical and 
clinical 
measurements at 
birth & 1yr) 
 
• Low 
The pre-defined 
outcomes (as 
reported in the 
methods)  are 
reported  
 
• Low 
None identified  
Chawes 
(2016) 
• Low  
Women were 
randomized using 
a computer-
generated list of 
random numbers, 
supplied by an 
external 
investigator who 
• Unclear 
No information 
how allocation has 
happened 
 
• Low 
The intervention 
code was un-
blinded when the 
youngest child 
reached age 3 
years or in case of 
a medical 
emergency. 
• Low 
The study 
paediatricians, acted 
as general 
practitioners for the 
cohort, were blinded 
to the intervention. 
 
• Low 
Between 6.3-7% of 
women are lost to F-
U. However 96.5% 
of pregnant women 
did not respond to 
the initial invitation 
letters to study. Of 
women responded, 
• Low 
The pre-defined 
outcomes in 
methodology are 
reported. 
 
• Unclear 
Women were also 
received n-3 LCPUFA 
supplementation during 
pregnancy and this is 
not stated how this 
could have enhanced 
the effect of Vit D3. The 
statistical analyses did 
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had no further 
involvement in the 
RCT 
 
 66.8% were excluded 
or declined and lost 
due to delayed 
ethical approval of 
the trial.  
not show an interaction 
with the 
supplementation effect, 
univariate & 
multivariate. 
Litonjua 
(2016) 
• Low  
Randomization 
was performed by 
the Data Centre 
Coordinating 
(DCC) using a 
system that 
automates the 
random 
assignment of 
treatment groups 
to Study ID No. 
The randomization 
scheme employed 
stratified permuted 
blocks with 
randomly varied 
block sizes of 4 and 
6, and one block 
allocation list per 
stratum (study site 
and racial/ethnic 
group).  
• Low 
Once consent was 
obtained, 
participants were 
assigned to a Study 
ID. The random 
assignment of 
treatment groups to 
Study ID numbers is 
automatically done. 
 
• Low 
Clinical Centre 
investigators and 
staff were 
blinded to the 
treatment code. 
The pill bottles 
labelled as 
"Study Drug A" 
through "Study 
Drug F" were 
shipped to the 
centres and each 
participant 
received 2 bottles 
(containing the 
standard 
prenatal 400IU 
Vit. D, and the 
other bottle 
contained the Int. 
pill containing 
4000IU Vit D or 
a placebo. 
• Low 
The study protocol says 
clinical centre 
investigators and staff 
were blind to the 
treatment code. After 
delivery, the research 
staff made telephone 
calls every 3 months 
inquiring the health 
and symptoms of 
infants. The mother and 
child came in for 3 
yearly follow-up visits, 
during which blood 
was drawn, skin 
pigmentation tests were 
performed, additional 
questionnaires were 
administered, and 
anthropometric 
measurements of the 
child were obtained.  
 
 
• Low 
Between 7-8% of 
participants are 
missing and reasons 
are similar across 
study arms. 
 
• Low 
All pre-defined 
outcomes in 
protocol are 
reported 
 
• Low 
None identified 
 
*Data extracted from original and companion papers, where applicable 
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Appendix 4.1. Search strategy (obesity outcomes) 
 
The following four important concepts were identified based on the research question:  
 Pregnancy 
 Diet  
 Obesity (Non-communicable diseases)  
 Randomised controlled trial 
A variety of keywords and synonyms were identified using the Patient Intervention 
Comparison Outcome Study (PICOS) approach. A full list of the used keywords for each 
concept in the databases is presented in the following table.  
Within groups of terms, the terms were combined using OR and the groups of terms 
themselves were then combined in the following manner: #1 AND #2 AND #3 AND 
#4. 
Relevant citations and key authors were identified. To prevent bias, no restriction was 
placed on the year of publication or language.  
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Search Log-MEDLINE (From inception-February 2015) (appendix 4.1) 
Search No. Date of search Concepts Terms used Hits Comments 
1 10/02/2015 1
st
 
 
filter
 
pregnan* OR ( antenatal OR ante-natal OR “ante natal” ) OR ( prenatal OR pre-
natal OR “pre natal” ) OR ( mother* or maternal )  
975,607  
2 10/02/2015  (MH "Pregnancy+")  714,997  
3 10/02/2015  S1 OR S2  (#1 & #2) 988,766  
4 10/02/2015 2
nd
 filter diet* OR ( food or consumption or intake ) OR ( mineral or nutrition or nutrient 
) OR ( milk or egg or peanut or fruit or vegetable ) OR ( vitamin* or fatty acid* 
or supplement* ) OR ( probiotic* or prebiotic* ) OR folic acid  
1,982,174  
5 10/02/2015  (MH "Diet") OR (MH "Nutritional Physiological Phenomena+")  396,003  
6 10/02/2015  S4 OR S5 (#4 & #5) 2,076,378  
7 10/02/2015 3
rd
 filter non-communicable disease* OR noncommunicable disease* OR non 
communicable disease*  
4,315 No MESH terms for non 
communicable diseases 
8 10/02/2015  obesity OR obes* OR ( overweight or body weight change ) OR ( weight gain 
or high bmi ) OR diet therapy OR ( overeat or body size )  
348,287  
9 10/02/2015  (MH "Obesity") OR (MH "Nutritional and Metabolic Diseases+")  933,119  
10 10/02/2015  S8 OR S9 (#8 or #9) 1,095,404  
11 10/02/2015  S7 OR S10 (#7 or #10) 1,098,269  
12 10/02/2015 4
th
 filter randomised controlled trial or randomised control trial or randomised controlled 
study or randomised clinical trial or controlled clinical trial or controlled trial or 
random allocation ) OR ( single blind or single blind method or single blind trial 
or double blind method OR double-blind method ) OR ( clinical trial* or quasi-
experimental study or placebo-controlled trial or placebo control or intervention 
study or follow-up stud* 
1,134,412  
13 10/02/2015  (MH "Clinical Trials as Topic+") OR (MH "Controlled Clinical Trials as 
Topic+")  
279,911  
14 10/02/2015  S12 OR S13 (#12 or #13) 1,195,071  
15 10/02/2015 combined S3 AND S6 AND S11 AND S14  2,321  
 
 
 408 
Search Log-COCHRANE (From inception-February 2015) (appendix 4.1) 
Search No. Date of search Concepts Terms used Hits Comments 
1 11/02/2015 1
st
 filter pregnan* or antenatal or ante-natal or ante natal or prenatal or pre-natal or pre natal or mother 
or maternal 
33049  
2 11/02/2015  MeSH descriptor: [Pregnancy] explode all trees  5824  
3 11/02/2015  #1 or #2 33172  
4 11/02/2015 2
nd
 filter diet or food or consumption or intake or mineral or nutrition or nutrient or milk or egg or 
peanut or fruit or vegetable or vitamin* or fatty acid* or supplement* or probiotic* or 
prebiotic* or folic acid 
115882  
5 11/02/2015  MeSH descriptor: [Nutritional Physiological Phenomena] explode all trees  20196  
6 11/02/2015  #4 or #5 119306  
7 11/02/2015 3
rd
 filter non-communicable disease* or non communicable disease* or noncommunicable disease* 322  
8 11/02/2015  obesity or obes* or overweight or body weight change or weight gain or high bmi or diet 
therapy or overeat or body size 
38757  
9 11/02/2015  MeSH descriptor: [Obesity] explode all trees 7673  
10 11/02/2015  #8 or #9 38781  
11 11/02/2015  #7 or #10 39008  
12 11/02/2015 4
th
 filter randomised controlled trial or randomised control trial or randomised controlled study or 
randomised clinical trial or controlled clinical trial or controlled trial or random allocation or 
single blind or single blind method or single blind trial or double blind method or double-
blind method or clinical trial* or quasi-experimental study or placebo-controlled trial or 
placebo control or intervention study or follow-up stud* 
652339  
13 11/02/2015  MeSH descriptor: [Randomized Controlled Trials] explode all trees 139  
14 11/02/2015  #12 or #13 652339  
15 11/02/2015 combined #3 and #6 and #11 and #14 
 
2880 In Cochrane 
Reviews 
(reviews and 
protocols, other 
reviews and 
trials), limited to 
trials only yields 
954 hits  
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Search Log-SCOPUS (From inception-February 2015) (appendix 4.1) 
Search No. Date of search Concepts Terms used Hits Comments 
1 12/02/2015 1
st
 filter (TITLE-ABS-KEY(pregnan*) OR TITLE-ABS-KEY(antenatal or ante-natal or ante 
natal) OR TITLE-ABS-KEY(prenatal or pre-natal or pre natal) OR TITLE-ABS-
KEY(mother or maternal)) 
1,151,775 Scopus does not 
use a controlled 
vocabulary, like 
MeSH to search 
2 12/02/2015 2
nd
 filter (TITLE-ABS-KEY(diet*) OR TITLE-ABS-KEY(food or consumption or intake or 
mineral) OR TITLE-ABS-KEY(nutrition or nutrient) OR TITLE-ABS-KEY(milk or egg 
or peanut or fruit or vegetable) OR TITLE-ABS-KEY(vitamin* or fatty acid* or 
supplement*) OR TITLE-ABS-KEY(probiotic* or prebiotic*) OR TITLE-ABS-
KEY(folic acid)) 
3,718,859  
3 12/02/2015 3
rd
 filter (TITLE-ABS-KEY ( non-communicable  disease* )  OR  TITLE-ABS-
KEY ( non  communicable  disease* ) OR  TITLE-ABS-
KEY ( noncommunicable  disease* ) )  
7,196  
4 12/02/2015  ( TITLE-ABS-KEY ( obes* )  OR  TITLE-ABS-KEY ( overweight )  OR  TITLE-ABS-
KEY ( body  weight change )  OR  TITLE-ABS-KEY ( weight  gain )  OR  TITLE-ABS-
KEY ( high  bmi )  OR  TITLE-ABS-KEY ( diet  therapy )  OR  TITLE-ABS-
KEY ( overeat )  OR  TITLE-ABS-KEY ( body  size ) )  
739,510  
5 12/02/2015  #3 or #4 745,238  
6 12/02/2015 4
th
 filter ( TITLE-ABS-KEY ( randomised  controlled  trial )  OR  TITLE-ABS-
KEY ( randomised  control  trial )  OR TITLE-ABS-
KEY ( randomised  controlled  study )  OR  TITLE-ABS-
KEY ( randomised  clinical  trial )  OR TITLE-ABS-
KEY ( controlled  clinical  trial )  OR  TITLE-ABS-KEY ( controlled  trial )  OR  TITLE-
ABS-KEY ( random  allocation )  OR  TITLE-ABS-KEY ( single  blind )  OR  TITLE-
ABS-KEY ( single  blind method )  OR  TITLE-ABS-
KEY ( single  blind  trial )  OR  TITLE-ABS-KEY ( double  blind  method )  OR TITLE-
ABS-KEY ( double-blind  method )  OR  TITLE-ABS-
KEY ( clinical  trial* )  OR  TITLE-ABS-KEY ( quasi-
experimental  study )  OR  TITLE-ABS-KEY ( placebo-controlled  trial )  OR  TITLE-
ABS-KEY ( placebo  control )  OR  TITLE-ABS-
KEY ( intervention  study )  OR  TITLE-ABS-KEY ( follow-up  
2,636,519  
7 12/02/2015 combined #1 and #2 and #5 and #6  4,926 Limited to 
original studies 
(n=3,636) 
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Search Log-Other databases (appendix 4.1) 
Search No. Date of search Concepts Terms used Hits Comments 
1 02/03/2015 Web of Science Primary prevention of obesity by perinatal dietary interventions 1 Same as main 
databases 
2   Prevention of obesity by maternal dietary interventions in pregnancy 13 all results are also 
identified in main 
databases’ search  
3  ETHoS Prevention of obesity by maternal dietary interventions 1 Non-relevant 
4  Clinicaltrials.gov Prevention of obesity by maternal dietary interventions in pregnancy 43  
5   Primary prevention of obesity by perinatal interventions 10 Non-relevant  
   Prevention of obesity by maternal nutritional interventions in pregnancy 19 Identified with 
other short phrases 
as well as in main 
databases 
6 02/03/2015 ICTRP** Prevention of obesity (in the title) or pregnancy (in the condition) or nutrition 
interventions (in the intervention)*** 
631 Mostly non-
relevant 
Others the same as 
results from main 
databases 
7   Maternal Health topic 1 RCT-Status: 
Recruiting  
*Short phrases were used using different synonyms and for each database, the phrases that have yielded any results are shown. 
**WHO International Clinical Trials Registry Platform 
***Also, the list of trials by health topic, from the WHO above-mentioned platform, was looked into and trials’ titles in some health topics were checked as follows: 
a. Child Health (103) 
b. Food Safety (3) 
c. Food Insecurity (6) 
d. Maternal Health (10) 
e. Women’s Health (15) 
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Study eligibility form-Obesity outcomes  
 
PICOS Yes Unclear No 
Participants 
 
   
Are the participants classed as pregnant women, from general population, and 
their offspring? 
   
    
Type of study  
Is the study one of the following designs during pregnancy or continued after 
pregnancy, either in mother or infant or both? 
   
 
Randomised controlled trial 
   
 
Cluster randomised controlled trial 
   
 
Quasi-randomised controlled trial 
   
    
Types of interventions (the intervention could be a combination of the 
followings) 
 
Food-based dietary advice (promoting a healthy diet) or nutrient intervention 
 
Multivitamins, supplementation and minerals 
 
Fatty acid supplement(s) 
 
Pre/Probiotic supplement(s)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcomes   
 
 
 
Do the outcome measure obesity, on its own as a general term, or any obesity 
related outcome(s) i.e. anthropometry, BMI, weight gain? 
 
Are the outcome measures validated? 
 
 
 
  
 
 
Study ID ___________ 
 
Reviewer ___________ 
 
Appendix 4.2 
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Appendix 4.3-Characteristics of the excluded studies-Obesity outcomes
* 
 
Studies  Reason for exclusion 
Fatty acids 
Cheatham 2011 Post-natal intervention (in lactating mothers) 
Courville 2011 Birth outcomes reported only 
Haghiac 2015 Birth outcomes are reported and not planning for further follow-up  
Innis 2008 Has not reported growth outcomes  
Jensen 2005 Post-natal intervention (in lactating mothers) 
Judge 2007 Has not reported growth outcomes 
Lauritzen 2005 Post-natal intervention (in lactating mothers) 
Makrides 2010 Has not reported growth outcomes 
Malcolm 2003 Has not reported growth outcomes 
Parisi 2013 Only abstract is available and reported early growth outcomes. Further to 
my personal communication, the author informed that they have not 
collected data on longer-term follow-up. 
Sanjuro 2004 Maternal outcomes reported  
Smithers 2011 Did not report growth outcomes 
Smuts 2003 Did not report growth outcomes 
Tofail 2006 Did not report growth outcomes 
Probiotics  
Allen 2014 Did not report growth outcomes 
Boyl 2011 Did not report growth outcomes 
Dotterud 2010  Did not report growth outcomes 
Huurre 2008 Did not report growth outcomes 
Kalliomäki 2001 Did not report growth outcomes 
Kim 2010 Did not report growth outcomes 
Kopp 2008 Did not report growth outcomes 
Niers 2009 Did not report growth outcomes 
Ou 2012 Did not report growth outcomes 
Rautava 2012 Did not report growth outcomes 
Low GI diet 
Donnely 2015 Infant outcomes reported within  
2-3 days after birth 
Koivusalo 2016 Maternal outcomes reported 
Moses 2007 Non-randomised trial 
Moses 2014 Only birth outcomes reported 
Perichart-Perera 2009 Neonatal outcomes reported 
Rhodes 2010 Maternal outcomes reported 
Seneviratne 2014 Study Protocol: only exercise defined as the intervention 
Lifestyle change 
Adamo 2013 Protocol, no further updates 
Althuizen 2013 Maternal outcomes reported  
Asbee 2009 Maternal outcomes reported 
Dodd 2016 Infants’ outcomes reported during their hospital stay after birth (<1 month) 
Ferrara 2011 Maternal outcomes reported 
Guelinchx 2010 Maternal outcomes reported 
Hawkins 2014 Maternal outcomes reported 
Hui 2014 Birth outcomes reported (planned for a further F-U if could fund the study) 
Petrella 2014 Maternal outcomes reported 
Phelan 2011 Maternal outcomes reported 
Polley 2002 Maternal outcomes reported 
Poston 2015 Birth outcomes reported 
Ruchat 2012 Maternal outcomes reported 
Sagedal 2016 Birth outcomes reported 
Taylor 2011 Postnatal intervention (in infants 0-24months) 
Thomson 2016
**
 Maternal outcomes reported 
Thornton 2009 Perinatal outcomes reported  
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Vesco 2014 Maternal and birth outcomes reported 
Vitolo 2011 Maternal outcomes reported 
Wolff 2008 Maternal outcomes reported 
Vitamins/Micronutrient 
Brough 2010 Birth outcome (low income population) 
Nazli 2014 Neonatal anthropometric outcomes 
Parul 2013 Birth outcomes (rural Bangladesh) 
Roberfroid 2008  Fetal growth (rural Burkina Faso) 
Wieringa 2010 Infant’s morbidity & immune function 
*Studies that were excluded at the final stage of screening are presented and also one publication, mainly a recent work for each original study is cited  
**The authors may publish growth outcomes in babies in their further follow-up(s)      
Fatty acid studies 
 Cheatham CL, Nerhammer AS, Asserhoj M. Fish oil supplementation during 
lactation: effects on cognition and behavior at 7 years of age. Lipids 2001; 46: 
637–645. 
 Courville AB, Harel O & Lammi-Keefe CJ. Consumption of a DHA-containing 
functional food during pregnancy is associated with lower infant ponderal index 
and cord plasma insulin concentration. Br J Nutr 2011; 27: 1–5. 
 Haghiac M, Yang X-h, Presley L, Smith S, Dettelback S, Minium J, et al. (2015) 
Dietary Omega- 3 Fatty Acid Supplementation Reduces Inflammation in Obese 
Pregnant Women: A Randomized Double- Blind Controlled Clinical Trial. PLoS 
ONE 10(9): e0137309. 
 Innis SM & Friesen RW. Essential n-3 fatty acids in pregnant women and early 
visual acuity maturation in term infants. Am J Clin Nutr 2008; 87: 548–557. 
 Jensen CL, Voigt RG, Prager TC. Effects of maternal docosahexaenoic acid 
intake on visual function and neurodevelopment in breastfed term infants. Am J 
Clin Nutr 2005; 82: 125–132. 
 Judge MP, Harel O & Lammi-Keefe CJ. A docosahexaenoic acid-functional food 
during pregnancy benefits infant visual acuity at four but not six months of age. 
Lipids 2007; 42: 117–122. 
 Lauritzen L, Hoppe C, Straarup EM, Michaelsen KF. Maternal fish oil 
supplementation in lactation and growth during the first 2.5 years of life. Pediatr 
Res 2005; 58:235–42. 11. 
 Makrides M, Gibson RA, McPhee AJ. Effect of DHA Supplementation During 
Pregnancy on Maternal Depression and Neurodevelopment of Young Children A 
Randomized Controlled Trial. JAMA 2010; 304: 1675–1683. 
 Malcolm CA, Hamilton R, McCulloch DL. Scotopic electroretinogram in term 
infants born of mothers supplemented with docosahexaenoic acid during 
pregnancy. Invest Ophthalmol Vis Sci 2003; 44: 3685–3691. 
 Parisi F, Brunetti M, Capriata I, Mazzocco M, Cnetin I. Effects of DHA 
supplementation during pregnancy on fetal body composition, presented in the 
Society for Gynaecological Investigation (SGI) - 60th Annual Meeting in 
Orlando, FL, USA, 2013.  
 Sanjurjo P, Ruiz-Sanz JI, Jimeno P. Supplementation with docosahexaenoic acid 
in the last trimester of pregnancy: maternal-fetal biochemical findings. J Perinat 
Med 2004; 32: 132–136. 
 Smithers LG, Gibson RA, Makrides M. Maternal supplementation with 
docosahexaenoic acid during pregnancy does not affect early visual development 
in the infant: a randomised controlled trial. Am J Clin Nutr 2001; 93: 1293–1299 
 Smuts CM, Borod E, Peeples JM. High-DHA eggs: feasibility as a means to 
enhance circulating DHA in mother and infant. Lipids 2003; 38: 407–414. 
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 Tofail F, Kabir I, Hamadani JD. Supplementation of fish-oil and soy-oil during 
pregnancy and psychomotor development of infants. J Health Popul Nutr 2006; 
24: 48–56. 
Probiotic studies 
 Allen SJ, Jordan S, Storey M, Thornton CA, Gravenor MB, et al. Probiotics in the 
prevention of eczema: A randomised controlled trial. Archives of Disease in 
Childhood 2014; 99: 1014-1019. 
 Boyle, RJ, Ismail IH, Kivivuori S, Licciardi, PV, Robins-Browne RM, et al. 
Lactobacillus GG treatment during pregnancy for the prevention of eczema: a 
randomized controlled trial. Allergy 2011; 66: 509-516. 
 Dotterud CK, Storrø O, Johnsen R, Oien T. Probiotics in pregnant women to 
prevent allergic disease: a randomized, double-blind trial. The Br J Drerma 2010; 
163: 6161-623. 
 Huurre A,  Laitinen K, Rautava S, Korkeamäki M, Isolauri E. Impact of maternal 
atopy and probiotic supplementation during pregnancy on infant sensitization: a 
double-blind placebo-controlled study. Clin & Exper Allergy 2008; 38: 1342-
1348. 
 Kalliomaki M, Salminen S,  Arvilommi H, Kero P, Koskinen P,  Isolauri,E. 
Probiotics in primary prevention of atopic disease: a randomised placebo-
controlled trial. Lancet 2001; 357: 1076-1079. 
 Kim JY, Kwon JH, Ahn SH, Lee SI, Han YS, et al. Effect of probiotic mix 
(Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in 
the primary prevention of eczema: A double-blind, randomized, placebo-
controlled trial. Pediatr Allergy & Immunol 2010; 21: e386-e393. 
 Kopp MV, Goldstein M, Dietschek A, Sofke J, Heinzmann A, Urbanek R. 
Lactobacillus GG has in vitro effects on enhanced interleukin-10 and interferon-γ 
release of mononuclear cells but no in vivo effects in supplemented mothers and 
their neonates. Clin & Exper Allergy 2008; 38: 602-608. 
 Niers L, Martín R, Rijkers,G, Sengers, F, Timmerman H, van Uden N, Smidt H, 
Kimpen J, Hoekstra M. The effects of selected probiotic strains on the 
development of eczema (the PandA study). Allergy 2009; 64: 1349-1358. 
 Ou CY, Kuo HC, Wang L, Hsu TY, Chuang H, et al. Prenatal and postnatal 
probiotics reduces maternal but not childhood allergic diseases: a randomized, 
double-blind, placebo-controlled trial. Clin & Experi Allergy 2012; 42: 1386-
1396. 
 Rautava S, Luoto R, Salminen S, Isolauri E. Microbial contact during pregnancy, 
intestinal colonization and human disease. Nature reviews 2012; 9: 565-76. 
Low GI diet 
 Donnelly JM, Walsh JM, Byrne J, Molloy EJ, McAuliffe FM. Impact of maternal 
diet on neonatal anthropometry: a randomized controlled trial. Paediatric obesity 
2015; 10: 52-56. 
 Koivusalo SB, Rono K, Klemetti MM, Roine RP, Lindstrom J, Erkola M, et al. 
Gestational diabetes mellitus can be prevented by lifestyle intervention: the 
Finish gestational diabetes prevention study (RADIEL): a randomised controlled 
trial. Diabetes Care 2016: 39: 24-30. 
 Moses RG, Petocz P, Brand-Miller JC. Maternal diet and infant size 2 y after the 
completion of a study of a low-glycemic-index diet in pregnancy. The Am J Clin 
Nutr 2007; 32: 210-6. 
 415 
 Moses RG, Casey ShA, Quinn EG, Cleary JM, Tapsell LC, et al. Pregnancy and 
Glycemic Index Outcomes study: effects of low glycemic index compared with 
conventional dietary advice on selected pregnancy outcomes. Am J Clin Nutr 
2014; 99: 517–23. 
 Perichart-Perera O, Balas-Nakash M, Parra-Covarrubias A, Rodriguez-Cano A, 
Ramirez-Torres A, et al. A Medical Nutrition Therapy Program Improves 
Perinatal Outcomes in Mexican Pregnant Women With Gestational Diabetes and 
Type 2 Diabetes Mellitus. The Diabetes Educator 2009; 35: 1004-1013. 
 Rhodes ET, Pawlak DB, Takoudes TC, Ebbeling CB, Feldman HA, et al. Effects 
of a low-glycemic load diet in overweight and obese pregnant women: a pilot 
randomized controlled trial. American Journal of Clinical Nutrition 2010; 92: 
1306–15. 
 Seneviratne SN, Parry GK, McCowan LME, Ekeroma A, Jiang Y, et al. 
Antenatal exercise in overweight and obese women and its effects on offspring 
and maternal health: design and rationale of the IMPROVE (Improving Maternal 
and Progeny Obesity Via Exercise) randomised controlled trial. BMC Pregnancy 
& Childbirth 2014; 14: 148 
Life-style change 
 Adamo K, Ferraro ZM, Goldfield G, Keely E, Stacey D, et al. The Maternal 
Obesity Management (MOM) Trial Protocol: A lifestyle intervention during 
pregnancy to minimize downstream obesity. Contemporary Clinical Trials 2013; 
35: 87-96. 
 Althuizen E, van der Wijden C, van Mechelen W, Seidell J, van Poppel M. The 
effect of a counselling intervention on weight changes during and after 
pregnancy: a randomised trial. BJOG : an International Journal of Obstetrics and 
Gynaecology 2013;120(1):92–9 
 Asbee SM, Jenkins TR, ButlerJR, White J, Elliot M, Rutledge A. Preventing 
excessive weight gain during pregnancy through dietary and lifestyle counseling: 
a randomized controlled trial. Obstetrics & Gynecology 2009; 113: 305–12 
 Dodd JM, Deussen AR, Mohamad I, Rifas-Shiman SL, Yelland LN, Louise J, 
McPhee AJ, Grivell RM, Owens JA, Gillman MW, Robinson JS. The effect of 
antenatal lifestyle advice for women who are overweight or obese on secondary 
measures of neonatal body composition: the LIMIT randomised trial. BJOG 
2016; 123:244–253 
 Ferrara A, Hedderson MM, Albright CL, Ehrlich SF, Quesenberry CP, Peng T, et 
al. A pregnancy and postpartum lifestyle intervention in women with gestational 
diabetes mellitus reduces diabetes risk factors: a feasibility randomized control 
trial. Diabetes Care 2011; 34:1519–25. 
 Guelinckx I, Devlieger R, Mullie P, Vansant G. Effect of lifestyle intervention on 
dietary habits, physical activity, and gestational weight gain in obese pregnant 
women: a randomized controlled trial. American Journal of Clinical Nutrition 
2010; 91: 373–80. 
 Hawkins M, Hosker M, Marcus BH, Rosal MC, Braun B, Stanek EJ, et al. A 
pregnancy lifestyle intervention to prevent gestational diabetes risk factors in 
overweight Hispanic women: a feasibility randomized controlled trial. Diabetic 
Medicine 2014; 32:108–15 
 Hui AL, Ludwig S, Gardiner P, Sevenhuysen G, Dean HJ, Sellers E, et al. Effects 
of lifestyle intervention on dietary intake, physical activity level, and gestational 
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weight gain in pregnant women with different pre-pregnancy Body Mass Index 
in a randomized control trial. BMC Pregnancy and Childbirth 2014; 14(1):331. 
 Petrella E, Malavolti M, Bertarini V, Pignatti L, Neri I, Battistini NC, et al. 
Gestational weight gain in overweight and obese women enrolled in a healthy 
lifestyle and eating habits program. Journal of Maternal-Fetal and Neonatal 
Medicine 2014; 27: 1348–52. 
 Phelan S, Phipps MG, Abrams B, Darroch F, Schaffner A, Wing RR. 
Randomized trial of a behavioral intervention to prevent excessive gestational 
weight gain: the Fit for Delivery Study. American Journal of Clinical Nutrition 
2011; 93: 772–9. 
 Polley BA, Wing RR, Sims CJ. Randomised controlled trial to prevent excessive 
weight gain in pregnant women. International Journal of Obesity & Related 
Metabolic Disorders: Journal of the International Association for the Study of 
Obesity 2002; 26: 1494–502. 
 Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, et al. Effect of a 
behavioural intervention in obese pregnant women (the UPBEAT study): a 
multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 2015; 3: 
767-777. 
 Ruchat SM, DavenportMH, Giroux I, Hillier M, Batada A, Sopper MM, et al. 
Nutrition and exercise reduce excessive weight gain in normal-weight pregnant 
women. Medicine and Science in Sports and Exercise 2012; 44: 1419–26. 
 Sagedal LR, Øverby NC, Bere E, Torstveit MK, Lohne-Seiler H, Smiastuen M, 
Hillesund ER, Henriksen T, Vistad I. Lifestyle intervention to limit gestational 
weight gain: the Norwegian Fit for Delivery randomised controlled trial. BJOG 
2017; 124: 97-109. 
 Taylor Heath AM, Galland BC, Gray AP, Lawrence JA, et al. Prevention of 
Overweight in Infancy (POI.nz) study: a randomised controlled trial of sleep, 
food and activity interventions for preventing overweight from birth. BMC 
Public Health 2011; 11:942. 
 Thomson J, Tussing-Humphreys LM, Goodman MH, Olender SE. Gestational 
weight gain: results from the Delta Healthy Sprouts Comparative Impact Trial. 
Journal of Pregnancy 2016; 2016 
 Thornton YS, Smarkola C, Kopacz SH, Ishoof SB. Perinatal outcomes in 
nutritionally monitored obese pregnant women: a randomised clinical trial. J Natl 
Med Assoc. 2009; 101:569-577 
 Vesco K, Karanja N, King JC, Gillman MW, Leo MC, et al. Efficacy of a group-
based dietary intervention for limiting gestational weight gain among obese 
women: a randomised trial. Obesity 2014; 22: 1989–1996. 
 Vitolo MR, Fraga Bueno MS, Mendes Gama C. Impact of a dietary counseling 
program on the gain weight speed of pregnant women attended in a primary care 
service. Revista Brasileira de Ginecologia e Obstetricia 2011; 33: 13–9. 
 Wolff S, Legarth J, Vangsgaard K, Toubro S, Astrup A. A randomized trial of 
the effects of dietary counseling on gestational weight gain and glucose 
metabolism in obese pregnant women. International Journal of Obesity 2008; 32: 
495–501. 
Vitamin/micronutrient studies 
 Brough L, Rees, GA, Crawford MA, Morton Rh, Dorman EK. Effect of multiple-
micronutrient supplementation on maternal nutrient status, infant birth weight 
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and gestational age at birth in a low-income, multi-ethnic population. The British 
J Nutr 2010; 104: 437-445. 
 Nazli H, Fatima KH, Shabana R, Robina K, Shabana A, et al. Obstetric and 
neonatal outcomes of maternal vitamin D supplementation: results of an open-
label, randomized controlled trial of antenatal vitamin D supplementation in 
Pakistani women. The J Clinical Endocrin & Metabol 2014; 99: 2448-2455. 
 Christian P, Khatry SK., Katz J, Pradhan E, Leclerq S, Shrestha S, et al. Effects 
of vitamin A and β-carotene supplementation on birth size and length of 
gestation in rural Bangladesh: a cluster-randomized trial. The Am J Of Clini Nutr 
2013: 97: 188-194. 
 Roberfroid D, Lieven H, Hermann L, Marie-Claire H, Nicolas M, et al. Effects of 
maternal multiple micronutrient supplementation on fetal growth: a double-blind 
randomized controlled trial in rural Burkina Faso. The Am J Clin Nutr 2008; 88: 
1330-1340. 
 Wieringa FT, Dijkhuizen MA, Muhilal der Meer JWM. Maternal micronutrient 
supplementation with zinc and β-carotene affects morbidity and immune function 
of infants during the first 6 months of life. European J Clin Nutr 2010; 64: 1072-
1079. 
 
Papers published after the search strategy for these systematic reviews were 
updated on January 2016 (not included in the current review) 
Study  Intervention & Outcome reported 
Vesco 2016 Life-style, Obesity outcomes at 1-year age 
Muhlhausler 2016 Fatty acid, Obesity outcomes at 3 and 5 years age 
 
 Vesco KK, Leo MC, Karanja N, Gillman MW, McEvoy T, et al. One-year 
postpartum outcomes following a weight management intervention in pregnant 
women with obesity. Obesity 2016; 24: 2042–2049. 
 Muhlhausler BS, Yelland LN, McDermott R, Linda Tapsell L, Andrew McPhee 
A, Gibson RA, Makrides M. DHA supplementation during pregnancy does not 
reduce BMI or body fat mass in children: follow-up of the DHA to Optimize 
Mother Infant Outcome randomized controlled trial. Am J Clin Nutr 2016; 103: 
1489-1496. 
 
Ongoing studies: 
 Rauh K, Kunath J, Rosenfeld E, Kick L, Ulma K, Hauner H. Healthy living in 
pregnancy: a cluster-randomized controlled trial to prevent excessive gestational 
weight gain - rationale and design of the GeliS study. BMC Pregnancy and 
Childbirth 2014, 14:119 [This is another on-going large-scale intervention study, 
named GeliS, of 2,500 pregnant women with a study population tenfold as large 
as the FeLIPO study (Rauh et al., 2015 which is included in the current systematic 
review)]. 
 Registered clinical trial: Life style intervention (Mediterranean diet, individual 
counseling and physical activity) during pregnancy for the prevention of obesity 
in offspring" with your name as the principle investigator. Further to my 
communication to Dr Calle-Pascual on September 2015, I was informed that 
recruitment would be completed by end of 2015. No data is published online and 
there was no reply to my further communication. 
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Appendix 4.4. Data extraction tool for obesity outcomes 
 Linked Record-Do not obtain data 
Includes abstracts and later follow-up studies, provided that the later follow-up 
has reported the same outcome(s) for the same sample at the earlier report  
 Study Details 
 Country 
 Recruitment Period 
Please record the months/years that the recruitment is done  
 Setting 
Where the sample are taken e.g. clinics, hospital, multicentre. Please record 
all reported information (provide page numbers for quotes)  
 Informed consent 
If not stated/unclear, please state as "NOT REPORTED/UNCLEAR"  
 Ethical Approval  
If stated, please record the relevant information and tick the box.  
If not stated/unclear, please state as "NOT REPORTED/UNCLEAR"  
 Source of Funding 
Please record, if stated. If not, please state "not reported".  
 Trial Type 
 PC-RCT 
Randomised Controlled Trial-Placebo Controlled 
Please provide brief description of study design.  
 RCT 
Randomised Controlled Trial 
Please provide brief description of study design.  
 CRT 
Cluster Randomised trial, please provide brief description of study design.  
 Quasi Experimental 
Please provide brief description of study design.  
 No. & name of Study Groups/Arms 
Please state the number and name of allocated treatment arms i.e. one 
treatment group vs. one placebo group, more than one treatment with/without 
placebo 
Please record all the relevant information briefly 
 ITT conducted 
Intention-to-treat analysis  
 Yes 
 No 
 Not mentioned 
 Compliance 
 Study Sample  
 Matched baseline characteristics 
 Yes 
 No 
 Women's age 
If there is any information about women's age, either stated as an inclusion 
criteria or other presented information, please record the age limits 
If possible, split the age data into target group, at the study start, and actual 
reported age in results  
 Inclusion criteria 
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 Exclusion criteria 
 Yes 
 No 
 Type of sample 
 Unselected sample 
Subjects are taken from an unselected population.  
 Atopic history 
 Undernourished women 
 Diagnosed with GDM 
 Obese women 
 History of macrosomic baby 
 ≥1 risk factor GDM 
 No. of participants at randomisation 
Please record the number of PREGNANT WOMEN at the time of 
randomisation, where recruitment occurred prenatally. 
 No. at F-U 
No. of subjects at the end of follow-up in both intervention and control 
groups.  
 Missing Participants 
Please record the reasons missing numbers at birth e.g. number of infants 
eligible at birth.  
 Reasons Missing 
 Time Points Measured 
Earlier follow-up(s) reported time points  
 Infant's age at last F-U 
Please record the reported age of infants at their last follow-up  
 Intervention 
 FA Type 
Fatty acid type, please tick all relevant boxes 
 Any FA 
 LCPUFA 
Long Chain Poly Unsaturated Fatty Acids  
 DHA 
Docosahexaenoic Acid  
 Fish oil 
 Daily Dosage 
Please record the total daily dosage taken in mother, infant or both, 
whichever is applicable with units 
If more than one type is taken, please record the total daily dosage for all 
with units  
 Mode of Int. delivery during Pregnancy 
 Mode of Int. delivery during Infancy 
 Probiotic type (Organism) 
Please tick all relevant boxes  
 Any Pro 
 Daily dosage 
Please record the total daily dosage taken in mother, infant or both, 
whichever is applicable with units 
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If more than one type is taken, please record the total daily dosage for all 
with units  
 Mode of Int. Delivery in Infancy 
Who has delivered the intervention and how e.g. mothers and oral  
 Mode of Int. delivery during Pregnancy 
e.g. oral use  
 Life Style Intervention 
 Dietary advice+ PA 
any nutrition counselling plus physical activity/exercise  
 Dietary advice 
 Protein-energy supplementation 
 Mode of Int. intake in pregnancy 
 Vitamin/Suppl. Type 
Vitamins/Multivitamins/Micronutrient supplements  
 Any Vit 
 Vit D3 
 Micronutrients 
 Folic Acid 
 Folic acid + iron 
 Folic acid + iron + zinc 
 Multiple Micronutrient 
 Daily Dosage 
Please record the total daily taken dosage, in mother, infant or both, 
whichever is applicable with units 
If more than on type is taken, please record the total daily dosage for all 
with units  
 Mode of Int. delivery during Pregnancy 
 Mode of Int. delivery in Infancy 
 LGI 
Low Glycemic Int.  
 Comparisons 
 Placebo/Control 
 Standard diet 
 No treatment 
 High Fibre 
 Routine care 
 When Int. has been applied? 
 Pregnancy alone 
 Pregnancy & after delivery-In mothers 
 In Pregnancy & after delivery in Mothers & Infants 
 Pregnant women & after birth in Infants  
 Timing in Pregnancy 
Please record intake of intervention FROM/UNTIL in pregnant women 
e.g.12-40 gestation week. 
 Duration of Int. in Pregnancy 
Please record the total duration of intake, within pregnancy e.g. 6 months 
 Intake IN MOTHERS after Birth 
If the intervention is continued after birth in mothers, please record the intake 
FROM/UNTIL for that period of time e.g. 6months after birth 
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 Total Duration in Women 
Please record the TOTAL duration of intake in MONTHS, including after 
birth, if continued e.g. 7 months (36 gestation wks. + 6 months after birth)  
 Timing in Infancy 
If applicable, please record the intake of intervention FROM/UNTIL in infants 
e.g. 6 months  
 Duration in Infancy 
If applicable, please record the total duration of intake in infants after birth, 
in MONTHS  
 Total duration of Int. 
 Feeding Restrictions 
If any feeding restrictions are stated in the study i.e. Breast feeding after 
birth, Formula feeding (quote the page number)  
 Type of delivery 
Please state if not reported  
 Caesarean 
 Vaginal 
 Instrumental 
 Side Effects 
 Yes 
 No 
 N/A-NM 
Not Applicable OR Not Mentioned  
 Outcomes 
The defined and measured endpoint(s) in the study  
 Head Circumference(cm) 
 Weight(Kg) 
 Length(cm) 
 Height (cm) 
 Arm circumference(cm) 
 Waist(cm) 
 BMI(kg/me2) 
 BMI Z-score 
 Ponderal index(kg/me3) 
 Biceps [mm] 
 Triceps [mm] 
 Subscapular [mm] 
 Suprailiacal [mm] 
 Sum 4 SFT[mm] 
Sum of 4 Skinfold Thickness measurements  
 Body fat [%] 
 Fat mass [kg] 
 LBM [g] 
Lean Body Mass  
 Subscapular/triceps-Ratio 
 Trunk-to-total SFT [%] 
Trunk-to-total SFTs were calculated as (subscapular + suprailiac)/sum of 4 
SFTs*100  
 Obesity 
 Overweight 
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 Overweight/Obese 
 Abdominal Circumference 
 Hip (cm) 
 AC/Hip ratio 
Abdominal Circumference/Hip ratio  
 Total fat (g) 
Dual Energy X-ray (DEXA scan), in Tanvig study  
 Insulin (pmol/L) 
 Blood glucose (mmol/L) 
 Hb A1c fraction (%) 
 HOMA-IR 
Homeostatic Model of Assessment of Insulin Resistance  
 Leptin (lg/L) 
 Adiponectin (microg/L) 
 IGF-I (microg/L) 
 hs-CRP (mg/L) 
 Diagnosis Methods 
Please tick all that apply  
 Blood sampling 
 Anthropometric measurements 
Please provide a brief description  
 Skinfold thickness measurements 
 Laboratory analysis 
Please provide a brief description  
 Dietary intake 
 Body composition assessment 
 Birth measurements 
 Parkin score 
 Self-report 
 Breast milk samples 
 Follow-up interviews 
 PA measurement 
 Outcome Classifications 
 Diagnosed with GDM 
Women diagnosed with Gestational Diabetes Mellitus  
 Unselected Sample 
 Undernourished women 
 Atopic history 
 Obese women 
 History of macrosomic child 
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 Appendix 4.5. Risk of bias judgement (fatty acid studies for prevention of obesity outcomes) 
Short 
Title 
Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Bergmann 
(2012) 
• Low  
Prospective mothers 
were randomized in 
blocks by a 
computer program 
and allocated to one 
of three groups 
(page 3, 1st column) 
 
 
• Unclear 
There is no 
information how 
women are allocated 
 
• Unclear 
There is no 
information whether 
the staff were blind 
at the extended F-U; 
however says that 
neither did the 
parents nor their 
children were aware 
of the original 
supplementation 
assignment (2012 
paper, page 2, 2nd 
column, 4th para). 
Also in the original 
paper they report 
blinding but not the 
methods by which it 
was achieved.  
• Low 
The examination was 
conducted by a 
pediatrician trained in 
anthropometric 
methods (K.E.B) who 
was not aware of the 
original 
supplementation 
assignment.  
 
• Low 
115 healthy 
children were 
examined for the 
6yrs F-U which 
accounts for 95% 
of the eligible 
cases. This data is 
for children 
whose mothers 
had at least 
participated in 
one F-U visit, 
even if they had 
not regularly 
taken the 
supplement or 
had not 
exclusively 
breastfed for 3m.  
• Low 
the secondary 
outcomes defined as 
attained growth of 
6-year-old children 
were applied as 
amendment to the 
original study and 
all reported.  
 
• Unclear 
there is no 
information whether 
the fish oil 
supplementation has 
been consumed by 
either the 
intervention or 
control groups, 
mothers or their 
children, after 
terminating the 
study period.  
 
Brei 
(2016) 
• Low  
Participants were 
randomly assigned 
on the basis of a 
computer-generated 
randomisation 
sequence provided 
by the Institute for 
Medical Statistics 
and Epidemiology, 
with 1:1 allocation 
in blocks (2012 
paper, page 2) 
• Unclear 
No information how 
allocation is done, 
just says 
randomization was 
performed in the 
14th–15th wks. of 
gestation by a 
research assistant 
(2012 paper, page 2, 
randomisation...) 
 
• High 
The design of the 
study was open-
label. 
 
• High 
Investigators who 
performed the 
measurements and 
analysis were not blind 
to the treatment. 
 
• High 
high loss to 
follow-up (54.8% 
approached) and 
the most common 
reasons for 
dropout were a 
lack of time or 
relocation. 
• Low 
primary & 
secondary endpoints 
in methodology are 
reported 
• Unclear 
It is not clear 
whether women in 
Int. group have 
consumed the FA 
supplement after 
discontinuing it at 
4months. 
Short Random Sequence Allocation Double Blinding Blinding of Outcome Incomplete Selective Outcome Other Sources of 
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Title Generation Concealment Assessment Outcome Data Reporting Bias 
Campoy 
(2011) 
• Unclear 
Block-wise 
randomization was 
performed by using 
stratification by 
centre before the 
study started and 
participating women 
were randomly 
assigned. 
 
• High 
There were risk that 
staff/participants 
would have known 
the No. from the 
containing envelops. 
(In each centre, 20 
envelopes containing 
cards from 1-4, for 
the 4 Int. groups 
were mixed into a 
closed box. By 
drawing, Int. group 
were consecutively 
assigned to subject 
identity No. (2007 
paper, pages 2 & 3) 
• Low 
Neither the 
participating women 
nor the study 
personnel knew the 
content of the 
sachets (2011 paper, 
page 2, study 
design).  
 
• Unclear 
There is not mention 
(i) who actually 
performed the outcome 
assessments for height 
etc. and (ii) whether or 
not they were blinded 
 
• High 
between 43.6 to 
55.6% of the 
sample have been 
reached for the F-
U at 6.5yrs; with 
loss of contact 
and unwillingness 
as the main 
reasons for lost to 
F-U. There were 
no differences in 
the dropout rates 
between 
intervention 
groups. 
• Low 
The primary and 
secondary endpoints 
of the study defined 
in methodology are 
reported. 
 
• Unclear 
no information as to 
whether the study 
sample have 
consumed FO 
supplements after 
the termination of 
study & by the time 
of F-U.  
 
Dunstan 
(2008) 
• Unclear 
just mentioned block 
randomisation was 
used according to 
some demographic 
characteristics. 
• Low 
allocation was 
conducted in a blind 
manner and also, 
capsules in the two 
groups were image 
matched 
• Low 
Mothers and 
research staff 
remained blinded 
until completion of 
the cognitive testing. 
 
• Low 
mothers and research 
staff remained blinded 
until completion of the 
outcome assessment. 
• Low 
Of those that 
completed the 
study, 82 & 90% 
were followed-up 
in the Int. & 
placebo arms 
respectively. 
Higher lost to f-u 
rate was observed 
in the Int. arm (12 
vs. 3) in the initial 
trial for allergy 
measures, 
because nausea in 
the intervention 
group was higher 
than the control 
(7 vs. 1).  
• Low 
the secondary 
outcomes reported 
in methodology are 
reported 
• Low 
none identified 
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Short 
Title 
Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Gonzalez-
Casanova 
(2015) 
• Unclear 
Block randomization 
was used to 
randomly create 
balanced replication 
of four treatments 
(two colours for 
DHA and two for 
control) using a 
block size of eight. 
• Low 
The assignment 
codes were placed in 
sealed envelopes at 
the beginning of the 
study and held in a 
sealed location by a 
faculty member at 
Emory University 
(2010, page 3). Also, 
suppl. distributed by 
trained field workers 
during weekly visits 
at the participant’s 
homes and/or work 
place (2011, page 2). 
• Low 
Researchers 
remained blinded to 
the treatment 
scheme until the end 
of the intervention, 
whereas 
participants and 
field personnel 
remain blinded to 
date. 
 
• Low 
Researchers remained 
blinded to the 
treatment scheme until 
the end of the 
intervention, whereas 
participants and field 
personnel remain 
blinded to date. 
 
• High 
73.67 and 72.94% 
of participants in 
the intervention 
and placebo 
groups were 
followed-up 
respectively, 
which is below 
80% f the 
satisfactory 
participation rate.  
• Low 
The primary 
outcome measures 
defined in 
methodology are 
reported.  
 
• Low 
There were no 
significant 
differences in 
reported 
consumption of any 
DHA-source foods 
by offspring between 
treatment groups at 
either time point. 
Helland 
(2008) 
• Low  
The randomization 
was performed by a 
computer program 
(2001 paper, 
materials & 
methods, 2nd 
column) 
 
 
• Unclear 
No information 
about the method of 
allocation (in 2001 
or 2008 papers) 
 
 
 
• Unclear 
No information 
about blinding of 
either research staff 
or participants are 
provided. Also no 
information about 
the differences 
between the Int. and 
control pills in terms 
of appearance, taste 
and smell. 
 
 
• Unclear 
For the outcomes of 
interest, the 
measurements were 
taken in routine clinic 
appointments where is 
unlikely the staff knew 
about the study and 
parents then sent a 
copy of the 
appropriate 
information to study 
staff. So, since it is 
unclear if parents were 
appropriately blinded, 
it is unclear whether 
there could have had 
an influence on the 
outcome assessment.  
• High 
Loss to F-U is 
high (<50% of the 
invited infants 
followed up 
during the 1st 
year of their life 
have attended the 
F-U at 7yrs age). 
Also the non-
compliance rate 
was higher in the 
Int. vs. control 
group.  
 
• Low 
the primary and 
secondary end 
points defined in 
methodology are 
reported 
 
• Low 
There was no 
statistical difference 
between the groups 
concerning intake of 
cod liver oil during 
the preschool age. 
(based on mothers’ 
report).  
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Short 
Title 
Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Rytter 
(2011) 
• Unclear 
Women were 
randomly assigned 
to the three groups 
in the ratio 2/1/1. 
Randomisation was 
stratified by parity 
(no previous full-
term childbirth vs 
one or more) and 
arranged in 
balanced blocks of 
between 8 and 12 
(Olsen 1992, page 4, 
1st para) 
 
 
• Low 
Randomisation 
numbers for each 
study number were 
kept in a sealed, 
opaque envelope that 
either identified a 
particular package 
of oil capsules or no 
oil supplement. The 
capsules and their 
boxes looked 
identical (Olsen 
1992, page 4, 1st 
para). 
 
 
• High 
Women would know 
if they were in the 
control group as 
they would not 
receive any tablets. 
This would very 
much depend on 
what information 
was provided to 
participants. If they 
are fully informed 
(i.e. in order to give 
proper consent) then 
they should have 
been told what being 
part of the control 
group would 
involve. Does not 
report blinding of 
investigators. 
• Low 
The 2 assistants, who 
made all the 
measurements, were 
blinded to group 
allocation (2011 
paper, page 2, 
subjects, 2nd para) 
 
• High 
High loss to F-U 
which is bigger in 
fish oil group, 
mostly due to 
refusing, not 
completing the 
clinical 
examinations and 
no responses. 
 
• Low 
All the defined 
outcomes mentioned 
in the methods are 
reported. 
 
• Low 
None identified (The 
3 groups were 
similar with respect 
to most covariates. 
The only difference 
that was statistically 
significant was the 
smoking status 
among the offspring, 
with smoking being 
more prevalent in 
participants from 
the olive oil group 
than in the other 2 
groups (Table 2)). 
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 Appendix 4.6. Risk of bias judgement (probiotic studies for prevention of obesity outcomes) 
Short title Random Sequence 
Generation  
Allocation 
Concealment  
Double Blinding 
 
Blinding of 
Outcome 
Assessment  
Incomplete 
Outcome Data  
Selective Outcome 
Reporting 
Other Sources 
of Bias 
Abrahamsson 
(2013) 
• Unclear 
Randomisation was 
stratified for each 
study centre. No 
more information is 
given 
• Low 
Each centre was 
provided an 
allocation list with 
unique ID numbers 
for each subject. 
Prior to 
randomisation, each 
study product bottle 
was labelled with 
the unique ID 
number and 
randomly mixed by 
an independent 
contract 
manufacturer. 
• High 
'The study was conducted 
in a double blind fashion 
until all infants had 
completed the 2ysr 
follow-up. 
• High 
The study was 
conducted in a 
double blind 
fashion until all 
infants had 
completed the 2y 
F-U. 
• High 
There was high loss 
to follow-up, but 
equally spread 
across both groups. 
However, reasons 
for being lost to 
follow-up are not 
reported. 
 
• Unclear 
Primarily designed 
to assess allergic 
outcomes in 
children and 
obesity measures 
reported as 
secondary 
outcomes 
• High 
Infants in the 
placebo group 
did not receive 
the supplement 
after birth. 
Also, At 7y of 
age, 19% vs. 
26% (L. reuteri 
vs. placebo) 
reported had 
taken any 
probiotic strain 
in the last 
month 
(p=0.30). 
Kuitunen 
(2009) 
• Low  
Computer-generated 
block randomisation 
• Low 
Throughout the 
study, the 
randomisation code 
was kept by the 
database consultant 
and revealed to the 
statistician only 
• Low 
The randomisation code 
was kept by the database 
consultant and revealed 
to the statistician only. 
The capsules and syrups, 
looked, smelled, and 
tasted identical 
• Unclear 
No statement as to 
whether the 
paediatrician was 
blinded to the 
treatment 
allocation at 5yrs 
F-U 
• Unclear 
A high number of 
mothers in both 
groups refused to 
participate and also, 
reasons for lost to 
follow-up not 
specified. 
• Unclear 
Primarily designed 
to assess allergic 
outcomes in 
children and 
obesity measures 
reported as 
secondary 
outcomes 
• Low 
non identified 
Luoto (2010) • Unclear 
Says women in the 
intervention group 
were randomized in 
a double-blind 
manner to receive 
either probiotic or 
placebo capsules 
• Unclear 
no information is 
provided 
 
• Low 
During the intervention 
period neither parents nor 
clinicians were aware of 
allocation, and the 
intervention/comparison 
capsules were similar in 
appearance, taste and 
• Low 
The clinician was 
un-blinded at 
termination of the 
original study 
(2001 paper). 
However, the 
follow-up data was 
• Unclear 
Reasons for lost to 
F-U are not 
provided 
 
• Low 
The defined 
outcomes in 
methodology are 
reported 
 
• Unclear 
no information 
whether 
children in the 
Int. group have 
consumed 
probiotics after 
the termination 
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with no more details 
 
smell (2001 paper). 
 
 
collected from 
parents, having 
been measured by 
school nurses, and 
it seems likely 
blinding was still 
in place for 
parents and that 
school nurses were 
also unaware of 
allocation. 
of study 
 
Wickens 
(2013) 
• Low  
Randomisation was 
stratified by study 
centre and 
performed in blocks 
of 15 according to a 
computer-generated 
randomisation list. 
• Low 
Randomisation and 
allocation of 
supplements were 
performed by a 
clinical trials 
pharmacist with no 
contact with the 
participants. 
• High 
After the 2-year follow-up 
parents were not blind to 
study group, and were 
subsequently asked to 
report subjectively on 
eczematous symptoms. 
• Low 
Study nurses 
remained blinded 
to participant 
study group 
through-out 
• High 
Imputed analysis is 
used for some of the 
reported outcomes; 
also the reasons for 
lost to F-U are not 
specified. 
• Unclear 
Primarily designed 
to assess allergic 
outcomes in 
children and 
obesity measures 
reported as 
secondary 
outcomes 
• Low 
Infants 
excluded if 
exposed to 
commercially 
available non-
study 
probiotics, 
either directly 
or through 
breast milk 
during the 
course of the 
study 
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 Appendix 4.7. Risk of bias judgement (LG index diet studies for prevention of obesity outcomes) 
Short 
Title 
Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding  Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
 
Horan 
2016 
• Low  
Using computer 
generated 
allocations in a ratio 
of one to one (Walsh, 
2012, patient 
selection) 
 
• Unclear 
The research 
midwife did the 
randomisation in 
sealed opaque 
envelopes (Walsh 
2012, patient 
selection) 
 
• High 
participants were 
aware of the type of 
intervention 
• Unclear 
There is no 
indication whether 
the measurements 
were conducted in a 
blind fashion (Horan 
2016, 2.3 section). 
 
• High 
Only 280 women 
(35%) returned for 
the 6months 
postpartum F-U and 
completed food 
diaries & other 
questionnaires. 
(2016 paper, page3, 
2.2 part)  
• Low 
[Info] All predefined 
outcomes in 
methodology are 
reported. 
 
• High 
No detailed dietary 
data was collected at 
6ms postpartum, so 
no information 
whether women 
continued the low GI 
diet or reverted to 
pre-pregnancy 
dietary habits.  
Louie 
(2013) 
• Low 
women were 
centrally randomised 
to study diet by 
computer-generated 
random numbers, 
stratified by BMI 
(BMI <30 vs. >=30 
kg/m2) and weeks of 
gestation (<28 or 
>=28 weeks).  
 
• Unclear 
Says the allocation 
sequence was 
unpredictable and 
concealed from the 
recruiter, but does 
not say the method 
by which they 
achieved this (2011 
paper, page 2, 
Subject 
recruitment...)  
 
• Unclear 
No information 
regarding the 
blinding of research 
staff and 
participants, also the 
study dieticians may 
well have known the 
allocation given that 
they were being 
asked to judge 
compliance with the 
diets based on 24hr 
food diaries. 
Whether they 
communicated this 
to participants or 
other study staff is 
unclear. 
• Unclear 
A biostatistician 
blinded to the diet 
allocation performed 
the statistical 
analyses at birth, but 
no information is 
provided for the F-U 
at 3mon. 
 
• High 
59% of the original 
cohort returned for 
F-U with no reasons 
mentioned for the 
attrition.  
 
• Low 
All the pre-defined 
outcomes in 
methodology are 
reported. 
 
• Unclear 
The post-partum diet 
was not formally 
assessed. Mothers 
were encouraged to 
continue their 
assigned diet; 
however, it is 
possible that they 
reverted to their 
habitual eating 
pattern 
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 Appendix 4.8. Risk of bias judgement (life-style change studies for prevention of obesity outcomes) 
Short 
Title 
Random Sequence 
Generation 
Allocation 
Concealment 
Double Blinding Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome Data 
Selective Outcome 
Reporting 
Other Sources of 
Bias 
Rauh 
2015 
• Low  
Randomisation was 
performed at the 
cluster level, i.e. 
gynecological 
practices were 
randomised (rather 
than individuals) 
using a computer-
generated 
randomisation 
allocation table 
(2013 paper). 
• Low 
Randomisation was 
performed by a 
researcher not 
involved in the study 
design thereby 
preventing 
allocation bias 
(2013 paper). 
 
• High 
The nature of the 
study meant that 
participants and 
study staff were not 
blinded to the types 
of intervention (2013 
paper, page 2). 
 
• High 
The nature of the 
study meant that 
participants and 
study staff were not 
blinded to the types 
of intervention. 
 
• High 
More women 
participated in 
practices allocated 
to the intervention 
group than in 
control practices (12 
vs. 22%), causing 
unequal group sizes. 
 
• Low 
All the pre-defined 
outcomes in 
methodology are 
reported. 
 
• Unclear 
The dietary intake & 
PA level are not 
assessed after 
delivery and its not 
clear whether 
mother adhered the 
consulted 
intervention.  
 
Tanvig 
(2015) 
• Low  
Women were 
randomised using 
computer-generated 
No. in closed 
envelopes (page 11, 
2014 report) 
• Unclear 
A doctor and a 
research midwife 
enrolled the patients 
and women 
themselves picked-up 
their randomisation 
number from a 
basket and opened 
(page 11, 2014 
report).  
• High 
There was no 
blinding to patients, 
care givers or the 
doctor (page 11, 
2014 report) 
 
• Low 
All children were 
examined by the 
same medical doctor 
(M.T.), blinded to 
the RCT Int. 
Information on who 
had received 
intervention was 
revealed after data 
collection was 
complete.  
• High 
Less than 50% are 
approached with no 
reasons mentioned 
for lost to F-U at 
2.8yrs (Figure 1) 
 
 
• Low 
The pre-defined 
outcomes in 
methodology are 
reported 
 
• Unclear 
Unclear if mother in 
the either study 
group have 
conducted any other 
exercise e.g. exercise 
at home, short length 
walking/brisk 
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Faculty of Science 
University of Portsmouth 
St Michael’s Building 
White Swan Road 
Portsmouth PO1 2DT 
United Kingdom 
T:  +44 0)23 9284 3004 
             F: +44 (0)23 9284 3335 
Portsmouth Birth Cohort Registry 
Food Frequency Questionnaire 
Instructions for completion 
 
Dear mother/parent 
You have received this questionnaire as part of the Portsmouth Birth Cohort Registry. Here, we would like to ask you about the foods you 
eat. To do this, there is a list of foods and we would like you to tell us how often you have eaten each food during the past 3 months, by 
ticking the boxes. The list may include foods you never eat or you may find foods which you eat a lot are missing. These can be added at the 
end. This questionnaire should take 10-15 minutes to complete.  
 
We will use the information from this questionnaire to see if there is any relationship between what women eat when they are pregnant and the 
development of allergies in their babies or how quickly their babies grow. We very much appreciate your time completing the questionnaire. 
Please return the completed questionnaire using the enclosed pre-paid addressed envelope.  The return  
of the questionnaire will be considered as your consent. 
 
If you have any queries, please do contact me in relation to my role as Principal Investigator for this study. 
 
Yours faithfully 
 
Professor Tara Dean 
Dean of Science 
Appendix 5.1. Food frequency questionnaire in pregnancy (FFQ-P), 
adapted from the Southampton Women’s Survey 
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Portsmouth Birth Cohort Study 
  
1. Are you currently excluding any foods from your diet? Yes
 
 No
 
 
 
 IF ‘NO’ GO TO Q. 4     
2. If yes, why? Please specify, even if because of 
morning sickness 
 
 
   
3. What food group(s) are you excluding? Please 
specify 
 
      
4. Have you taken any medication (e.g. antibiotics, paracetamol     
or aspirin) during your pregnancy so far? Yes
 
 
 
No
 
 
      
5. If yes, what?       (If no tick assume answer to be NO) 
 Antibiotics Yes
 
 No
 
    
 Paracetamol Yes
 
 No
 
    
 Aspirin Yes
 
 No
 
    
 Other medication Yes
 
 No
 
 Please specify  
 Do you take any 
nutritional supplements 
e.g. Vitamins?  
Yes
 
 No
 
 Please specify all  
 
6. Do you know how much you weighed before pregnancy?  Yes
 
 
 
No
 
 
  
7. If yes, please state (kg)  
 
        
8. How much attention do you pay to your diet in terms 
of healthy eating? 
Very little
 
 Somewhat
 
 A great deal
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Food Frequency Questionnaire (Define the 3 month period)  
 
On average how often have you eaten the following foods during the last three months? (please tick) 
 
 FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD  
CODE 
STARCHY CARBOHYDRATES  
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Times 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
1 
 
White bread 
        
 When you eat bread/toast/sandwiches, how many 
slices/rolls do you eat at a typical meal? 
Rolls (count as 2 slices) French bread (baguette) (2″ 
counts as 1 slice)                                     
  
 
2 
 
Brown and wholemeal bread/rolls                          
        
 How many slices/rolls do you eat at a typical meal? 
Rolls (count as 2 slices)                                                     
  
 
3 
 
Crackers   
        
 
4 
 
Wholemeal and rye  crackers                             
        
 
5 
 
High fibre breakfast cereals (e.g. Weetabix)                                      
        
 
6 
 
Other breakfast cereals 
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 FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD  
CODE 
  
Never 
 
Once 
every 
2-3 
Months 
Once 
a 
Month 
 
Once 
a 
Fortnight 
1-2 
Times 
per 
Week 
3-6 
Times 
per 
Week 
Once 
a 
day 
More 
than 
once a 
day 
 
7 
 
Added bran to foods                                                                    
        
 
8 
 
Potatoes boiled and jacket 
        
 When you eat these how many potatoes do you eat at a typical 
meal?  
Large baking (count as 3)/new (count as 0.5)                                                                             
 
        
 
9 
 
Roast potatoes and chips 
        
 When you eat these how many potatoes do you eat at a typical 
meal?              
                                     
 
10 
 
Yorkshire puddings and savoury pancakes                              
        
 
11 
 
White rice 
        
 
12 
 
Brown rice 
        
 
13 
 
Pasta  
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 FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD  
CODE 
VEGETABLES 
 
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Times 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
14 
 
Peas and green beans 
        
 
15 
 
Carrots                                     
        
 
16 
 
Parsnips, swede and turnip                                      
        
 
17 
 
Sweetcorn and mixed veg 
        
 
18 
 
Beans and pulses 
        
 
19 
 
Tomatoes  
        
 
20 
 
Spinach  
        
 
21 
 
Broccoli, Brussels sprouts and spring greens                                
        
 
22 
 
Cabbage and cauliflower                                       
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 FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD  
CODE 
  
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Times 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
23 
 
Peppers and watercress                                    
        
 
24 
 
Onion                                    
        
 
25 
 
Green salad                                    
        
 
26 
 
Side salads in dressing  
        
 
27 
Courgettes, marrow and leeks                                         
        
 
28 
 
Mushrooms                                                    
        
 
29 
 
Vegetable dishes  
        
 
30 
 
Soup 
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 FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD  
CODE 
FRUIT 
 
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Times 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
31 
Fresh apples and pears 
        
 
32 
Bananas 
        
 
33 
Strawberries, raspberries and blueberries 
        
 
34 
 
Fresh peaches, plums, cherries and grapes                              
        
 
35 
 
Fresh pineapple, melon, kiwi fruit and other tropical fruits 
        
 
36 
Fresh oranges and orange juice                                          
        
 
37 
 
Tinned fruit not including grapefruit, prunes, figs or 
blackcurrants 
        
 
38 
 
Cooked fruit not including blackcurrants 
        
 
39 
 
Dried fruit 
        
40 
 
Grapefruit and grapefruit juice                               
        
41 
 
Blackcurrants, Ribena and hi-juice blackcurrant drinks 
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FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD  
CODE 
DRINKS  
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Times 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
42 
 
Cola drinks 
        
 
43 
 
Diet cola drinks                                           
        
 
44 
 
Soft drinks not including diet drinks                        
  
        
 
45 
 
Energy drinks 
        
 
46 
 
Water 
        
 
47 
 
Alcohol 
        
 
48 
 
Tea 
        
49 
Coffee 
        
50 Decaffeinated tea or coffee       
                                      
        
 
51 
 
Drinking chocolate and milk shakes not including McDonalds 
style milkshakes      
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 FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD 
CODE 
MEAT AND SUBSTITUTES 
 
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Times 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
52 
 
Bacon and gammon  
        
 
53 
 
Pork (e.g. pork chop) 
        
 
54 
 
Sausages 
        
 
55 
 
Ham or luncheon meat  
        
 
56 
 
Chicken and turkey breast                                   
        
 
57 
 
Chicken and turkey in breadcrumbs  
        
 
58 
 
Lamb 
        
 
59 
 
Beef 
        
 
60 
 
Minced meat dishes (e.g. lasagne, bolognaise) 
        
61 
 
Meat pies 
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 FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD 
CODE 
  
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Times 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
62 
 
Liver and kidney                              
        
 
63 
 
Paté and liver sausage  
        
 
64 
 
Vegetarian substitutes (e.g. Quorn)                                      
        
 
65 
 
Take away/fast food (e.g. KFC, McDonalds)  
        
 
66 
 
Ready meals (e.g. pot noodles, microwave meals)                                    
        
 
 
 
FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD 
CODE 
FISH, EGGS AND DAIRY 
 
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Times 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
67 
 
Fish in breadcrumbs  
        
 
68 
 
White fish not in breadcrumbs                                      
        
 
69 
 
Oily fish (e.g. Salmon, Mackerel, Sardines) 
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70 
 
Shellfish  
        
 
71 
 
Boiled and poached eggs  
        
 
72 
 
Omelette and fried eggs                              
        
 
73 
 
Cottage Cheese                                               
        
 
74 
 
Cheese  
        
 
75 
 
Pizza, quiches and cheese flans 
        
 
 
 FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD 
CODE 
  
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Times 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
76 
 
Yoghurt and fruit fools                                                                                        
        
 
77 
 
Cream                                                     
        
  
 
 
Less than ½ a cup 
(<75 ml)
 
½ to 1 cup  
(75-150ml)
 
1-2 cups 
(150-300ml)
 
More than 2 cups 
(≥300ml) 
 
78 
 
On average how much milk do you consume per day (including milk 
in coffee, tea, cereal)? 
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 Skimmed or 1%
 
Semi skimmed
 
Full fat
 Alternative milk  
(e.g. soya)
 
Not 
applicable
 
 
79 
 
Which type of milk do you predominantly drink? Circle one 
     
 
 FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD 
CODE 
SWEET AND MISCELLANEOUS FOODS 
 
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Times 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
80 
 
Milk based puddings (e.g. custard)   
        
 
81 
 
Ice cream 
        
 
82 
 
Chocolate  
        
 
83 
 
Other sweets (not chocolate) 
        
 
84 
 
Cakes and gateaux 
        
 
85 
 
Buns 
        
 
86 
 
Pastries                                         
        
 
87 
 
Chocolate or digestive biscuits                                   
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 FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD  
CODE 
  
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Times 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
88 
 
Other biscuits                                    
        
 
89 
 
Sweet spreads (e.g. jam/honey/chocolate spread)                                
        
 
90 
 
Added sugar (e.g. added to cereal, coffee, tea)                                    
        
 
91 
 
Gravy  
        
 
92 
Stock cubes or marmite                                         
        
 
93 
 
Mayonnaise and salad cream                                                   
        
 
94 
 
Pickles, chutney, tomato ketchup and brown sauce 
        
 
95 
 
Crisps and savoury snacks 
        
 
96 
 
Nuts 
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 FOOD DESCRIPTION FREQUENCY EATEN 
 FOOD  
CODE 
  
Never
 
 
Once 
every 
2-3 
Months
 
Once 
a 
Month
 
 
Once 
a 
Fortnight
 
1-2 
Times 
per 
Week
 
3-6 
Time
s 
per 
Week
 
Once 
a 
day
 
More 
than 
once a 
day
 
 
97 
 
Spreading fat (please specify)            ________________________                         
 
98 
 
Frying fat or oil (please specify)   _______________________                               
 
99 
 
Other vegetable oil e.g. salad dressings,  
marinades (please specify)                ____________________    
    
        
 
Are there food or drinks which you have eaten or drunk once a week or more which are not on the list?  
                                                            No                                          Yes 
 If Yes 
 
Name of food/drink 
 
1-2 times 
per week 
3-6 
times 
per week 
Once a 
day 
More than once a 
day 
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Faculty of Science 
University of Portsmouth 
St Michael’s Building 
White Swan Road 
Portsmouth PO1 2DT 
United Kingdom 
T:  +44 0)23 9284 3004 
Portsmouth Birth Cohort Registry (PBC) 
Infant Milk Diary Record 
Instructions for completion 
 
Dear parent 
 
You have received this questionnaire as part of the Portsmouth Birth Cohort Registry. In this questionnaire will ask you about what your baby is 
eating and drinking. We want to find out whether the foods and drinks that babies have when they are very young affects how quickly they grow 
or whether they develop allergies later in life.  We will ask you about milk(s) that your baby has during the next 4 days. You can start any day of 
the week and carry on for four days. All you need to do is as follows: 
● Simply write down ANY MILK your infant has during the next 4 days e.g. a breastfeed, formula milk or both breast/formula. 
● If breastfed, please write down the approximate duration of the feed (e.g. 15 minutes). 
● If a formula feed, please give details of what is given (e.g. brand and type of milk). Please also provide details of the amount taken e.g. 
4floz or 120mls 
● If your baby has any other liquids in the next four days (e.g. water), please also write them down. 
We very much appreciate your time completing the questionnaire. Please return the completed questionnaire, using the enclosed pre-paid 
addressed envelope. The return of the questionnaire will be considered as your consent. If you have any queries, please do contact me in relation 
to my role as Principal Investigator for this study. 
 
 
Yours faithfully 
 
Professor Tara Dean 
Dean of Science  
Appendix 5.2. Milk diary questionnaire 
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Please answer these questions before completing the diary: 
 
1 What is your baby’s current or most recent 
weight (please look in your red book)? 
Weight: 
 
Date  
weighed: 
   
2 Have you introduced any formula feeds to your baby’s diet?  
(if no please go to Q3) 
Yes  
 
No   
 If yes,   
2.1 How old was your baby when you first introduced formula?  
 
2.2 What type of formula do you feed your baby? 
 
 
 Regular infant milk such as SMA, Aptamil etc.  
(please specify) 
 
  
 
Specialised formula (please specify) 
 
       
3 Have you introduced any other drinks (including water)?  
(if no please go to Q4) 
Yes  No  
 
3.1 
 
If yes, have you given any of the following drinks to your baby? And how old was your baby when 
you first gave them these drinks? 
  Never Given < 1 month 1-2 months 2-3 months >3 months 
 Water      
 Baby Juice      
 Fruit Juice      
 Squash (not low calorie or 
low sugar) 
     
 Low-calorie or low sugar      
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squash 
 Fizzy drinks      
 Tea      
 Other (please state)      
       
4 Do you ever add anything into your baby’s bottle e.g. rusk or 
baby rice? 
Yes  No  
 If yes, please specify (if no please go to Q5)  
 
   
5 Have you introduced any solids into your baby’s diet? Yes  No  
 If yes, please specify (if no please go to Q6)  
 
 
 
  
   
6 How much did you weigh at the end of your pregnancy (if 
known)? 
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Please record what your baby actually drank, not what was offered to them. Please remember to include liquids given by any other 
carer/family member 
 
Milk Diary Started on:                       (Please add date)  
 Morning 
5am-12pm 
Afternoon 
12pm-4pm 
Evening 
4pm-10pm 
Night 
10pm-5am 
Day 1 
 
 
 
 
 
   
Day 2 
 
 
 
 
 
 
   
Day 3 
 
 
 
 
 
 
   
Day 4 
 
 
 
 
 
   
 
Example: 
 
Milk Diary Started on:  Tuesday 10
th
 May                  (Please add date)  
 Morning 
5am-12pm 
Afternoon 
12pm-4pm 
Evening 
4pm-10pm 
Night 
10pm-5am 
Day 1 
 
 
4oz Aptamil First formula 
 
10 minute breastfeed x 2 
15 minute breast feed 
 
30ml water 
20 minute breastfeed x 1 
 
  
4oz Aptamil First formula 
 
3oz Aptamil First formula 
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Appendix 5.3. Study information sheet  
 
PARTICIPANT INFORMATION SHEET 
PORTSMOUTH BIRTH COHORT REGISTRY 
Researchers 
Professor Tara Dean, Epidemiology and Health Services Research 
Dr Saseendran Pallikadavath, Health Demographer 
Senior Research Fellows: Dr Suzannah Helps, Dr Kate Maslin 
Research Midwives: Zoe Garner, Jess Madgwick, Linda Lishman 
Database Manager: Jill Glasby 
What is a birth cohort registry? 
It is a register (list) of children born during a specified time period. Details of health and 
other information are collected for each child born in the particular time period and these 
details are added into an electronic database. In this case the database will include all 
Portsmouth children born during 2015-2016 to women who have consented to be 
included. Registered children would be on the database from birth onwards, for the rest 
of their lives. However, they can, from the age of 16, or earlier if their mother wishes, 
withdraw from the register at any time without giving any reason. 
Why do we need a birth cohort registry in Portsmouth? 
Portsmouth is different from other cities in the South of England.  The overall health of 
people living in Portsmouth is worse than the average for England.  To help health, 
social, and education services provide what is needed for people of the city, they need 
good information; at the moment there is not enough information to base policies on and 
plan services for the local population in Portsmouth.  The information in the register 
would be used by researchers to help find out what services the local people need. 
Why have I been chosen? 
You have been chosen because you are pregnant and your baby will be born in 
Portsmouth in the next 12 months. We want to study things like how your diet, social 
environment, and health status influence the health of your child so we would like to ask 
you some questions about yourself and ask you whether you would consent for your child 
and his or her information to be included in the register. Also we need your permission to 
register your child with the birth cohort so that we can study how children in Portsmouth 
grow and develop over the years.  
As part of this study you will be approached for an interview to discuss issues such as 
your health, diet and social circumstances. If you are happy to take part in this interview 
you will be asked to sign the consent form.  
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We will also ask your permission to register your child with the birth cohort registry and 
obtain health information on your child from the hospital at birth. 
In order to understand more about your child we will need to ask about his or her father 
and his or her brothers and sisters. We will be asking you to make sure that the baby’s 
father is happy for you to provide information about him.  As you will be the responsible 
person to sign the consent for the child till she/he reaches sufficient maturity to decide for 
themselves at age 16 and after, we will be asking your consent to approach you for any 
future study.  
Do I have to take part in the cohort registry? 
No. You do not have to take part in the registry. It is voluntary. Even if you take part you 
are completely free to leave the registry at any time. You will not be asked for your 
reasons. If you do decide to leave the registry we will still use the information that we 
have already collected (with your name and any information that might let people 
identify you removed), unless you ask us to delete all of your data from the registry. 
What does the registry mean to me? 
The registry will help the researchers at the University of Portsmouth to contribute to 
policies and programmes of ‘Portsmouth City’ which includes the Portsmouth City 
Council and Portsmouth NHS organisations.  Birth cohort information will be an 
important resource for answering many questions which eventually contribute to 
scientific knowledge.  
What are the benefits of taking part? 
There is no direct benefit to you. However, if we find any health or social issues related 
to you and your family we will advise you to get appropriate help/support.  
What are the possible risks or disadvantages of taking part? 
There is minimal risk in participating in this registry. Your child will be in the registry as 
long as you wish. If you have given consent you will be approached, until the child 
reaches maturity at age 16 years, to see whether you would be interested in associated  
future studies and further information collection which may occur every 3-4 years. On 
maturity, at age 16, your child will be responsible for giving consent to any future study 
and information collection. Each time your child is invited to participate in future studies, 
we will make sure we have appropriate ethical approval.  
Will my participation be confidential? 
Yes. The part of the registry which can be accessed by researchers will have no 
information which could be used to identify you. All identifiable information will be 
stored in a Master file with access only to the Chief Investigator and Data Manager. We 
may share anonymised data with academic researchers with approval from the data 
management committee and ethical approval from local research ethics committees.  
What if I do have any questions? 
You can contact us using the study email  (PortsmouthBirthCohort@port.ac.uk) or our 
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phone number 07738688089. You can also ask questions through the dedicated website 
for this study - the Portsmouth birth cohort registry.  
www.port.ac.uk/portsmouthbirthcohort 
What happens now? 
If you are willing to participate in the registry please complete the consent form. You can 
either give it to the Midwife now or return it at your next antenatal visit.   
Thank you for considering this study. 
 
 452 
Appendix 5.4. Study consent form 
 
PORTSMOUTH BIRTH COHORT REGISTRY 
Reference number: 15/SC/0008  
Participant Identification Number for this study: ………………………………………. 
CONSENT FORM 
Title of Project: PORTSMOUTH BIRTH COHORT REGISTRY 
Name of Researcher: Professor Tara Dean 
                                                                                                                                           Please initial each box 
1 I confirm that I have read and understood the information sheet version 4 dated 
28/10/2015 for the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily.   
 
2 I understand that my participation is voluntary and that I am free to withdraw at any 
time. 
 
3 I understand that relevant sections of my medical notes and data collected during the 
information collection, may be looked at by individuals from the University of 
Portsmouth, from regulatory authorities or from the NHS Trust, where it is relevant. I 
give permission for these individuals to have access to my records. 
 
4 I understand that data collected during the study may be used for research by 
responsible individuals from the University of Portsmouth and other university 
approved researchers. 
 
5 I understand that I may be contacted (until my child reaches maturity, at age 16), should 
the researchers plan to undertake any studies or collect more information and my 
consent will be obtained before undertaking any interviews regarding my child.                                                        
 
6 I have discussed the research with the child’s father and he understands that I will be 
asked to answer questions relating to him, the father and the baby’s siblings. I 
understand that, sibling details will be asked only if I am also their biological parent. 
 
7 I agree to my child going into the registry.  
 
________________________ ________________ ____________________ 
Name of Participant Date Signature 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
_________________________ ________________ ____________________ 
Researcher Date  Signature 
 
When completed, 1 for participant; 1 for researcher site file 
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Appendix 5.5. Ethical approval letter for the Portsmouth Birth Cohort (PBC) 
registry from Berkshire NHS  
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Appendix 5.6. Portsmouth Birth Cohort (PBC) recruitment 
questionnaire (wave 0) 
 
 
PORTSMOUTH BIRTH COHORT REGISTRY 
 
                     Wave 0 Questionnaire for Pregnant Women  
 
        Unique Identification Number (UIN):…………………… 
 
 
IDENTIFICATION 
 
Name & Address  Date seen      /     / 
 
 
Expected date of delivery      /     / 
 
 
Is this pregnancy Single  Multiple  
 
 
Gestational age  
 
 
Weight  
 
 
Height  
 
 
NHS Number  
   
Hospital Number     
Mother’s date of Birth    
 
Tel No:  (Home) Other contact: 
              (Work) 
              (Mobile) 
Email address: 
 
Consultant  
Community Midwife Clinic 
GP Surgery 
 
 
Detach after data collection…………………………............... 
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Appendix 5.6. Portsmouth Birth Cohort (PBC) wave 0 questionnaire 
PORTSMOUTH BIRTH COHORT STUDY 
 
Wave 0 Questionnaire for Pregnant Women  
 
Unique Identification Number (UIN):……………………… 
 
Date seen      /     / 
Expected date of delivery      /     / 
Is this pregnancy Single  Multiple  
Gestational age  
Weight  
Height  
MODULE 1: SOCIO-ECONOMIC AND DEMOGRAPHIC BACKGROUND 
1.1 What is your marital status?  
   
 
 
 
 
Domestic partnership
1 
 
 
 
 
 
Married
2 
 
 
 
 
 
Separated
3 
     
Divorced
4
      
Widowed
5
      
Single
6
      
1.2   With whom do you live? 
 
 
 
 
 
 
   
 
     
 Husband/partner
1
  
 
     
Parents
2
        
Alone
3
        
Others
4 
(specify)        
1.3 Is your husband/partner the biological father of your current child? (in pregnancy)  
       
 Yes      
 No      
 Don’t know      
1.3a Did you use any of the following for this pregnancy? 
 Donor Egg   
 Donor Sperm   
 None of these   
    
1.4 Who owns the property in which you live?  
 Own home
1 
 
 
 
 
 
 Parents’ home2      
 Housing Association
3 
     
 Private rent
4 
     
 Other
5 
(specify      
1.5 What is your highest level of education?  
 School
1 
 
 
 
 
 
 
 
 Further (after GCSEs)
2
        
 Higher (University)
3
        
 Don’t know7        
 
1.6 What is your husband/partner’s highest level of education?  
 School
1 
 
 
 
 
 
 
 
 Further (after GCSEs)
2
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 Higher (University)
3
        
 Don’t know7        
 
 
 
 
 
  
 
1.7 What is your occupation (or usual occupation)?  
 
      
 
 
1.8 What is your husband/partner’s occupation?  
 
1.9 How many children have you had prior to this pregnancy?   
  Sex Current Age (years)   
 
 
 Child 1     
 
 
 Child 2     
 
 
 Child 3     
 
 
 Child 4     
 
 
 Child 5     
 
 
1.10 How many children live with you in your house?   
 
1.11 How many are your biological children?  
 
 
1.12 Have you ever had an induced abortion, miscarriage, stillbirth or infant 
death? 
Yes
1 
 No
2 
 
      
 If yes: Number of induced abortions
   
 
  Number of spontaneous abortions/miscarriages
   
 
  Number of stillbirths
   
 
  Number of infant deaths (within 1 year of birth)
   
 
1.13 Have any of the following persons ever lived in care?  
 You Yes
1   
  No
2   
  Don’t know3   
     
 Your partner/husband Yes
1   
  No
2   
  Don’t know3   
     
 Any children (you are the biological parent) Yes
1   
  No
2   
  Don’t know3   
     
 Child’s father (if different) Yes
1   
  No
2   
  Don’t know3   
 
 
1.14 Are any of the following persons currently in care? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
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Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
    
Child’s father (if different) Yes
1   
 No
2   
 Don’t know3   
    
1.15 Do you have any pets at home? Cat Yes
1 
 No
2 
  
   Dog Yes
1 
 No
2 
  
   Other Yes
1 
 No
2 
 What? 
MODULE 2: TYPE OF DIET AT HOME 
 
2.1 Which kind of diet best describes your eating habits? 
 
 
 Normal diet
1  
  
 
 
 Vegetarian diet
2
 
 
    
 Vegan diet
3
 
 
    
 Special diet (specify)
4 
 
 
 
2.2 Which method best describes your food preparation methods?  
 Mainly home cooked food
1 
 
 
 
 Mainly commercially prepared foods
2
    
 50/50    
 
These next questions are about the food eaten in your family. People do different things when 
they are running out of money for food to make their food or their food money go further. 
 
2.3  In the last 12 months since (date 12 months ago) did you (or other adults in your household) ever cut the 
size of your meals or skip meals because there wasn’t enough money for food 
  
 
Yes
1 
 No
2
  
2.4 If yes, How often did this happen?  
  
 
 Almost every month
1 
 Some months but not every 
month
2
 
 Only in 1 or 2 months
3
  
   
2.5   In the last 12 months did you ever eat less than you felt you should 
because there wasn’t enough money to buy food? 
Yes
1  
No
2
  
 
 
 
2.6   In the last 12 months since (date 12 months ago) were you ever hungry but didn’t eat because 
you couldn’t afford food? 
   
  
Yes
1 
 No
2
  
Now I’m going to read you 2 statements that people have made about their food situation. For 
these statements please tell me whether the statement was often, sometimes or never true for 
you (or the other members of your household) in the last 12 months. 
 
2.7. The first statement is ‘The food that I bought just didn’t last and I didn’t have enough 
money to get  
       more.’ 
Often
1  
Sometimes
2
   Never true
3 
 
 
2.8 ‘I couldn’t afford to eat balanced meals’ 
Often
1  
Sometimes
2
   Never true
3 
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MODULE 3: SMOKING / DRINKING HABITS OF PREGNANT WOMEN 
3.1 Do you normally smoke?  Yes
1  
No
2
  
 If No go to Q 3.3  
 
 
3.2 If yes: Have you stopped smoking during this pregnancy? Yes
1  
No
2
  
  Have you cut down during this pregnancy? Yes
1  
No
2
  
  How many cigarettes do you smoke daily on average?  
3.3 Do other people in the house smoke? Yes
1  
No
2
  
3.4 If yes, who in the household smokes? 
 
 
 Husband/partner
1 
 
 
 
 
 
 Parents
2
      
 Children
3
(you are the biological parent)      
 Others
4
      
3.5 Do they smoke inside the house? Yes
1  
No
2
  
   
 
 
3.6 When you are not pregnant, do you normally consume alcohol? Yes
1  
No
2
  
 If No go to Q. 4  
 
 
3.7 If yes, how much do you normally drink each week, when you are not pregnant? 
 Less than 1 unit
1     
 
 2-10 units
2
 
 
 
 
  
 11-21 units
3
 
 
 
 
  
 22-35 units
4     
 
 36-50 units
5
 
 
 
 
  
 51 units and over
6
 
 
 
 
  
3.8 Have you stopped drinking during this pregnancy?     Yes
1  
No
2
  
 If yes, go to Q.4 
 
 
3.9 If no, have you cut down alcohol consumption during this pregnancy? Yes
1  
No
2
  
 
3.10 How often do you drink?  
 
 
 Almost every day
1     
 
 5-6 days a week
2     
 
 3-4 days a week
3
 
 
 
 
  
 Once or twice a week
4
 
 
 
 
  
 Once or twice a month
5
 
 
 
 
  
 Once every couple of months
6
 
 
 
 
  
3.11 How many units of alcohol do you currently drink each week?
 
 
 Less than 1 unit
1         
 
 2-10 units
2
 
 
 
 
  
 11-21 units
3
 
 
 
 
  
 22-35 units
4     
 
 36-50 units
5
 
 
 
 
  
 51 units and over
6
 
 
 
 
  
MODULE 4: FAMILY HISTORY OF MENTAL HEALTH 
4.1 Have you or any of the following people in your family ever been diagnosed with clinical depression? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
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 Don’t know3   
4.2 Do you or any of the following people in your family currently suffer with clinical depression? 
 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
4.3 Have you or any of the following people in your family ever had a diagnosis of anxiety? 
You Yes
1   
 No
2   
 Don’t know3   
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
    
4.4 Do you or any of the following people in your family currently suffer with anxiety? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
4.5 Have any of the following persons ever been diagnosed with learning difficulties e.g. dyslexia? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
4.6 Have any of the following persons ever been diagnosed with autism? 
You Yes
1   
 No
2   
 Don’t know3   
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MODULE 5: FAMILY HISTORY OF PHYSICAL HEALTH  
5.1 Have you or any of the following persons ever had Cardio-Vascular Disease? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
    
5.2 Have you or any of the following persons ever had Diabetes Mellitus? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
5.3 Have you or any of the following persons ever had Epilepsy? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
  
5.4 Have you or any of the following persons ever had High blood pressure? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
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 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
 
5.5 Have any of the following persons ever suffered from cancer? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
    
5.6 Have any of the following persons ever been diagnosed with asthma? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
    
5.7 Have any of the following persons ever been diagnosed with hay fever? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
  
5.8 Have any of the following ever had an itchy rash which was coming and going for at least six months? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
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Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
 
5.9 Have any of the following persons ever had wheezing or whistling in the chest at any time in the past? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
    
5.10 Have any of the following persons ever suffered from an itchy, stuffy or runny nose and/or swollen, 
itchy eyes when they did not have a cold? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
    
5.11 Have any of the following persons ever suffered from food allergy or intolerance at any time in the 
past? 
You Yes
1   
 No
2   
 Don’t know3   
    
Your partner/husband Yes
1   
 No
2   
 Don’t know3   
    
Any children (you are the biological parent) Yes
1   
 No
2   
 Don’t know3   
    
5.12 If yes, what food/s? 
  Food 1  Food 2  Food 3  
 You     
 Your partner/husband     
 Child 1     
 Child 2     
 Child 3     
 Child 4     
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 Child 5     
MODULE 6: PHYSICAL EXERCISE 
6.1 Do you usually take regular exercise (including brisk walking- more than 
15 minutes at a time)? 
Yes
1 
 No
2 
 
 
 
  
    
6.2 If yes what sort of exercise (write all exercise that is undertaken each week) 
  
 
 
 
MODULE 7: MEDICATION 
7.1 Are you currently taking any medications? Yes
1
  No
2
  
      
7.2 If yes, please specify all  
 
 
 
 
 
MODULE 8: ETHNICITY AND RELIGION 
8.1 What is your religion? 
 Christian
1
 (including Church of England, Catholic, Protestant and all other Christian denominations)  
 No religion
2
 
Buddhist
3
 
Hindu
4
 
Jewish
5 
Muslim
6
 
Sikh
7
 
 
  
  
  
  
  
 Any other religion, please describe
8
  
 
8.2 What is your ethnic group?  
 White
1
   
 English/Welsh/Scottish/Northern   
 Irish/British   
 Irish    
 Gypsy or Irish Traveller   
 Any other White background, please describe   
 Mixed/Multiple ethnic groups
2
  
 White and Black Caribbean   
 White and Black African   
 White and Asian   
 Any other Mixed/Multiple ethnic background, please describe   
 Asian/Asian British
3
  
 Indian   
 Pakistani   
 Bangladeshi   
 Chinese   
 Any other Asian background, please describe   
 Black/African/Caribbean/Black British
4
 
 African   
 Caribbean   
 Any other Black/African/Caribbean background, please describe   
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 Other ethnic group
5
  
 Arab   
 Any other ethnic group, please describe   
 
MODULE 9: GENERAL 
9.1  What language do you normally speak at home? Please specify all: 
 Language normally spoken in the home: 
 
Other languages spoken in the home: 
 
  
9.2 OTHER COMMENTS 
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Appendix 5.7. Portsmouth Birth Cohort (PBC) birth questionnaire (wave 1) 
 
 
 
Portsmouth Birth Cohort Registry 
Wave 1  
 
Unique Identification Number (UIN): 
(MULTIPLE BIRTHS WILL SHARE SAME IDENTIFICATION NUMBER WITH A 
SUPERSCRIPT OF 1,2..Etc) 
 
IDENTIFICATION 
Mother’s Name:  
Mother’s Address:  
  
  
Postcode:  
Mother’s Hospital Number:   
Child’s Hospital Number:  
 
 
  Detach after data collection…………………..……………. 
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Appendix 5.7. Portsmouth Birth Cohort (PBC) birth questionnaire (wave 1) 
 
Portsmouth Birth Cohort Study 
Wave 1  
 
Unique Identification Number (UIN): 
To be collected soon after discharge from the hospital 
(MULTIPLE BIRTHS WILLSHARE SAME IDENTIFICATION NUMBER 
WITH A SUPERSCRIPT OF 1,2… Etc) 
 
1. DELIVERY AND RELATED INFORMATION 
Pregnancy outcome   
Live 
birth
1
 
 Spontaneous abortion
2
  Induced abortion
3
            Still birth
4
                       
Twins/multiples Yes
 1
  No
2
  
Date of Delivery  
Child’s sex Male1  Female2  
Child’s DOB  
Birth weight kg          lb             oz 
Type of delivery   
Normal 
1
  Caesarian
2
  Instrumental
3
  
Perineal trauma or Episiotomy 
1
st 
degree  2
nd 
degree  3
rd 
degree  Episiotomy  None  
Estimated blood loss at delivery  (mls) 
Method of feeding on the day of birth 
Breast
1
  Bottle
2
  Both
3
  
Apgars at birth   
1 minute  5 minutes  N/A
-100
  
   
Problems   
 
   
Admitted to NICU Yes
1
  No
2
  D/K
3
  
Number of days spent at QA after delivery?  
Was it more than expected number of days? Yes
1
  No
2
  D/K
3
  
 
If more than normal, why? Was there any postnatal complications? 
 
 
2. ANY OTHER COMMENTS 
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Appendix 5.8. Ethical approval for the PBC revised questionnaires from 
Berkshire NHS  
 470 
 471 
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Appendix 5.9. R&D approval letter for the PBC registry from Portsmouth 
Hospitals, NHS Trust 
 473 
 474 
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Appendix 5.10. Ethical approval letter for amendments requested for the FFQ-P  
 476 
 477 
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Appendix 5.11. Ethical approval letter for amendments requested for the MD 
questionnaire 
 
 
 479 
 480 
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Appendix 5.12. Ethical approval letter for the 6 months follow-up questionnaire 
 482 
 483 
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Appendix 6.1. Infant’s food frequency questionnaire (FFQ) at 6 months 
 
Faculty of Science 
University of Portsmouth 
St Michael’s Building 
White Swan Road 
Portsmouth PO1 2DT 
United Kingdom 
T: +44 (0)23 9284 3004 
F: +44 (0)23 9284 3335 
 
Portsmouth Birth Cohort Study 
 
Six Month Questionnaire 
Instructions for completion 
Dear parent 
 
You have received this questionnaire as part of the Portsmouth Birth Cohort Study.  
 
Now that your baby is six months old we are interested in finding out about how 
he/she is growing. 
 
In this questionnaire, we will ask you about: 
 
 Your baby’s health 
 The kinds of foods that your baby is eating 
 How well your baby sleeps 
 Your baby’s behaviour 
 
This questionnaire will take about 30 minutes to complete. 
 
We would really appreciate it if you can answer all of the questions. 
  
Please send back the completed form using the enclosed pre-paid addressed 
envelope. If you have any queries, please do contact me in relation to my role 
as Principal Investigator for this study.  
  
Yours faithfully 
 
Professor Tara Dean 
Dean of Science 
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Date Questionnaire is completed  
 
   
     
Who completed the questionnaire? Mother    
  Father    
  Grandparent    
  Other  Who?  
      
1.1 What is your baby’s current 
or most recent weight (please 
look in your red book)? 
Weight: Date weighed: 
      
1.2 What is your baby’s length (if 
known)? 
Length: Date measured: 
      
2 YOUR BABY’S HEALTH 
 
    
 We would like to know about your baby’s health.  
Has your baby experienced any of the following since they were born? 
       
2.1 Has your baby ever had wheezing or whistling in the chest ? 
 
   
 
 
    Yes  No
 
 Don’t 
know
 
 
   
2.2 Has your baby had a dry cough at night, apart from the cough associated with a cold or 
a chest infection? 
  Yes  No
 
 Don’t 
know
 
 
     
2.3 Has your baby ever had an itchy rash that was coming and going ? 
 If No or Don’t know,  go to Q 2.4 Yes  No  Don’t 
know
 
 
   
2.3.1 If yes, where on their body does your baby get the itchy rash?   
    
  
 
        
2.3.2 Have you identified the cause of the itchy rash? Yes  No
 
 Don’t 
know
 
 
2.3.3 If yes, what?     
 Food Yes  No  Please specify: 
 Animals Yes  No    
 House dust mite Yes  No    
 Other Yes  No  Please specify: 
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2.4 Has your child ever suffered from vomiting (> 1 
tbsp)? 
If No or Don’t know go to Q2.5 
Yes
 
 No
 
 Don’t 
know
 
 
     
2.4.1 Have you identified the cause of the vomiting? 
If No or Don’t know go to Q2.5 
Yes
 
 No
 
 Don’t 
know
 
 
     
2.4.2 If yes, what?    
 Food Yes  No  Please specify: 
 Other Yes  No  Please specify: 
     
2.5 Has your baby ever suffered from diarrhoea? 
If No or Don’t know go to Q2.6 
Yes
 
 No
 
 Don’t 
know
 
 
     
2.5.1 Have you identified the cause of the diarrhoea? 
If No or Don’t know go to Q2.6 
Yes
 
 No
 
 Don’t 
know
 
 
     
2.5.2 If yes, what?    
 Food Yes  No  Please specify: 
 Other Yes  No  Please specify: 
     
2.6 Has your baby ever suffered from constipation? 
If No or Don’t know go to Q2.7 
Yes
 
 No
  Don’t 
know 
 
     
2.6.1 Have you identified the cause of the constipation? 
If No or Don’t know go to Q2.7 
Yes
 
 No
 
 Don’t 
know
 
 
     
2.6.2 If yes, what?    
 Food Yes  No  Please specify: 
 Other Yes  No  Please specify: 
     
2.7 Has your baby ever suffered from colic/tummy 
ache? 
If No or Don’t know go to Q2.8 
Yes
 
 No
 
 Don’t 
know
 
 
     
2.7.1 Have you identified the cause of the colic/tummy 
ache? 
If No or Don’t know go to Q2.8 
Yes
 
 No
 
 Don’t 
know
 
 
     
2.7.2 If yes, what?    
 Food Yes  No  Please specify: 
 Other Yes  No  Please specify: 
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2.8 Has your baby ever suffered from any other food related problem? 
If No or Don’t know go to Q3 
 
    Yes
 
 No
 
 Don’t know  
   
2.8.1 If yes, what was the problem and did you identify 
the cause? 
 
 Problem  Cause if identified  
   
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
  
      
 Did you consult your GP or paediatrician about any the 
symptoms we have asked you about? 
Yes   No  
    
 If yes, which symptoms did you speak to 
your GP about and what did the GP 
recommend?  
If no, please go to Q2.9 
     
       
2.9  Have any of your baby’s teeth started to come through? Yes  No  Don’t 
know 
 
        
2.9.1 If yes, when did your baby’s first tooth come through? 
If no, go to Q3 
 
Months 
        
2.9.2 If yes, do you brush your baby’s teeth? Yes  No  Don’t 
know 
 
        
3 YOUR BABY’S FEEDING     
    
3.1 What milk are you feeding your baby? Exclusively breast milk  
   Exclusively formula  
   Mix of breast milk and formula  
      
3.2 If your baby drinks formula milk, how old was he/she 
when you first introduced formula?  
If your baby doesn’t have formula please go to Q 3.3 
 
   
3.2.1 If your baby has formula, what type do they drink e.g. 
Aptamil, SMA, hungry baby milk, follow on milk, 
specialised infant formula? 
 
3.2.2 What does your baby have their formula milk from? Bottle 
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   Sippy/trainer cup 
 
 
   Cup 
 
 
  My baby doesn’t have formula  
    
3.3 When did you first introduce solids into your baby’s diet? 
If you have not introduced solids please go to Q3.18 
Weeks 
 
3.4 Which three foods did you introduce to your baby’s diet first? 
 
 
 Food 1    
 Food 2     
 Food 3     
      
3.5 Did you first feed your baby pureed food or finger food (baby-led weaning)? 
      Pureed    
      Finger food   
      Mixed   
      Don’t know   
         
 
3.6 Have you given your baby any of these foods, and if so when did you first give it to 
them? 
  Never  < 3 
months 
 3-6 
months 
 6-9 
months 
 
Wheat: e.g. baby rusk, cereals, pasta, bread, 
cakes, biscuits 
 
 
        
        
Egg: e.g. cooked egg, cakes, brioche, jaffa 
cakes, quiche 
 
         
          
Milk: e.g. yoghurt, fromage frais, custard, ice 
cream, butter, cheese, cow’s milk in foods  
         
          
Fish: e.g. fish fingers, fish cakes, fish pie  
 
        
        
Nuts: e.g. peanut butter, peanut cookies, 
crunchy nut cornflakes 
         
          
Sesame: e.g. humous, tahini, seed rolls, 
cereal bars 
 
 
        
         
3.7 Are you avoiding any foods from your baby’s diet 
because of allergy? 
  
Yes  No  
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 If yes, which  foods?  
  
   
3.8 Do you mainly feed your baby homemade or shop bought 
baby foods? 
 
   Homemade  
  Shop bought  
  50/50  
        
3.9 Does your baby have any medical conditions that 
affects what you feed them? 
Yes
 
 No
 
 Don’t 
know
 
 
 
 If yes, please specify: 
 
      
        
3.10 Does your baby currently take any dietary 
supplements (e.g. vitamins) 
Yes  No  Don’t 
know 
 
 If yes, please specify: 
 
      
        
3.11 How much attention is paid to your baby’s diet in terms of healthy eating? 
 
 Very little  Some
what 
 A great deal  
       
3.12 Where did you get advice about weaning (which foods and when to feed) your 
baby?  
Please tick ALL the ones that apply 
    Health visitor  
    Internet  
    Books  
    Mother  
    Grandmother  
    Friends with same age 
children 
 
    Friends with older children  
    Leaflet  
    GP or other medical 
professional 
 
  Other, please state   
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3.13 Which ONE source of advice about weaning (which foods and when to feed your baby) 
did you find the most influential? Please tick ONE 
   Health visitor  
   Internet  
   Books  
   Mother  
   Grandmother  
   Friends with same age children  
   Friends with older children  
   Leaflet  
   GP or other medical professional  
  Other, please state   
      
  
3.14 Thinking about the advice you were given on what and when to feed your baby. How 
consistent (giving the same advice) was the information from different sources e.g. 
health visitor, internet, books, family and friends. 
 
Please tick on the scale below 
 
 Very consistent 
they gave the 
same advice 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
Very conflicting 
they gave very 
different advice 
5 
      
      
3.15 How confident are you deciding which foods and when to feed your baby? 
 
Please tick on the scale below 
 
 Very confident 
1 
 
2 
 
3 
 
4 
Not at all 
confident 
5 
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3.16 We would like to know about the foods your baby has eaten in the past month. We have 
listed various foods many of which may not have been eaten in the past month or ever. 
 
You should only include food actually eaten, do not include food that was left over or spilled.  
 
Thinking about the PAST MONTH please tick to say how often your baby has eaten each food. 
 Never 1-3 
per 
month 
Number of times 
per week 
More 
than 
once a 
day 
1 2 3 4 5 6 7  
READY MADE BABY FOODS           
Pure baby rice (not including fruit flavoured 
rice) 
          
Other dried baby cereals           
Rusks           
Dried meat or fish based meals            
Dried vegetable, pasta or rice based meals           
Dried desserts           
Ready-made breakfast meals (e.g. porridge)           
Ready-made meat or fish based meals           
Ready-made vegetable, pasta or rice based 
savoury meals 
          
Ready-made milk of cereal based deserts           
Ready-made pure fruit puree           
Other ready-made fruit based desserts (not 
including pure fruit puree) 
          
OTHER FOODS           
Weetabix or other wheat biscuits            
Other cereals, not including Weetabix or baby 
cereals  
          
Potatoes           
Rice             
Pasta including tinned spaghetti            
Meat            
Fish            
Beans and pulses, including baked beans, kidney 
beans, chick peas and lentils  
          
Other vegetables (e.g. parsnip/carrot)            
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3.17. Thinking about the PAST MONTH, please tick how often your baby has had the 
following drinks 
 Never 1-3 per 
month 
Number of times per week 
 
More 
than once 
a day 1 2 3 4 5 6 7 
Yogurt and fromage frais           
Cooked Fruit           
Banana           
Other fresh fruit            
Bread or toast           
Crackers or breadsticks           
Biscuits           
Drinks Never 1-3 
per 
month 
Number of times 
per week 
More 
than 
once a 
day 
1 2 3 4 5 6 7 
Baby juice           
Pure fruit juice           
Fruit drinks           
Ribena, or high juice squash           
Squash, not including low calorie           
Low calorie squash           
Fizzy drinks, not including low calorie           
Low calorie fizzy drinks           
Tea           
Water           
           
3.18 What does your baby have these drinks from? Bottle 
 
 
   Sippy/trainer 
cup 
 
 
   Cup 
 
 
  My baby doesn’t have these 
drinks 
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4 YOUR BABY’S SLEEP  
4.1 Where does your baby normally sleep? Infant crib in separate room  
  Infant crib in parent’s room  
  In parent’s bed  
  Infant crib in room with sibling  
  Other, specify    
      
4.2 In what position does your child sleep most of the time?   
  On his/her belly  
  On his/her side  
  On his/her back  
     
4.3 How much time does your child spend in sleep during the NIGHT (between 7 in the 
evening and 7 in the morning? 
  Hours:                                   Minutes: 
     
4.4 How much time does your child spend in sleep during the DAY (between 7 in the 
morning and 7 in the evening? 
  Hours:                                      Minutes: 
     
4.5 Average number of night wakings per night:   
     
4.6 How much time during the night does your child spend in 
wakefulness (from 10 in the evening to 6 in the morning)? 
Hours: 
Minutes: 
     
4.7 How long does it take to put your baby to sleep in the evening? Hours:  
   Minutes:  
     
4.8 How does your baby fall asleep?   
  While feeding  
  Being rocked  
  Being held  
  In bed alone  
  In bed near parent  
     
4.9 When does your baby usually fall asleep for the night? Time:  
     
4.10 Do you consider your child’s sleep as a problem?   
  A very serious problem  
  A small problem  
  Not a problem at all  
     
4.11 How often does your baby snore? Never  
 Sometimes (Less than once a week)  
 Often (Once a week or more)  
 Every Day  
3.19 Does your baby use a dummy/pacifier? Yes  No  
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5 YOUR BABY’S BEHAVIOUR   
 We would like to ask about your baby’s behaviour. 
As you read each description of the baby’s behaviour below, please indicate how often the 
baby did this during the LAST WEEK (the past seven days). 
 
 The “Does Not Apply” column is used when you did not see the baby in the situation described  
during the last week.  For example, if the situation mentions the baby having to wait for food 
or liquids and there was no time during the last week when the baby had to wait, circle the  
“Does Not Apply” column.  
 
“Does Not Apply” is different from “Never”.  “Never” is used when you saw the baby in the 
situation but the baby never engaged in the behaviour listed during the last week.   
For example, if the baby did have to wait for food or liquids at least once but never cried loudly  
while waiting, circle the “Never” column. 
  
 Never Very 
Rarely 
Less Than 
Half the 
Time 
About Half 
the Time 
More Than 
Half the 
Time 
Almost 
Always 
Always Does 
Not 
Apply 
 1 2 3 4 5 6 7 N/A 
  
1 When being dressed or undressed during the last week, how 
often did the baby squirm and/or try to roll away? 
1 2 3 4 5 6 7 N/A 
2 When tossed around playfully how often did the baby laugh? 1 2 3 4 5 6 7 N/A 
3 When tired, how often did your baby show distress? 1 2 3 4 5 6 7 N/A 
4 When introduced to an unfamiliar adult, how often did the 
baby cling to a parent? 
1 2 3 4 5 6 7 N/A 
5 How often during the last week did the baby enjoy being read 
to? 
1 2 3 4 5 6 7 N/A 
6 How often during the last week did the baby play with one toy 
or object for 5-10 minutes? 
1 2 3 4 5 6 7 N/A 
7 How often during the week did your baby move quickly 
toward new objects? 
1 2 3 4 5 6 7 N/A 
8 When put into the bath water, how often did the baby laugh? 1 2 3 4 5 6 7 N/A 
9 When it was time for bed or a nap and your baby did not want 
to go, how often did s/he whimper or sob? 
1 2 3 4 5 6 7 N/A 
10 After sleeping, how often did the baby cry if someone doesn’t 
come within a few minutes? 
1 2 3 4 5 6 7 N/A 
11 In the last week, while being fed in your lap, how often did the 
baby seem eager to get away as soon as the feeding was over? 
1 2 3 4 5 6 7 N/A 
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Never Very 
Rarely 
Less Than Half 
the Time 
About Half 
the Time 
More Than 
Half the Time 
Almost 
Always 
Alwa
ys 
Does Not 
Apply 
1 2 3 4 5 6 7 N/A 
 
12 When singing or talking to your baby, how often did s/he soothe 
immediately? 
1 2 3 4 5 6 7 N/A 
13 When placed on his/her back, how often did the baby squirm 
and/or turn body? 
1 2 3 4 5 6 7 N/A 
14 During a peekaboo game, how often did the baby laugh? 1 2 3 4 5 6 7 N/A 
15 How often does the infant look up from playing when the 
telephone rings? 
1 2 3 4 5 6 7 N/A 
 
16 How often did the baby seem angry (crying and fussing) when 
you left her/him in the crib? 
1 2 3 4 5 6 7 N/A 
17 How often during the last week did the baby startle at a sudden 
change in body position (e.g., when moved suddenly)? 
1 2 3 4 5 6 7 N/A 
18 How often during the last week did the baby enjoy hearing the 
sound of words, as in nursery rhymes? 
1 2 3 4 5 6 7 N/A 
19 How often during the last week did the baby look at pictures in 
books and/or magazines for 5 minutes or longer at a time? 
1 2 3 4 5 6 7 N/A 
20 When visiting a new place, how often did your baby get excited 
about exploring new surroundings? 
1 2 3 4 5 6 7 N/A 
21 How often during the last week did the baby smile or laugh 
when given a toy? 
1 2 3 4 5 6 7 N/A 
22 At the end of an exciting day, how often did your baby become 
tearful? 
1 2 3 4 5 6 7 N/A 
23 How often during the last week did the baby protest being 
placed in a confining place (infant seat, play pen, car seat, etc.)? 
1 2 3 4 5 6 7 N/A 
24 When being held, in the last week, did your baby seem to enjoy 
him/herself? 
1 2 3 4 5 6 7 N/A 
25 When showing the baby something to look at, how often did 
s/he soothe immediately? 
1 2 3 4 5 6 7 N/A 
26 When hair was washed, how often did the baby vocalize? 1 2 3 4 5 6 7 N/A 
27 How often did your baby notice the sound of an airplane passing 
overhead? 
1 2 3 4 5 6 7 N/A 
28 When introduced to an unfamiliar adult, how often did the baby 
refuse to go to the unfamiliar person? 
1 2 3 4 5 6 7 N/A 
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29 When you were busy with another activity, and your baby was 
not able to get your attention, how often did s/he cry? 
1 2 3 4 5 6 7 N/A 
 
Never Very 
Rarely 
Less Than 
Half the 
Time 
About 
Half the 
Time 
More Than 
Half the 
Time 
Almost 
Always 
Always Does Not 
Apply 
1 2 3 4 5 6 7 N/A 
 
30 How often during the last week did the baby enjoy gentle 
rhythmic activities, such as rocking or swaying? 
1 2 3 4 5 6 7 N/A 
31 How often during the last week did the baby stare at a mobile, 
crib bumper or picture for 5 minutes or longer? 
1 2 3 4 5 6 7 N/A 
32 When the baby wanted something, how often did s/he become 
upset when s/he could not get what s/he wanted? 
1 2 3 4 5 6 7 N/A 
33 When in the presence of several unfamiliar adults, how often 
did the baby cling to a parent? 
1 2 3 4 5 6 7 N/A 
34 When rocked or hugged, in the last week, did your baby seem 
to enjoy him/herself? 
1 2 3 4 5 6 7 N/A 
35 When patting or gently rubbing some part of the baby’s body, 
how often did s/he soothe immediately? 
1 2 3 4 5 6 7 N/A 
36 How often did your baby make talking sounds when riding in a 
car? 
1 2 3 4 5 6 7 N/A 
37 When placed in an infant seat or car seat, how often did the 
baby squirm and turn body? 
1 2 3 4 5 6 7 N/A 
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Appendix 6.2. Food items included in each food group of the FFQ at 6 months 
and number of missing values 
 
Food group Food items included Missing replies  
Allergenic foods (6 items) Questions 3.6 14 
Ready-made baby foods (12 
items) 
Question 3.16, 1
st
 table 31 
Starchy foods (8 items) Questions 3.16, part of 2
nd
 table 
(Weetabix, other cereals, 
potatoes, rice, pasta, bread/toast, 
crackers/breadsticks, biscuits) 
24 
Vegetables (2 items) Questions 3.16, part of 2
nd
 table 
(beans/pulses, other vegetables) 
3 
Fruits (3 items) Questions 3.16, part of 2
nd
 table 
(cooked fruit, banana, other 
fresh fruit) 
4 
Yogurt and fromage frais (1 
item) 
Questions 3.16, part of 2
nd
 table 4 
Meat/Fish (2 items) Questions 3.16, part of 2
nd
 table 8 
 
 
 
 
